We O
previously O
reported O
that O
treatment O
of O
patients O
with O
symptomatic O
advanced O
non-small O
cell O
lung O
cancer O
with O
single O
agent O
Gemcitabine O
( O
GEM O
) O
resulted O
in O
a O
superior O
clinical-benefit O
response O
rate O
( O
RR O
) O
compared O
to O
cisplatin-based O
combination O
chemotherapy O
. O

We O
now O
report O
the O
detailed O
individual O
symptom O
control O
analysis O
, O
and O
the O
influence O
of O
cisplatin-use O
, O
age O
, O
performance O
status O
( O
PS O
) O
and O
duration O
of O
treatment O
. O

Patients O
received O
either O
GEM O
( O
1000 O
mg/m O
( O
2 O
) O
, O
days O
1 O
, O
8 O
and O
15 O
) O
or O
cisplatin O
( O
100 O
mg/m O
( O
2 O
) O
, O
day O
1 O
) O
plus O
Vindesine O
( O
3 O
mg/m O
( O
2 O
) O
, O
days O
1 O
and O
15 O
) O
( O
PV O
) O
, O
both O
every O
4 O
weeks O
. O

Scores O
of O
9 O
symptoms O
were O
listed O
weekly O
by O
the O
patient O
on O
visual O
analogue O
scales O
. O

Improvement O
of O
a O
symptom O
was O
defined O
as O
2 O
consecutive O
cycles O
of O
improvement O
over O
baseline O
. O

Baseline O
symptoms O
in O
the O
169 O
patients O
were O
well O
balanced O
between O
the O
2 O
arms O
( O
84 O
GEM O
, O
85 O
PV O
) O
. O

Both B-Premise
patients I-Premise
with I-Premise
objective I-Premise
response I-Premise
and I-Premise
disease I-Premise
stabilisation I-Premise
had I-Premise
clearly I-Premise
better I-Premise
symptom I-Premise
control I-Premise
than I-Premise
those I-Premise
with I-Premise
disease I-Premise
progression I-Premise
. I-Premise

Symptom B-Premise
control I-Premise
in I-Premise
both I-Premise
arms I-Premise
was I-Premise
similar I-Premise
for I-Premise
'disease-specific I-Premise
' I-Premise
symptoms I-Premise
such I-Premise
as I-Premise
cough I-Premise
, I-Premise
dyspnea I-Premise
, I-Premise
pain I-Premise
or I-Premise
haemoptysis I-Premise
. I-Premise

Compared B-Premise
to I-Premise
PV I-Premise
, I-Premise
a I-Premise
significantly I-Premise
larger I-Premise
number I-Premise
of I-Premise
GEM-patients I-Premise
had I-Premise
better I-Premise
scores I-Premise
for I-Premise
'constitutional I-Premise
' I-Premise
items I-Premise
such I-Premise
as I-Premise
anorexia I-Premise
( I-Premise
P=0.007 I-Premise
) I-Premise
, I-Premise
ability I-Premise
to I-Premise
carry I-Premise
on I-Premise
with I-Premise
daily I-Premise
activities I-Premise
( I-Premise
P=0.04 I-Premise
) I-Premise
and I-Premise
overall I-Premise
impression I-Premise
of I-Premise
quality-of-life I-Premise
( I-Premise
P=0.008 I-Premise
) I-Premise
. I-Premise

Symptom B-Premise
control I-Premise
was I-Premise
very I-Premise
similar I-Premise
in I-Premise
younger I-Premise
( I-Premise
< I-Premise
65 I-Premise
years I-Premise
) I-Premise
versus I-Premise
older I-Premise
( I-Premise
> I-Premise
/=65 I-Premise
years I-Premise
) I-Premise
patients I-Premise
, I-Premise
and I-Premise
only I-Premise
slightly I-Premise
better I-Premise
in I-Premise
those I-Premise
with I-Premise
a I-Premise
Karnofsky I-Premise
PS I-Premise
> I-Premise
/=80 I-Premise
% I-Premise
compared I-Premise
to I-Premise
those I-Premise
< I-Premise
80 I-Premise
% I-Premise
. I-Premise

Most B-Premise
of I-Premise
the I-Premise
symptom I-Premise
improvement I-Premise
occurred I-Premise
in I-Premise
the I-Premise
first I-Premise
3 I-Premise
cycles I-Premise
, I-Premise
with I-Premise
some I-Premise
further I-Premise
symptom I-Premise
improvement I-Premise
in I-Premise
the I-Premise
following I-Premise
cycles I-Premise
in I-Premise
the I-Premise
GEM-arm I-Premise
only I-Premise
. I-Premise

Both B-Claim
GEM I-Claim
and I-Claim
PV I-Claim
yield I-Claim
a I-Claim
symptom I-Claim
control I-Claim
rate I-Claim
much I-Claim
higher I-Claim
than I-Claim
expected I-Claim
by I-Claim
the I-Claim
objective I-Claim
tumour I-Claim
RR I-Claim
. I-Claim

GEM B-Claim
is I-Claim
equally I-Claim
effective I-Claim
in I-Claim
controlling I-Claim
'disease-specific I-Claim
' I-Claim
symptoms I-Claim
, I-Claim
but I-Claim
superior I-Claim
in I-Claim
controlling I-Claim
'constitutional I-Claim
' I-Claim
symptoms I-Claim
. I-Claim

Most B-Premise
of I-Premise
the I-Premise
symptom I-Premise
control I-Premise
was I-Premise
achieved I-Premise
during I-Premise
the I-Premise
first I-Premise
3 I-Premise
cycles I-Premise
of I-Premise
treatment I-Premise
, I-Premise
with I-Premise
some I-Premise
further I-Premise
improvement I-Premise
thereafter I-Premise
in I-Premise
the I-Premise
GEM-arm I-Premise
only I-Premise
. I-Premise

The O
objective O
of O
this O
study O
was O
to O
compare O
the O
quality O
of O
life O
( O
QoL O
) O
of O
ovarian O
cancer O
patients O
treated O
with O
paclitaxel/carboplatin O
( O
TC O
) O
versus O
paclitaxel/cisplatin O
( O
PT O
) O
and O
to O
determine O
the O
impact O
of O
treatment O
toxicity O
on O
the O
various O
QoL O
domains O
. O

In O
this O
phase O
III O
trial O
, O
798 O
patients O
with O
ovarian O
cancer O
stages O
IIB-IV O
were O
randomly O
assigned O
to O
receive O
TC O
or O
PT O
. O

The O
primary O
end O
point O
was O
progression-free O
survival O
";" O
secondary O
end O
points O
included O
toxicity O
, O
QoL O
, O
and O
response O
to O
treatment O
. O

Patients O
completed O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
before O
treatment O
, O
within O
3 O
days O
before O
the O
second O
and O
the O
fourth O
chemotherapy O
cycle O
, O
and O
3 O
weeks O
after O
completion O
of O
chemotherapy O
. O

Previously O
reported O
data O
showed O
that O
patients O
undergoing O
TC O
or O
PT O
did O
not O
differ O
in O
progression-free O
survival O
and O
overall O
survival O
. O

However O
, O
the O
TC O
arm O
was O
superior O
, O
indicating O
a O
better O
overall O
QoL O
compared O
with O
the O
PT O
arm O
. O

Controlling O
for O
toxicity O
and O
age O
, O
a O
significant O
treatment O
by O
assessment O
time O
interaction O
was O
found O
for O
four O
QoL O
functioning O
scales O
and O
three O
symptoms O
scales O
. O

Patients B-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
showed I-Premise
better I-Premise
means I-Premise
scores I-Premise
after I-Premise
treatment I-Premise
on I-Premise
overall I-Premise
QoL I-Premise
( I-Premise
P I-Premise
= I-Premise
.012 I-Premise
) I-Premise
, I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
P I-Premise
= I-Premise
.012 I-Premise
) I-Premise
, I-Premise
role I-Premise
functioning I-Premise
( I-Premise
P I-Premise
= I-Premise
.005 I-Premise
) I-Premise
, I-Premise
and I-Premise
cognitive I-Premise
functioning I-Premise
( I-Premise
P I-Premise
= I-Premise
.024 I-Premise
) I-Premise
, I-Premise
compared I-Premise
with I-Premise
the I-Premise
PT I-Premise
arm I-Premise
. I-Premise

Concerning B-Premise
symptom I-Premise
experience I-Premise
, I-Premise
patients I-Premise
undergoing I-Premise
TC I-Premise
showed I-Premise
less I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
less I-Premise
appetite I-Premise
loss I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
less I-Premise
fatigue I-Premise
( I-Premise
P I-Premise
= I-Premise
.033 I-Premise
) I-Premise
after I-Premise
completion I-Premise
of I-Premise
treatment I-Premise
compared I-Premise
with I-Premise
patients I-Premise
undergoing I-Premise
PT I-Premise
. I-Premise

The B-Claim
TC I-Claim
regimen I-Claim
achieved I-Claim
better I-Claim
QoL I-Claim
outcomes I-Claim
compared I-Claim
with I-Claim
the I-Claim
PT I-Claim
regimen I-Claim
. I-Claim

Thus B-Claim
, I-Claim
clinicians I-Claim
may I-Claim
consider I-Claim
replacing I-Claim
cisplatin I-Claim
with I-Claim
carboplatin I-Claim
when I-Claim
treating I-Claim
ovarian I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
chemotherapy I-Claim
. I-Claim

To O
compare O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
in O
patients O
with O
metastatic O
breast O
cancer O
receiving O
the O
combination O
of O
doxorubicin O
and O
paclitaxel O
( O
AT O
) O
or O
doxorubicin O
and O
cyclophosphamide O
( O
AC O
) O
as O
first-line O
chemotherapy O
treatment O
. O

Eligible O
patients O
( O
n O
= O
275 O
) O
with O
anthracycline-naive O
measurable O
metastatic O
breast O
cancer O
were O
randomly O
assigned O
to O
AT O
( O
doxorubicin O
60 O
mg/m O
( O
2 O
) O
as O
an O
intravenous O
bolus O
plus O
paclitaxel O
175 O
mg/m O
( O
2 O
) O
as O
a O
3-hour O
infusion O
) O
or O
AC O
( O
doxorubicin O
60 O
mg/m O
( O
2 O
) O
plus O
cyclophosphamide O
600 O
mg/m O
( O
2 O
) O
) O
every O
3 O
weeks O
for O
a O
maximum O
of O
six O
cycles O
. O

Dose O
escalation O
of O
paclitaxel O
( O
200 O
mg/m O
( O
2 O
) O
) O
and O
cyclophosphamide O
( O
750 O
mg/m O
( O
2 O
) O
) O
was O
planned O
at O
cycle O
2 O
to O
reach O
equivalent O
myelosuppression O
in O
the O
two O
groups O
. O

HRQOL O
was O
assessed O
with O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
C30 O
and O
the O
EORTC O
Breast O
Module O
at O
baseline O
and O
the O
start O
of O
cycles O
2 O
, O
4 O
, O
and O
6 O
, O
and O
3 O
months O
after O
the O
last O
cycle O
. O

Seventy-nine O
percent O
of O
the O
patients O
( O
n O
= O
219 O
) O
completed O
a O
baseline O
measure O
. O

However O
, O
there B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
HRQOL I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

In B-Premise
both I-Premise
groups I-Premise
, I-Premise
selected I-Premise
aspects I-Premise
of I-Premise
HRQOL I-Premise
were I-Premise
impaired I-Premise
over I-Premise
time I-Premise
, I-Premise
with I-Premise
increased I-Premise
fatigue I-Premise
, I-Premise
although B-Premise
some I-Premise
clinically I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
emotional I-Premise
functioning I-Premise
were I-Premise
seen I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
a I-Premise
reduction I-Premise
in I-Premise
pain I-Premise
over I-Premise
time I-Premise
. I-Premise

Overall B-Claim
, I-Claim
global I-Claim
quality I-Claim
of I-Claim
life I-Claim
was I-Claim
maintained I-Claim
in I-Claim
both I-Claim
treatment I-Claim
groups I-Claim
. I-Claim

This B-Claim
information I-Claim
is I-Claim
important I-Claim
when I-Claim
advising I-Claim
women I-Claim
patients I-Claim
of I-Claim
the I-Claim
expected I-Claim
HRQOL I-Claim
consequences I-Claim
of I-Claim
treatment I-Claim
regimens I-Claim
and I-Claim
should I-Claim
help I-Claim
clinicians I-Claim
and I-Claim
their I-Claim
patients I-Claim
make I-Claim
informed I-Claim
treatment I-Claim
decisions I-Claim
. I-Claim

Research O
suggests O
that O
cancer O
rehabilitation O
reduces O
fatigue O
in O
survivors O
of O
cancer O
. O

To O
date O
, O
it O
is O
unclear O
what O
type O
of O
rehabilitation O
is O
most O
beneficial O
. O

This O
randomized O
controlled O
trial O
compared O
the O
effect O
on O
cancer-related O
fatigue O
of O
physical O
training O
combined O
with O
cognitive O
behavioral O
therapy O
with O
physical O
training O
alone O
and O
with O
no O
intervention O
. O

In O
this O
multicenter O
randomized O
controlled O
trial O
, O
147 O
survivors O
of O
cancer O
were O
randomly O
assigned O
to O
a O
group O
that O
received O
physical O
training O
combined O
with O
cognitive-behavioral O
therapy O
( O
PT+CBT O
group O
, O
n=76 O
) O
or O
to O
a O
group O
that O
received O
physical O
training O
alone O
( O
PT O
group O
, O
n=71 O
) O
. O

In O
addition O
, O
a O
nonintervention O
control O
group O
( O
WLC O
group O
) O
consisting O
of O
62 O
survivors O
of O
cancer O
who O
were O
on O
the O
waiting O
lists O
of O
rehabilitation O
centers O
elsewhere O
was O
included O
. O

The O
study O
was O
conducted O
at O
4 O
rehabilitation O
centers O
in O
the O
Netherlands O
. O

All O
patients O
were O
survivors O
of O
cancer O
. O

Physical O
training O
consisting O
of O
2 O
hours O
of O
individual O
training O
and O
group O
sports O
took O
place O
twice O
weekly O
, O
and O
cognitive-behavioral O
therapy O
took O
place O
once O
weekly O
for O
2 O
hours O
. O

Fatigue O
was O
assessed O
with O
the O
Multidimensional O
Fatigue O
Inventory O
before O
and O
immediately O
after O
intervention O
( O
12 O
weeks O
after O
enrollment O
) O
. O

The O
WLC O
group O
completed O
questionnaires O
at O
the O
same O
time O
points O
. O

Baseline O
fatigue O
did O
not O
differ O
significantly O
among O
the O
3 O
groups O
. O

Over B-Premise
time I-Premise
, I-Premise
levels I-Premise
of I-Premise
fatigue I-Premise
significantly I-Premise
decreased I-Premise
in I-Premise
all I-Premise
domains I-Premise
in I-Premise
all I-Premise
groups I-Premise
, I-Premise
except B-Premise
in I-Premise
mental I-Premise
fatigue I-Premise
in I-Premise
the I-Premise
WLC I-Premise
group I-Premise
. I-Premise

Analyses B-Premise
of I-Premise
variance I-Premise
of I-Premise
postintervention I-Premise
fatigue I-Premise
showed I-Premise
statistically I-Premise
significant I-Premise
group I-Premise
effects I-Premise
on I-Premise
general I-Premise
fatigue I-Premise
, I-Premise
on I-Premise
physical I-Premise
and I-Premise
mental I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
on I-Premise
reduced I-Premise
activation I-Premise
but I-Premise
not I-Premise
on I-Premise
reduced I-Premise
motivation I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
WLC I-Premise
group I-Premise
, I-Premise
the I-Premise
PT I-Premise
group I-Premise
reported I-Premise
significantly I-Premise
greater I-Premise
decline I-Premise
in I-Premise
4 I-Premise
domains I-Premise
of I-Premise
fatigue I-Premise
, I-Premise
whereas I-Premise
the I-Premise
PT+CBT I-Premise
group I-Premise
reported I-Premise
significantly I-Premise
greater I-Premise
decline I-Premise
in I-Premise
physical I-Premise
fatigue I-Premise
only I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
in I-Premise
decline I-Premise
in I-Premise
fatigue I-Premise
were I-Premise
found I-Premise
between I-Premise
the I-Premise
PT+CBT I-Premise
and I-Premise
PT I-Premise
groups I-Premise
. I-Premise

Physical B-Premise
training I-Premise
combined I-Premise
with I-Premise
cognitive-behavioral I-Premise
therapy I-Premise
and I-Premise
physical I-Premise
training I-Premise
alone I-Premise
had I-Premise
significant I-Premise
and I-Premise
beneficial I-Premise
effects I-Premise
on I-Premise
fatigue I-Premise
compared I-Premise
with I-Premise
no I-Premise
intervention I-Premise
. I-Premise

Physical B-Claim
training I-Claim
was I-Claim
equally I-Claim
effective I-Claim
as I-Claim
or I-Claim
more I-Claim
effective I-Claim
than I-Claim
physical I-Claim
training I-Claim
combined I-Claim
with I-Claim
cognitive-behavioral I-Claim
therapy I-Claim
in I-Claim
reducing I-Claim
cancer-related I-Claim
fatigue I-Claim
, I-Claim
suggesting O
that O
cognitive-behavioral B-Claim
therapy I-Claim
did I-Claim
not I-Claim
have I-Claim
additional I-Claim
beneficial I-Claim
effects I-Claim
beyond I-Claim
the I-Claim
benefits I-Claim
of I-Claim
physical I-Claim
training I-Claim
. I-Claim

The O
standard O
treatment O
for O
patients O
with O
clinically O
resectable O
rectal O
cancer O
is O
surgery O
. O

Postoperative B-Claim
radiochemotherapy I-Claim
( I-Claim
RCT I-Claim
) I-Claim
is I-Claim
recommended I-Claim
for I-Claim
advanced I-Claim
disease I-Claim
( I-Claim
pT3/4 I-Claim
or I-Claim
pN+ I-Claim
) I-Claim
. I-Claim

In O
recent O
years O
, O
encouraging O
results O
of O
pre-operative O
radiotherapy O
have O
been O
reported O
. O

This O
prospective O
randomized O
phase-III-trial O
( O
CAO/ARO/AIO-94 O
) O
compares O
the O
efficacy O
of O
neoadjuvant O
RCT O
to O
standard O
postoperative O
RCT O
. O

We O
report O
on O
the O
design O
of O
the O
study O
and O
first O
results O
with O
regard O
to O
toxicity O
of O
RCT O
and O
postoperative O
morbidity O
. O

Patients O
with O
locally O
advanced O
operable O
rectal O
cancer O
( O
uT3/4 O
or O
uN+ O
, O
Mason O
CS O
III/IV O
) O
were O
randomly O
assigned O
to O
pre O
or O
postoperative O
RCT O
: O
A O
total O
dose O
of O
50.4 O
Gy O
( O
single O
dose O
1.8 O
Gy O
) O
was O
applied O
to O
the O
tumour O
and O
the O
pelvic O
lymph O
nodes O
. O

5-FU O
( O
1000 O
mg/m2/d O
) O
was O
administered O
concomitantly O
in O
the O
1th O
and O
5th O
week O
of O
radiation O
as O
120 O
h-continuous O
infusion O
. O

Four O
additional O
cycles O
of O
5-FU-chemotherapy O
( O
500 O
mg/m2/d O
, O
i.v.-bolus O
) O
were O
applied O
. O

RCT O
was O
identical O
in O
both O
arms O
except O
for O
a O
small-volume O
boost O
of O
5.4 O
Gy O
postoperatively O
. O

The O
time O
interval O
between O
RCT O
and O
surgery O
was O
4-6 O
weeks O
in O
both O
arms O
. O

Techniques O
of O
surgery O
were O
standardized O
and O
included O
total O
mesorectal O
excision O
. O

Primary O
endpoints O
of O
the O
study O
are O
5-year O
survival O
and O
local O
and O
distant O
control O
. O

Secondary O
endpoints O
include O
the O
rate O
of O
curative O
( O
R0 O
) O
resection O
and O
sphincter O
saving O
procedures O
, O
toxicity O
of O
RCT O
, O
surgical O
complications O
and O
quality O
of O
life O
. O

As O
of O
July O
2002 O
, O
805 O
patients O
were O
randomized O
from O
26 O
participating O
institutions O
. O

Acute B-Premise
toxicity I-Premise
( I-Premise
WHO I-Premise
) I-Premise
of I-Premise
RCT I-Premise
was I-Premise
low I-Premise
, I-Premise
with I-Premise
less I-Premise
than I-Premise
15 I-Premise
% I-Premise
of I-Premise
patients I-Premise
experiencing I-Premise
grade I-Premise
3 I-Premise
or I-Premise
higher I-Premise
toxicity I-Premise
: O
The B-Premise
principal I-Premise
toxicity I-Premise
was I-Premise
diarrhea I-Premise
, I-Premise
with I-Premise
12 I-Premise
% I-Premise
in I-Premise
the I-Premise
postoperative I-Premise
RCT-arm I-Premise
and I-Premise
11 I-Premise
% I-Premise
in I-Premise
the I-Premise
pre-operative I-Premise
RCT-arm I-Premise
having I-Premise
grade I-Premise
-3 I-Premise
, I-Premise
and I-Premise
1 I-Premise
% I-Premise
in I-Premise
either I-Premise
arm I-Premise
having I-Premise
grade I-Premise
4-diarrhea I-Premise
. I-Premise

Erythema B-Premise
, I-Premise
nausea I-Premise
and I-Premise
leukopenia I-Premise
were I-Premise
the I-Premise
next I-Premise
common I-Premise
toxicities I-Premise
, I-Premise
with I-Premise
less I-Premise
than I-Premise
3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
in I-Premise
either I-Premise
arm I-Premise
suffering I-Premise
grade I-Premise
3 I-Premise
or I-Premise
greater I-Premise
leukopenia I-Premise
or I-Premise
nausea I-Premise
. I-Premise

Postoperative B-Premise
complication I-Premise
rates I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
with I-Premise
12 I-Premise
% I-Premise
( I-Premise
postop I-Premise
. I-Premise
RCT I-Premise
) I-Premise
and I-Premise
12 I-Premise
% I-Premise
( I-Premise
pre-op I-Premise
. I-Premise
RCT I-Premise
) I-Premise
of I-Premise
patients I-Premise
, I-Premise
respectively I-Premise
, I-Premise
suffering I-Premise
from I-Premise
anastomotic I-Premise
leakage I-Premise
, I-Premise
3 I-Premise
% I-Premise
( I-Premise
postop I-Premise
. I-Premise
RCT I-Premise
) I-Premise
and I-Premise
3 I-Premise
% I-Premise
( I-Premise
pre-op I-Premise
. I-Premise
RCT I-Premise
) I-Premise
from I-Premise
postoperative I-Premise
bleeding I-Premise
, I-Premise
and I-Premise
6 I-Premise
% I-Premise
( I-Premise
postop I-Premise
. I-Premise
RCT I-Premise
) I-Premise
and I-Premise
4 I-Premise
% I-Premise
( I-Premise
pre-op I-Premise
. I-Premise
RCT I-Premise
) I-Premise
from I-Premise
delayed I-Premise
wound I-Premise
healing I-Premise
. I-Premise

The B-Claim
patient I-Claim
accrual I-Claim
to I-Claim
the I-Claim
trial I-Claim
is I-Claim
satisfactory I-Claim
. O

Neoadjuvant B-Claim
RCT I-Claim
is I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
bears I-Claim
no I-Claim
higher I-Claim
risk I-Claim
for I-Claim
postoperative I-Claim
morbidity I-Claim
. I-Claim

Sentinel O
lymph O
node O
resection O
( O
SNR O
) O
may O
reduce O
morbidity O
while O
providing O
the O
same O
clinical O
utility O
as O
conventional O
axillary O
dissection O
( O
AD O
) O
. O

National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
( O
NSABP O
) O
B-32 O
is O
a O
randomized O
phase O
III O
trial O
comparing O
SNR O
immediately O
followed O
by O
AD O
( O
SNAD O
) O
to O
SNR O
and O
subsequent O
AD O
if O
SN O
is O
positive O
. O

We O
report O
the O
definitive O
patient-reported O
outcomes O
( O
PRO O
) O
comparisons O
. O

Eligible O
patients O
had O
clinically O
node-negative O
, O
operable O
invasive O
breast O
cancer O
. O

The O
PRO O
substudy O
included O
all O
SN-negative O
participants O
enrolled O
May O
2001 O
to O
February O
2004 O
at O
community O
institutions O
in O
the O
United O
States O
( O
n O
= O
749 O
";" O
78 O
% O
age O
> O
or O
= O
50 O
";" O
87 O
% O
clinical O
tumor O
size O
< O
or O
= O
2.0 O
cm O
";" O
84 O
% O
lumpectomy O
";" O
87 O
% O
white O
) O
. O

They O
completed O
questionnaires O
presurgery O
, O
1 O
and O
2 O
to O
3 O
weeks O
postoperatively O
, O
and O
every O
6 O
months O
through O
year O
3 O
. O

Arm O
symptoms O
, O
arm O
use O
avoidance O
, O
activity O
limitations O
, O
and O
quality O
of O
life O
( O
QOL O
) O
were O
compared O
with O
intent-to-treat O
two-sample O
t-tests O
and O
repeated O
measures O
analyses O
. O

Arm B-Premise
symptoms I-Premise
were I-Premise
significantly I-Premise
more I-Premise
bothersome I-Premise
for I-Premise
SNAD I-Premise
compared I-Premise
with I-Premise
SNR I-Premise
patients I-Premise
at I-Premise
6 I-Premise
months I-Premise
( I-Premise
mean I-Premise
, I-Premise
4.8 I-Premise
v I-Premise
3.0 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
at I-Premise
12 I-Premise
months I-Premise
( I-Premise
3.6 I-Premise
v I-Premise
2.5 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
. I-Premise

Longitudinally B-Premise
, I-Premise
SNAD I-Premise
patients I-Premise
were I-Premise
more I-Premise
likely I-Premise
to I-Premise
experience I-Premise
ipsilateral I-Premise
arm I-Premise
and I-Premise
breast I-Premise
symptoms I-Premise
, I-Premise
restricted I-Premise
work I-Premise
and I-Premise
social I-Premise
activity I-Premise
, I-Premise
and I-Premise
impaired I-Premise
QOL I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.002 I-Premise
all I-Premise
items I-Premise
) I-Premise
. I-Premise

From B-Premise
12 I-Premise
to I-Premise
36 I-Premise
months I-Premise
, I-Premise
fewer I-Premise
than I-Premise
15 I-Premise
% I-Premise
of I-Premise
either I-Premise
SNAD I-Premise
or I-Premise
SNR I-Premise
patients I-Premise
reported I-Premise
moderate I-Premise
or I-Premise
greater I-Premise
severity I-Premise
of I-Premise
any I-Premise
given I-Premise
symptom I-Premise
or I-Premise
activity I-Premise
limitation I-Premise
. I-Premise

Arm B-Claim
morbidity I-Claim
was I-Claim
greater I-Claim
with I-Claim
SNAD I-Claim
than I-Claim
with I-Claim
SNR I-Claim
. I-Claim

Despite O
considerable O
fears O
about O
complications O
from O
AD O
for O
breast O
cancer O
, O
this B-Claim
study I-Claim
demonstrates I-Claim
that I-Claim
initial I-Claim
problems I-Claim
with I-Claim
either I-Claim
surgery I-Claim
resolve I-Claim
over I-Claim
time I-Claim
. I-Claim

Postcancer B-Claim
fatigue I-Claim
is I-Claim
a I-Claim
frequently I-Claim
occurring I-Claim
problem I-Claim
, I-Claim
impairing I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Until O
now O
, O
little O
is O
known O
about O
( O
neuro O
) O
physiological O
factors O
determining O
postcancer O
fatigue O
. O

For O
non-cancer O
patients O
with O
chronic O
fatigue O
syndrome O
, O
certain O
characteristics O
of O
brain O
morphology O
and O
metabolism O
have O
been O
identified O
in O
previous O
studies O
. O

We O
investigated O
whether O
these O
volumetric O
and O
metabolic O
traits O
are O
a O
reflection O
of O
fatigue O
in O
general O
and O
thus O
also O
of O
importance O
for O
postcancer O
fatigue O
. O

Fatigued O
patients O
were O
randomly O
assigned O
to O
either O
the O
intervention O
condition O
( O
cognitive O
behavior O
therapy O
) O
or O
the O
waiting O
list O
condition O
. O

Twenty-five O
patients O
in O
the O
intervention O
condition O
and O
fourteen O
patients O
in O
the O
waiting O
list O
condition O
were O
assessed O
twice O
, O
at O
baseline O
and O
six O
months O
later O
. O

Baseline O
measurements O
of O
20 O
fatigued O
patients O
were O
compared O
with O
20 O
matched O
non-fatigued O
controls O
. O

All O
participants O
had O
completed O
treatment O
of O
a O
malignant O
, O
solid O
tumor O
minimal O
one O
year O
earlier O
. O

Global O
brain O
volumes O
, O
subcortical O
brain O
volumes O
, O
metabolite O
tissue O
concentrations O
, O
and O
metabolite O
ratios O
were O
primary O
outcome O
measures O
. O

Volumetric O
and O
metabolic O
parameters O
were O
not O
significantly O
different O
between O
fatigued O
and O
non-fatigued O
patients O
. O

Change B-Premise
scores I-Premise
of I-Premise
volumetric I-Premise
and I-Premise
metabolic I-Premise
parameters I-Premise
from I-Premise
baseline I-Premise
to I-Premise
follow-up I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
patients I-Premise
in I-Premise
the I-Premise
therapy I-Premise
and I-Premise
the I-Premise
waiting I-Premise
list I-Premise
group I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
therapy I-Premise
group I-Premise
reported I-Premise
a I-Premise
significant I-Premise
larger I-Premise
decrease I-Premise
in I-Premise
fatigue I-Premise
scores I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
waiting I-Premise
list I-Premise
group I-Premise
. I-Premise

No B-Premise
relation I-Premise
was I-Premise
found I-Premise
between I-Premise
postcancer I-Premise
fatigue I-Premise
and I-Premise
the I-Premise
studied I-Premise
volumetric I-Premise
and I-Premise
metabolic I-Premise
markers I-Premise
. I-Premise

This B-Claim
may I-Claim
suggest I-Claim
that I-Claim
, I-Claim
although I-Claim
postcancer I-Claim
fatigue I-Claim
and I-Claim
chronic I-Claim
fatigue I-Claim
syndrome I-Claim
show I-Claim
strong I-Claim
resemblances I-Claim
as I-Claim
a I-Claim
clinical I-Claim
syndrome I-Claim
, I-Claim
the I-Claim
underlying I-Claim
physiology I-Claim
is I-Claim
different I-Claim
. I-Claim

The O
efficacy O
of O
a O
home-based O
physical O
activity O
( O
PA O
) O
intervention O
for O
colorectal O
cancer O
patients O
versus O
contact O
control O
was O
evaluated O
in O
a O
randomized O
controlled O
trial O
. O

Forty-six O
patients O
( O
mean O
age O
= O
57.3 O
years O
[ O
SD O
= O
9.7 O
] O
, O
57 O
% O
female O
, O
mean O
= O
2.99 O
years O
post-diagnosis O
[ O
SD O
= O
1.64 O
] O
) O
who O
had O
completed O
treatment O
for O
stages O
1-3 O
colorectal O
cancer O
were O
randomized O
to O
telephone O
counseling O
to O
support O
PA O
( O
PA O
group O
, O
n O
= O
20 O
) O
or O
contact O
control O
( O
control O
group O
, O
n O
= O
26 O
) O
. O

PA O
group O
participants O
received O
3 O
months O
of O
PA O
counseling O
( O
based O
on O
the O
transtheoretical O
model O
and O
the O
social O
cognitive O
theory O
) O
delivered O
via O
telephone O
, O
as O
well O
as O
weekly O
PA O
tip O
sheets O
. O

Assessments O
of O
PA O
( O
Seven-day O
Physical O
Activity O
Recall O
[ O
7-day O
PAR O
] O
and O
Community O
Healthy O
Activities O
Model O
Program O
for O
Seniors O
[ O
CHAMPS O
] O
) O
, O
submaximal O
aerobic O
fitness O
( O
Treadwalk O
test O
) O
, O
motivational O
readiness O
for O
PA O
, O
and O
psychosocial O
outcomes O
were O
conducted O
at O
baseline O
, O
3 O
, O
6 O
, O
and O
12 O
months O
post-baseline O
. O

Objective O
accelerometer O
data O
were O
collected O
at O
the O
same O
time O
points O
. O

The B-Premise
PA I-Premise
group I-Premise
reported I-Premise
significant I-Premise
increases I-Premise
in I-Premise
minutes I-Premise
of I-Premise
PA I-Premise
at I-Premise
3 I-Premise
months I-Premise
( I-Premise
7-day I-Premise
PAR I-Premise
) I-Premise
and I-Premise
caloric I-Premise
expenditure I-Premise
( I-Premise
CHAMPS I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
but B-Premise
the I-Premise
group I-Premise
differences I-Premise
were I-Premise
attenuated I-Premise
over I-Premise
time I-Premise
. I-Premise

The B-Premise
PA I-Premise
group I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
fitness I-Premise
at I-Premise
3 I-Premise
, I-Premise
6 I-Premise
, I-Premise
and I-Premise
12 I-Premise
months I-Premise
versus I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Improvements B-Premise
in I-Premise
motivational I-Premise
readiness I-Premise
for I-Premise
PA I-Premise
were I-Premise
reported I-Premise
in I-Premise
the I-Premise
PA I-Premise
group I-Premise
only I-Premise
at I-Premise
3 I-Premise
months I-Premise
. I-Premise

No B-Premise
significant I-Premise
group I-Premise
differences I-Premise
were I-Premise
found I-Premise
for I-Premise
fatigue I-Premise
, I-Premise
self-reported I-Premise
physical I-Premise
functioning I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
3 I-Premise
, I-Premise
6 I-Premise
, I-Premise
and I-Premise
12 I-Premise
months I-Premise
. I-Premise

A B-Claim
home-based I-Claim
intervention I-Claim
improved I-Claim
survivors I-Claim
' I-Claim
PA I-Claim
and I-Claim
motivational I-Claim
readiness I-Claim
at I-Claim
3 I-Claim
months I-Claim
and I-Claim
increased I-Claim
submaximal I-Claim
aerobic I-Claim
fitness I-Claim
at I-Claim
3 I-Claim
, I-Claim
6 I-Claim
, I-Claim
and I-Claim
12 I-Claim
months I-Claim
. I-Claim

Cancer O
treatment O
can O
profoundly O
impact O
the O
patient O
's O
quality O
of O
life O
( O
QOL O
) O
. O

It O
has O
been O
well O
documented O
that O
there O
are O
gender O
differences O
in O
the O
symptoms O
associated O
with O
cancer O
treatment O
. O

This O
study O
explores O
the O
impact O
of O
gender O
on O
QOL O
for O
patients O
with O
newly O
diagnosed O
advanced O
cancer O
. O

A O
randomized O
, O
controlled O
clinical O
trial O
in O
patients O
receiving O
radiotherapy O
for O
advanced O
cancer O
demonstrated O
maintenance O
of O
QOL O
with O
a O
six O
session O
multidisciplinary O
structured O
intervention O
compared O
to O
controls O
. O

This O
current O
study O
reports O
the O
gender O
differences O
in O
that O
trial O
. O

Outcome O
measures O
included O
the O
functional O
assessment O
of O
cancer O
therapy-general O
( O
FACT-G O
) O
, O
linear O
analog O
self-assessment O
( O
LASA O
) O
, O
and O
profile O
of O
mood O
states O
( O
POMS O
) O
at O
baseline O
and O
weeks O
4 O
, O
27 O
, O
and O
52 O
. O

Kruskal-Wallis O
was O
used O
to O
compare O
QOL O
scores O
. O

One O
hundred O
thirty-one O
patients O
( O
45 O
women O
and O
86 O
men O
, O
mean O
age O
58.7 O
) O
participated O
in O
the O
clinical O
trial O
. O

At B-Premise
week I-Premise
4 I-Premise
postintervention I-Premise
, I-Premise
women I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
had I-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
their I-Premise
FACT-G I-Premise
score I-Premise
, I-Premise
FACT-G I-Premise
physical I-Premise
well-being I-Premise
subscale I-Premise
, I-Premise
LASA I-Premise
fatigue I-Premise
, I-Premise
POMS I-Premise
total I-Premise
score I-Premise
, I-Premise
POMS I-Premise
fatigue-inertia I-Premise
subscale I-Premise
, I-Premise
and I-Premise
POMS I-Premise
confusion-bewilderment I-Premise
subscale I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Men B-Premise
receiving I-Premise
the I-Premise
intervention I-Premise
had I-Premise
a I-Premise
smaller I-Premise
decrease I-Premise
in I-Premise
FACT-G I-Premise
score I-Premise
compared I-Premise
to I-Premise
controls I-Premise
( I-Premise
p I-Premise
= I-Premise
0.048 I-Premise
) I-Premise
and I-Premise
also I-Premise
worsened I-Premise
on I-Premise
the I-Premise
LASA I-Premise
financial I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

At B-Premise
week I-Premise
27 I-Premise
, I-Premise
the I-Premise
only I-Premise
gender I-Premise
difference I-Premise
was I-Premise
that I-Premise
intervention I-Premise
group I-Premise
men I-Premise
had I-Premise
more I-Premise
POMS I-Premise
anger-hostility I-Premise
( I-Premise
p I-Premise
= I-Premise
0.009 I-Premise
) I-Premise
. I-Premise

By B-Premise
week I-Premise
52 I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
gender I-Premise
differences I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
QOL I-Premise
measures I-Premise
. I-Premise

Gender-based B-Claim
differences I-Claim
appear I-Claim
to I-Claim
play I-Claim
a I-Claim
role I-Claim
in I-Claim
the I-Claim
early I-Claim
, I-Claim
but I-Claim
not I-Claim
late I-Claim
, I-Claim
response I-Claim
to I-Claim
a I-Claim
multidisciplinary I-Claim
intervention I-Claim
to I-Claim
improve I-Claim
QOL I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
, I-Claim
suggesting O
that O
early B-Claim
interventions I-Claim
can I-Claim
be I-Claim
tailored I-Claim
for I-Claim
each I-Claim
gender I-Claim
. I-Claim

Surgical O
resection O
enhances O
long-term O
survival O
after O
lung O
cancer O
, O
but O
survivors O
face O
functional O
deficits O
and O
report O
on O
poor O
quality O
of O
life O
long O
time O
after O
surgery O
. O

This O
study O
evaluated O
short O
and O
long-term O
effects O
of O
supervised O
group O
exercise O
training O
on O
health-related O
quality O
of O
life O
and O
physical O
performance O
in O
patients O
, O
who O
were O
radically O
operated O
for O
lung O
cancer O
. O

A O
randomized O
, O
assessor-blinded O
, O
controlled O
trial O
was O
performed O
on O
78 O
patients O
undergoing O
lung O
cancer O
surgery O
. O

The O
intervention O
group O
( O
IG O
, O
n=41 O
) O
participated O
in O
supervised O
out-patient O
exercise O
training O
sessions O
, O
one O
hour O
once O
a O
week O
for O
ten O
weeks O
. O

The O
sessions O
were O
based O
on O
aerobic O
exercises O
with O
target O
intensity O
of O
60-80 O
% O
of O
work O
capacity O
, O
resistance O
training O
and O
dyspnoea O
management O
. O

The O
control O
group O
( O
CG O
, O
n=37 O
) O
received O
one O
individual O
instruction O
in O
exercise O
training O
. O

Measurements O
consisted O
of O
: O
health-related O
quality O
of O
life O
( O
SF36 O
) O
, O
six O
minute O
walk O
test O
( O
6MWT O
) O
and O
lung O
function O
( O
spirometry O
) O
, O
assessed O
three O
weeks O
after O
surgery O
and O
after O
four O
and O
twelve O
months O
. O

Both O
groups O
were O
comparable O
at O
baseline O
on O
demographic O
characteristic O
and O
outcome O
values O
. O

We B-Premise
found I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
effect I-Premise
after I-Premise
four I-Premise
months I-Premise
in I-Premise
the I-Premise
bodily I-Premise
pain I-Premise
domain I-Premise
of I-Premise
SF36 I-Premise
, I-Premise
with I-Premise
an I-Premise
estimated I-Premise
mean I-Premise
difference I-Premise
( I-Premise
EMD I-Premise
) I-Premise
of I-Premise
15.3 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI:4 I-Premise
to I-Premise
26.6 I-Premise
, I-Premise
p=0.01 I-Premise
) I-Premise
and I-Premise
a I-Premise
trend I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
intervention I-Premise
for I-Premise
role I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
EMD I-Premise
12.04 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
-1 I-Premise
to I-Premise
25.1 I-Premise
, I-Premise
p=0.07 I-Premise
) I-Premise
and I-Premise
physical I-Premise
component I-Premise
summary I-Premise
( I-Premise
EMD I-Premise
3.76 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
-0.1 I-Premise
to I-Premise
7.6 I-Premise
, I-Premise
p=0.06 I-Premise
) I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
the I-Premise
tendency I-Premise
was I-Premise
reversed I-Premise
, I-Premise
with I-Premise
the I-Premise
CG I-Premise
presenting I-Premise
overall I-Premise
slightly I-Premise
better I-Premise
measures I-Premise
. I-Premise

We B-Claim
found I-Claim
no I-Claim
effect I-Claim
of I-Claim
the I-Claim
intervention I-Claim
on I-Claim
6MWT I-Claim
or I-Claim
lung I-Claim
volumes I-Claim
at I-Claim
any I-Claim
time-point I-Claim
. I-Claim

Supervised B-Claim
compared I-Claim
to I-Claim
unsupervised I-Claim
exercise I-Claim
training I-Claim
resulted I-Claim
in I-Claim
no I-Claim
improvement I-Claim
in I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
except B-Claim
for I-Claim
the I-Claim
bodily I-Claim
pain I-Claim
domain I-Claim
, I-Claim
four I-Claim
months I-Claim
after I-Claim
lung I-Claim
cancer I-Claim
surgery I-Claim
. I-Claim

No B-Claim
effects I-Claim
of I-Claim
the I-Claim
intervention I-Claim
were I-Claim
found I-Claim
for I-Claim
any I-Claim
outcome I-Claim
after I-Claim
one I-Claim
year I-Claim
. I-Claim

We O
analyzed O
the O
long-term O
survival O
of O
children O
under O
6 O
years O
of O
age O
( O
< O
6 O
years O
) O
enrolled O
upon O
the O
Children O
's O
Cancer O
Group O
( O
CCG O
) O
-945 O
high-grade O
glioma O
( O
HGG O
) O
study O
to O
determine O
the O
impact O
of O
intrinsic O
biological O
characteristics O
as O
well O
as O
treatment O
upon O
both O
survival O
and O
quality O
of O
life O
( O
QOL O
) O
in O
this O
younger O
age O
population O
. O

Analyses O
were O
undertaken O
on O
patients O
< O
6 O
years O
with O
institutionally O
diagnosed O
HGG O
enrolled O
on O
the O
CCG-945 O
trial O
. O

Comparisons O
of O
survival O
were O
performed O
for O
patients O
< O
3 O
years O
of O
age O
( O
< O
3 O
years O
) O
( O
treated O
with O
intent O
to O
avoid O
irradiation O
) O
versus O
those O
between O
3 O
and O
6 O
years O
of O
age O
( O
3-6 O
years O
) O
( O
treated O
with O
irradiation O
and O
chemotherapy O
) O
at O
diagnosis O
. O

Discordance O
between O
the O
institutional O
diagnoses O
of O
HGG O
and O
consensus-reviewed O
diagnoses O
led O
us O
to O
perform O
further O
survival O
analyses O
for O
both O
groups O
. O

We O
compared O
the O
two O
groups O
of O
patients O
for O
biological O
markers O
, O
and O
evaluated O
the O
neuropsychological O
and O
QOL O
outcomes O
of O
long-term O
survivors O
. O

Patients B-Premise
< I-Premise
3 I-Premise
years I-Premise
( I-Premise
n I-Premise
= I-Premise
49 I-Premise
, I-Premise
19.5 I-Premise
% I-Premise
of I-Premise
all I-Premise
enrolled I-Premise
patients I-Premise
) I-Premise
at I-Premise
diagnosis I-Premise
had I-Premise
a I-Premise
10-year I-Premise
EFS I-Premise
and I-Premise
OS I-Premise
of I-Premise
29 I-Premise
± I-Premise
6.5 I-Premise
% I-Premise
and I-Premise
37.5 I-Premise
± I-Premise
7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
while I-Premise
for I-Premise
patients I-Premise
3-6 I-Premise
years I-Premise
( I-Premise
n I-Premise
= I-Premise
34 I-Premise
, I-Premise
13.5 I-Premise
% I-Premise
of I-Premise
all I-Premise
enrolled I-Premise
patients I-Premise
) I-Premise
10-year I-Premise
EFS I-Premise
and I-Premise
OS I-Premise
were I-Premise
35 I-Premise
± I-Premise
8 I-Premise
% I-Premise
and I-Premise
36 I-Premise
± I-Premise
8 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Molecular B-Premise
marker I-Premise
analysis I-Premise
showed I-Premise
that I-Premise
a I-Premise
smaller I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
< I-Premise
3 I-Premise
years I-Premise
harbored I-Premise
TP53 I-Premise
mutations I-Premise
( I-Premise
P I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Analysis B-Premise
of I-Premise
QOL I-Premise
outcomes I-Premise
with I-Premise
a I-Premise
median I-Premise
length I-Premise
of I-Premise
follow-up I-Premise
of I-Premise
15.1 I-Premise
years I-Premise
( I-Premise
9.5-19.2 I-Premise
) I-Premise
showed I-Premise
comparable I-Premise
results I-Premise
. I-Premise

QOL B-Claim
and I-Claim
survival I-Claim
data I-Claim
were I-Claim
similar I-Claim
for I-Claim
the I-Claim
two I-Claim
groups I-Claim
. I-Claim

A B-Claim
larger I-Claim
prospective I-Claim
study I-Claim
is I-Claim
justified I-Claim
to I-Claim
study I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
chemotherapy I-Claim
only I-Claim
regimens I-Claim
in I-Claim
younger I-Claim
children I-Claim
. I-Claim

Debilitating B-Claim
hot I-Claim
flushes I-Claim
and I-Claim
sleep I-Claim
dysfunction I-Claim
often I-Claim
affect I-Claim
survivors I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
most I-Claim
notably I-Claim
in I-Claim
those I-Claim
taking I-Claim
anti-oestrogen I-Claim
medications I-Claim
. I-Claim

Conventional B-Claim
treatments I-Claim
have I-Claim
been I-Claim
only I-Claim
partially I-Claim
effective I-Claim
in I-Claim
diminishing I-Claim
these I-Claim
issues I-Claim
, I-Claim
and I-Claim
some I-Claim
have I-Claim
serious I-Claim
risks I-Claim
. I-Claim

We O
did O
a O
pilot O
study O
to O
investigate O
our O
hypothesis O
that O
stellate-ganglion O
block O
can O
be O
a O
safe O
and O
effective O
treatment O
for O
hot O
flushes O
and O
sleep O
dysfunction O
in O
this O
patient O
population O
. O

13 O
survivors O
of O
breast O
cancer O
( O
in O
remission O
) O
with O
severe O
hot O
flushes O
and O
night O
awakenings O
were O
treated O
with O
stellate-ganglion O
block O
at O
the O
anterolateral O
aspect O
of O
the O
C6 O
vertebra O
on O
the O
right O
side O
under O
fluoroscopy O
. O

Patients O
recorded O
hot O
flushes O
in O
a O
daily O
diary O
by O
use O
of O
the O
Hot-Flash O
Score O
, O
devised O
by O
Sloan O
and O
colleagues O
, O
and O
night O
awakenings O
by O
use O
of O
the O
Pittsburgh O
Sleep O
Quality O
Index O
. O

Both O
instruments O
were O
used O
1 O
week O
before O
the O
procedure O
[ O
A40 O
] O
and O
then O
weekly O
after O
the O
procedure O
for O
12 O
weeks O
. O

We O
used O
the O
generalised-estimating-equations O
method O
to O
analyse O
the O
longitudinal O
measurements O
of O
the O
number O
of O
hot O
flushes O
and O
night O
awakenings O
over O
time O
. O

This O
method O
is O
a O
popular O
approach O
to O
analysing O
datasets O
that O
have O
repeated O
measures O
from O
the O
same O
person O
, O
and O
is O
robust O
because O
it O
does O
not O
need O
the O
complete O
distribution O
of O
the O
outcomes O
to O
be O
specified O
. O

This O
trial O
is O
registered O
on O
the O
International O
Standard O
Randomised O
Controlled O
Trial O
Number O
register O
( O
ISRCTN14318565 O
) O
. O

There O
were O
no O
adverse O
events O
resulting O
from O
the O
stellate-ganglion O
block O
, O
although O
patients O
had O
temporary O
Horner O
's O
syndrome O
indicating O
the O
effectiveness O
of O
the O
block O
. O

Five O
patients O
had O
only O
one O
stellate-ganglion O
block O
and O
eight O
had O
two O
stellate-ganglion O
blocks O
. O

The B-Premise
total I-Premise
number I-Premise
of I-Premise
hot I-Premise
flushes I-Premise
decreased I-Premise
from I-Premise
a I-Premise
mean I-Premise
of I-Premise
79.4 I-Premise
( I-Premise
SD I-Premise
37.4 I-Premise
) I-Premise
per I-Premise
week I-Premise
before I-Premise
the I-Premise
procedure I-Premise
to I-Premise
a I-Premise
mean I-Premise
of I-Premise
49.9 I-Premise
( I-Premise
SD I-Premise
39.9 I-Premise
) I-Premise
per I-Premise
week I-Premise
during I-Premise
the I-Premise
first I-Premise
2 I-Premise
weeks I-Premise
after I-Premise
the I-Premise
procedure I-Premise
( I-Premise
p=0.0002 I-Premise
) I-Premise
. I-Premise

The B-Premise
total I-Premise
number I-Premise
of I-Premise
hot I-Premise
flushes I-Premise
continued I-Premise
to I-Premise
decrease I-Premise
over I-Premise
the I-Premise
remaining I-Premise
follow-up I-Premise
period I-Premise
( I-Premise
weeks I-Premise
3-12 I-Premise
) I-Premise
, I-Premise
and I-Premise
stabilised I-Premise
at I-Premise
a I-Premise
mean I-Premise
of I-Premise
8.1 I-Premise
( I-Premise
SD I-Premise
5.6 I-Premise
) I-Premise
per I-Premise
week I-Premise
( I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
number I-Premise
of I-Premise
very I-Premise
severe I-Premise
hot I-Premise
flushes I-Premise
was I-Premise
decreased I-Premise
to I-Premise
near I-Premise
zero I-Premise
by I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
follow-up I-Premise
period I-Premise
( I-Premise
week I-Premise
12 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

Night B-Premise
awakenings I-Premise
decreased I-Premise
from I-Premise
a I-Premise
mean I-Premise
of I-Premise
19.5 I-Premise
( I-Premise
SD I-Premise
14.8 I-Premise
) I-Premise
per I-Premise
week I-Premise
before I-Premise
the I-Premise
procedure I-Premise
to I-Premise
a I-Premise
mean I-Premise
of I-Premise
7.3 I-Premise
( I-Premise
SD I-Premise
7.1 I-Premise
) I-Premise
per I-Premise
week I-Premise
during I-Premise
the I-Premise
first I-Premise
2 I-Premise
weeks I-Premise
after I-Premise
the I-Premise
procedure I-Premise
( I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
total I-Premise
number I-Premise
of I-Premise
night I-Premise
awakenings I-Premise
continued I-Premise
to I-Premise
decrease I-Premise
over I-Premise
the I-Premise
remaining I-Premise
follow-up I-Premise
period I-Premise
( I-Premise
weeks I-Premise
3-12 I-Premise
) I-Premise
and I-Premise
stabilised I-Premise
at I-Premise
a I-Premise
mean I-Premise
of I-Premise
1.4 I-Premise
( I-Premise
SD I-Premise
1.2 I-Premise
) I-Premise
per I-Premise
week I-Premise
( I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

The B-Claim
findings I-Claim
of I-Claim
this I-Claim
study I-Claim
suggest I-Claim
that I-Claim
stellate-ganglion I-Claim
block I-Claim
can I-Claim
provide I-Claim
survivors I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
with I-Claim
relief I-Claim
from I-Claim
hot I-Claim
flushes I-Claim
and I-Claim
sleep I-Claim
dysfunction I-Claim
with I-Claim
few I-Claim
or I-Claim
no I-Claim
side-effects I-Claim
. I-Claim

Long-term B-Claim
relief I-Claim
of I-Claim
symptoms I-Claim
has I-Claim
the I-Claim
potential I-Claim
to I-Claim
improve I-Claim
overall I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
increase I-Claim
compliance I-Claim
with I-Claim
anti-oestrogen I-Claim
medications I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

One O
attempt O
to O
improve O
long-term O
survival O
in O
patients O
with O
advanced O
ovarian O
cancer O
was O
thought O
to O
be O
the O
addition O
of O
more O
non-cross-resistant O
drugs O
to O
platinum-paclitaxel O
combination O
regimens O
. O

Gemcitabine O
was O
among O
the O
candidates O
for O
a O
third O
drug O
. O

We O
performed O
a O
prospective O
, O
randomized O
, O
phase O
III O
, O
intergroup O
trial O
to O
compare O
carboplatin O
plus O
paclitaxel O
( O
TC O
";" O
area O
under O
the O
curve O
[ O
AUC O
] O
5 O
and O
175 O
mg/m O
( O
2 O
) O
, O
respectively O
) O
with O
the O
same O
combination O
and O
additional O
gemcitabine O
800 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
( O
TCG O
) O
in O
previously O
untreated O
patients O
with O
advanced O
epithelial O
ovarian O
cancer O
. O

TC O
was O
administered O
intravenously O
( O
IV O
) O
on O
day O
1 O
every O
21 O
days O
for O
a O
planned O
minimum O
of O
six O
courses O
. O

Gemcitabine O
was O
administered O
by O
IV O
on O
days O
1 O
and O
8 O
of O
each O
cycle O
in O
the O
TCG O
arm O
. O

Between O
2002 O
and O
2004 O
, O
1,742 O
patients O
were O
randomly O
assigned O
";" O
882 O
and O
860 O
patients O
received O
TC O
and O
TCG O
, O
respectively O
. O

Grades B-Premise
3 I-Premise
to I-Premise
4 I-Premise
hematologic I-Premise
toxicity I-Premise
and I-Premise
fatigue I-Premise
occurred I-Premise
more I-Premise
frequently I-Premise
in I-Premise
the I-Premise
TCG I-Premise
arm I-Premise
. I-Premise

Accordingly O
, O
quality-of-life B-Claim
analysis I-Claim
during I-Claim
chemotherapy I-Claim
showed I-Claim
a I-Claim
disadvantage I-Claim
in I-Claim
the I-Claim
TCG I-Claim
arm I-Claim
. I-Claim

Although B-Premise
objective I-Premise
response I-Premise
was I-Premise
slightly I-Premise
higher I-Premise
in I-Premise
the I-Premise
TCG I-Premise
arm I-Premise
, I-Premise
this B-Premise
did I-Premise
not I-Premise
translate I-Premise
into I-Premise
improved I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
or I-Premise
overall I-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
. I-Premise

Median B-Premise
PFS I-Premise
was I-Premise
17.8 I-Premise
months I-Premise
for I-Premise
the I-Premise
TCG I-Premise
arm I-Premise
and I-Premise
19.3 I-Premise
months I-Premise
for I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1.18 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.06 I-Premise
to I-Premise
1.32 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0044 I-Premise
) I-Premise
. I-Premise

Median B-Premise
OS I-Premise
was I-Premise
49.5 I-Premise
for I-Premise
the I-Premise
TCG I-Premise
arm I-Premise
and I-Premise
51.5 I-Premise
months I-Premise
for I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.05 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.91 I-Premise
to I-Premise
1.20 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.5106 I-Premise
) I-Premise
. I-Premise

The B-Claim
addition I-Claim
of I-Claim
gemcitabine I-Claim
to I-Claim
carboplatin I-Claim
plus I-Claim
paclitaxel I-Claim
increased I-Claim
treatment I-Claim
burden I-Claim
, I-Claim
reduced I-Claim
PFS I-Claim
time I-Claim
, I-Claim
and I-Claim
did I-Claim
not I-Claim
improve I-Claim
OS I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
epithelial I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

Therefore B-Claim
, I-Claim
we I-Claim
recommend I-Claim
no I-Claim
additional I-Claim
clinical I-Claim
use I-Claim
of I-Claim
TCG I-Claim
in I-Claim
this I-Claim
population I-Claim
. I-Claim

The O
CO.20 O
trial O
randomized O
patients O
with O
K-RAS O
wild-type O
, O
chemotherapy-refractory O
, O
metastatic O
colorectal O
cancer O
to O
receive O
cetuximab O
( O
CET O
) O
plus O
brivanib O
alaninate O
( O
BRIV O
) O
or O
CET O
plus O
placebo O
( O
CET/placebo O
) O
. O

Quality O
of O
life O
( O
QoL O
) O
was O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
at O
baseline O
and O
at O
2 O
, O
4 O
, O
6 O
, O
8 O
, O
12 O
, O
16 O
, O
and O
24 O
weeks O
until O
disease O
progression O
. O

Predefined O
coprimary O
QoL O
endpoints O
were O
time O
to O
deterioration O
( O
first O
worsening O
from O
baseline O
of O
≥ O
10 O
points O
) O
on O
the O
Physical O
Function O
( O
PF O
) O
and O
Global O
( O
GHS O
) O
scales O
. O

Of O
750 O
randomized O
patients O
, O
721 O
( O
358 O
of O
whom O
received O
CET/BRIV O
) O
were O
assessable O
for O
QoL O
. O

QoL O
compliance O
and O
baseline O
PF O
and O
GHS O
scores O
did O
not O
differ O
by O
treatment O
arm O
. O

The B-Premise
median I-Premise
time I-Premise
to I-Premise
deterioration I-Premise
was I-Premise
1.6 I-Premise
months I-Premise
versus I-Premise
1.1 I-Premise
months I-Premise
for I-Premise
GHS I-Premise
( I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
and I-Premise
5.6 I-Premise
months I-Premise
versus I-Premise
1.7 I-Premise
months I-Premise
for I-Premise
PF I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
favoring I-Premise
CET/placebo I-Premise
. I-Premise

Secondary B-Premise
analysis I-Premise
favored I-Premise
CET/placebo I-Premise
for I-Premise
QOL I-Premise
response I-Premise
on I-Premise
the I-Premise
PF I-Premise
, I-Premise
Cognitive I-Premise
Function I-Premise
, I-Premise
Fatigue I-Premise
, I-Premise
Nausea I-Premise
, I-Premise
Appetite I-Premise
, I-Premise
and I-Premise
Diarrhea I-Premise
scales I-Premise
. I-Premise

A B-Premise
greater I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
on I-Premise
the I-Premise
CET/BRIV I-Premise
arm I-Premise
had I-Premise
PF I-Premise
worsening I-Premise
at I-Premise
6 I-Premise
weeks I-Premise
( I-Premise
31 I-Premise
% I-Premise
vs I-Premise
17 I-Premise
% I-Premise
) I-Premise
. I-Premise

Clinical B-Premise
adverse I-Premise
events I-Premise
of I-Premise
≥ I-Premise
grade I-Premise
3 I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
CET/BRIV I-Premise
than I-Premise
with I-Premise
CET/placebo I-Premise
, I-Premise
including I-Premise
fatigue I-Premise
( I-Premise
25 I-Premise
% I-Premise
vs I-Premise
11 I-Premise
% I-Premise
) I-Premise
, I-Premise
hypertension I-Premise
, I-Premise
rash I-Premise
, I-Premise
diarrhea I-Premise
, I-Premise
abdominal I-Premise
pain I-Premise
, I-Premise
dehydration I-Premise
, I-Premise
and I-Premise
anorexia I-Premise
. I-Premise

Compared B-Claim
with I-Claim
CET/placebo I-Claim
, I-Claim
the I-Claim
combination I-Claim
of I-Claim
CET/BRIV I-Claim
worsened I-Claim
time I-Claim
to I-Claim
QoL I-Claim
deterioration I-Claim
for I-Claim
patients I-Claim
with I-Claim
K-RAS I-Claim
wild-type I-Claim
, I-Claim
chemotherapy-refractory I-Claim
, I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
on I-Claim
the I-Claim
PF I-Claim
and I-Claim
GHS I-Claim
scales I-Claim
of I-Claim
European I-Claim
Organization I-Claim
for I-Claim
Research I-Claim
and I-Claim
Treatment I-Claim
of I-Claim
Cancer I-Claim
Quality I-Claim
of I-Claim
Life I-Claim
Questionnaire I-Claim
C30 I-Claim
. I-Claim

This B-Claim
result I-Claim
may I-Claim
be I-Claim
due I-Claim
to I-Claim
higher I-Claim
rates I-Claim
of I-Claim
fatigue I-Claim
and I-Claim
gastrointestinal I-Claim
adverse I-Claim
events I-Claim
. I-Claim

This O
study O
sought O
to O
continue O
research O
on O
psychosocial O
interventions O
for O
patients O
being O
treated O
with O
radiation O
therapy O
across O
multiple O
centers O
and O
to O
replicate O
positive O
findings O
of O
a O
single-center O
study O
of O
patients O
being O
treated O
with O
chemotherapy O
. O

The O
primary O
objective O
of O
this O
study O
was O
to O
determine O
if O
a O
stress O
management O
intervention O
was O
effective O
in O
improving O
quality O
of O
life O
and O
decreasing O
psychological O
distress O
in O
patients O
undergoing O
radiotherapy O
for O
cancer O
. O

A O
total O
of O
310 O
patients O
about O
to O
begin O
radiotherapy O
treatment O
were O
randomly O
assigned O
to O
receive O
usual O
care O
only O
or O
self-administered O
stress O
management O
training O
. O

Quality-of-life O
assessments O
occurred O
at O
baseline O
and O
for O
3 O
weeks O
after O
the O
beginning O
of O
radiotherapy O
treatment O
. O

Overall B-Premise
, I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
receive I-Premise
stress I-Premise
management I-Premise
training I-Premise
did I-Premise
not I-Premise
report I-Premise
significantly I-Premise
less I-Premise
psychological I-Premise
distress I-Premise
on I-Premise
the I-Premise
Medical I-Premise
Outcomes I-Premise
Study I-Premise
36-Item I-Premise
Short I-Premise
Form I-Premise
( I-Premise
SF-36 I-Premise
) I-Premise
Mental I-Premise
Component I-Premise
Summary I-Premise
Scale I-Premise
than I-Premise
did I-Premise
those I-Premise
assigned I-Premise
to I-Premise
usual I-Premise
care I-Premise
. I-Premise

When O
divided O
into O
subgroups O
based O
on O
the O
SF-36 O
Mental O
Component O
Summary O
Scale O
scores O
immediately O
after O
their O
first O
radiotherapy O
treatment O
, O
patients B-Premise
with I-Premise
above-average I-Premise
levels I-Premise
of I-Premise
psychological I-Premise
distress I-Premise
( I-Premise
scores I-Premise
< I-Premise
or I-Premise
= I-Premise
50 I-Premise
) I-Premise
who I-Premise
were I-Premise
randomly I-Premise
assigned I-Premise
to I-Premise
the I-Premise
intervention I-Premise
condition I-Premise
reported I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
their I-Premise
distress I-Premise
compared I-Premise
with I-Premise
those I-Premise
assigned I-Premise
to I-Premise
usual I-Premise
care I-Premise
only I-Premise
on I-Premise
the I-Premise
SF-36 I-Premise
Mental I-Premise
Health I-Premise
Subscale I-Premise
and I-Premise
the I-Premise
Center I-Premise
for I-Premise
Epidemiologic I-Premise
Studies I-Premise
Depression I-Premise
Scale I-Premise
. I-Premise

This B-Claim
study I-Claim
found I-Claim
that I-Claim
self-administered I-Claim
stress I-Claim
management I-Claim
training I-Claim
is I-Claim
effective I-Claim
only I-Claim
in I-Claim
those I-Claim
radiotherapy I-Claim
patients I-Claim
with I-Claim
initially I-Claim
higher I-Claim
levels I-Claim
of I-Claim
psychological I-Claim
distress I-Claim
. I-Claim

Additional B-Claim
research I-Claim
should I-Claim
examine I-Claim
the I-Claim
benefits I-Claim
of I-Claim
stress I-Claim
management I-Claim
training I-Claim
targeted I-Claim
specifically I-Claim
to I-Claim
patients I-Claim
experiencing I-Claim
heightened I-Claim
distress I-Claim
. I-Claim

Both O
Billroth O
I O
( O
B-I O
) O
and O
Roux-en-Y O
( O
R-Y O
) O
reconstructions O
are O
commonly O
performed O
as O
standard O
procedures O
, O
but O
it O
has O
yet O
to O
be O
determined O
which O
reconstruction O
is O
better O
for O
patients O
. O

A O
randomized O
prospective O
phase O
II O
trial O
with O
body O
weight O
loss O
at O
1 O
year O
after O
surgery O
as O
a O
primary O
endpoint O
was O
performed O
to O
address O
this O
issue O
. O

The O
current O
report O
delivers O
data O
on O
the O
quality O
of O
life O
and O
degree O
of O
postoperative O
dysfunction O
, O
which O
were O
the O
secondary O
endpoints O
of O
this O
study O
. O

Gastric O
cancer O
patients O
who O
underwent O
distal O
gastrectomy O
were O
intraoperatively O
randomized O
to O
B-I O
or O
R-Y O
. O

Postsurgical O
QOL O
was O
evaluated O
using O
the O
EORTC O
QLQ-C30 O
and O
DAUGS O
20 O
. O

Between O
August O
2005 O
and O
December O
2008 O
, O
332 O
patients O
were O
enrolled O
in O
a O
randomized O
trial O
comparing O
B-I O
versus O
R-Y O
. O

A O
mail O
survey O
questionnaire O
sent O
to O
327 O
patients O
was O
completed O
by O
268 O
( O
86.2 O
% O
) O
of O
them O
. O

EORTC O
QLQ-C30 O
scores O
were O
as O
follows O
: O
global O
health O
status O
was O
similar O
in O
each O
group O
( O
B-I O
73.5 O
± O
18.8 O
, O
R-Y O
73.2 O
± O
20.2 O
, O
p O
= O
0.87 O
) O
. O

Scores O
of O
five O
functional O
scales O
were O
also O
similar O
. O

Only B-Premise
the I-Premise
dyspnea I-Premise
symptom I-Premise
scale I-Premise
showed I-Premise
superior I-Premise
results I-Premise
for I-Premise
R-Y I-Premise
than I-Premise
for I-Premise
B-I I-Premise
( I-Premise
B-I I-Premise
13.6 I-Premise
± I-Premise
17.9 I-Premise
, I-Premise
R-Y I-Premise
8.6 I-Premise
± I-Premise
16.3 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

With B-Premise
respect I-Premise
to I-Premise
DAUGS I-Premise
20 I-Premise
, I-Premise
the I-Premise
total I-Premise
score I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
between I-Premise
the I-Premise
R-Y I-Premise
and I-Premise
B-I I-Premise
groups I-Premise
( I-Premise
24.8 I-Premise
vs. I-Premise
23.6 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.41 I-Premise
) I-Premise
. I-Premise

Only B-Premise
reflux I-Premise
symptoms I-Premise
were I-Premise
significantly I-Premise
worse I-Premise
for I-Premise
B-I I-Premise
than I-Premise
for I-Premise
R-Y I-Premise
( I-Premise
0.7 I-Premise
± I-Premise
0.6 I-Premise
vs. I-Premise
0.5 I-Premise
± I-Premise
0.6 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The B-Claim
B-I I-Claim
and I-Claim
R-Y I-Claim
techniques I-Claim
were I-Claim
generally I-Claim
equivalent I-Claim
in I-Claim
terms I-Claim
of I-Claim
postoperative I-Claim
QOL I-Claim
and I-Claim
dysfunction I-Claim
. I-Claim

Both B-Claim
procedures I-Claim
seem I-Claim
acceptable I-Claim
as I-Claim
standard I-Claim
reconstructions I-Claim
after I-Claim
distal I-Claim
gastrectomy I-Claim
with I-Claim
regard I-Claim
to I-Claim
postoperative I-Claim
QOL I-Claim
and I-Claim
dysfunction I-Claim
. I-Claim

Delirium B-Claim
is I-Claim
a I-Claim
serious I-Claim
and I-Claim
common I-Claim
postoperative I-Claim
complication I-Claim
, O
especially O
in O
frail O
elderly O
patients O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
a O
geriatric O
liaison O
intervention O
in O
comparison O
with O
standard O
care O
on O
the O
incidence O
of O
postoperative O
delirium O
in O
frail O
elderly O
cancer O
patients O
treated O
with O
an O
elective O
surgical O
procedure O
for O
a O
solid O
tumour O
. O

Patients O
over O
65 O
years O
of O
age O
who O
were O
undergoing O
elective O
surgery O
for O
a O
solid O
tumour O
were O
recruited O
to O
a O
multicentre O
, O
prospective O
, O
randomized O
, O
controlled O
trial O
. O

The O
patients O
were O
randomized O
to O
standard O
treatment O
versus O
a O
geriatric O
liaison O
intervention O
. O

The O
intervention O
consisted O
of O
a O
preoperative O
geriatric O
consultation O
, O
an O
individual O
treatment O
plan O
targeted O
at O
risk O
factors O
for O
delirium O
, O
daily O
visits O
by O
a O
geriatric O
nurse O
during O
the O
hospital O
stay O
and O
advice O
on O
managing O
any O
problems O
encountered O
. O

The O
primary O
outcome O
was O
the O
incidence O
of O
postoperative O
delirium O
. O

The O
secondary O
outcome O
measures O
were O
the O
severity O
of O
delirium O
, O
length O
of O
hospital O
stay O
, O
complications O
, O
mortality O
, O
care O
dependency O
, O
quality O
of O
life O
, O
return O
to O
an O
independent O
preoperative O
living O
situation O
and O
additional O
care O
at O
home O
. O

In O
total O
, O
the O
data O
of O
260 O
patients O
were O
analysed O
. O

Delirium B-Premise
occurred I-Premise
in I-Premise
31 I-Premise
patients I-Premise
( I-Premise
11.9 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
incidence I-Premise
of I-Premise
delirium I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
and I-Premise
the I-Premise
usual-care I-Premise
group I-Premise
( I-Premise
9.4 I-Premise
% I-Premise
vs. I-Premise
14.3 I-Premise
% I-Premise
, I-Premise
OR I-Premise
: I-Premise
0.63 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
0.29-1.35 I-Premise
) I-Premise
. I-Premise

Within B-Claim
this I-Claim
study I-Claim
, I-Claim
a I-Claim
geriatric I-Claim
liaison I-Claim
intervention I-Claim
based I-Claim
on I-Claim
frailty I-Claim
for I-Claim
the I-Claim
prevention I-Claim
of I-Claim
postoperative I-Claim
delirium I-Claim
in I-Claim
frail I-Claim
elderly I-Claim
cancer I-Claim
patients I-Claim
undergoing I-Claim
elective I-Claim
surgery I-Claim
for I-Claim
a I-Claim
solid I-Claim
tumour I-Claim
has I-Claim
not I-Claim
proven I-Claim
to I-Claim
be I-Claim
effective I-Claim
. I-Claim

To O
evaluate O
the O
efficacy O
and O
tolerability O
of O
two O
doses O
of O
gefitinib O
( O
Iressa O
[ O
ZD1839 O
] O
";" O
AstraZeneca O
, O
Wilmington O
, O
DE O
) O
, O
a O
novel O
epidermal O
growth O
factor O
receptor O
tyrosine O
kinase O
inhibitor O
, O
in O
patients O
with O
pretreated O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

This O
was O
a O
randomized O
, O
double-blind O
, O
parallel-group O
, O
multicenter O
phase O
II O
trial O
. O

Two O
hundred O
ten O
patients O
with O
advanced O
NSCLC O
who O
were O
previously O
treated O
with O
one O
or O
two O
chemotherapy O
regimens O
( O
at O
least O
one O
containing O
platinum O
) O
were O
randomly O
assigned O
to O
receive O
either O
250-mg O
or O
500-mg O
oral O
doses O
of O
gefitinib O
once O
daily O
. O

Efficacy B-Premise
was I-Premise
similar I-Premise
for I-Premise
the I-Premise
-250 I-Premise
and I-Premise
500-mg/d I-Premise
groups I-Premise
. I-Premise

Objective B-Premise
tumor I-Premise
response I-Premise
rates I-Premise
were I-Premise
18.4 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
11.5 I-Premise
to I-Premise
27.3 I-Premise
) I-Premise
and I-Premise
19.0 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12.1 I-Premise
to I-Premise
27.9 I-Premise
) I-Premise
";" I-Premise
among I-Premise
evaluable I-Premise
patients I-Premise
, I-Premise
symptom I-Premise
improvement I-Premise
rates I-Premise
were I-Premise
40.3 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
28.5 I-Premise
to I-Premise
53.0 I-Premise
) I-Premise
and I-Premise
37.0 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
26.0 I-Premise
to I-Premise
49.1 I-Premise
) I-Premise
";" I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
times I-Premise
were I-Premise
2.7 I-Premise
and I-Premise
2.8 I-Premise
months I-Premise
";" I-Premise
and I-Premise
median I-Premise
overall I-Premise
survival I-Premise
times I-Premise
were I-Premise
7.6 I-Premise
and I-Premise
8.0 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Symptom B-Premise
improvements I-Premise
were I-Premise
recorded I-Premise
for I-Premise
69.2 I-Premise
% I-Premise
( I-Premise
250 I-Premise
mg/d I-Premise
) I-Premise
and I-Premise
85.7 I-Premise
% I-Premise
( I-Premise
500 I-Premise
mg/d I-Premise
) I-Premise
of I-Premise
patients I-Premise
with I-Premise
a I-Premise
tumor I-Premise
response I-Premise
. I-Premise

Adverse B-Premise
events I-Premise
( I-Premise
AEs I-Premise
) I-Premise
at I-Premise
both I-Premise
dose I-Premise
levels I-Premise
were I-Premise
generally I-Premise
mild I-Premise
( I-Premise
grade I-Premise
1 I-Premise
or I-Premise
2 I-Premise
) I-Premise
and I-Premise
consisted I-Premise
mainly I-Premise
of I-Premise
skin I-Premise
reactions I-Premise
and I-Premise
diarrhea I-Premise
. I-Premise

Drug-related B-Premise
toxicities I-Premise
were I-Premise
more I-Premise
frequent I-Premise
in I-Premise
the I-Premise
higher-dose I-Premise
group I-Premise
. I-Premise

Withdrawal B-Premise
due I-Premise
to I-Premise
drug-related I-Premise
AEs I-Premise
was I-Premise
1.9 I-Premise
% I-Premise
and I-Premise
9.4 I-Premise
% I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
gefitinib I-Premise
250 I-Premise
and I-Premise
500 I-Premise
mg/d I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Gefitinib B-Claim
showed I-Claim
clinically I-Claim
meaningful I-Claim
antitumor I-Claim
activity I-Claim
and I-Claim
provided I-Claim
symptom I-Claim
relief I-Claim
as I-Claim
second- I-Claim
and I-Claim
third-line I-Claim
treatment I-Claim
in I-Claim
these I-Claim
patients I-Claim
. I-Claim

At B-Claim
250 I-Claim
mg/d I-Claim
, I-Claim
gefitinib I-Claim
had I-Claim
a I-Claim
favorable I-Claim
AE I-Claim
profile I-Claim
. I-Claim

Gefitinib B-Claim
250 I-Claim
mg/d I-Claim
is I-Claim
an I-Claim
important I-Claim
, I-Claim
novel I-Claim
treatment I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
pretreated I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Data O
from O
experimental O
studies O
suggest O
that O
octreotide B-Claim
, I-Claim
the I-Claim
long I-Claim
acting I-Claim
somatostatin I-Claim
analogue I-Claim
, I-Claim
improves I-Claim
survival I-Claim
of I-Claim
animals I-Claim
with I-Claim
pancreatic I-Claim
cancer I-Claim
. I-Claim

To O
assess O
the O
antitumour O
effect O
of O
octreotide O
, O
a O
randomized O
trial O
was O
performed O
comparing O
octreotide O
with O
supportive O
care O
in O
advanced O
pancreatic O
cancer O
patients O
. O

All O
patients O
, O
aged O
59-75 O
years O
, O
were O
not O
liable O
to O
radical O
surgical O
treatment O
and O
were O
not O
submitted O
to O
other O
treatments O
( O
chemo O
and/or O
radiotherapy O
) O
. O

Six O
patients O
were O
enrolled O
, O
4 O
of O
these O
treated O
with O
octreotide O
( O
500 O
micrograms O
two O
times O
a O
day O
subcutaneous O
for O
six O
months O
) O
and O
the O
other O
2 O
were O
inserted O
a O
control O
group O
. O

The B-Premise
patients I-Premise
treated I-Premise
with I-Premise
octreotide I-Premise
showed I-Premise
a I-Premise
significant I-Premise
advantage I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
restored I-Premise
appetite I-Premise
, I-Premise
improvement I-Premise
of I-Premise
digestion I-Premise
and I-Premise
intestine I-Premise
function I-Premise
, I-Premise
remission I-Premise
of I-Premise
abdominal I-Premise
pain I-Premise
and I-Premise
preservation I-Premise
of I-Premise
baseline I-Premise
body I-Premise
weight I-Premise
) I-Premise
with I-Premise
a I-Premise
mean I-Premise
> I-Premise
80 I-Premise
of I-Premise
karnofsky I-Premise
performance I-Premise
score I-Premise
. I-Premise

Monitoring B-Premise
of I-Premise
tumour I-Premise
size I-Premise
changes I-Premise
( I-Premise
US-TC I-Premise
) I-Premise
over I-Premise
the I-Premise
6 I-Premise
months I-Premise
study I-Premise
period I-Premise
, I-Premise
showed I-Premise
slackened I-Premise
neoplastic I-Premise
growth I-Premise
in I-Premise
all I-Premise
treated I-Premise
patients I-Premise
, I-Premise
whereas B-Premise
neoplasm I-Premise
grew I-Premise
according I-Premise
to I-Premise
an I-Premise
almost I-Premise
exponential I-Premise
trend I-Premise
in I-Premise
untreated I-Premise
patients I-Premise
. O

Also O
survival B-Premise
was I-Premise
better I-Premise
in I-Premise
treated I-Premise
patients I-Premise
: O
in O
particular O
, O
2 O
patients O
out O
of O
4 O
who O
completed O
the O
study O
underwent O
follow-up O
until O
they O
died O
12 O
and O
16 O
months O
after O
beginning O
of O
treatment O
, O
respectively O
. O

Karnofsky B-Premise
performance I-Premise
score I-Premise
was I-Premise
particularly I-Premise
high I-Premise
in I-Premise
both I-Premise
patients I-Premise
. I-Premise

This O
supports O
the O
view O
that O
octreotide B-Claim
is I-Claim
endowed I-Claim
with I-Claim
antiproliferative I-Claim
activity I-Claim
. I-Claim

In O
conclusion O
octreotide B-Claim
therapy I-Claim
seems I-Claim
to I-Claim
confer I-Claim
a I-Claim
survival I-Claim
benefit I-Claim
and I-Claim
a I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
advanced I-Claim
pancreatic I-Claim
tumour I-Claim
. I-Claim

Additional O
studies O
are O
needed O
to O
confirm O
these O
results O
and O
to O
clarify O
other O
questions O
about O
dose O
and O
somatostatin O
receptors O
in O
this O
kind O
of O
tumour O
. O

To O
determine O
the O
safety O
and O
efficacy O
of O
oral O
bexarotene O
( O
Targretin O
capsules O
";" O
Ligand O
Pharmaceuticals O
Incorporated O
, O
San O
Diego O
, O
Calif O
) O
. O

The O
effects O
of O
2 O
randomized O
doses O
of O
6.5 O
mg/m O
( O
2 O
) O
per O
day O
( O
with O
crossover O
for O
progression O
) O
vs O
650 O
mg/m O
( O
2 O
) O
per O
day O
( O
later O
modified O
to O
300 O
mg/m O
( O
2 O
) O
per O
day O
) O
were O
evaluated O
in O
an O
open-label O
, O
multicenter O
, O
phase O
2 O
and O
3 O
study O
conducted O
between O
February O
1997 O
and O
November O
1998 O
. O

Eighteen O
international O
cutaneous O
T-cell O
lymphoma O
clinics O
at O
academic O
referral O
centers O
. O

Fifty-eight O
patients O
with O
biopsy-proven O
stage O
IA O
through O
IIA O
cutaneous O
T-cell O
lymphoma O
that O
was O
refractory O
to O
( O
or O
patients O
were O
intolerant O
of O
) O
treatment O
or O
had O
reached O
at O
least O
a O
6-month O
response O
plateau O
under O
at O
least O
2 O
forms O
of O
prior O
therapy O
( O
median O
of O
3.5 O
prior O
therapies O
) O
. O

Bexarotene O
( O
Targretin O
capsules O
) O
administered O
once O
daily O
with O
meal O
for O
16 O
weeks O
or O
longer O
. O

Primary O
end O
point O
classification O
of O
overall O
response O
rate O
of O
complete O
and O
partial O
remissions O
determined O
by O
either O
the O
Physician O
's O
Global O
Assessment O
of O
Clinical O
Condition O
or O
the O
objective O
Composite O
Assessment O
of O
Index O
Lesion O
Severity O
. O

Body O
surface O
area O
, O
time O
to O
response O
, O
duration O
of O
disease O
control O
, O
time O
to O
disease O
progression O
, O
individual O
index O
lesion O
signs O
and O
symptoms O
, O
and O
quality O
of O
life O
parameters O
were O
secondary O
outcomes O
. O

Responses B-Premise
( I-Premise
> I-Premise
or I-Premise
= I-Premise
50 I-Premise
% I-Premise
improvement I-Premise
) I-Premise
were I-Premise
seen I-Premise
in I-Premise
3 I-Premise
( I-Premise
20 I-Premise
% I-Premise
) I-Premise
of I-Premise
15 I-Premise
patients I-Premise
with I-Premise
an I-Premise
initial I-Premise
dose I-Premise
at I-Premise
6.5 I-Premise
mg/m I-Premise
( I-Premise
2 I-Premise
) I-Premise
per I-Premise
day I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
0 I-Premise
% I-Premise
-40 I-Premise
% I-Premise
) I-Premise
, I-Premise
15 I-Premise
( I-Premise
54 I-Premise
% I-Premise
) I-Premise
of I-Premise
28 I-Premise
patients I-Premise
at I-Premise
300 I-Premise
mg/m I-Premise
( I-Premise
2 I-Premise
) I-Premise
per I-Premise
day I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
35 I-Premise
% I-Premise
-72 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
10 I-Premise
( I-Premise
67 I-Premise
% I-Premise
) I-Premise
of I-Premise
15 I-Premise
patients I-Premise
at I-Premise
above I-Premise
300 I-Premise
mg/m I-Premise
( I-Premise
2 I-Premise
) I-Premise
per I-Premise
day I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
43 I-Premise
% I-Premise
-91 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
progressive I-Premise
disease I-Premise
was I-Premise
47 I-Premise
% I-Premise
, I-Premise
21 I-Premise
% I-Premise
, I-Premise
and I-Premise
13 I-Premise
% I-Premise
at I-Premise
the I-Premise
same I-Premise
dose I-Premise
levels I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Eight B-Premise
( I-Premise
73 I-Premise
% I-Premise
) I-Premise
of I-Premise
11 I-Premise
patients I-Premise
crossing I-Premise
over I-Premise
from I-Premise
6.5 I-Premise
mg/m I-Premise
( I-Premise
2 I-Premise
) I-Premise
per I-Premise
day I-Premise
to I-Premise
higher I-Premise
doses I-Premise
subsequently I-Premise
responded I-Premise
. I-Premise

The B-Premise
median I-Premise
duration I-Premise
of I-Premise
response I-Premise
from I-Premise
start I-Premise
of I-Premise
therapy I-Premise
could I-Premise
not I-Premise
be I-Premise
estimated I-Premise
for I-Premise
the I-Premise
15 I-Premise
patients I-Premise
at I-Premise
300 I-Premise
mg/m I-Premise
( I-Premise
2 I-Premise
) I-Premise
per I-Premise
day I-Premise
owing I-Premise
to I-Premise
low I-Premise
relapse I-Premise
rates I-Premise
in I-Premise
2 I-Premise
patients I-Premise
( I-Premise
13 I-Premise
% I-Premise
) I-Premise
";" I-Premise
at I-Premise
higher I-Premise
doses I-Premise
it I-Premise
was I-Premise
516 I-Premise
days I-Premise
. I-Premise

The B-Premise
following I-Premise
drug-related I-Premise
adverse I-Premise
effects I-Premise
were I-Premise
reversible I-Premise
and I-Premise
treatable I-Premise
: I-Premise
hypertriglyceridemia I-Premise
( I-Premise
46 I-Premise
patients I-Premise
[ I-Premise
79 I-Premise
% I-Premise
] I-Premise
) I-Premise
, I-Premise
hypercholesterolemia I-Premise
( I-Premise
28 I-Premise
patients I-Premise
[ I-Premise
48 I-Premise
% I-Premise
] I-Premise
) I-Premise
, I-Premise
headache I-Premise
( I-Premise
27 I-Premise
patients I-Premise
[ I-Premise
47 I-Premise
% I-Premise
] I-Premise
) I-Premise
, I-Premise
central I-Premise
hypothyroidism I-Premise
( I-Premise
23 I-Premise
patients I-Premise
[ I-Premise
40 I-Premise
% I-Premise
] I-Premise
) I-Premise
, I-Premise
asthenia I-Premise
( I-Premise
21 I-Premise
patients I-Premise
[ I-Premise
36 I-Premise
% I-Premise
] I-Premise
) I-Premise
, I-Premise
and I-Premise
leukopenia I-Premise
( I-Premise
16 I-Premise
patients I-Premise
[ I-Premise
28 I-Premise
% I-Premise
] I-Premise
) I-Premise
. I-Premise

No B-Premise
cases I-Premise
of I-Premise
drug-related I-Premise
neutropenic I-Premise
fever I-Premise
, I-Premise
sepsis I-Premise
, I-Premise
or I-Premise
death I-Premise
occurred I-Premise
. I-Premise

Pancreatitis B-Premise
occurred I-Premise
in I-Premise
3 I-Premise
patients I-Premise
with I-Premise
triglyceride I-Premise
levels I-Premise
higher I-Premise
than I-Premise
14.69 I-Premise
mmol/L I-Premise
( I-Premise
1300 I-Premise
mg/dL I-Premise
) I-Premise
, I-Premise
all I-Premise
of I-Premise
whom I-Premise
were I-Premise
taking I-Premise
300 I-Premise
mg/m I-Premise
( I-Premise
2 I-Premise
) I-Premise
or I-Premise
more I-Premise
of I-Premise
oral I-Premise
bexarotene I-Premise
per I-Premise
day I-Premise
. I-Premise

Bexarotene B-Claim
( I-Claim
Targretin I-Claim
capsules I-Claim
) I-Claim
( I-Claim
the I-Claim
first I-Claim
retinoid I-Claim
X I-Claim
receptor-selective I-Claim
rexinoid I-Claim
) I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
effective I-Claim
as I-Claim
an I-Claim
oral I-Claim
treatment I-Claim
for I-Claim
15 I-Claim
( I-Claim
54 I-Claim
% I-Claim
) I-Claim
of I-Claim
28 I-Claim
patients I-Claim
with I-Claim
refractory I-Claim
or I-Claim
persistent I-Claim
early-stage I-Claim
cutaneous I-Claim
T-cell I-Claim
lymphoma I-Claim
at I-Claim
doses I-Claim
of I-Claim
300 I-Claim
mg/m I-Claim
( I-Claim
2 I-Claim
) I-Claim
per I-Claim
day I-Claim
. I-Claim

Hypertriglyceridemia B-Claim
and I-Claim
hypothyroidism I-Claim
require I-Claim
monitoring I-Claim
but I-Claim
are I-Claim
reversible I-Claim
and I-Claim
manageable I-Claim
with I-Claim
concomitant I-Claim
medication I-Claim
. I-Claim

The O
primary O
goal O
of O
this O
study O
was O
to O
evaluate O
the O
feasibility O
and O
effectiveness O
of O
a O
structured O
, O
multidisciplinary O
intervention O
targeted O
to O
maintain O
the O
overall O
quality O
of O
life O
( O
QOL O
) O
, O
which O
is O
more O
comprehensive O
than O
psychosocial O
distress O
, O
of O
patients O
undergoing O
radiation O
therapy O
for O
advanced-stage O
cancer O
. O

Radiation O
therapy O
patients O
with O
advanced O
cancer O
and O
an O
estimated O
5-year O
survival O
rate O
of O
0 O
% O
to O
50 O
% O
were O
randomly O
assigned O
to O
either O
an O
eight-session O
structured O
multidisciplinary O
intervention O
arm O
or O
a O
standard O
care O
arm O
. O

The O
eight O
90-minute O
sessions O
addressed O
the O
five O
domains O
of O
QOL O
including O
cognitive O
, O
physical O
, O
emotional O
, O
spiritual O
, O
and O
social O
functioning O
. O

The O
primary O
end O
point O
of O
maintaining O
overall O
QOL O
was O
assessed O
by O
a O
single-item O
linear O
analog O
scale O
( O
Linear O
Analog O
Scale O
of O
Assessment O
or O
modified O
Spitzer O
Uniscale O
) O
. O

QOL O
was O
assessed O
at O
baseline O
, O
week O
4 O
( O
end O
of O
multidisciplinary O
intervention O
) O
, O
week O
8 O
, O
and O
week O
27 O
. O

Of B-Premise
the I-Premise
103 I-Premise
participants I-Premise
, I-Premise
overall I-Premise
QOL I-Premise
at I-Premise
week I-Premise
4 I-Premise
was I-Premise
maintained I-Premise
by I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
intervention I-Premise
( I-Premise
n I-Premise
= I-Premise
49 I-Premise
) I-Premise
, I-Premise
whereas I-Premise
QOL I-Premise
at I-Premise
week I-Premise
4 I-Premise
significantly I-Premise
decreased I-Premise
for I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
54 I-Premise
) I-Premise
. I-Premise

This B-Premise
change I-Premise
reflected I-Premise
a I-Premise
3-point I-Premise
increase I-Premise
from I-Premise
baseline I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
and I-Premise
a I-Premise
9-point I-Premise
decrease I-Premise
from I-Premise
baseline I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
. I-Premise

Intervention B-Premise
participants I-Premise
maintained I-Premise
their I-Premise
QOL I-Premise
, I-Premise
and I-Premise
controls I-Premise
gradually I-Premise
returned I-Premise
to I-Premise
baseline I-Premise
by I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
6-month I-Premise
follow-up I-Premise
period I-Premise
. I-Premise

Although B-Claim
intervention I-Claim
participants I-Claim
maintained I-Claim
and I-Claim
actually I-Claim
improved I-Claim
their I-Claim
QOL I-Claim
during I-Claim
radiation I-Claim
therapy I-Claim
, I-Claim
control I-Claim
participants I-Claim
experienced I-Claim
a I-Claim
significant I-Claim
decrease I-Claim
in I-Claim
their I-Claim
QOL I-Claim
. O

Thus B-Claim
, I-Claim
a I-Claim
structured I-Claim
multidisciplinary I-Claim
intervention I-Claim
can I-Claim
help I-Claim
maintain I-Claim
or I-Claim
even I-Claim
improve I-Claim
QOL I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
who I-Claim
are I-Claim
undergoing I-Claim
cancer I-Claim
treatment I-Claim
. I-Claim

Major O
depressive O
disorder O
develops O
in O
up O
to O
half O
the O
patients O
undergoing O
treatment O
for O
head O
and O
neck O
cancer O
, O
resulting O
in O
significant O
morbidity O
";" O
therefore O
, O
preventing O
depression O
during O
cancer O
treatment O
may O
be O
of O
great O
benefit O
. O

To O
determine O
whether O
prophylactic O
use O
of O
the O
antidepressant O
escitalopram O
oxalate O
would O
decrease O
the O
incidence O
of O
depression O
in O
patients O
receiving O
primary O
therapy O
for O
head O
and O
neck O
cancer O
. O

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
escitalopram O
vs O
placebo O
was O
conducted O
in O
a O
group O
of O
nondepressed O
patients O
diagnosed O
as O
having O
head O
and O
neck O
cancer O
who O
were O
about O
to O
enter O
cancer O
treatment O
. O

Patients O
were O
stratified O
by O
sex O
, O
site O
, O
stage O
( O
early O
vs O
advanced O
) O
, O
and O
primary O
modality O
of O
treatment O
( O
radiation O
vs O
surgery O
) O
. O

The O
primary O
outcome O
measure O
was O
the O
number O
of O
participants O
who O
developed O
moderate O
or O
greater O
depression O
( O
scores O
on O
the O
Quick O
Inventory O
of O
Depressive O
Symptomology-Self O
Rated O
of O
≥11 O
) O
. O

From O
January O
6 O
, O
2008 O
, O
to O
December O
28 O
, O
2011 O
, O
148 O
patients O
were O
randomized O
. O

Significantly B-Premise
fewer I-Premise
patients I-Premise
receiving I-Premise
escitalopram I-Premise
developed I-Premise
depression I-Premise
( I-Premise
24.6 I-Premise
% I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
vs I-Premise
10.0 I-Premise
% I-Premise
in I-Premise
the I-Premise
escitalopram I-Premise
group I-Premise
";" I-Premise
stratified I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
. I-Premise

A O
Cox O
proportional O
hazards O
regression O
model O
compared O
the O
2 O
treatment O
groups O
after O
controlling O
for O
age O
, O
baseline O
smoking O
status O
, O
and O
stratification O
variables O
. O

The B-Premise
hazard I-Premise
ratio I-Premise
of I-Premise
0.37 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.14-0.96 I-Premise
) I-Premise
demonstrated I-Premise
an I-Premise
advantage I-Premise
of I-Premise
escitalopram I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
undergoing I-Premise
radiotherapy I-Premise
as I-Premise
the I-Premise
initial I-Premise
modality I-Premise
were I-Premise
significantly I-Premise
more I-Premise
likely I-Premise
to I-Premise
develop I-Premise
depression I-Premise
than I-Premise
those I-Premise
undergoing I-Premise
surgery I-Premise
( I-Premise
radiotherapy I-Premise
compared I-Premise
with I-Premise
surgery I-Premise
group I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
3.6 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.38-9.40 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
escitalopram I-Premise
group I-Premise
who I-Premise
completed I-Premise
the I-Premise
study I-Premise
and I-Premise
were I-Premise
not I-Premise
depressed I-Premise
rated I-Premise
their I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
as I-Premise
significantly I-Premise
better I-Premise
for I-Premise
3 I-Premise
consecutive I-Premise
months I-Premise
after I-Premise
cessation I-Premise
of I-Premise
drug I-Premise
use I-Premise
. I-Premise

In B-Claim
nondepressed I-Claim
patients I-Claim
undergoing I-Claim
treatment I-Claim
for I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
, I-Claim
prophylactic I-Claim
escitalopram I-Claim
reduced I-Claim
the I-Claim
risk I-Claim
of I-Claim
developing I-Claim
depression I-Claim
by I-Claim
more I-Claim
than I-Claim
50 I-Claim
% I-Claim
. I-Claim

In B-Claim
nondepressed I-Claim
patients I-Claim
who I-Claim
completed I-Claim
the I-Claim
trial I-Claim
, I-Claim
quality I-Claim
of I-Claim
life I-Claim
was I-Claim
also I-Claim
significantly I-Claim
better I-Claim
for I-Claim
3 I-Claim
consecutive I-Claim
months I-Claim
after I-Claim
cessation I-Claim
of I-Claim
drug I-Claim
use I-Claim
in I-Claim
the I-Claim
escitalopram I-Claim
group I-Claim
. I-Claim

These B-Claim
findings I-Claim
have I-Claim
important I-Claim
implications I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
patients I-Claim
with I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
. I-Claim

In O
a O
prospective O
randomized O
study O
, O
287 O
patients O
with O
advanced O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
stage O
IIIb O
or O
IV O
with O
ECOG O
performance O
status O
( O
PS O
) O
0-1 O
or O
2 O
were O
randomly O
assigned O
to O
receive O
either O
best O
supportive O
care O
( O
BSC O
) O
or O
supportive O
care O
plus O
combination O
chemotherapy O
( O
IEP O
regimen O
: O
ifosfamide O
3 O
gm/m2 O
IV O
with O
mesna O
uroprotection O
, O
epirubicin O
60 O
mg/m2 O
IV O
on O
day O
1 O
and O
cisplatin O
60 O
mg/m2 O
IV O
on O
day O
2 O
";" O
or O
MVP O
regimen O
: O
mitomycin-C O
8 O
mg/m2 O
, O
cisplatin O
100 O
mg/m2 O
IV O
on O
day O
1 O
, O
vinblastine O
4 O
mg/m2 O
IV O
on O
days O
1 O
and O
15 O
) O
. O

Serial O
assessment O
of O
Karnofsky O
performance O
status O
( O
KPS O
) O
, O
modified O
Functional O
Living O
Index-Cancer O
( O
T-FLIC O
) O
and O
modified O
Quality O
of O
Life-Index O
( O
T-QLI O
) O
were O
used O
to O
estimate O
the O
quality O
of O
life O
. O

Interviews O
were O
done O
at O
entry O
, O
at O
the O
third O
month O
and O
at O
2 O
months O
post O
complete O
treatment O
. O

At O
least O
two O
courses O
of O
chemotherapy O
were O
considered O
to O
be O
adequate O
for O
response O
evaluation O
. O

Patients O
were O
treated O
for O
a O
total O
of O
four O
to O
six O
courses O
or O
until O
progression O
of O
disease O
. O

Partial B-Premise
response I-Premise
rates I-Premise
were I-Premise
40 I-Premise
and I-Premise
41.7 I-Premise
% I-Premise
in I-Premise
IEP I-Premise
and I-Premise
MVP I-Premise
arms I-Premise
. I-Premise

Median B-Premise
survival I-Premise
durations I-Premise
were I-Premise
5.9 I-Premise
and I-Premise
8.1 I-Premise
months I-Premise
for I-Premise
the I-Premise
IEP I-Premise
and I-Premise
MVP I-Premise
chemotherapy I-Premise
arms I-Premise
, I-Premise
and I-Premise
4.1 I-Premise
months I-Premise
for I-Premise
BSC I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
: I-Premise
P I-Premise
= I-Premise
0.0003 I-Premise
) I-Premise
. I-Premise

One B-Premise
year I-Premise
survival I-Premise
was I-Premise
13 I-Premise
, I-Premise
29.8 I-Premise
and I-Premise
39.3 I-Premise
% I-Premise
for I-Premise
the I-Premise
BSC I-Premise
, I-Premise
IEP I-Premise
and I-Premise
MVP I-Premise
regimens I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Two B-Premise
years I-Premise
survival I-Premise
was I-Premise
7.8 I-Premise
, I-Premise
6.4 I-Premise
and I-Premise
13.1 I-Premise
% I-Premise
for I-Premise
the I-Premise
BSC I-Premise
, I-Premise
IEP I-Premise
and I-Premise
MVP I-Premise
regimens I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Improvement B-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
scores I-Premise
at I-Premise
the I-Premise
first I-Premise
, I-Premise
second I-Premise
and I-Premise
third I-Premise
interview I-Premise
were I-Premise
seen I-Premise
in I-Premise
chemotherapy I-Premise
arms I-Premise
only I-Premise
, I-Premise
not I-Premise
in I-Premise
the I-Premise
BSC I-Premise
arm I-Premise
. I-Premise

We O
conclude O
that O
combination B-Claim
chemotherapy I-Claim
improves I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
as I-Claim
well I-Claim
as I-Claim
prolonging I-Claim
the I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Low B-Claim
anterior I-Claim
resection I-Claim
with I-Claim
coloanal I-Claim
anastomosis I-Claim
prevents I-Claim
a I-Claim
definitive I-Claim
stoma I-Claim
in I-Claim
patients I-Claim
with I-Claim
distal I-Claim
rectal I-Claim
cancer I-Claim
. I-Claim

However B-Premise
, I-Premise
imperative I-Premise
stool I-Premise
urge I-Premise
, I-Premise
stool I-Premise
fragmentation I-Premise
, I-Premise
prolonged I-Premise
stooling I-Premise
sessions I-Premise
, I-Premise
and I-Premise
minor I-Premise
problems I-Premise
of I-Premise
incontinence I-Premise
are I-Premise
frequently I-Premise
observed I-Premise
in I-Premise
the I-Premise
postoperative I-Premise
situation I-Premise
and I-Premise
negatively I-Premise
affect I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Therefore O
, O
the O
colonic O
J-pouch O
was O
originally O
constructed O
to O
create O
a O
stool O
reservoir O
. O

In O
a O
randomized O
, O
prospective O
study O
, O
the O
short O
( O
5 O
cm O
) O
colonic O
J-pouch O
was O
tested O
for O
function O
and O
continence O
vs. O
straight O
coloanal O
anastomosis O
. O

Over O
a O
period O
of O
30 O
months O
, O
74 O
consecutive O
patients O
( O
55 O
males O
) O
with O
rectal O
cancer O
in O
the O
lower O
and O
middle O
third O
of O
the O
rectum O
were O
included O
and O
randomized O
into O
two O
groups O
. O

Anastomosis O
was O
performed O
either O
as O
a O
coloanal O
or O
a O
colon-pouch-anal O
anastomosis O
. O

The O
standardized O
surgical O
procedure O
included O
mobilization O
of O
the O
left O
hemicolon O
, O
central O
ligation O
of O
the O
inferior O
mesenteric O
artery O
and O
vein O
, O
preaortal O
lymph O
node O
dissection O
, O
autonomic O
nerve O
preservation O
, O
and O
total O
mesorectal O
excision O
. O

The O
anastomosis O
was O
performed O
at O
the O
upper O
anal O
canal O
or O
at O
the O
intersphincteric O
level O
. O

All O
patients O
were O
evaluated O
preoperatively O
and O
six O
months O
postoperatively O
for O
fecal O
continence O
, O
including O
sphincter O
manometry O
and O
defecation O
habits O
. O

In O
addition O
, O
quality O
of O
life O
was O
determined O
by O
use O
of O
a O
standardized O
questionnaire O
( O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
, O
EORTC-QLQ-C30 O
) O
. O

Thirty-seven O
patients O
were O
randomized O
into O
each O
group O
. O

In O
general O
, O
problems B-Premise
with I-Premise
continence I-Premise
for I-Premise
liquids I-Premise
or I-Premise
gas I-Premise
occurred I-Premise
less I-Premise
frequently I-Premise
in I-Premise
the I-Premise
colonic I-Premise
J-pouch I-Premise
group I-Premise
6 I-Premise
months I-Premise
after I-Premise
surgery I-Premise
. I-Premise

The B-Premise
frequency I-Premise
of I-Premise
bowel I-Premise
movements I-Premise
was I-Premise
lower I-Premise
in I-Premise
the I-Premise
J-pouch I-Premise
group I-Premise
( I-Premise
2.5 I-Premise
per I-Premise
day I-Premise
) I-Premise
than I-Premise
in I-Premise
the I-Premise
coloanal I-Premise
group I-Premise
( I-Premise
4.7 I-Premise
per I-Premise
day I-Premise
) I-Premise
. I-Premise

Importantly O
, O
in B-Premise
a I-Premise
manometric I-Premise
study I-Premise
at I-Premise
the I-Premise
same I-Premise
postoperative I-Premise
point I-Premise
, I-Premise
neorectal I-Premise
capacity I-Premise
was I-Premise
decreased I-Premise
to I-Premise
a I-Premise
similar I-Premise
degree I-Premise
in I-Premise
both I-Premise
groups I-Premise
compared I-Premise
with I-Premise
the I-Premise
preoperative I-Premise
rectal I-Premise
volume I-Premise
. I-Premise

Thus O
, O
the B-Premise
expected I-Premise
and I-Premise
postulated I-Premise
reservoir I-Premise
effect I-Premise
could I-Premise
not I-Premise
be I-Premise
achieved I-Premise
by I-Premise
forming I-Premise
a I-Premise
5-cm I-Premise
colonic I-Premise
J-pouch I-Premise
. I-Premise

The B-Claim
colonic I-Claim
J-pouch I-Claim
was I-Claim
superior I-Claim
with I-Claim
regard I-Claim
to I-Claim
continence I-Claim
for I-Claim
gas I-Claim
and I-Claim
liquids I-Claim
compared I-Claim
with I-Claim
a I-Claim
straight I-Claim
coloanal I-Claim
anastomosis I-Claim
. I-Claim

Furthermore O
, O
stool B-Claim
frequency I-Claim
was I-Claim
significantly I-Claim
lower I-Claim
in I-Claim
the I-Claim
J-pouch I-Claim
group I-Claim
than I-Claim
in I-Claim
the I-Claim
coloanal I-Claim
reconstruction I-Claim
group I-Claim
. I-Claim

However O
, O
because B-Premise
neorectal I-Premise
capacity I-Premise
decreased I-Premise
equally I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
we B-Claim
speculate I-Claim
that I-Claim
the I-Claim
advantage I-Claim
of I-Claim
the I-Claim
colonic I-Claim
J-pouch I-Claim
is I-Claim
not I-Claim
in I-Claim
the I-Claim
creation I-Claim
of I-Claim
a I-Claim
larger I-Claim
neorectal I-Claim
reservoir I-Claim
but I-Claim
rather I-Claim
may I-Claim
be I-Claim
related I-Claim
to I-Claim
decreased I-Claim
motility I-Claim
. I-Claim

Non-randomised O
studies O
have O
suggested O
that O
the B-Claim
postoperative I-Claim
complications I-Claim
of I-Claim
( I-Claim
Campos I-Claim
LS I-Claim
, I-Claim
Limberger I-Claim
LF I-Claim
, I-Claim
Stein I-Claim
AT I-Claim
, I-Claim
Kalil I-Claim
AN I-Claim
) I-Claim
laparoscopic I-Claim
radical I-Claim
hysterectomy I-Claim
are I-Claim
similar I-Claim
to I-Claim
those I-Claim
in I-Claim
abdominal I-Claim
radical I-Claim
hysterectomy I-Claim
. I-Claim

However O
, O
no O
study O
evaluating O
postoperative O
pain O
comparing O
both O
techniques O
has O
been O
published O
thus O
far O
. O

Our O
objective O
was O
to O
compare O
pain O
intensity O
and O
other O
perioperative O
outcomes O
between O
laparoscopic O
radical O
hysterectomy O
( O
LRH O
) O
and O
abdominal O
radical O
hysterectomy O
( O
ARH O
) O
in O
early O
cervical O
cancer O
. O

This O
single O
centre O
, O
randomised O
, O
controlled O
trial O
enrolled O
30 O
cervical O
cancer O
patients O
who O
were O
clinically O
staged O
IA2 O
with O
lymph O
vascular O
invasion O
and O
IB O
according O
to O
the O
FIGO O
( O
International O
Federation O
of O
Gynaecology O
and O
Obstetrics O
) O
classification O
, O
and O
underwent O
LRH O
or O
ARH O
between O
late O
1999 O
and O
early O
2004 O
. O

Postoperative O
pain O
, O
as O
measured O
by O
a O
10-point O
numerical O
rate O
scale O
, O
was O
considered O
the O
primary O
endpoint O
. O

Postoperative O
pain O
was O
assessed O
every O
six O
hours O
during O
a O
patient O
's O
usual O
postoperative O
care O
. O

Perioperative O
outcomes O
were O
also O
registered O
. O

Both O
surgical O
techniques O
were O
executed O
by O
the O
same O
surgical O
team O
. O

Secondary O
outcomes O
included O
intraoperative O
and O
other O
postoperative O
surgicopathological O
factors O
and O
5-year O
survival O
rates O
. O

IA2 O
patients O
with O
lymphatic O
vascular O
space O
invasion O
and O
IB O
cervical O
cancer O
patients O
were O
randomised O
to O
either O
the O
LRH O
group O
( O
16 O
patients O
) O
or O
the O
ARH O
group O
( O
14 O
patients O
) O
. O

Four B-Premise
patients I-Premise
( I-Premise
25 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
LRH I-Premise
group I-Premise
and I-Premise
5 I-Premise
patients I-Premise
( I-Premise
36 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
ARH I-Premise
group I-Premise
presented I-Premise
with I-Premise
transoperative I-Premise
or I-Premise
serious I-Premise
postoperative I-Premise
complications I-Premise
. I-Premise

All B-Premise
of I-Premise
the I-Premise
transoperative I-Premise
complications I-Premise
occurred I-Premise
in I-Premise
the I-Premise
LRH I-Premise
group I-Premise
. I-Premise

The B-Premise
relative I-Premise
risk I-Premise
of I-Premise
presenting I-Premise
with I-Premise
complications I-Premise
was I-Premise
0.70 I-Premise
";" I-Premise
CI I-Premise
95 I-Premise
% I-Premise
( I-Premise
0.23-2.11 I-Premise
) I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.694 I-Premise
. I-Premise

LRH B-Premise
group I-Premise
mean I-Premise
pain I-Premise
score I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
ARH I-Premise
after I-Premise
36 I-Premise
h I-Premise
of I-Premise
observation I-Premise
( I-Premise
P I-Premise
= I-Premise
0.044 I-Premise
";" I-Premise
mean I-Premise
difference I-Premise
score I-Premise
: I-Premise
1.42 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
0.04-2.80 I-Premise
) I-Premise
. I-Premise

The O
survival O
results O
will O
be O
published O
elsewhere O
. O

LRH B-Claim
provided I-Claim
lower I-Claim
pain I-Claim
scores I-Claim
after I-Claim
36 I-Claim
h I-Claim
of I-Claim
observation I-Claim
in I-Claim
this I-Claim
series I-Claim
. I-Claim

The B-Claim
perioperative I-Claim
and I-Claim
serious I-Claim
postoperative I-Claim
complications I-Claim
ratios I-Claim
were I-Claim
comparable I-Claim
between I-Claim
the I-Claim
groups I-Claim
. I-Claim

Fatigue O
is O
one O
of O
the O
most O
common O
symptoms O
experienced O
by O
patients O
with O
cancer O
. O

This O
trial O
was O
developed O
to O
evaluate O
the O
efficacy O
of O
long-acting O
methylphenidate O
for O
improving O
cancer-related O
fatigue O
and O
to O
assess O
its O
toxicities O
. O

Adults O
with O
cancer O
were O
randomly O
assigned O
in O
a O
double-blinded O
manner O
to O
receive O
methylphenidate O
( O
target O
dose O
, O
54 O
mg/d O
) O
or O
placebo O
for O
4 O
weeks O
. O

The O
Brief O
Fatigue O
Inventory O
was O
the O
primary O
outcome O
measure O
, O
while O
secondary O
outcome O
measures O
included O
a O
Symptom O
Experience O
Diary O
( O
SED O
) O
, O
the O
Short O
Form-36 O
( O
SF-36 O
) O
Vitality O
Subscale O
, O
a O
linear O
analog O
self-assessment O
, O
the O
Pittsburgh O
Sleep O
Quality O
Index O
, O
and O
the O
Subject O
Global O
Impression O
of O
Change O
. O

In O
total O
, O
148 O
patients O
were O
enrolled O
. O

Using B-Premise
an I-Premise
area I-Premise
under I-Premise
the I-Premise
serum I-Premise
concentration-time I-Premise
curve I-Premise
analysis I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
evidence I-Premise
that I-Premise
methylphenidate I-Premise
, I-Premise
as I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
, I-Premise
improved I-Premise
the I-Premise
primary I-Premise
end I-Premise
point I-Premise
of I-Premise
cancer-related I-Premise
fatigue I-Premise
in I-Premise
this I-Premise
patient I-Premise
population I-Premise
( I-Premise
P I-Premise
= I-Premise
.35 I-Premise
) I-Premise
. I-Premise

Comparisons B-Premise
of I-Premise
secondary I-Premise
end I-Premise
points I-Premise
, I-Premise
including I-Premise
clinically I-Premise
significant I-Premise
changes I-Premise
in I-Premise
quality-of-life I-Premise
variables I-Premise
and I-Premise
cancer-related I-Premise
fatigue I-Premise
change I-Premise
from I-Premise
baseline I-Premise
, I-Premise
were I-Premise
similarly I-Premise
negative I-Premise
. I-Premise

However B-Premise
, I-Premise
a I-Premise
subset I-Premise
analysis I-Premise
suggested I-Premise
that I-Premise
patients I-Premise
with I-Premise
more I-Premise
severe I-Premise
fatigue I-Premise
and/or I-Premise
with I-Premise
more I-Premise
advanced I-Premise
disease I-Premise
did I-Premise
have I-Premise
some I-Premise
fatigue I-Premise
improvement I-Premise
with I-Premise
methylphenidate I-Premise
( I-Premise
eg I-Premise
, I-Premise
in I-Premise
patients I-Premise
with I-Premise
stage I-Premise
III I-Premise
or I-Premise
IV I-Premise
disease I-Premise
, I-Premise
the I-Premise
mean I-Premise
improvement I-Premise
in I-Premise
usual I-Premise
fatigue I-Premise
was I-Premise
19.7 I-Premise
with I-Premise
methylphenidate I-Premise
v I-Premise
2.1 I-Premise
with I-Premise
placebo I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
self-reported I-Premise
toxicities I-Premise
( I-Premise
SED I-Premise
) I-Premise
, I-Premise
with I-Premise
increased I-Premise
levels I-Premise
of I-Premise
nervousness I-Premise
and I-Premise
appetite I-Premise
loss I-Premise
in I-Premise
the I-Premise
methylphenidate I-Premise
arm I-Premise
. I-Premise

This B-Claim
clinical I-Claim
trial I-Claim
was I-Claim
unable I-Claim
to I-Claim
support I-Claim
the I-Claim
primary I-Claim
prestudy I-Claim
hypothesis I-Claim
that I-Claim
the I-Claim
chosen I-Claim
long-acting I-Claim
methylphenidate I-Claim
product I-Claim
would I-Claim
decrease I-Claim
cancer-related I-Claim
fatigue I-Claim
. I-Claim

In O
1980 O
the O
EORTC-BCCG O
initiated O
a O
multicentre O
randomised O
clinical O
trial O
comparing O
modified O
radical O
mastectomy O
( O
MRM O
) O
with O
breast-conserving O
therapy O
( O
BCT O
) O
in O
stage O
I O
and O
II O
breast O
cancer O
. O

The O
main O
endpoint O
of O
the O
trial O
was O
survival O
. O

A O
brief O
quality O
of O
life O
( O
QoL O
) O
questionnaire O
consisting O
of O
two O
multi-item O
scales O
( O
body O
image O
and O
fear O
of O
recurrence O
) O
and O
two O
single O
items O
( O
satisfaction O
with O
treatment O
and O
cosmetic O
result O
) O
was O
included O
in O
the O
trial O
. O

A O
cosmetic O
evaluation O
of O
the O
breast O
after O
conservative O
surgery O
was O
also O
performed O
. O

This O
report O
concentrates O
on O
the O
results O
of O
the O
QoL O
study O
and O
the O
cosmetic O
evaluation O
. O

Multitrait O
scaling O
analysis O
was O
employed O
to O
verify O
the O
hypothesised O
scale O
structure O
of O
the O
questionnaire O
. O

Treatment O
comparison O
of O
the O
QoL O
scores O
at O
2 O
years O
post-treatment O
was O
performed O
using O
a O
stratified O
Wilcoxon O
rank O
sum O
test O
. O

Both O
patients O
' O
and O
doctors O
' O
ratings O
of O
the O
cosmetic O
result O
were O
documented O
on O
the O
clinical O
follow-up O
form O
. O

A O
multivariate O
analysis O
was O
performed O
to O
identify O
which O
factors O
influenced O
the O
cosmetic O
outcome O
. O

In O
total O
, O
127 O
patients O
in O
the O
MRM O
arm O
and O
151 O
in O
the O
BCT O
arm O
completed O
a O
QoL O
questionnaire O
at O
approximately O
2 O
years O
after O
randomisation O
( O
months O
25-36 O
) O
. O

The B-Premise
Cronbach I-Premise
's I-Premise
alpha I-Premise
coefficients I-Premise
were I-Premise
0.79 I-Premise
and I-Premise
0.73 I-Premise
for I-Premise
the I-Premise
body I-Premise
image I-Premise
and I-Premise
fear I-Premise
of I-Premise
recurrence I-Premise
scales I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Significant B-Premise
benefit I-Premise
in I-Premise
body I-Premise
image I-Premise
and I-Premise
satisfaction I-Premise
with I-Premise
treatment I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
BCT I-Premise
patients I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
was I-Premise
observed I-Premise
in I-Premise
fear I-Premise
of I-Premise
recurrence I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

Ratings B-Premise
of I-Premise
cosmetic I-Premise
results I-Premise
decreased I-Premise
with I-Premise
time I-Premise
, I-Premise
in I-Premise
line I-Premise
with I-Premise
clinical I-Premise
observations I-Premise
of I-Premise
long-term I-Premise
side-effects I-Premise
of I-Premise
radiotherapy I-Premise
. I-Premise

Wide B-Claim
excision I-Claim
appeared I-Claim
to I-Claim
be I-Claim
the I-Claim
most I-Claim
important I-Claim
predictive I-Claim
factor I-Claim
for I-Claim
poor I-Claim
cosmetic I-Claim
result I-Claim
. I-Claim

In B-Claim
this I-Claim
multicentre I-Claim
randomised I-Claim
study I-Claim
, I-Claim
BCT I-Claim
helped I-Claim
to I-Claim
maintain I-Claim
the I-Claim
patients I-Claim
' I-Claim
body I-Claim
image I-Claim
, I-Claim
resulted I-Claim
in I-Claim
higher I-Claim
satisfaction I-Claim
with I-Claim
treatment I-Claim
and I-Claim
yielded I-Claim
no I-Claim
significant I-Claim
difference I-Claim
from I-Claim
MRM I-Claim
with I-Claim
respect I-Claim
to I-Claim
fear I-Claim
of I-Claim
recurrence I-Claim
. I-Claim

To O
assess O
the O
cost-effectiveness O
of O
Mohs O
micrographic O
surgery O
( O
MMS O
) O
compared O
with O
the O
surgical O
excision O
for O
both O
primary O
and O
recurrent O
basal O
cell O
carcinoma O
( O
BCC O
) O
. O

A O
cost-effectiveness O
study O
performed O
alongside O
a O
prospective O
randomized O
clinical O
trial O
in O
which O
MMS O
was O
compared O
with O
surgical O
excision O
. O

The O
study O
was O
carried O
out O
from O
1999 O
to O
2002 O
at O
the O
dermatology O
outpatient O
clinic O
of O
the O
University O
Hospital O
Maastricht O
, O
Maastricht O
, O
The O
Netherlands O
. O

A O
total O
of O
408 O
primary O
( O
374 O
patients O
) O
and O
204 O
recurrent O
( O
191 O
patients O
) O
cases O
of O
facial O
BCC O
were O
included O
. O

The O
mean O
total O
treatment O
costs O
of O
MMS O
and O
surgical O
excision O
for O
both O
primary O
and O
recurrent O
BCC O
and O
the O
incremental O
cost-effectiveness O
ratio O
, O
calculated O
as O
the O
difference O
in O
costs O
between O
MMS O
and O
surgical O
excision O
divided O
by O
their O
difference O
in O
effectiveness O
. O

The O
resulting O
ratio O
is O
defined O
as O
the O
incremental O
costs O
of O
MMS O
compared O
with O
surgical O
excision O
to O
prevent O
1 O
additional O
recurrence O
. O

Compared B-Premise
with I-Premise
surgical I-Premise
excision I-Premise
, I-Premise
the I-Premise
total I-Premise
treatment I-Premise
costs I-Premise
of I-Premise
MMS I-Premise
are I-Premise
significantly I-Premise
higher I-Premise
( I-Premise
cost I-Premise
difference I-Premise
: I-Premise
primary I-Premise
BCC I-Premise
, I-Premise
254 I-Premise
euros I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
181-324 I-Premise
euros I-Premise
";" I-Premise
recurrent I-Premise
BCC I-Premise
, I-Premise
249 I-Premise
euros I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
175-323 I-Premise
euros I-Premise
) I-Premise
. I-Premise

For B-Premise
primary I-Premise
BCC I-Premise
, I-Premise
the I-Premise
incremental I-Premise
cost-effectiveness I-Premise
ratio I-Premise
was I-Premise
29,231 I-Premise
euros I-Premise
, I-Premise
while I-Premise
the I-Premise
ratio I-Premise
for I-Premise
recurrent I-Premise
BCC I-Premise
amounted I-Premise
to I-Premise
8094 I-Premise
euros I-Premise
. I-Premise

The B-Premise
acceptability I-Premise
curves I-Premise
showed I-Premise
that I-Premise
for I-Premise
these I-Premise
ratios I-Premise
, I-Premise
the I-Premise
probability I-Premise
of I-Premise
MMS I-Premise
being I-Premise
more I-Premise
cost-effective I-Premise
than I-Premise
surgical I-Premise
excision I-Premise
never I-Premise
reached I-Premise
50 I-Premise
% I-Premise
. I-Premise

At B-Claim
present I-Claim
, I-Claim
it I-Claim
does I-Claim
not I-Claim
seem I-Claim
cost-effective I-Claim
to I-Claim
introduce I-Claim
MMS I-Claim
on I-Claim
a I-Claim
large I-Claim
scale I-Claim
for I-Claim
both I-Claim
primary I-Claim
and I-Claim
recurrent I-Claim
BCC I-Claim
. I-Claim

However O
, O
because B-Premise
a I-Premise
5-year I-Premise
period I-Premise
is I-Premise
normally I-Premise
required I-Premise
to I-Premise
determine I-Premise
definite I-Premise
recurrence I-Premise
rates I-Premise
, O
it B-Claim
is I-Claim
possible I-Claim
that I-Claim
MMS I-Claim
may I-Claim
become I-Claim
a I-Claim
cost-effective I-Claim
treatment I-Claim
for I-Claim
recurrent I-Claim
BCC I-Claim
. I-Claim

The O
aim O
of O
this O
study O
was O
determine O
the O
effectiveness O
of O
a O
mindfulness-based O
stress-reduction O
( O
MBSR O
) O
program O
on O
quality O
of O
life O
( O
QOL O
) O
and O
psychosocial O
outcomes O
in O
women O
with O
early-stage O
breast O
cancer O
, O
using O
a O
three-arm O
randomized O
controlled O
clinical O
trial O
( O
RCT O
) O
. O

This O
RCT O
consisting O
of O
172 O
women O
, O
aged O
20-65 O
with O
stage O
I O
or O
II O
breast O
cancer O
consisted O
of O
the O
8-week O
MBSR O
, O
which O
was O
compared O
to O
a O
nutrition O
education O
program O
( O
NEP O
) O
and O
usual O
supportive O
care O
( O
UC O
) O
. O

Follow-up O
was O
performed O
at O
three O
post-intervention O
points O
: O
4 O
months O
, O
1 O
, O
and O
2 O
years O
. O

Standardized O
, O
validated O
self-administered O
questionnaires O
were O
adopted O
to O
assess O
psychosocial O
variables O
. O

Statistical O
analysis O
included O
descriptive O
and O
regression O
analyses O
incorporating O
both O
intention-to-treat O
and O
post O
hoc O
multivariable O
approaches O
of O
the O
163 O
women O
with O
complete O
data O
at O
baseline O
, O
those O
who O
were O
randomized O
to O
MBSR O
experienced O
a O
significant O
improvement O
in O
the O
primary O
measures O
of O
QOL O
and O
coping O
outcomes O
compared O
to O
the O
NEP O
, O
UC O
, O
or O
both O
, O
including O
the O
spirituality O
subscale O
of O
the O
FACT-B O
as O
well O
as O
dealing O
with O
illness O
scale O
increases O
in O
active O
behavioral O
coping O
and O
active O
cognitive O
coping O
. O

Secondary B-Premise
outcome I-Premise
improvements I-Premise
resulting I-Premise
in I-Premise
significant I-Premise
between-group I-Premise
contrasts I-Premise
favoring I-Premise
the I-Premise
MBSR I-Premise
group I-Premise
at I-Premise
4 I-Premise
months I-Premise
included I-Premise
meaningfulness I-Premise
, I-Premise
depression I-Premise
, I-Premise
paranoid I-Premise
ideation I-Premise
, I-Premise
hostility I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
unhappiness I-Premise
, I-Premise
and I-Premise
emotional I-Premise
control I-Premise
. I-Premise

Results B-Premise
tended I-Premise
to I-Premise
decline I-Premise
at I-Premise
12 I-Premise
months I-Premise
and I-Premise
even I-Premise
more I-Premise
at I-Premise
24 I-Premise
months I-Premise
, I-Premise
though I-Premise
at I-Premise
all I-Premise
times I-Premise
, I-Premise
they I-Premise
were I-Premise
as I-Premise
robust I-Premise
in I-Premise
women I-Premise
with I-Premise
lower I-Premise
expectation I-Premise
of I-Premise
effect I-Premise
as I-Premise
in I-Premise
those I-Premise
with I-Premise
higher I-Premise
expectation I-Premise
. I-Premise

The B-Claim
MBSR I-Claim
intervention I-Claim
appears I-Claim
to I-Claim
benefit I-Claim
psychosocial I-Claim
adjustment I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
over I-Claim
and I-Claim
above I-Claim
the I-Claim
effects I-Claim
of I-Claim
usual I-Claim
care I-Claim
or I-Claim
a I-Claim
credible I-Claim
control I-Claim
condition I-Claim
. I-Claim

The B-Claim
universality I-Claim
of I-Claim
effects I-Claim
across I-Claim
levels I-Claim
of I-Claim
expectation I-Claim
indicates I-Claim
a I-Claim
potential I-Claim
to I-Claim
utilize I-Claim
this I-Claim
stress I-Claim
reduction I-Claim
approach I-Claim
as I-Claim
complementary I-Claim
therapy I-Claim
in I-Claim
oncologic I-Claim
practice I-Claim
. I-Claim

In O
an O
international O
, O
randomized O
phase O
III O
trial O
, O
sunitinib O
demonstrated O
statistically O
significant O
efficacy O
over O
interferon O
alfa O
( O
IFN-alpha O
) O
as O
first-line O
therapy O
in O
patients O
with O
metastatic O
renal O
cell O
carcinoma O
( O
mRCC O
) O
( O
progression-free O
survival O
time O
, O
11 O
v O
5 O
months O
, O
respectively O
";" O
P O
< O
.001 O
";" O
objective O
response O
rate O
, O
31 O
% O
v O
6 O
% O
, O
respectively O
";" O
P O
< O
.001 O
) O
. O

We O
report O
health-related O
quality-of-life O
( O
QOL O
) O
results O
from O
this O
trial O
. O

Seven O
hundred O
fifty O
mRCC O
patients O
were O
randomly O
assigned O
to O
sunitinib O
( O
6-week O
cycles O
: O
50 O
mg O
orally O
once O
daily O
for O
4 O
weeks O
, O
followed O
by O
2 O
weeks O
off O
) O
or O
IFN-alpha O
( O
9 O
million O
units O
subcutaneous O
injections O
, O
three O
times O
weekly O
) O
. O

QOL O
measures O
included O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-General O
( O
FACT-G O
) O
, O
the O
FACT-Kidney O
Symptom O
Index-15 O
item O
( O
FKSI-15 O
) O
, O
and O
the O
EuroQoL-5D O
's O
utility O
score O
( O
EQ-5D O
Index O
) O
and O
its O
visual O
analog O
scale O
( O
EQ-VAS O
) O
. O

The O
primary O
QOL O
end O
point O
was O
the O
FKSI O
Disease-Related O
Symptoms O
( O
FKSI-DRS O
) O
subscale O
. O

Higher O
scores O
indicated O
better O
outcomes O
( O
better O
QOL O
or O
fewer O
symptoms O
) O
. O

Data O
were O
analyzed O
for O
the O
intent-to-treat O
population O
using O
mixed-effects O
models O
, O
supplemented O
with O
pattern-mixture O
models O
. O

Patients B-Premise
receiving I-Premise
sunitinib I-Premise
reported I-Premise
higher I-Premise
FKSI-15 I-Premise
and I-Premise
FKSI-DRS I-Premise
scores I-Premise
at I-Premise
each I-Premise
cycle I-Premise
than I-Premise
those I-Premise
receiving I-Premise
IFN-alpha I-Premise
, I-Premise
with I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
overall I-Premise
least I-Premise
squares I-Premise
means I-Premise
( I-Premise
3.27 I-Premise
and I-Premise
1.98 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

Similarly O
, O
differences B-Premise
in I-Premise
least I-Premise
squares I-Premise
means I-Premise
for I-Premise
FACT-G I-Premise
( I-Premise
and I-Premise
all I-Premise
subscales I-Premise
) I-Premise
, I-Premise
EQ-5D I-Premise
Index I-Premise
, I-Premise
and I-Premise
EQ-VAS I-Premise
were I-Premise
all I-Premise
significantly I-Premise
favorable I-Premise
for I-Premise
sunitinib I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Per O
pre-established O
thresholds O
, O
between-treatment O
differences O
in O
the O
mean O
scores O
were O
clinically O
meaningful O
after O
cycle O
4 O
for O
FKSI-DRS O
and O
at O
all O
assessments O
for O
FKSI-15 O
, O
FACT-G O
, O
and O
the O
FACT-G O
functional O
well-being O
subscale O
. O

Sunitinib B-Claim
provides I-Claim
superior I-Claim
QOL I-Claim
compared I-Claim
with I-Claim
IFN-alpha I-Claim
in I-Claim
mRCC I-Claim
patients I-Claim
. I-Claim

The O
Medical O
Research O
Council O
CR07/National O
Cancer O
Institute O
of O
Canada O
Clinical O
Trials O
Group O
C016 O
( O
MRC O
CR07/NCIC O
CTG O
C016 O
) O
trial O
showed O
that O
, O
in O
patients O
with O
operable O
rectal O
cancer O
, O
short-course O
preoperative O
radiotherapy O
( O
PRE O
) O
reduced O
the O
rate O
of O
local O
recurrence O
compared O
with O
surgery O
followed O
by O
selective O
postoperative O
chemoradiotherapy O
for O
patients O
with O
a O
positive O
circumferential O
resection O
margin O
. O

However O
, O
the O
advantages O
of O
giving O
PRE O
to O
all O
patients O
needs O
to O
be O
balanced O
against O
any O
negative O
impact O
on O
patients O
' O
quality O
of O
life O
. O

All O
1,350 O
patients O
were O
asked O
to O
complete O
the O
Medical O
Outcomes O
Study O
Short-Form O
36-item O
( O
MOS O
SF-36 O
) O
and O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
Colorectal O
38-item O
( O
EORTC O
QLQ-CR38 O
) O
questionnaires O
. O

A O
priori O
hypotheses O
related O
to O
the O
impact O
of O
treatment O
on O
sexual O
, O
bowel O
, O
and O
physical O
function O
and O
general O
health O
. O

Male B-Premise
sexual I-Premise
dysfunction I-Premise
was I-Premise
significantly I-Premise
increased I-Premise
following I-Premise
surgery I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
although B-Premise
there I-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

However O
, O
a O
treatment O
difference O
had O
emerged O
at O
6 O
months O
( O
PRE O
patients O
reporting O
significantly O
greater O
dysfunction O
";" O
P O
= O
.004 O
) O
, O
which O
persisted O
out O
to O
at O
least O
2 O
years O
( O
an O
insufficient O
number O
of O
female O
patients O
completed O
the O
sexual O
dysfunction O
questions O
to O
draw O
firm O
conclusions O
) O
. O

Both B-Premise
treatment I-Premise
groups I-Premise
reported I-Premise
similar I-Premise
levels I-Premise
of I-Premise
decreased I-Premise
physical I-Premise
function I-Premise
at I-Premise
3 I-Premise
months I-Premise
, I-Premise
but B-Premise
thereafter I-Premise
it I-Premise
returned I-Premise
to I-Premise
baseline I-Premise
levels I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
any I-Premise
major I-Premise
changes I-Premise
between I-Premise
treatments I-Premise
or I-Premise
time I-Premise
points I-Premise
in I-Premise
terms I-Premise
of I-Premise
general I-Premise
health I-Premise
or I-Premise
bowel I-Premise
function I-Premise
, I-Premise
but B-Premise
exploratory I-Premise
analysis I-Premise
indicated I-Premise
a I-Premise
significant I-Premise
( I-Premise
P I-Premise
= I-Premise
.006 I-Premise
at I-Premise
2 I-Premise
years I-Premise
) I-Premise
increase I-Premise
in I-Premise
the I-Premise
level I-Premise
of I-Premise
fecal I-Premise
incontinence I-Premise
with I-Premise
PRE I-Premise
. I-Premise

These B-Claim
results I-Claim
from I-Claim
a I-Claim
large I-Claim
randomized I-Claim
trial I-Claim
using I-Claim
validated I-Claim
patient-completed I-Claim
questionnaires I-Claim
show I-Claim
that I-Claim
, I-Claim
for I-Claim
males I-Claim
, I-Claim
the I-Claim
main I-Claim
adverse I-Claim
effect I-Claim
was I-Claim
sexual I-Claim
dysfunction I-Claim
, I-Claim
and I-Claim
the I-Claim
main I-Claim
cause I-Claim
of I-Claim
this I-Claim
was I-Claim
surgery I-Claim
, I-Claim
but O
that O
PRE B-Claim
also I-Claim
affected I-Claim
sexual I-Claim
and I-Claim
some I-Claim
aspects I-Claim
of I-Claim
bowel I-Claim
functioning I-Claim
. I-Claim

Persistent O
insomnia O
is O
a O
common O
complaint O
in O
cancer O
survivors O
, O
but O
is O
seldom O
satisfactorily O
addressed O
. O

The O
adaptation O
to O
cancer O
care O
of O
a O
validated O
, O
cost-effective O
intervention O
may O
offer O
a O
practicable O
solution O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
clinical O
effectiveness O
of O
protocol-driven O
cognitive O
behavior O
therapy O
( O
CBT O
) O
for O
insomnia O
, O
delivered O
by O
oncology O
nurses O
. O

Randomized O
, O
controlled O
, O
pragmatic O
, O
two-center O
trial O
of O
CBT O
versus O
treatment O
as O
usual O
( O
TAU O
) O
in O
150 O
patients O
( O
103 O
females O
";" O
mean O
age O
, O
61 O
years O
. O
) O

who O
had O
completed O
active O
therapy O
for O
breast O
, O
prostate O
, O
colorectal O
, O
or O
gynecological O
cancer O
. O

The O
study O
conformed O
to O
CONSORT O
guidelines O
. O

Primary O
outcomes O
were O
sleep O
diary O
measures O
at O
baseline O
, O
post-treatment O
, O
and O
6-month O
follow-up O
. O

Actigraphic O
sleep O
, O
health-related O
quality O
of O
life O
( O
QOL O
) O
, O
psychopathology O
, O
and O
fatigue O
were O
secondary O
measures O
. O

CBT O
comprised O
five O
, O
small O
group O
sessions O
across O
consecutive O
weeks O
, O
after O
a O
manualized O
protocol O
. O

TAU O
represented O
normal O
clinical O
practice O
";" O
the O
appropriate O
control O
for O
a O
clinical O
effectiveness O
study O
. O

CBT B-Premise
was I-Premise
associated I-Premise
with I-Premise
mean I-Premise
reductions I-Premise
in I-Premise
wakefulness I-Premise
of I-Premise
55 I-Premise
minutes I-Premise
per I-Premise
night I-Premise
compared I-Premise
with I-Premise
no I-Premise
change I-Premise
in I-Premise
TAU I-Premise
. I-Premise

These O
outcomes O
were O
sustained O
6 O
months O
after O
treatment O
. O

Standardized B-Premise
relative I-Premise
effect I-Premise
sizes I-Premise
were I-Premise
large I-Premise
for I-Premise
complaints I-Premise
of I-Premise
difficulty I-Premise
initiating I-Premise
sleep I-Premise
, I-Premise
waking I-Premise
from I-Premise
sleep I-Premise
during I-Premise
the I-Premise
night I-Premise
, I-Premise
and I-Premise
for I-Premise
sleep I-Premise
efficiency I-Premise
( I-Premise
percentage I-Premise
of I-Premise
time I-Premise
in I-Premise
bed I-Premise
spent I-Premise
asleep I-Premise
) I-Premise
. I-Premise

CBT B-Premise
was I-Premise
associated I-Premise
with I-Premise
moderate I-Premise
to I-Premise
large I-Premise
effect I-Premise
sizes I-Premise
for I-Premise
five I-Premise
of I-Premise
seven I-Premise
QOL I-Premise
outcomes I-Premise
, I-Premise
including I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
daytime I-Premise
fatigue I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
interaction I-Premise
effect I-Premise
between I-Premise
any I-Premise
of I-Premise
these I-Premise
outcomes I-Premise
and I-Premise
baseline I-Premise
demographic I-Premise
, I-Premise
clinical I-Premise
, I-Premise
or I-Premise
sleep I-Premise
characteristics I-Premise
. I-Premise

CBT B-Claim
for I-Claim
insomnia I-Claim
may I-Claim
be I-Claim
both I-Claim
clinically I-Claim
effective I-Claim
and I-Claim
feasible I-Claim
to I-Claim
deliver I-Claim
in I-Claim
real I-Claim
world I-Claim
practice I-Claim
. I-Claim

Performance O
status O
( O
PS O
) O
2 O
patients O
with O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
experience O
more O
toxicity O
, O
lower O
response O
rates O
, O
and O
shorter O
survival O
times O
than O
healthier O
patients O
treated O
with O
standard O
chemotherapy O
. O

Paclitaxel O
poliglumex O
( O
PPX O
) O
, O
a O
macromolecule O
drug O
conjugate O
of O
paclitaxel O
and O
polyglutamic O
acid O
, O
reduces O
systemic O
exposure O
to O
peak O
concentrations O
of O
free O
paclitaxel O
and O
may O
lead O
to O
increased O
concentrations O
in O
tumors O
due O
to O
enhanced O
vascular O
permeability O
. O

Chemotherapy-naive O
PS O
2 O
patients O
with O
advanced O
NSCLC O
were O
randomized O
to O
receive O
carboplatin O
( O
area O
under O
the O
curve O
= O
6 O
) O
and O
either O
PPX O
( O
210 O
mg/m/10 O
min O
without O
routine O
steroid O
premedication O
) O
or O
paclitaxel O
( O
225 O
mg/m/3 O
h O
with O
standard O
premedication O
) O
every O
3 O
weeks O
. O

The O
primary O
end O
point O
was O
overall O
survival O
. O

A O
total O
of O
400 O
patients O
were O
enrolled O
. O

Alopecia B-Premise
, I-Premise
arthralgias/myalgias I-Premise
, I-Premise
and I-Premise
cardiac I-Premise
events I-Premise
were I-Premise
significantly I-Premise
less I-Premise
frequent I-Premise
with I-Premise
PPX/carboplatin I-Premise
, I-Premise
whereas I-Premise
grade I-Premise
> I-Premise
or I-Premise
3 I-Premise
neutropenia I-Premise
and I-Premise
grade I-Premise
3 I-Premise
neuropathy I-Premise
showed I-Premise
a I-Premise
trend I-Premise
of I-Premise
worsening I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
incidence I-Premise
of I-Premise
hypersensitivity I-Premise
reactions I-Premise
despite I-Premise
the I-Premise
absence I-Premise
of I-Premise
routine I-Premise
premedication I-Premise
in I-Premise
the I-Premise
PPX I-Premise
arm I-Premise
. I-Premise

Overall B-Premise
survival I-Premise
was I-Premise
similar I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.97 I-Premise
";" I-Premise
log I-Premise
rank I-Premise
p I-Premise
= I-Premise
0.769 I-Premise
) I-Premise
. I-Premise

Median B-Premise
and I-Premise
1-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
7.9 I-Premise
months I-Premise
and I-Premise
31 I-Premise
% I-Premise
, I-Premise
for I-Premise
PPX I-Premise
versus I-Premise
8 I-Premise
months I-Premise
and I-Premise
31 I-Premise
% I-Premise
for I-Premise
paclitaxel I-Premise
. I-Premise

Disease O
control O
rates O
were O
64 O
% O
and O
69 O
% O
for O
PPX O
and O
paclitaxel O
, O
respectively O
. O

Time O
to O
progression O
was O
similar O
: O
3.9 O
months O
for O
PPX/carboplatin O
versus O
4.6 O
months O
for O
paclitaxel/carboplatin O
( O
p O
= O
0.210 O
) O
. O

PPX/carboplatin B-Claim
failed I-Claim
to I-Claim
provide I-Claim
superior I-Claim
survival I-Claim
compared I-Claim
with I-Claim
paclitaxel/carboplatin I-Claim
in I-Claim
the I-Claim
first-line I-Claim
treatment I-Claim
of I-Claim
PS I-Claim
2 I-Claim
patients I-Claim
with I-Claim
NSCLC I-Claim
, I-Claim
but B-Claim
the I-Claim
results I-Claim
with I-Claim
respect I-Claim
to I-Claim
progression-free I-Claim
survival I-Claim
and I-Claim
overall I-Claim
survival I-Claim
were I-Claim
comparable I-Claim
and I-Claim
the I-Claim
PPX I-Claim
regimen I-Claim
was I-Claim
more I-Claim
convenient I-Claim
. I-Claim

To O
investigate O
the O
effect O
of O
recombinant O
human O
erythropoietin O
( O
epoetin O
beta O
) O
on O
anemia O
, O
transfusion O
need O
, O
and O
quality O
of O
life O
( O
QOL O
) O
in O
severely O
anemic O
patients O
with O
low-grade O
non-Hodgkin O
's O
lymphoma O
( O
NHL O
) O
, O
chronic O
lymphocytic O
leukemia O
( O
CLL O
) O
, O
or O
multiple O
myeloma O
( O
MM O
) O
. O

Transfusion-dependent O
patients O
with O
NHL O
( O
n O
= O
106 O
) O
, O
CLL O
( O
n O
= O
126 O
) O
, O
or O
MM O
( O
n O
= O
117 O
) O
and O
a O
low O
serum O
erythropoietin O
concentration O
were O
randomized O
to O
receive O
epoetin O
beta O
150 O
IU/kg O
or O
placebo O
subcutaneously O
three O
times O
a O
week O
for O
16 O
weeks O
. O

Primary O
efficacy O
criteria O
were O
transfusion-free O
and O
transfusion- O
and O
severe O
anemia-free O
survival O
( O
hemoglobin O
[ O
Hb O
] O
> O
8.5 O
g/dL O
) O
between O
weeks O
5 O
to O
16 O
. O

Response O
was O
defined O
as O
an O
increase O
in O
Hb O
> O
or O
= O
2 O
g/dL O
with O
elimination O
of O
transfusion O
need O
. O

QOL O
was O
assessed O
by O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
scale O
. O

Transfusion-free B-Premise
( I-Premise
P I-Premise
=.0012 I-Premise
) I-Premise
survival I-Premise
and I-Premise
transfusion- I-Premise
and I-Premise
severe I-Premise
anemia-free I-Premise
survival I-Premise
( I-Premise
P I-Premise
=.0001 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
beta I-Premise
group I-Premise
versus I-Premise
placebo I-Premise
( I-Premise
Wald I-Premise
chi I-Premise
( I-Premise
2 I-Premise
) I-Premise
test I-Premise
) I-Premise
, I-Premise
giving I-Premise
a I-Premise
relative I-Premise
risk I-Premise
reduction I-Premise
of I-Premise
43 I-Premise
% I-Premise
and I-Premise
51 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
response I-Premise
rate I-Premise
was I-Premise
67 I-Premise
% I-Premise
and I-Premise
27 I-Premise
% I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
beta I-Premise
versus I-Premise
the I-Premise
placebo I-Premise
group I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

After B-Premise
12 I-Premise
and I-Premise
16 I-Premise
weeks I-Premise
of I-Premise
treatment I-Premise
, I-Premise
QOL I-Premise
significantly I-Premise
improved I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
beta I-Premise
group I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
this B-Premise
improvement I-Premise
correlated I-Premise
with I-Premise
an I-Premise
increase I-Premise
in I-Premise
Hb I-Premise
concentration I-Premise
( I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
g/dL I-Premise
) I-Premise
. I-Premise

A O
target O
Hb O
that O
could O
be O
generally O
recommended O
could O
not O
be O
identified O
. O

Many B-Claim
severely I-Claim
anemic I-Claim
and I-Claim
transfusion-dependent I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
MM I-Claim
, I-Claim
NHL I-Claim
, I-Claim
and I-Claim
CLL I-Claim
and I-Claim
a I-Claim
low I-Claim
performance I-Claim
status I-Claim
benefited I-Claim
from I-Claim
epoetin I-Claim
therapy I-Claim
, I-Claim
with I-Claim
elimination I-Claim
of I-Claim
severe I-Claim
anemia I-Claim
and I-Claim
transfusion I-Claim
need I-Claim
, I-Claim
and I-Claim
improvement I-Claim
in I-Claim
QOL I-Claim
. I-Claim

The O
Australian O
and O
New O
Zealand O
Germ O
Cell O
Trials O
Group O
conducted O
a O
multicenter O
randomized O
phase O
III O
trial O
in O
men O
with O
good-prognosis O
germ O
cell O
tumors O
of O
two O
standard O
chemotherapy O
regimens O
that O
contained O
bleomycin O
, O
etoposide O
, O
and O
cisplatin O
but O
differed O
in O
the O
scheduling O
and O
total O
dose O
of O
cisplatin O
, O
the O
total O
dose O
of O
bleomycin O
, O
and O
the O
scheduling O
and O
dose O
intensity O
of O
etoposide O
. O

The O
trial O
was O
stopped O
early O
at O
a O
median O
follow-up O
of O
33 O
months O
after O
a O
planned O
interim O
analysis O
found O
a O
survival O
benefit O
for O
the O
more O
dose-intense O
regimen O
. O

The O
aim O
of O
this O
analysis O
was O
to O
determine O
if O
this O
survival O
benefit O
was O
maintained O
with O
long-term O
follow-up O
. O

Between O
February O
1994 O
and O
April O
2000 O
, O
166 O
men O
with O
good-prognosis O
metastatic O
germ O
cell O
tumors O
defined O
by O
modified O
Memorial O
Sloan-Kettering O
criteria O
were O
randomly O
assigned O
to O
receive O
3B O
( O
90 O
) O
E O
( O
500 O
) O
P O
( O
three O
cycles O
, O
repeated O
every O
21 O
days O
, O
of O
30 O
kU O
bleomycin O
on O
days O
1 O
, O
8 O
, O
and O
15 O
";" O
100 O
mg/m O
( O
2 O
) O
etoposide O
on O
days O
1-5 O
";" O
and O
20 O
mg/m O
( O
2 O
) O
cisplatin O
on O
days O
1-5 O
";" O
n O
= O
83 O
) O
or O
4B O
( O
30 O
) O
E O
( O
360 O
) O
P O
( O
four O
cycles O
, O
repeated O
every O
21 O
days O
, O
of O
30 O
kU O
bleomycin O
on O
day O
1 O
, O
120 O
mg/m O
( O
2 O
) O
etoposide O
on O
days O
1-3 O
, O
and O
100 O
mg/m O
( O
2 O
) O
cisplatin O
on O
day O
1 O
";" O
n O
= O
83 O
) O
. O

Endpoints O
included O
overall O
survival O
, O
progression-free O
survival O
, O
and O
quality O
of O
life O
and O
side O
effects O
, O
which O
were O
assessed O
using O
the O
Spitzer O
Quality O
of O
Life O
Index O
and O
the O
GLQ-8 O
, O
respectively O
, O
before O
random O
assignment O
and O
during O
and O
after O
treatment O
. O

All O
analyses O
were O
by O
intention O
to O
treat O
. O

All O
P O
values O
are O
two-sided O
. O

The O
median O
follow-up O
was O
8.5 O
years O
. O

All O
but O
five O
survivors O
( O
3 O
% O
) O
were O
followed O
up O
for O
at O
least O
5 O
years O
. O

Overall B-Premise
survival I-Premise
remained I-Premise
better I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
3B I-Premise
( I-Premise
90 I-Premise
) I-Premise
E I-Premise
( I-Premise
500 I-Premise
) I-Premise
P I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
4B I-Premise
( I-Premise
30 I-Premise
) I-Premise
E I-Premise
( I-Premise
360 I-Premise
) I-Premise
P I-Premise
( I-Premise
8-year I-Premise
survival I-Premise
: I-Premise
92 I-Premise
% I-Premise
vs I-Premise
83 I-Premise
% I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
of I-Premise
death I-Premise
= I-Premise
0.38 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
= I-Premise
0.15 I-Premise
to I-Premise
0.97 I-Premise
, I-Premise
P I-Premise
= I-Premise
.037 I-Premise
) I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
favored I-Premise
3B I-Premise
( I-Premise
90 I-Premise
) I-Premise
E I-Premise
( I-Premise
500 I-Premise
) I-Premise
P I-Premise
but I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
8-year I-Premise
progression-free I-Premise
survival I-Premise
, I-Premise
3B I-Premise
( I-Premise
90 I-Premise
) I-Premise
E I-Premise
( I-Premise
500 I-Premise
) I-Premise
P I-Premise
vs I-Premise
4B I-Premise
( I-Premise
30 I-Premise
) I-Premise
E I-Premise
( I-Premise
360 I-Premise
) I-Premise
P I-Premise
: I-Premise
86 I-Premise
% I-Premise
vs I-Premise
79 I-Premise
% I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
of I-Premise
progression I-Premise
= I-Premise
0.6 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
= I-Premise
0.3 I-Premise
to I-Premise
1.1 I-Premise
, I-Premise
P I-Premise
= I-Premise
.15 I-Premise
) I-Premise
. I-Premise

At B-Claim
the I-Claim
end I-Claim
of I-Claim
treatment I-Claim
, I-Claim
average I-Claim
scores I-Claim
for I-Claim
most I-Claim
side I-Claim
effect I-Claim
scales I-Claim
favored I-Claim
3B I-Claim
( I-Claim
90 I-Claim
) I-Claim
E I-Claim
( I-Claim
500 I-Claim
) I-Claim
P. I-Claim
After B-Premise
the I-Premise
completion I-Premise
of I-Premise
treatment I-Premise
, I-Premise
average I-Premise
GLQ-8 I-Premise
scores I-Premise
for I-Premise
numbness I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
and I-Premise
hair I-Premise
loss I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
and I-Premise
the I-Premise
Spitzer I-Premise
Quality I-Premise
of I-Premise
Life I-Premise
Index I-Premise
( I-Premise
P I-Premise
= I-Premise
.05 I-Premise
) I-Premise
favored I-Premise
3B I-Premise
( I-Premise
90 I-Premise
) I-Premise
E I-Premise
( I-Premise
500 I-Premise
) I-Premise
P. I-Premise
The B-Claim
survival I-Claim
benefit I-Claim
of I-Claim
3B I-Claim
( I-Claim
90 I-Claim
) I-Claim
E I-Claim
( I-Claim
500 I-Claim
) I-Claim
P I-Claim
over I-Claim
4B I-Claim
( I-Claim
30 I-Claim
) I-Claim
E I-Claim
( I-Claim
360 I-Claim
) I-Claim
P I-Claim
was I-Claim
maintained I-Claim
with I-Claim
long-term I-Claim
follow-up I-Claim
. I-Claim

To O
assess O
comparatively O
, O
in O
terms O
of O
quality-adjusted O
survival O
, O
three O
front-line O
treatments O
in O
patients O
with O
stage O
B- O
or O
C-chronic O
lymphocytic O
leukemia O
( O
CLL O
) O
. O

To O
describe O
better O
and O
compare O
the O
survival O
after O
randomization O
of O
patients O
from O
the O
CLL90 O
trial O
that O
randomly O
compared O
ChOP O
( O
cyclophosphamide O
, O
doxorubicin O
, O
oncovin O
, O
prednisone O
) O
, O
CAP O
( O
cyclophosphamide O
, O
doxorubicin O
, O
prednisone O
) O
and O
fludarabine O
in O
advanced O
CLL O
, O
we O
performed O
a O
quality-adjusted O
survival O
analysis O
. O

This O
consisted O
of O
defining O
four O
clinical O
states O
( O
toxicity O
, O
treatment O
free O
of O
toxicity O
, O
no O
treatment O
nor O
symptoms O
, O
relapse O
) O
, O
then O
summing O
up O
the O
average O
times O
spent O
in O
each O
state O
weighted O
by O
utility O
coefficients O
that O
reflect O
relative O
value O
according O
to O
quality O
of O
life O
. O

The O
resulting O
quality-adjusted O
time O
without O
symptoms O
or O
toxicity O
( O
Q-TWIST O
) O
was O
compared O
between O
randomized O
groups O
, O
and O
sensitivity O
( O
threshold O
) O
analyses O
to O
the O
choice O
of O
utility O
coefficients O
was O
performed O
. O

Over B-Premise
73 I-Premise
months I-Premise
after I-Premise
randomization I-Premise
, I-Premise
the I-Premise
fludarabine I-Premise
group I-Premise
gained I-Premise
a I-Premise
mean I-Premise
of I-Premise
45 I-Premise
days I-Premise
of I-Premise
toxicity-free I-Premise
survival I-Premise
at I-Premise
CAP I-Premise
, I-Premise
and I-Premise
61 I-Premise
days I-Premise
over I-Premise
ChOP I-Premise
. I-Premise

The B-Premise
mean I-Premise
TWIST I-Premise
was I-Premise
27.05 I-Premise
months I-Premise
with I-Premise
CAP I-Premise
, I-Premise
31.5 I-Premise
months I-Premise
with I-Premise
ChOP I-Premise
and I-Premise
32.95 I-Premise
months I-Premise
with I-Premise
fludarabine I-Premise
. I-Premise

The B-Premise
threshold I-Premise
analyses I-Premise
showed I-Premise
that I-Premise
, I-Premise
whatever I-Premise
the I-Premise
utility I-Premise
weights I-Premise
, I-Premise
the I-Premise
mean I-Premise
Q-TWIST I-Premise
was I-Premise
always I-Premise
greater I-Premise
with I-Premise
ChOP I-Premise
or I-Premise
fludarabine I-Premise
as I-Premise
compared I-Premise
to I-Premise
CAP I-Premise
. I-Premise

Fludarabine B-Claim
was I-Claim
consistently I-Claim
a I-Claim
better I-Claim
treatment I-Claim
than I-Claim
ChOP I-Claim
, I-Claim
except B-Premise
in I-Premise
the I-Premise
unlikely I-Premise
case I-Premise
of I-Premise
high I-Premise
utility I-Premise
weights I-Premise
attributed I-Premise
to I-Premise
toxicity I-Premise
and I-Premise
low I-Premise
utility I-Premise
weights I-Premise
attributed I-Premise
to I-Premise
treatment I-Premise
. I-Premise

Nevertheless O
, O
from B-Premise
a I-Premise
clinical I-Premise
point I-Premise
of I-Premise
view I-Premise
, I-Premise
differences I-Premise
between I-Premise
ChOP I-Premise
and I-Premise
fludarabine I-Premise
were I-Premise
moderate I-Premise
or I-Premise
event I-Premise
slight I-Premise
( I-Premise
mean I-Premise
difference I-Premise
in I-Premise
TWIST I-Premise
of I-Premise
1.45 I-Premise
months I-Premise
) I-Premise
. I-Premise

We O
conclude O
that O
patients B-Claim
with I-Claim
advanced I-Claim
CLL I-Claim
have I-Claim
a I-Claim
moderate I-Claim
benefit I-Claim
in I-Claim
terms I-Claim
of I-Claim
Q-TWIST I-Claim
when I-Claim
treated I-Claim
with I-Claim
fludarabine I-Claim
over I-Claim
ChOP I-Claim
. I-Claim

These B-Claim
two I-Claim
treatments I-Claim
are I-Claim
always I-Claim
superior I-Claim
to I-Claim
CAP I-Claim
. I-Claim

There O
will O
be O
a O
detectable O
increase O
in O
overall O
survival O
( O
OS O
) O
using O
preoperative O
( O
PRE O
) O
as O
opposed O
to O
perioperative O
( O
PERI O
) O
chemotherapy O
in O
resectable O
StageI-II O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

This O
multicenter O
, O
open-label O
, O
randomised O
trial O
with O
a O
2×2 O
factorial O
design O
first O
compared O
two O
chemotherapy O
strategies O
( O
PRE O
versus O
PERI O
) O
, O
then O
two O
chemotherapy O
regimens O
( O
gemcitabine-cisplatin O
[ O
GP O
] O
versus O
paclitaxel-carboplatin O
[ O
TC O
] O
) O
. O

The O
PRE O
group O
received O
two O
preoperative O
cycles O
followed O
by O
two O
additional O
preoperative O
cycles O
, O
while O
the O
PERI O
group O
underwent O
two O
preoperative O
cycles O
followed O
by O
two O
postoperative O
cycles O
, O
the O
3rd O
and O
4th O
cycles O
being O
given O
only O
to O
responders O
in O
both O
cases O
. O

A O
total O
of O
528 O
patients O
were O
randomised O
, O
267 O
of O
which O
were O
assigned O
to O
the O
PRE O
group O
and O
261 O
to O
the O
PERI O
group O
. O

Three-year O
OS O
did O
not O
differ O
between O
the O
two O
groups O
( O
67.4 O
% O
and O
67.7 O
% O
, O
respectively O
";" O
hazard O
ratio O
( O
HR O
) O
=1.01 O
[ O
0.79-1.30 O
] O
, O
p=0.92 O
) O
, O
nor O
did O
3-year O
disease-free O
survival O
, O
response O
rates O
, O
toxicity O
, O
or O
postoperative O
mortality O
. O

Pathological B-Premise
complete I-Premise
response I-Premise
was I-Premise
observed I-Premise
in I-Premise
22 I-Premise
( I-Premise
8.2 I-Premise
% I-Premise
) I-Premise
and I-Premise
16 I-Premise
patients I-Premise
( I-Premise
6.1 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Although B-Premise
quality I-Premise
of I-Premise
life I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
, I-Premise
chemotherapy B-Premise
compliance I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
PRE I-Premise
group I-Premise
. I-Premise

The B-Premise
proportion I-Premise
of I-Premise
responders I-Premise
who I-Premise
received I-Premise
Cycles I-Premise
3 I-Premise
and I-Premise
4 I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
PRE I-Premise
group I-Premise
( I-Premise
90.4 I-Premise
% I-Premise
versus I-Premise
75.2 I-Premise
% I-Premise
, I-Premise
p=0.001 I-Premise
) I-Premise
. I-Premise

In B-Premise
responders I-Premise
, I-Premise
the I-Premise
dose I-Premise
intensity I-Premise
of I-Premise
Cycles I-Premise
3 I-Premise
and I-Premise
4 I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
PRE I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
PERI I-Premise
group I-Premise
( I-Premise
mean I-Premise
relative I-Premise
dose I-Premise
intensity I-Premise
of I-Premise
90.4 I-Premise
% I-Premise
versus I-Premise
82.6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
p=0.0007 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
GP I-Premise
and I-Premise
TC I-Premise
in I-Premise
3-year I-Premise
OS I-Premise
( I-Premise
HR=0.97 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
: I-Premise
0.76-1.25 I-Premise
] I-Premise
, I-Premise
p=0.80 I-Premise
) I-Premise
or I-Premise
response I-Premise
rates I-Premise
. I-Premise

However O
, O
the B-Premise
regimens I-Premise
' I-Premise
toxicity I-Premise
profiles I-Premise
differed I-Premise
. I-Premise

This B-Claim
study I-Claim
failed I-Claim
to I-Claim
demonstrate I-Claim
any I-Claim
difference I-Claim
in I-Claim
survival I-Claim
between I-Claim
patients I-Claim
receiving I-Claim
preoperative I-Claim
and I-Claim
perioperative I-Claim
chemotherapy I-Claim
in I-Claim
early-stage I-Claim
NSCLC I-Claim
. I-Claim

The B-Claim
increase I-Claim
from I-Claim
two I-Claim
to I-Claim
four I-Claim
preoperative I-Claim
chemotherapy I-Claim
cycles I-Claim
did I-Claim
not I-Claim
increase I-Claim
the I-Claim
pathological I-Claim
response I-Claim
rate I-Claim
. I-Claim

To O
evaluate O
the O
efficacy O
and O
safety O
of O
a O
slow-release O
formulation O
of O
cytarabine O
( O
DepoCyt O
";" O
Chiron O
Corp O
, O
Emeryville O
, O
CA O
, O
and O
Skye O
Pharma O
, O
Inc O
, O
San O
Diego O
, O
CA O
) O
that O
maintains O
cytotoxic O
concentrations O
of O
cytarabine O
( O
ara-C O
) O
in O
the O
CSF O
of O
most O
patients O
for O
more O
than O
14 O
days O
. O

Twenty-eight O
patients O
with O
lymphoma O
and O
a O
positive O
CSF O
cytology O
were O
randomized O
to O
receive O
DepoCyt O
50 O
mg O
once O
every O
2 O
weeks O
or O
free O
ara-C O
50 O
mg O
twice O
a O
week O
for O
1 O
month O
. O

Patients O
whose O
CSF O
cytology O
converted O
to O
negative O
and O
who O
did O
not O
have O
neurologic O
progression O
received O
an O
additional O
3 O
months O
of O
consolidation O
therapy O
and O
then O
4 O
months O
of O
maintenance O
therapy O
. O

All O
patients O
received O
dexamethasone O
4 O
mg O
orally O
bid O
on O
days O
1 O
through O
5 O
of O
each O
2-week O
cycle O
. O

The B-Premise
response I-Premise
rate I-Premise
was I-Premise
71 I-Premise
% I-Premise
for I-Premise
DepoCyt I-Premise
and I-Premise
15 I-Premise
% I-Premise
for I-Premise
ara-C I-Premise
on I-Premise
an I-Premise
intent-to-treat I-Premise
basis I-Premise
( I-Premise
P I-Premise
=.006 I-Premise
) I-Premise
. I-Premise

All B-Premise
of I-Premise
the I-Premise
patients I-Premise
on I-Premise
the I-Premise
DepoCyt I-Premise
arm I-Premise
but I-Premise
only I-Premise
53 I-Premise
% I-Premise
of I-Premise
those I-Premise
on I-Premise
the I-Premise
ara-C I-Premise
arm I-Premise
were I-Premise
able I-Premise
to I-Premise
complete I-Premise
the I-Premise
planned I-Premise
1-month I-Premise
induction I-Premise
therapy I-Premise
regimen I-Premise
. I-Premise

Time B-Premise
to I-Premise
neurologic I-Premise
progression I-Premise
and I-Premise
survival I-Premise
trend I-Premise
in I-Premise
favor I-Premise
of I-Premise
DepoCyt I-Premise
( I-Premise
median I-Premise
, I-Premise
78.5 I-Premise
v I-Premise
42 I-Premise
days I-Premise
and I-Premise
99.5 I-Premise
v I-Premise
63 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
> I-Premise
.05 I-Premise
) I-Premise
. I-Premise

DepoCyt B-Premise
treatment I-Premise
was I-Premise
associated I-Premise
with I-Premise
an I-Premise
improved I-Premise
mean I-Premise
change I-Premise
in I-Premise
Karnofsky I-Premise
performance I-Premise
score I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
induction I-Premise
( I-Premise
P I-Premise
=.041 I-Premise
) I-Premise
. I-Premise

The B-Premise
major I-Premise
adverse I-Premise
events I-Premise
on I-Premise
both I-Premise
arms I-Premise
were I-Premise
headache I-Premise
and I-Premise
arachnoiditis I-Premise
, I-Premise
which I-Premise
were I-Premise
often I-Premise
caused I-Premise
by I-Premise
the I-Premise
underlying I-Premise
disease I-Premise
. I-Premise

DepoCyt B-Claim
injected I-Claim
once I-Claim
every I-Claim
2 I-Claim
weeks I-Claim
produced I-Claim
a I-Claim
high I-Claim
response I-Claim
rate I-Claim
and I-Claim
a I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
as I-Claim
measured I-Claim
by I-Claim
Karnofsky I-Claim
score I-Claim
relative I-Claim
to I-Claim
that I-Claim
produced I-Claim
by I-Claim
free I-Claim
ara-C I-Claim
injected I-Claim
twice I-Claim
a I-Claim
week I-Claim
. I-Claim

Patients O
receiving O
chemoradiation O
for O
cervical O
cancer O
are O
at O
risk O
for O
distress O
, O
chemoradiation-related O
side-effects O
, O
and O
immunosuppression O
. O

This O
prospective O
randomized O
clinical O
trial O
examined O
effects O
of O
a O
complementary O
therapy O
, O
Healing O
Touch O
( O
HT O
) O
, O
versus O
relaxation O
training O
( O
RT O
) O
and O
usual O
care O
( O
UC O
) O
for O
( O
1 O
) O
supporting O
cellular O
immunity O
, O
( O
2 O
) O
improving O
mood O
and O
quality O
of O
life O
( O
QOL O
) O
, O
and O
( O
3 O
) O
reducing O
treatment-associated O
toxicities O
and O
treatment O
delay O
in O
cervical O
cancer O
patients O
receiving O
chemoradiation O
. O

Sixty O
women O
with O
stages O
IB1 O
to O
IVA O
cervical O
cancer O
were O
randomly O
assigned O
to O
receive O
UC O
or O
4 O
×/weekly O
individual O
sessions O
of O
either O
HT O
or O
RT O
immediately O
following O
radiation O
during O
their O
6-week O
chemoradiation O
treatment O
. O

Patients O
completed O
psychosocial O
assessments O
and O
blood O
sampling O
before O
chemoradiation O
at O
baseline O
, O
weeks O
4 O
and O
6 O
. O

Multilevel O
regression O
analyses O
using O
orthogonal O
contrasts O
tested O
for O
differences O
between O
treatment O
conditions O
over O
time O
. O

HT B-Premise
patients I-Premise
had I-Premise
a I-Premise
minimal I-Premise
decrease I-Premise
in I-Premise
natural I-Premise
killer I-Premise
cell I-Premise
cytotoxicity I-Premise
( I-Premise
NKCC I-Premise
) I-Premise
over I-Premise
the I-Premise
course I-Premise
of I-Premise
treatment I-Premise
whereas I-Premise
NKCC I-Premise
of I-Premise
RT I-Premise
and I-Premise
UC I-Premise
patients I-Premise
declined I-Premise
sharply I-Premise
during I-Premise
chemoradiation I-Premise
( I-Premise
group I-Premise
by I-Premise
time I-Premise
interaction I-Premise
: I-Premise
p I-Premise
= I-Premise
0.018 I-Premise
) I-Premise
. I-Premise

HT B-Premise
patients I-Premise
showed I-Premise
greater I-Premise
decreases I-Premise
in I-Premise
two I-Premise
different I-Premise
indicators I-Premise
of I-Premise
depressed I-Premise
mood I-Premise
( I-Premise
CES-D I-Premise
depressed I-Premise
mood I-Premise
subscale I-Premise
and I-Premise
POMS I-Premise
depression I-Premise
scale I-Premise
) I-Premise
compared I-Premise
to I-Premise
RT I-Premise
and I-Premise
UC I-Premise
( I-Premise
group I-Premise
by I-Premise
time I-Premise
interactions I-Premise
: I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

No B-Premise
between I-Premise
group I-Premise
differences I-Premise
were I-Premise
observed I-Premise
in I-Premise
QOL I-Premise
, I-Premise
treatment I-Premise
delay I-Premise
, I-Premise
or I-Premise
clinically-rated I-Premise
toxicities I-Premise
. I-Premise

HT B-Claim
may I-Claim
benefit I-Claim
cervical I-Claim
cancer I-Claim
patients I-Claim
by I-Claim
moderating I-Claim
effects I-Claim
of I-Claim
chemoradiation I-Claim
on I-Claim
depressed I-Claim
mood I-Claim
and I-Claim
cellular I-Claim
immunity I-Claim
. I-Claim

Effects B-Claim
of I-Claim
HT I-Claim
on I-Claim
toxicities I-Claim
, I-Claim
treatment I-Claim
delay I-Claim
, I-Claim
QOL I-Claim
, I-Claim
and I-Claim
fatigue I-Claim
were I-Claim
not I-Claim
observed I-Claim
. I-Claim

Long-term O
clinical O
implications O
of O
findings O
are O
not O
known O
. O

Exercise O
improves O
physical O
functioning O
and O
symptom O
management O
during O
breast O
cancer O
chemotherapy O
, O
but O
the O
effects O
of O
different O
doses O
and O
types O
of O
exercise O
are O
unknown O
. O

A O
multicenter O
trial O
in O
Canada O
randomized O
301 O
breast O
cancer O
patients O
to O
thrice-weekly O
supervised O
exercise O
during O
chemotherapy O
consisting O
of O
either O
a O
standard O
dose O
of O
25 O
to O
30 O
minutes O
of O
aerobic O
exercise O
( O
STAN O
";" O
n O
= O
96 O
) O
, O
a O
higher O
dose O
of O
50 O
to O
60 O
minutes O
of O
aerobic O
exercise O
( O
HIGH O
";" O
n O
= O
101 O
) O
, O
or O
a O
combined O
dose O
of O
50 O
to O
60 O
minutes O
of O
aerobic O
and O
resistance O
exercise O
( O
COMB O
";" O
n O
= O
104 O
) O
. O

The O
primary O
endpoint O
was O
physical O
functioning O
assessed O
by O
the O
Medical O
Outcomes O
Survey-Short O
Form O
( O
SF O
) O
-36 O
. O

Secondary O
endpoints O
were O
other O
physical O
functioning O
scales O
, O
symptoms O
, O
fitness O
, O
and O
chemotherapy O
completion O
. O

All O
statistical O
tests O
were O
linear O
mixed O
model O
analyses O
, O
and O
the O
P O
values O
were O
two-sided O
. O

Follow-up O
assessment O
of O
patient-reported O
outcomes O
was O
99.0 O
% O
. O

Adjusted B-Premise
linear I-Premise
mixed-model I-Premise
analyses I-Premise
showed I-Premise
that I-Premise
neither I-Premise
HIGH I-Premise
( I-Premise
+0.8 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
-0.8 I-Premise
to I-Premise
2.4 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.30 I-Premise
) I-Premise
nor I-Premise
COMB I-Premise
( I-Premise
+0.5 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-1.1 I-Premise
to I-Premise
2.1 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.52 I-Premise
] I-Premise
were I-Premise
superior I-Premise
to I-Premise
STAN I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
. I-Premise

In B-Premise
secondary I-Premise
analyses I-Premise
not I-Premise
adjusted I-Premise
for I-Premise
multiple I-Premise
comparisons I-Premise
, I-Premise
HIGH I-Premise
was I-Premise
superior I-Premise
to I-Premise
STAN I-Premise
for I-Premise
the I-Premise
SF-36 I-Premise
physical I-Premise
component I-Premise
summary I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
, I-Premise
SF-36 I-Premise
bodily I-Premise
pain I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
and I-Premise
endocrine I-Premise
symptoms I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

COMB B-Premise
was I-Premise
superior I-Premise
to I-Premise
STAN I-Premise
for I-Premise
endocrine I-Premise
symptoms I-Premise
( I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
and I-Premise
superior I-Premise
to I-Premise
STAN I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
HIGH I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
for I-Premise
muscular I-Premise
strength I-Premise
. I-Premise

HIGH B-Premise
was I-Premise
superior I-Premise
to I-Premise
COMB I-Premise
for I-Premise
the I-Premise
SF-36 I-Premise
bodily I-Premise
pain I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
and I-Premise
aerobic I-Premise
fitness I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
. I-Premise

No B-Premise
differences I-Premise
emerged I-Premise
for I-Premise
body I-Premise
composition I-Premise
or I-Premise
chemotherapy I-Premise
completion I-Premise
. I-Premise

A B-Claim
higher I-Claim
volume I-Claim
of I-Claim
aerobic I-Claim
or I-Claim
combined I-Claim
exercise I-Claim
is I-Claim
achievable I-Claim
and I-Claim
safe I-Claim
during I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
and I-Claim
may I-Claim
manage I-Claim
declines I-Claim
in I-Claim
physical I-Claim
functioning I-Claim
and I-Claim
worsening I-Claim
symptoms I-Claim
better I-Claim
than I-Claim
standard I-Claim
volumes I-Claim
. I-Claim

For B-Claim
several I-Claim
decades I-Claim
, I-Claim
both I-Claim
preoperative I-Claim
intra-arterial I-Claim
chemotherapy I-Claim
and I-Claim
preoperative I-Claim
irradiation I-Claim
have I-Claim
been I-Claim
accepted I-Claim
treatments I-Claim
for I-Claim
patients I-Claim
with I-Claim
tumors I-Claim
of I-Claim
the I-Claim
head I-Claim
and I-Claim
neck I-Claim
. I-Claim

Unfortunately O
, O
arguments O
have O
often O
been O
put O
forward O
in O
favor O
of O
one O
or O
other O
of O
the O
two O
methods O
, O
but O
without O
the O
performance O
of O
an O
objective O
, O
randomized O
investigation O
. O

To O
resolve O
this O
situation O
, O
the O
authors O
have O
carried O
out O
a O
multicenter O
, O
randomized O
prospective O
study O
of O
selected O
patients O
with O
a O
view O
to O
deciding O
which O
method O
affords O
better O
results O
in O
complex O
tumor O
therapy O
from O
the O
aspects O
of O
survival O
and O
postoperative O
quality O
of O
life O
. O

One O
hundred O
thirty-one O
patients O
with O
operable O
sublingual O
or O
lingual O
squamous O
cell O
carcinoma O
in O
stages O
T2NXM0 O
to O
T4MXM0 O
were O
randomized O
into O
2 O
groups O
: O
1 O
group O
participated O
in O
preoperative O
chemotherapy O
with O
cisplatin O
and O
epirubicin O
( O
total O
doses O
: O
200 O
mg O
cisplatin O
, O
120 O
mg O
epirubicin O
) O
via O
the O
external O
carotid O
artery O
, O
whereas O
the O
other O
group O
received O
preoperative O
radiation O
therapy O
( O
46 O
grays O
) O
. O

Following O
subsequent O
radical O
surgery O
, O
the O
patients O
received O
regular O
follow-up O
for O
5 O
years O
. O

By O
the O
end O
of O
the O
5 O
years O
, O
95 O
of O
the O
131 O
patients O
had O
conformed O
to O
the O
protocol O
. O

Of O
those O
95 O
, O
47 O
had O
received O
preoperative O
chemotherapy O
and O
48 O
preoperative O
irradiation O
. O

After B-Premise
5 I-Premise
years I-Premise
, I-Premise
18 I-Premise
of I-Premise
the I-Premise
47 I-Premise
patients I-Premise
who I-Premise
received I-Premise
chemotherapy I-Premise
and I-Premise
15 I-Premise
of I-Premise
the I-Premise
48 I-Premise
patients I-Premise
who I-Premise
received I-Premise
irradiation I-Premise
were I-Premise
still I-Premise
alive I-Premise
and I-Premise
tumor I-Premise
free I-Premise
. I-Premise

A B-Premise
few I-Premise
more I-Premise
patients I-Premise
had I-Premise
died I-Premise
of I-Premise
recurrence I-Premise
or I-Premise
regional I-Premise
metastasis I-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
( I-Premise
23 I-Premise
patients I-Premise
) I-Premise
than I-Premise
in I-Premise
the I-Premise
irradiation I-Premise
group I-Premise
( I-Premise
20 I-Premise
patients I-Premise
) I-Premise
. I-Premise

Occurrence B-Premise
of I-Premise
a I-Premise
second I-Premise
carcinoma I-Premise
was I-Premise
3 I-Premise
times I-Premise
as I-Premise
frequent I-Premise
in I-Premise
the I-Premise
irradiation I-Premise
group I-Premise
( I-Premise
9 I-Premise
patients I-Premise
) I-Premise
as I-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
( I-Premise
3 I-Premise
patients I-Premise
) I-Premise
. I-Premise

Overall O
, O
the B-Claim
survival I-Claim
rates I-Claim
were I-Claim
by-and-large I-Claim
the I-Claim
same I-Claim
for I-Claim
the I-Claim
two I-Claim
groups I-Claim
. I-Claim

Regarding B-Claim
postoperative I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
the I-Claim
chemotherapy I-Claim
group I-Claim
presented I-Claim
a I-Claim
more I-Claim
favorable I-Claim
picture I-Claim
. I-Claim

The B-Claim
long I-Claim
term I-Claim
survival I-Claim
results I-Claim
subsequent I-Claim
to I-Claim
preoperative I-Claim
intra-arterial I-Claim
chemotherapy I-Claim
or I-Claim
preoperative I-Claim
radiotherapy I-Claim
were I-Claim
practically I-Claim
the I-Claim
same I-Claim
. I-Claim

Regarding B-Claim
postoperative I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
patients I-Claim
who I-Claim
underwent I-Claim
intra-arterial I-Claim
chemotherapy I-Claim
appeared I-Claim
to I-Claim
be I-Claim
in I-Claim
a I-Claim
slightly I-Claim
more I-Claim
favorable I-Claim
situation I-Claim
. I-Claim

The O
authors O
consider O
it O
important O
to O
stress O
these O
findings O
, O
as O
they O
are O
not O
aware O
of O
a O
similar O
randomized O
study O
of O
patients O
with O
tumors O
of O
the O
oral O
cavity O
. O

To O
investigate O
the O
effects O
of O
medroxyprogesterone O
acetate O
( O
MPA O
) O
on O
appetite O
, O
weight O
, O
and O
quality O
of O
life O
( O
QL O
) O
in O
patients O
with O
advanced-stage O
, O
incurable O
, O
non-hormone-sensitive O
cancer O
. O

Two O
hundred O
six O
eligible O
patients O
were O
randomized O
between O
double-blind O
MPA O
500 O
mg O
twice O
daily O
or O
placebo O
. O

Appetite O
( O
0 O
to O
10 O
numerical O
rating O
scale O
) O
, O
weight O
, O
and O
QL O
( O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
[ O
EORTC-QLQ-C30 O
] O
) O
were O
assessed O
before O
the O
start O
of O
treatment O
( O
t O
= O
0 O
) O
, O
and O
6 O
weeks O
( O
t O
= O
6 O
) O
and O
12 O
weeks O
( O
t O
= O
12 O
) O
thereafter O
. O

One O
hundred O
thirty-four O
patients O
( O
68 O
MPA O
and O
66 O
placebo O
) O
were O
assessable O
at O
t O
= O
6 O
and O
99 O
patients O
( O
53 O
MPA O
and O
46 O
placebo O
) O
at O
t O
= O
12 O
. O

A B-Premise
beneficial I-Premise
effect I-Premise
of I-Premise
MPA I-Premise
on I-Premise
appetite I-Premise
was I-Premise
observed I-Premise
after I-Premise
both I-Premise
6 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
and I-Premise
12 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
of I-Premise
treatment I-Premise
. I-Premise

After B-Premise
12 I-Premise
weeks I-Premise
, I-Premise
a I-Premise
mean I-Premise
weight I-Premise
gain I-Premise
of I-Premise
0.6 I-Premise
+/- I-Premise
4.4 I-Premise
kg I-Premise
was I-Premise
seen I-Premise
in I-Premise
the I-Premise
MPA I-Premise
, I-Premise
versus I-Premise
an I-Premise
ongoing I-Premise
mean I-Premise
weight I-Premise
loss I-Premise
of I-Premise
1.4 I-Premise
+/- I-Premise
4.6 I-Premise
kg I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

This B-Premise
difference I-Premise
of I-Premise
2.0 I-Premise
kg I-Premise
was I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
. I-Premise

During B-Premise
the I-Premise
study I-Premise
, I-Premise
several I-Premise
areas I-Premise
of I-Premise
QL I-Premise
deteriorated I-Premise
in I-Premise
the I-Premise
total I-Premise
group I-Premise
of I-Premise
patients I-Premise
. I-Premise

With B-Claim
the I-Claim
exception I-Claim
of I-Claim
an I-Claim
improvement I-Claim
in I-Claim
appetite I-Claim
and I-Claim
possible I-Claim
also I-Claim
a I-Claim
reduction I-Claim
in I-Claim
nausea I-Claim
and I-Claim
vomiting I-Claim
, I-Claim
no I-Claim
measurable I-Claim
beneficial I-Claim
effects I-Claim
of I-Claim
MPA I-Claim
on I-Claim
QL I-Claim
could I-Claim
be I-Claim
demonstrated I-Claim
. I-Claim

The B-Premise
side I-Premise
effects I-Premise
profile I-Premise
of I-Premise
MPA I-Premise
was I-Premise
favorable I-Premise
: I-Premise
only I-Premise
a I-Premise
trend I-Premise
toward I-Premise
an I-Premise
increase I-Premise
in I-Premise
( I-Premise
usually I-Premise
mild I-Premise
) I-Premise
peripheral I-Premise
edema I-Premise
was I-Premise
observed I-Premise
. I-Premise

In B-Claim
weight-losing I-Claim
, I-Claim
advanced-stage I-Claim
non-hormone-sensitive I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
MPA I-Claim
exhibits I-Claim
a I-Claim
mild I-Claim
side I-Claim
effects I-Claim
profile I-Claim
, I-Claim
has I-Claim
a I-Claim
beneficial I-Claim
effect I-Claim
on I-Claim
appetite I-Claim
, I-Claim
and I-Claim
may I-Claim
prevent I-Claim
further I-Claim
weight I-Claim
loss I-Claim
. I-Claim

However B-Claim
, I-Claim
general I-Claim
QL I-Claim
in I-Claim
the I-Claim
present I-Claim
study I-Claim
was I-Claim
not I-Claim
measurably I-Claim
influenced I-Claim
by I-Claim
MPA I-Claim
treatment I-Claim
. I-Claim

Cerebral B-Claim
metastasis I-Claim
is I-Claim
a I-Claim
common I-Claim
oncologic I-Claim
problem I-Claim
that I-Claim
occurs I-Claim
in I-Claim
15-30 I-Claim
% I-Claim
of I-Claim
cancer I-Claim
patients I-Claim
";" I-Claim
approximately O
half O
such O
metastases O
are O
single O
. O

Previous O
retrospective O
studies O
and O
two O
randomized O
trials O
reported O
that O
the O
addition O
of O
surgical O
extirpation O
prior O
to O
radiation O
therapy O
increased O
survival O
, O
neurologic O
function O
, O
and O
quality O
of O
life O
compared O
with O
radiation O
alone O
in O
patients O
with O
a O
single O
brain O
metastasis O
. O

A O
randomized O
controlled O
trial O
was O
conducted O
in O
which O
patients O
with O
a O
single O
brain O
metastasis O
were O
allocated O
to O
undergo O
radiation O
alone O
or O
surgery O
plus O
radiation O
. O

Radiation O
consisted O
of O
3000 O
centigray O
to O
the O
whole O
brain O
in O
10 O
fractions O
. O

Forty-three O
patients O
received O
radiation O
alone O
and O
41 O
patients O
surgery O
plus O
radiation O
. O

All O
but O
two O
of O
the O
study O
patients O
died O
. O

No B-Premise
difference I-Premise
in I-Premise
survival I-Premise
was I-Premise
detected I-Premise
between I-Premise
the I-Premise
groups I-Premise
";" I-Premise
the B-Premise
median I-Premise
survival I-Premise
for I-Premise
the I-Premise
radiation I-Premise
group I-Premise
was I-Premise
6.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
3-11.4 I-Premise
) I-Premise
compared I-Premise
with I-Premise
5.6 I-Premise
months I-Premise
for I-Premise
the I-Premise
surgery I-Premise
plus I-Premise
radiation I-Premise
group I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
3.9-7.2 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
0.24 I-Premise
) I-Premise
. I-Premise

Most B-Premise
patients I-Premise
died I-Premise
within I-Premise
the I-Premise
first I-Premise
year I-Premise
( I-Premise
69.8 I-Premise
% I-Premise
in I-Premise
the I-Premise
radiation I-Premise
arm I-Premise
vs. I-Premise
87.8 I-Premise
% I-Premise
in I-Premise
the I-Premise
surgery I-Premise
plus I-Premise
radiation I-Premise
arm I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
the I-Premise
30-day I-Premise
mortality I-Premise
, I-Premise
morbidity I-Premise
, I-Premise
or I-Premise
causes I-Premise
of I-Premise
death I-Premise
. I-Premise

Extracranial B-Premise
metastases I-Premise
was I-Premise
an I-Premise
important I-Premise
predictor I-Premise
of I-Premise
mortality I-Premise
( I-Premise
relative I-Premise
risk I-Premise
, I-Premise
2.3 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
proportion I-Premise
of I-Premise
days I-Premise
that I-Premise
the I-Premise
Karnofsky I-Premise
performance I-Premise
status I-Premise
was I-Premise
> I-Premise
or I-Premise
= I-Premise
70 I-Premise
% I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
2 I-Premise
groups I-Premise
. I-Premise

This B-Claim
trial I-Claim
failed I-Claim
to I-Claim
demonstrate I-Claim
that I-Claim
the I-Claim
addition I-Claim
of I-Claim
surgery I-Claim
to I-Claim
radiation I-Claim
therapy I-Claim
improved I-Claim
outcome I-Claim
of I-Claim
patients I-Claim
with I-Claim
a I-Claim
single I-Claim
brain I-Claim
metastasis I-Claim
. I-Claim

Thus B-Claim
, I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
surgery I-Claim
plus I-Claim
radiation I-Claim
compared I-Claim
with I-Claim
radiation I-Claim
alone I-Claim
needs I-Claim
to I-Claim
be I-Claim
addressed I-Claim
by I-Claim
further I-Claim
clinical I-Claim
trials I-Claim
and/or I-Claim
a I-Claim
meta-analysis I-Claim
. I-Claim

To O
investigate O
whether O
uterine O
artery O
embolization O
( O
UAE O
) O
is O
a O
cost-effective O
alternative O
to O
hysterectomy O
for O
patients O
with O
symptomatic O
uterine O
fibroids O
, O
the O
authors O
performed O
an O
economic O
evaluation O
alongside O
the O
multicenter O
randomized O
EMMY O
( O
EMbolization O
versus O
hysterectoMY O
) O
trial O
. O

Between O
February O
2002 O
and O
February O
2004 O
, O
177 O
patients O
were O
randomized O
to O
undergo O
UAE O
( O
n O
= O
88 O
) O
or O
hysterectomy O
( O
n O
= O
89 O
) O
and O
followed O
up O
until O
24 O
months O
after O
initial O
treatment O
allocation O
. O

Conditional O
on O
the O
equivalence O
of O
clinical O
outcome O
, O
a O
cost O
minimization O
analysis O
was O
performed O
according O
to O
the O
intention O
to O
treat O
principle O
. O

Costs O
included O
health O
care O
costs O
inside O
and O
outside O
the O
hospital O
as O
well O
as O
costs O
related O
to O
absence O
from O
work O
( O
societal O
perspective O
) O
. O

Cumulative O
standardized O
costs O
were O
estimated O
as O
volumes O
multiplied O
with O
prices O
. O

The O
nonparametric O
bootstrap O
method O
was O
used O
to O
quantify O
differences O
in O
mean O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
) O
costs O
between O
the O
strategies O
. O

In O
total O
, O
81 O
patients O
underwent O
UAE O
and O
75 O
underwent O
hysterectomy O
. O

In O
the O
UAE O
group O
, O
19 O
patients O
( O
23 O
% O
) O
underwent O
secondary O
hysterectomies O
. O

The B-Premise
mean I-Premise
total I-Premise
costs I-Premise
per I-Premise
patient I-Premise
in I-Premise
the I-Premise
UAE I-Premise
group I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
those I-Premise
in I-Premise
the I-Premise
hysterectomy I-Premise
group I-Premise
( I-Premise
$ I-Premise
11,626 I-Premise
vs I-Premise
$ I-Premise
18,563 I-Premise
";" I-Premise
mean I-Premise
difference I-Premise
, I-Premise
- I-Premise
$ I-Premise
6,936 I-Premise
[ I-Premise
-37 I-Premise
% I-Premise
] I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
- I-Premise
$ I-Premise
9,548 I-Premise
, I-Premise
$ I-Premise
4,281 I-Premise
) I-Premise
. I-Premise

The B-Premise
direct I-Premise
medical I-Premise
in-hospital I-Premise
costs I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
UAE I-Premise
group I-Premise
: I-Premise
$ I-Premise
6,688 I-Premise
vs I-Premise
$ I-Premise
8,313 I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
- I-Premise
$ I-Premise
1,624 I-Premise
[ I-Premise
-20 I-Premise
% I-Premise
] I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
- I-Premise
$ I-Premise
2,605 I-Premise
, I-Premise
- I-Premise
$ I-Premise
586 I-Premise
) I-Premise
. I-Premise

Direct B-Premise
medical I-Premise
out-of-hospital I-Premise
and I-Premise
direct I-Premise
nonmedical I-Premise
costs I-Premise
were I-Premise
low I-Premise
in I-Premise
both I-Premise
groups I-Premise
( I-Premise
mean I-Premise
cost I-Premise
difference I-Premise
, I-Premise
$ I-Premise
156 I-Premise
in I-Premise
favor I-Premise
of I-Premise
hysterectomy I-Premise
) I-Premise
. I-Premise

The B-Premise
costs I-Premise
related I-Premise
to I-Premise
absence I-Premise
from I-Premise
work I-Premise
differed I-Premise
significantly I-Premise
between I-Premise
the I-Premise
treatment I-Premise
strategies I-Premise
in I-Premise
favor I-Premise
of I-Premise
UAE I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
- I-Premise
$ I-Premise
5,453 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
- I-Premise
$ I-Premise
7,718 I-Premise
, I-Premise
- I-Premise
$ I-Premise
3,107 I-Premise
) I-Premise
. I-Premise

The O
costs O
of O
absence O
from O
work O
accounted O
for O
79 O
% O
of O
the O
difference O
in O
total O
costs O
. O

The B-Premise
24-month I-Premise
cumulative I-Premise
cost I-Premise
of I-Premise
UAE I-Premise
is I-Premise
lower I-Premise
than I-Premise
that I-Premise
of I-Premise
hysterectomy I-Premise
. I-Premise

From B-Claim
a I-Claim
societal I-Claim
economic I-Claim
perspective I-Claim
, I-Claim
UAE I-Claim
is I-Claim
the I-Claim
superior I-Claim
treatment I-Claim
strategy I-Claim
in I-Claim
women I-Claim
with I-Claim
symptomatic I-Claim
uterine I-Claim
fibroids I-Claim
. I-Claim

Prospective B-Claim
investigations I-Claim
of I-Claim
complete I-Claim
decongestive I-Claim
lymphatic I-Claim
physiotherapy I-Claim
( I-Claim
CDPT I-Claim
) I-Claim
, I-Claim
including I-Claim
manual I-Claim
lymphatic I-Claim
drainage I-Claim
( I-Claim
MLD I-Claim
) I-Claim
, I-Claim
have I-Claim
validated I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
these I-Claim
interventions I-Claim
for I-Claim
the I-Claim
initial I-Claim
reduction I-Claim
of I-Claim
edema I-Claim
and I-Claim
long-term I-Claim
maintenance I-Claim
of I-Claim
limb I-Claim
volume I-Claim
in I-Claim
lymphedema I-Claim
. I-Claim

However O
, O
CDPT O
demands O
substantial O
time O
and O
effort O
from O
patients O
to O
maintain O
these O
benefits O
";" O
the B-Claim
treatments I-Claim
are I-Claim
not I-Claim
always I-Claim
well-accepted I-Claim
, I-Claim
and O
patients B-Claim
may I-Claim
suffer I-Claim
from I-Claim
a I-Claim
deterioration I-Claim
in I-Claim
quality-of-life I-Claim
or I-Claim
a I-Claim
time-dependent I-Claim
loss I-Claim
of I-Claim
initial I-Claim
treatment I-Claim
benefits I-Claim
. I-Claim

A O
new O
device O
designed O
for O
home O
use O
by O
the O
patient O
, O
the O
Flexitouch O
, O
has O
been O
developed O
to O
mechanically O
simulate O
MLD O
. O

We O
have O
undertaken O
a O
prospective O
, O
randomized O
, O
crossover O
study O
of O
the O
efficacy O
of O
the O
Flexitouch O
, O
when O
compared O
to O
massage O
, O
in O
the O
self-administered O
maintenance O
therapy O
of O
lymphedema O
. O

A O
prospective O
, O
randomized O
, O
crossover O
study O
of O
maintenance O
therapy O
was O
performed O
in O
10 O
patients O
with O
unilateral O
breast O
cancer-associated O
lymphedema O
of O
the O
arm O
. O

Each O
observation O
phase O
included O
self-administered O
treatment O
with O
the O
Flexitouch O
or O
massage O
, O
1 O
hour O
daily O
for O
14 O
days O
, O
respectively O
, O
followed O
by O
crossover O
to O
the O
alternate O
treatment O
phase O
. O

Each O
treatment O
phase O
was O
preceded O
by O
a O
1 O
week O
treatment O
washout O
, O
with O
use O
of O
garment O
only O
. O

The O
sequence O
of O
treatment O
was O
randomly O
assigned O
. O

The O
potential O
impact O
of O
treatment O
modality O
on O
quality O
of O
life O
was O
assessed O
with O
serial O
administration O
of O
the O
SF-36 O
. O

Statistical O
analysis O
disclosed O
that O
the O
order O
of O
treatment O
had O
no O
outcome O
influence O
, O
permitting O
10 O
comparisons O
within O
each O
treatment O
group O
. O

Post-treatment B-Premise
arm I-Premise
volume I-Premise
reduced I-Premise
significantly I-Premise
after I-Premise
the I-Premise
Flexitouch I-Premise
, I-Premise
but I-Premise
not I-Premise
after I-Premise
self-administered I-Premise
massage I-Premise
. I-Premise

The B-Premise
patients I-Premise
' I-Premise
mean I-Premise
weight I-Premise
decreased I-Premise
significantly I-Premise
with I-Premise
Flexitouch I-Premise
use I-Premise
, I-Premise
but I-Premise
not I-Premise
with I-Premise
massage I-Premise
. I-Premise

The B-Premise
Flexitouch I-Premise
device I-Premise
was I-Premise
apparently I-Premise
well-tolerated I-Premise
and I-Premise
accepted I-Premise
by I-Premise
patients I-Premise
. I-Premise

Serial B-Premise
SF-36 I-Premise
administration I-Premise
showed I-Premise
no I-Premise
deterioration I-Premise
in I-Premise
physical I-Premise
or I-Premise
psychosocial I-Premise
scores I-Premise
compared I-Premise
to I-Premise
baseline I-Premise
measurements I-Premise
";" I-Premise
there B-Premise
were I-Premise
no I-Premise
statistical I-Premise
differences I-Premise
in I-Premise
scores I-Premise
when I-Premise
the I-Premise
two I-Premise
treatment I-Premise
modalities I-Premise
were I-Premise
compared I-Premise
. I-Premise

This B-Claim
short-term I-Claim
prospective I-Claim
evaluation I-Claim
of I-Claim
the I-Claim
Flexitouch I-Claim
suggests I-Claim
that I-Claim
the I-Claim
device I-Claim
may I-Claim
provide I-Claim
better I-Claim
maintenance I-Claim
edema I-Claim
control I-Claim
than I-Claim
self-adiminstered I-Claim
massage I-Claim
in I-Claim
breast I-Claim
cancer-associated I-Claim
lymphedema I-Claim
. I-Claim

The B-Claim
apparent I-Claim
ease I-Claim
of I-Claim
use I-Claim
and I-Claim
reliability I-Claim
of I-Claim
response I-Claim
to I-Claim
the I-Claim
device I-Claim
suggest I-Claim
that I-Claim
further I-Claim
broad-scale I-Claim
testing I-Claim
is I-Claim
warranted I-Claim
. I-Claim

Patients B-Claim
receiving I-Claim
chemotherapy I-Claim
for I-Claim
cancer I-Claim
often I-Claim
develop I-Claim
anemia I-Claim
, I-Claim
which I-Claim
can I-Claim
contribute I-Claim
to I-Claim
increased I-Claim
morbidity I-Claim
and I-Claim
reduced I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
. I-Claim

Chemotherapy-induced B-Claim
anemia I-Claim
can I-Claim
be I-Claim
successfully I-Claim
treated I-Claim
using I-Claim
recombinant I-Claim
human I-Claim
erythropoietin I-Claim
( I-Claim
rHuEPO I-Claim
) I-Claim
. I-Claim

To O
demonstrate O
the O
effectiveness O
of O
once-weekly O
( O
QW O
) O
rHuEPO O
dosing O
to O
effect O
improved O
hemoglobin O
levels O
, O
decreased O
transfusion O
use O
, O
and O
improved O
functional O
outcomes O
and O
QOL O
in O
pediatric O
leukemic O
patients O
( O
ALL O
) O
receiving O
maintenance O
chemotherapy O
. O

This O
was O
a O
prospective O
randomized O
, O
single-center O
, O
open-label O
, O
12-week O
case-control O
study O
of O
epoetin O
alfa O
in O
pediatric O
patients O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
in O
remission O
receiving O
maintenance O
chemotherapy O
. O

Sixty O
patients O
were O
randomly O
assigned O
to O
receive O
either O
epoetin O
alfa O
( O
rHuEPO O
group O
= O
30 O
cases O
, O
17 O
males O
and O
13 O
females O
, O
age O
";" O
6.8 O
+/- O
2.33 O
years O
) O
, O
or O
no O
epoetin O
alfa O
( O
control O
group O
= O
30 O
cases O
, O
16 O
males O
and O
14 O
females O
, O
age O
";" O
6.76 O
+/- O
2.28 O
years O
) O
. O

Both O
groups O
were O
matched O
as O
regard O
age O
, O
sex O
, O
baseline O
Hb O
concentration O
, O
remission O
state O
, O
chemotherapy O
regimen O
, O
numbers O
and O
amount O
of O
blood O
transfusion O
, O
and O
leukemia O
state O
( O
both O
were O
low O
and O
standard O
risk O
) O
. O

Epoetin O
alfa O
was O
administered O
at O
a O
dose O
of O
450 O
IU/kg O
, O
once O
weekly O
, O
subcutaneously O
( O
s.c. O
) O
for O
12 O
consecutive O
weeks O
. O

Endpoints O
were O
changes O
in O
hematologic O
and O
QOL O
parameters O
. O

Among B-Premise
the I-Premise
30 I-Premise
patients I-Premise
evaluable I-Premise
for I-Premise
hematologic I-Premise
response I-Premise
, I-Premise
the I-Premise
mean I-Premise
increase I-Premise
in I-Premise
Hb I-Premise
from I-Premise
baseline I-Premise
to I-Premise
time I-Premise
of I-Premise
final I-Premise
evaluation I-Premise
was I-Premise
3.08 I-Premise
+/- I-Premise
1.48 I-Premise
g/dl I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

An B-Premise
increase I-Premise
in I-Premise
Hb I-Premise
of I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
g/dl I-Premise
, I-Premise
in I-Premise
the I-Premise
absence I-Premise
of I-Premise
blood I-Premise
transfusion I-Premise
, I-Premise
occurred I-Premise
in I-Premise
70 I-Premise
% I-Premise
of I-Premise
patients I-Premise
( I-Premise
21 I-Premise
of I-Premise
30 I-Premise
patients I-Premise
) I-Premise
who I-Premise
were I-Premise
on I-Premise
the I-Premise
study I-Premise
for I-Premise
> I-Premise
or I-Premise
= I-Premise
30 I-Premise
days I-Premise
. I-Premise

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
( I-Premise
Hb I-Premise
increase I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
g/dl I-Premise
or I-Premise
Hb I-Premise
> I-Premise
or I-Premise
= I-Premise
12 I-Premise
g/dl I-Premise
in I-Premise
the I-Premise
absence I-Premise
of I-Premise
blood I-Premise
transfusion I-Premise
) I-Premise
was I-Premise
90 I-Premise
% I-Premise
( I-Premise
27 I-Premise
of I-Premise
30 I-Premise
patients I-Premise
) I-Premise
. I-Premise

In B-Premise
30 I-Premise
patients I-Premise
who I-Premise
were I-Premise
evaluable I-Premise
for I-Premise
QOL I-Premise
assessment I-Premise
, I-Premise
epoetin-alpha I-Premise
therapy I-Premise
was I-Premise
found I-Premise
to I-Premise
significantly I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
improve I-Premise
mean I-Premise
cancer I-Premise
linear I-Premise
analog I-Premise
scale I-Premise
( I-Premise
CLAS I-Premise
) I-Premise
scores I-Premise
for I-Premise
energy I-Premise
level I-Premise
, I-Premise
ability I-Premise
to I-Premise
perform I-Premise
daily I-Premise
activity I-Premise
, I-Premise
and I-Premise
overall I-Premise
QOL I-Premise
from I-Premise
baseline I-Premise
to I-Premise
the I-Premise
time I-Premise
of I-Premise
final I-Premise
evaluation I-Premise
. I-Premise

QW B-Premise
epoetin-alpha I-Premise
was I-Premise
found I-Premise
to I-Premise
be I-Premise
well I-Premise
tolerated I-Premise
. I-Premise

Treatment B-Claim
with I-Claim
QW I-Claim
epoetin-alpha I-Claim
was I-Claim
found I-Claim
to I-Claim
increase I-Claim
Hb I-Claim
levels I-Claim
, I-Claim
decrease I-Claim
transfusion I-Claim
requirement I-Claim
, I-Claim
and I-Claim
improve I-Claim
functional I-Claim
status I-Claim
and I-Claim
QOL I-Claim
in I-Claim
anemic I-Claim
patients I-Claim
with I-Claim
ALL I-Claim
in I-Claim
maintenance I-Claim
receiving I-Claim
chemotherapy I-Claim
. I-Claim

The B-Claim
once-weekly I-Claim
schedule I-Claim
is I-Claim
convenient I-Claim
, I-Claim
safe I-Claim
, I-Claim
and I-Claim
may I-Claim
reduce I-Claim
the I-Claim
burden I-Claim
on I-Claim
patients I-Claim
, I-Claim
parents I-Claim
, I-Claim
and I-Claim
their I-Claim
caregivers I-Claim
by I-Claim
reducing I-Claim
the I-Claim
number I-Claim
of I-Claim
visits I-Claim
to I-Claim
the I-Claim
clinic I-Claim
. I-Claim

Quality O
of O
life O
is O
an O
important O
outcome O
measure O
in O
the O
care O
of O
patients O
with O
cancer O
. O

We O
developed O
a O
new O
scoring O
system O
specifically O
for O
the O
evaluation O
of O
patients O
with O
upper O
gastrointestinal O
cancer O
and O
postoperative O
gastrointestinal O
dysfunction O
. O

This O
study O
was O
undertaken O
to O
evaluate O
the O
scoring O
system O
's O
validity O
in O
comparing O
outcomes O
after O
gastric O
resection O
. O

Patients O
with O
gastric O
cancer O
, O
3 O
months O
to O
3 O
years O
postoperatively O
, O
were O
surveyed O
using O
the O
survey O
instrument O
. O

Postoperative O
dysfunction O
scores O
and O
the O
status O
of O
resuming O
activities O
of O
daily O
living O
were O
compared O
with O
the O
surgical O
procedure O
performed O
by O
analysis O
of O
variance O
and O
multiple-comparison O
techniques O
. O

Of O
211 O
patients O
surveyed O
, O
165 O
( O
119 O
men O
, O
46 O
women O
";" O
mean O
age O
, O
65.1 O
± O
10.5 O
years O
) O
responded O
. O

Procedures O
included O
distal O
gastrectomy O
in O
100 O
, O
total O
gastrectomy O
in O
57 O
, O
and O
pylorus-preserving O
gastrectomy O
in O
8 O
. O

The O
overall O
dysfunction O
score O
was O
61.8 O
± O
15.5 O
. O

The B-Premise
dysfunction I-Premise
score I-Premise
was I-Premise
58.9 I-Premise
± I-Premise
15.0 I-Premise
after I-Premise
distal I-Premise
gastrectomy I-Premise
, I-Premise
66.8 I-Premise
± I-Premise
14.1 I-Premise
after I-Premise
total I-Premise
gastrectomy I-Premise
, I-Premise
and I-Premise
62.4 I-Premise
± I-Premise
21.6 I-Premise
after I-Premise
pylorus-preserving I-Premise
gastrectomy I-Premise
. I-Premise

These B-Premise
values I-Premise
differed I-Premise
significantly I-Premise
among I-Premise
the I-Premise
groups I-Premise
( I-Premise
P I-Premise
= I-Premise
.007 I-Premise
) I-Premise
. I-Premise

Dysfunction B-Premise
scores I-Premise
according I-Premise
to I-Premise
postoperative I-Premise
activity I-Premise
status I-Premise
were I-Premise
49.1 I-Premise
± I-Premise
15.6 I-Premise
in I-Premise
71 I-Premise
patients I-Premise
who I-Premise
resumed I-Premise
their I-Premise
activities I-Premise
, I-Premise
56.9 I-Premise
± I-Premise
15.7 I-Premise
in I-Premise
39 I-Premise
patients I-Premise
with I-Premise
reduced I-Premise
activities I-Premise
, I-Premise
57.3 I-Premise
± I-Premise
8.8 I-Premise
in I-Premise
15 I-Premise
patients I-Premise
with I-Premise
minimal I-Premise
activities I-Premise
, I-Premise
and I-Premise
63.3 I-Premise
± I-Premise
11.8 I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
in I-Premise
16 I-Premise
patients I-Premise
who I-Premise
did I-Premise
not I-Premise
resume I-Premise
activities I-Premise
because I-Premise
of I-Premise
poor I-Premise
physical I-Premise
condition I-Premise
. I-Premise

This B-Claim
scoring I-Claim
system I-Claim
for I-Claim
postoperative I-Claim
gastrointestinal I-Claim
dysfunction I-Claim
provides I-Claim
an I-Claim
objective I-Claim
measure I-Claim
of I-Claim
dysfunction I-Claim
related I-Claim
to I-Claim
specific I-Claim
surgical I-Claim
procedures I-Claim
and I-Claim
correlates I-Claim
with I-Claim
activities I-Claim
of I-Claim
daily I-Claim
living I-Claim
in I-Claim
the I-Claim
postoperative I-Claim
period I-Claim
. I-Claim

Analgesia B-Claim
and I-Claim
early I-Claim
quality I-Claim
of I-Claim
recovery I-Claim
may I-Claim
be I-Claim
improved I-Claim
by I-Claim
epidural I-Claim
analgesia I-Claim
. I-Claim

We O
aimed O
to O
assess O
the O
effect O
of O
receiving O
epidural O
analgesia O
on O
surgical O
adverse O
events O
and O
quality O
of O
life O
after O
laparotomy O
for O
endometrial O
cancer O
. O

Patients O
were O
enrolled O
in O
an O
international O
, O
multicentre O
, O
prospective O
randomised O
trial O
of O
outcomes O
for O
laparoscopic O
versus O
open O
surgical O
treatment O
for O
the O
management O
of O
apparent O
stage O
I O
endometrial O
cancer O
( O
LACE O
trial O
) O
. O

The O
current O
analysis O
focussed O
on O
patients O
who O
received O
an O
open O
abdominal O
hysterectomy O
via O
vertical O
midline O
incision O
only O
( O
n=257 O
) O
, O
examining O
outcomes O
in O
patients O
who O
did O
( O
n=108 O
) O
and O
did O
not O
( O
n=149 O
) O
receive O
epidural O
analgesia O
. O

Baseline O
characteristics O
were O
comparable O
between O
patients O
with O
or O
without O
epidural O
analgesia O
. O

More B-Premise
patients I-Premise
without I-Premise
epidural I-Premise
( I-Premise
34 I-Premise
% I-Premise
) I-Premise
ceased I-Premise
opioid I-Premise
analgesia I-Premise
3-5 I-Premise
days I-Premise
after I-Premise
surgery I-Premise
compared I-Premise
to I-Premise
patients I-Premise
who I-Premise
had I-Premise
an I-Premise
epidural I-Premise
( I-Premise
7 I-Premise
% I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Postoperative B-Premise
complications I-Premise
( I-Premise
any I-Premise
grade I-Premise
) I-Premise
occurred I-Premise
in I-Premise
86 I-Premise
% I-Premise
of I-Premise
patients I-Premise
with I-Premise
and I-Premise
in I-Premise
66 I-Premise
% I-Premise
of I-Premise
patients I-Premise
without I-Premise
an I-Premise
epidural I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
but O
there B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
serious I-Premise
adverse I-Premise
events I-Premise
( I-Premise
p=0.19 I-Premise
) I-Premise
. I-Premise

Epidural B-Premise
analgesia I-Premise
was I-Premise
associated I-Premise
with I-Premise
increased I-Premise
length I-Premise
of I-Premise
stay I-Premise
( I-Premise
up I-Premise
to I-Premise
48 I-Premise
days I-Premise
compared I-Premise
to I-Premise
up I-Premise
to I-Premise
34 I-Premise
days I-Premise
in I-Premise
the I-Premise
non-epidural I-Premise
group I-Premise
) I-Premise
. I-Premise

There B-Claim
was I-Claim
no I-Claim
difference I-Claim
in I-Claim
postoperative I-Claim
quality I-Claim
of I-Claim
life I-Claim
up I-Claim
to I-Claim
six I-Claim
months I-Claim
after I-Claim
surgery I-Claim
. I-Claim

Epidural B-Claim
analgesia I-Claim
was I-Claim
associated I-Claim
with I-Claim
an I-Claim
increase I-Claim
in I-Claim
any I-Claim
, I-Claim
but I-Claim
not I-Claim
serious I-Claim
, I-Claim
postoperative I-Claim
complications I-Claim
and I-Claim
length I-Claim
of I-Claim
stay I-Claim
after I-Claim
abdominal I-Claim
hysterectomy I-Claim
. I-Claim

Randomised B-Claim
controlled I-Claim
trials I-Claim
are I-Claim
needed I-Claim
to I-Claim
examine I-Claim
the I-Claim
effect I-Claim
of I-Claim
epidural I-Claim
analgesia I-Claim
on I-Claim
surgical I-Claim
adverse I-Claim
events I-Claim
, I-Claim
especially O
as O
the B-Claim
present I-Claim
data I-Claim
do I-Claim
not I-Claim
support I-Claim
a I-Claim
quality I-Claim
of I-Claim
life I-Claim
benefit I-Claim
with I-Claim
epidural I-Claim
analgesia I-Claim
. I-Claim

Cancer-related B-Claim
fatigue I-Claim
is I-Claim
the I-Claim
most I-Claim
disabling I-Claim
symptom I-Claim
experienced I-Claim
by I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
following I-Claim
the I-Claim
cancer I-Claim
treatment I-Claim
. I-Claim

The B-Premise
positive I-Premise
effects I-Premise
of I-Premise
physical I-Premise
activity I-Premise
in I-Premise
the I-Premise
rehabilitation I-Premise
of I-Premise
breast I-Premise
cancer I-Premise
patients I-Premise
are I-Premise
documented I-Premise
in I-Premise
several I-Premise
studies I-Premise
. I-Premise

In O
a O
randomized O
controlled O
study O
the O
effects O
of O
a O
structured O
physical O
training O
program O
on O
fatigue O
and O
health-related O
quality O
of O
life O
were O
evaluated O
. O

63 O
breast O
cancer O
patients O
with O
cancer-related O
chronic O
fatigue O
were O
randomized O
at O
the O
beginning O
of O
the O
inpatient O
rehabilitation O
. O

The O
control O
group O
received O
the O
standard O
complex O
rehabilitation O
program O
, O
the O
intervention O
group O
a O
structured O
physical O
training O
program O
and O
additional O
muscle O
strength O
and O
aerobic O
exercises O
. O

The O
effects O
of O
the O
treatment O
were O
evaluated O
by O
questionnaires O
at O
the O
start O
of O
rehabilitation O
( O
t1 O
) O
, O
end O
of O
rehabilitation O
( O
t2 O
) O
, O
and O
3 O
months O
after O
t2 O
( O
t3 O
) O
. O

Isometric O
muscle O
strength O
and O
aerobic O
capacity O
were O
evaluated O
at O
t1 O
and O
t2 O
. O

There B-Premise
was I-Premise
an I-Premise
improvement I-Premise
of I-Premise
muscle I-Premise
strength I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
rehabilitation I-Premise
for I-Premise
both I-Premise
groups I-Premise
. I-Premise

The B-Premise
increase I-Premise
from I-Premise
t1 I-Premise
to I-Premise
t2 I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
for I-Premise
the I-Premise
training I-Premise
group I-Premise
. I-Premise

The B-Premise
scores I-Premise
for I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
physical I-Premise
well-being I-Premise
, I-Premise
and I-Premise
functionality I-Premise
increased I-Premise
from I-Premise
t1 I-Premise
to I-Premise
t2 I-Premise
, I-Premise
but B-Premise
further I-Premise
improvement I-Premise
in I-Premise
the I-Premise
follow-up I-Premise
( I-Premise
t3 I-Premise
) I-Premise
was I-Premise
only I-Premise
observed I-Premise
in I-Premise
the I-Premise
training I-Premise
group I-Premise
. I-Premise

The B-Premise
cancer-related I-Premise
fatigue I-Premise
was I-Premise
significantly I-Premise
reduced I-Premise
in I-Premise
the I-Premise
training I-Premise
group I-Premise
from I-Premise
t1 I-Premise
to I-Premise
t3 I-Premise
, I-Premise
however I-Premise
, I-Premise
not I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Structured B-Claim
physical I-Claim
training I-Claim
programs I-Claim
initiated I-Claim
during I-Claim
inpatient I-Claim
rehabilitation I-Claim
and I-Claim
continuously I-Claim
practiced I-Claim
in I-Claim
the I-Claim
time I-Claim
thereafter I-Claim
can I-Claim
improve I-Claim
symptoms I-Claim
of I-Claim
chronic I-Claim
fatigue I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

The O
standard O
treatment O
for O
patients O
with O
clinically O
resectable O
rectal O
cancer O
is O
surgery O
. O

Postoperative B-Claim
radiochemotherapy I-Claim
is I-Claim
recommended I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
disease I-Claim
( I-Claim
pT3/4 I-Claim
or I-Claim
pN+ I-Claim
) I-Claim
. I-Claim

In B-Claim
recent I-Claim
years I-Claim
, I-Claim
encouraging I-Claim
results I-Claim
of I-Claim
preoperative I-Claim
radiotherapy I-Claim
have I-Claim
been I-Claim
reported I-Claim
. I-Claim

This O
prospective O
randomized O
phase-III O
trial O
( O
CAO/ARO/AIO-94 O
) O
compares O
the O
efficacy O
of O
neoadjuvant O
radiochemotherapy O
to O
standard O
postoperative O
radiochemotherapy O
. O

We O
report O
on O
the O
design O
of O
the O
study O
and O
first O
results O
with O
regard O
to O
toxicity O
of O
radiochemotherapy O
and O
postoperative O
morbidity O
. O

Patients O
with O
locally O
advanced O
operable O
rectal O
cancer O
( O
uT3/4 O
or O
uN+ O
, O
Mason O
CS O
III/IV O
) O
were O
randomly O
assigned O
to O
pre- O
or O
postoperative O
radiochemotherapy O
: O
A O
total O
dose O
of O
50.4 O
Gy O
( O
single O
dose O
1.8 O
Gy O
) O
was O
applied O
to O
the O
tumor O
and O
the O
pelvic O
lymph O
nodes O
. O

5-FU O
( O
1,000 O
mg/m2/d O
) O
was O
administered O
concomitantly O
in O
the O
first O
and O
fifth O
week O
of O
radiation O
as O
120-h O
continuous O
infusion O
. O

Four O
additional O
cycles O
of O
5-FU O
chemotherapy O
( O
500 O
mg/m2/d O
, O
i.v O
. O

bolus O
) O
were O
applied O
. O

Radiochemotherapy O
was O
identical O
in O
both O
arms O
except O
for O
a O
small-volume O
boost O
of O
5.4 O
Gy O
in O
the O
postoperative O
setting O
. O

Time O
interval O
between O
radiochemotherapy O
and O
surgery O
was O
4-6 O
weeks O
in O
both O
arms O
. O

Techniques O
of O
surgery O
were O
standardized O
and O
included O
total O
mesorectal O
excision O
. O

In O
addition O
, O
stratification O
according O
to O
surgeons O
involved O
has O
been O
provided O
for O
. O

Primary O
endpoints O
of O
the O
study O
are O
5-year O
overall-survival O
, O
local O
and O
distant O
control O
, O
secondary O
endpoints O
include O
rate O
of O
curative O
( O
R0 O
) O
resections O
and O
sphincter O
saving O
procedures O
, O
toxicity O
of O
radiochemotherapy O
, O
surgical O
complications O
and O
quality O
of O
life O
. O

As O
of O
15th O
November O
2000 O
, O
628 O
patients O
were O
randomized O
from O
26 O
participating O
institutions O
: O
310 O
patients O
were O
randomized O
to O
postoperative O
radiochemotherapy O
, O
318 O
patients O
to O
preoperative O
radiochemotherapy O
. O

Acute B-Premise
toxicity I-Premise
( I-Premise
WHO I-Premise
) I-Premise
of I-Premise
radiochemotherapy I-Premise
was I-Premise
low I-Premise
, I-Premise
with I-Premise
less I-Premise
than I-Premise
15 I-Premise
% I-Premise
of I-Premise
patients I-Premise
experiencing I-Premise
Grade I-Premise
3 I-Premise
or I-Premise
higher I-Premise
toxicity I-Premise
: O
The B-Premise
principal I-Premise
toxicity I-Premise
was I-Premise
diarrhea I-Premise
, I-Premise
with I-Premise
12 I-Premise
% I-Premise
in I-Premise
the I-Premise
postoperative I-Premise
radiochemotherapy I-Premise
arm I-Premise
and I-Premise
10 I-Premise
% I-Premise
in I-Premise
the I-Premise
preoperative I-Premise
radiochemotherapy I-Premise
arm I-Premise
having I-Premise
Grade-3 I-Premise
, I-Premise
and I-Premise
1 I-Premise
% I-Premise
in I-Premise
either I-Premise
arm I-Premise
having I-Premise
Grade-4 I-Premise
diarrhea I-Premise
. I-Premise

Erythema B-Premise
, I-Premise
nausea I-Premise
and I-Premise
leukopenia I-Premise
were I-Premise
the I-Premise
next I-Premise
common I-Premise
toxicities I-Premise
, I-Premise
with I-Premise
less I-Premise
than I-Premise
3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
in I-Premise
either I-Premise
arm I-Premise
suffering I-Premise
Grade I-Premise
3 I-Premise
or I-Premise
greater I-Premise
leukopenia I-Premise
or I-Premise
nausea I-Premise
. I-Premise

Postoperative B-Premise
complication I-Premise
rates I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
with I-Premise
12 I-Premise
% I-Premise
( I-Premise
postoperative I-Premise
radiochemotherapy I-Premise
) I-Premise
and I-Premise
13 I-Premise
% I-Premise
( I-Premise
preoperative I-Premise
radiochemotherapy I-Premise
) I-Premise
of I-Premise
patients I-Premise
, I-Premise
respectively I-Premise
, I-Premise
suffering I-Premise
from I-Premise
anastomotic I-Premise
leakage I-Premise
, I-Premise
4 I-Premise
% I-Premise
( I-Premise
postoperative I-Premise
radiochemotherapy I-Premise
) I-Premise
and I-Premise
3 I-Premise
% I-Premise
( I-Premise
preoperative I-Premise
radiochemotherapy I-Premise
) I-Premise
from I-Premise
postoperative I-Premise
bleeding I-Premise
, I-Premise
and I-Premise
6 I-Premise
% I-Premise
( I-Premise
postoperative I-Premise
radiochemotherapy I-Premise
) I-Premise
and I-Premise
5 I-Premise
% I-Premise
( I-Premise
preoperative I-Premise
radiochemotherapy I-Premise
) I-Premise
from I-Premise
delayed I-Premise
wound I-Premise
healing I-Premise
. I-Premise

The B-Claim
patient I-Claim
accrual I-Claim
of I-Claim
our I-Claim
trial I-Claim
is I-Claim
satisfactory I-Claim
, I-Claim
neoadjuvant B-Claim
radiochemotherapy I-Claim
is I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
bears I-Claim
no I-Claim
higher I-Claim
risk I-Claim
for I-Claim
postoperative I-Claim
morbidity I-Claim
. I-Claim

In O
a O
phase O
3 O
trial O
comparing O
the O
efficacy O
and O
safety O
of O
axitinib O
versus O
sorafenib O
as O
second-line O
treatment O
for O
metastatic O
renal O
cell O
carcinoma O
, O
patients O
given O
axitinib O
had O
a O
longer O
progression-free O
survival O
( O
PFS O
) O
. O

Here O
, O
we O
report O
overall O
survival O
and O
updated O
efficacy O
, O
quality O
of O
life O
, O
and O
safety O
results O
. O

Eligible O
patients O
had O
clear O
cell O
metastatic O
renal O
cell O
carcinoma O
, O
progressive O
disease O
after O
one O
approved O
systemic O
treatment O
, O
and O
an O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
( O
ECOG O
PS O
) O
of O
0-1 O
. O

723 O
patients O
were O
stratified O
by O
ECOG O
PS O
and O
previous O
treatment O
and O
randomly O
allocated O
( O
1:1 O
) O
to O
receive O
axitinib O
( O
5 O
mg O
twice O
daily O
";" O
n=361 O
) O
or O
sorafenib O
( O
400 O
mg O
twice O
daily O
";" O
n=362 O
) O
. O

The O
primary O
endpoint O
was O
PFS O
assessed O
by O
a O
masked O
, O
independent O
radiology O
review O
committee O
. O

We O
assessed O
patient-reported O
outcomes O
using O
validated O
questionnaires O
. O

Baseline O
characteristics O
and O
development O
of O
hypertension O
on O
treatment O
were O
studied O
as O
prognostic O
factors O
. O

Efficacy O
was O
assessed O
in O
the O
intention-to-treat O
population O
, O
and O
safety O
was O
assessed O
in O
patients O
who O
received O
at O
least O
one O
dose O
of O
the O
study O
drug O
. O

Median B-Premise
overall I-Premise
survival I-Premise
was I-Premise
20.1 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
16.7-23.4 I-Premise
) I-Premise
with I-Premise
axitinib I-Premise
and I-Premise
19.2 I-Premise
months I-Premise
( I-Premise
17.5-22.3 I-Premise
) I-Premise
with I-Premise
sorafenib I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0.969 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.800-1.174 I-Premise
";" I-Premise
one-sided I-Premise
p=0.3744 I-Premise
) I-Premise
. I-Premise

Median B-Premise
investigator-assessed I-Premise
PFS I-Premise
was I-Premise
8.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
6.7-9.2 I-Premise
) I-Premise
with I-Premise
axitinib I-Premise
and I-Premise
5·7 I-Premise
months I-Premise
( I-Premise
4.7-6.5 I-Premise
) I-Premise
with I-Premise
sorafenib I-Premise
( I-Premise
HR I-Premise
0.656 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.552-0.779 I-Premise
";" I-Premise
one-sided I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

Patient-reported B-Premise
outcomes I-Premise
scores I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
at I-Premise
baseline I-Premise
, I-Premise
were I-Premise
maintained I-Premise
during I-Premise
treatment I-Premise
, I-Premise
but B-Premise
decreased I-Premise
at I-Premise
end-of-treatment I-Premise
. I-Premise

Common B-Premise
grade I-Premise
3 I-Premise
or I-Premise
higher I-Premise
treatment-related I-Premise
adverse I-Premise
events I-Premise
were I-Premise
hypertension I-Premise
( I-Premise
60 I-Premise
[ I-Premise
17 I-Premise
% I-Premise
] I-Premise
) I-Premise
, I-Premise
diarrhoea I-Premise
( I-Premise
40 I-Premise
[ I-Premise
11 I-Premise
% I-Premise
] I-Premise
) I-Premise
, I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
37 I-Premise
[ I-Premise
10 I-Premise
% I-Premise
] I-Premise
) I-Premise
in I-Premise
359 I-Premise
axitinib-treated I-Premise
patients I-Premise
and I-Premise
hand-foot I-Premise
syndrome I-Premise
( I-Premise
61 I-Premise
[ I-Premise
17 I-Premise
% I-Premise
] I-Premise
) I-Premise
, I-Premise
hypertension I-Premise
( I-Premise
43 I-Premise
[ I-Premise
12 I-Premise
% I-Premise
] I-Premise
) I-Premise
, I-Premise
and I-Premise
diarrhoea I-Premise
( I-Premise
27 I-Premise
[ I-Premise
8 I-Premise
% I-Premise
] I-Premise
) I-Premise
in I-Premise
355 I-Premise
sorafenib-treated I-Premise
patients I-Premise
. I-Premise

In B-Premise
a I-Premise
post-hoc I-Premise
12-week I-Premise
landmark I-Premise
analysis I-Premise
, I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
with I-Premise
a I-Premise
diastolic I-Premise
blood I-Premise
pressure I-Premise
of I-Premise
90 I-Premise
mm I-Premise
Hg I-Premise
or I-Premise
greater I-Premise
than I-Premise
in I-Premise
those I-Premise
with I-Premise
a I-Premise
diastolic I-Premise
blood I-Premise
pressure I-Premise
of I-Premise
less I-Premise
than I-Premise
90 I-Premise
mm I-Premise
Hg I-Premise
: I-Premise
20.7 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
18.4-24.6 I-Premise
) I-Premise
versus I-Premise
12.9 I-Premise
months I-Premise
( I-Premise
10.1-20.4 I-Premise
) I-Premise
in I-Premise
the I-Premise
axitinib I-Premise
group I-Premise
( I-Premise
p=0.0116 I-Premise
) I-Premise
, I-Premise
and I-Premise
20.2 I-Premise
months I-Premise
( I-Premise
17.1-32.0 I-Premise
) I-Premise
versus I-Premise
14.8 I-Premise
months I-Premise
( I-Premise
12.0-17.7 I-Premise
) I-Premise
in I-Premise
the I-Premise
sorafenib I-Premise
group I-Premise
( I-Premise
one-sided I-Premise
p=0.0020 I-Premise
) I-Premise
. I-Premise

Although O
overall B-Claim
survival I-Claim
, I-Claim
a I-Claim
secondary I-Claim
endpoint I-Claim
for I-Claim
the I-Claim
study I-Claim
, I-Claim
did I-Claim
not I-Claim
differ I-Claim
between I-Claim
the I-Claim
two I-Claim
groups I-Claim
, I-Claim
investigator-assessed B-Claim
PFS I-Claim
remained I-Claim
longer I-Claim
in I-Claim
the I-Claim
axitinib I-Claim
group I-Claim
compared I-Claim
with I-Claim
the I-Claim
sorafenib I-Claim
group I-Claim
. I-Claim

These B-Claim
results I-Claim
establish I-Claim
axitinib I-Claim
as I-Claim
a I-Claim
second-line I-Claim
treatment I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
renal I-Claim
cell I-Claim
carcinoma I-Claim
. I-Claim

Imatinib B-Claim
( I-Claim
Gleevec I-Claim
) I-Claim
, I-Claim
a I-Claim
highly I-Claim
effective I-Claim
specific I-Claim
tyrosine I-Claim
kinase I-Claim
inhibitor I-Claim
, I-Claim
demonstrates I-Claim
a I-Claim
better I-Claim
side I-Claim
effect I-Claim
profile I-Claim
than I-Claim
interferon-alpha I-Claim
( I-Claim
IFN I-Claim
) I-Claim
, I-Claim
which I-Claim
impairs I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QoL I-Claim
) I-Claim
. I-Claim

This O
phase O
III O
international O
study O
evaluated O
QoL O
outcomes O
in O
1,106 O
newly O
diagnosed O
patients O
with O
chronic-phase O
chronic O
myeloid O
leukemia O
( O
CML O
) O
who O
were O
randomized O
to O
receive O
either O
imatinib O
400 O
mg O
daily O
or O
IFN O
up O
to O
5 O
MU/m O
( O
2 O
) O
/d O
with O
cytarabine O
( O
Ara-C O
) O
20 O
mg/m O
( O
2 O
) O
/d O
added O
for O
10 O
days O
every O
month O
( O
IFN O
+ O
LDAC O
) O
. O

Crossover O
to O
the O
other O
treatment O
arm O
was O
permitted O
due O
to O
a O
lack O
of O
efficacy O
or O
treatment O
intolerance O
. O

QoL O
was O
assessed O
with O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Biologic O
Response O
Modifiers O
( O
FACT-BRM O
) O
at O
baseline O
, O
monthly O
for O
6 O
months O
and O
then O
at O
months O
9 O
, O
12 O
, O
and O
18 O
. O

The O
Trial O
Outcome O
Index O
( O
TOI O
";" O
a O
composite O
endpoint O
of O
physical/functional/treatment-specific O
subscales O
) O
was O
the O
primary O
endpoint O
. O

Secondary O
endpoints O
measured O
were O
social/family O
well-being O
( O
SFWB O
) O
and O
emotional O
well-being O
( O
EWB O
) O
. O

QoL O
was O
analyzed O
for O
the O
first O
18 O
months O
of O
treatment O
using O
mixed O
effects O
growth O
curve O
models O
. O

The O
primary O
analyses O
were O
intention-to-treat O
( O
ITT O
) O
";" O
secondary O
analyses O
incorporated O
crossover O
as O
a O
time-dependent O
covariate O
. O

A O
total O
of O
1,049 O
patients O
completed O
at O
least O
one O
QoL O
assessment O
. O

Two B-Premise
hundred I-Premise
sixty-one I-Premise
patients I-Premise
( I-Premise
50 I-Premise
% I-Premise
) I-Premise
crossed I-Premise
over I-Premise
from I-Premise
IFN I-Premise
to I-Premise
imatinib I-Premise
and I-Premise
11 I-Premise
( I-Premise
2 I-Premise
% I-Premise
) I-Premise
crossed I-Premise
over I-Premise
from I-Premise
imatinib I-Premise
to I-Premise
IFN I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
decline I-Premise
in I-Premise
TOI I-Premise
scores I-Premise
for I-Premise
the I-Premise
IFN I-Premise
treatment I-Premise
arm I-Premise
compared I-Premise
with I-Premise
preservation I-Premise
of I-Premise
baseline I-Premise
TOI I-Premise
scores I-Premise
in I-Premise
the I-Premise
imatinib I-Premise
arm I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
, I-Premise
ITT I-Premise
) I-Premise
. I-Premise

Mean B-Premise
social/family I-Premise
and I-Premise
EWB I-Premise
scores I-Premise
were I-Premise
22.8 I-Premise
and I-Premise
19.5 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
imatinib I-Premise
and I-Premise
21.6 I-Premise
and I-Premise
17.6 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
IFN I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
, I-Premise
ITT I-Premise
) I-Premise
. I-Premise

After B-Premise
crossing I-Premise
over I-Premise
from I-Premise
IFN I-Premise
to I-Premise
imatinib I-Premise
, I-Premise
patients I-Premise
experienced I-Premise
a I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
increase I-Premise
in I-Premise
TOI I-Premise
scores I-Premise
. I-Premise

Imatinib B-Claim
offers I-Claim
clear I-Claim
QoL I-Claim
advantages I-Claim
over I-Claim
IFN I-Claim
as I-Claim
first-line I-Claim
treatment I-Claim
of I-Claim
chronic-phase I-Claim
CML I-Claim
. I-Claim

In O
addition O
, O
patients B-Claim
who I-Claim
crossed I-Claim
over I-Claim
to I-Claim
imatinib I-Claim
reported I-Claim
higher I-Claim
QoL I-Claim
than I-Claim
those I-Claim
who I-Claim
remained I-Claim
on I-Claim
IFN I-Claim
. I-Claim

The O
management O
of O
recurrent O
ovarian O
cancer O
remains O
controversial O
. O

Single-agent O
topotecan O
is O
an O
established O
treatment O
option O
, O
and O
preliminary O
evidence O
suggests O
improved O
tumor O
control O
by O
combining O
topotecan O
with O
etoposide O
or O
gemcitabine O
. O

Women O
with O
relapsed O
ovarian O
cancer O
after O
primary O
surgery O
and O
platinum-based O
chemotherapy O
were O
randomly O
assigned O
to O
topotecan O
monotherapy O
1.25 O
mg/m O
( O
2 O
) O
/d O
, O
topotecan O
1.0 O
mg/m O
( O
2 O
) O
plus O
oral O
etoposide O
50 O
mg/d O
, O
or O
topotecan O
0.5 O
mg/m O
( O
2 O
) O
/d O
plus O
gemcitabine O
800 O
mg/m O
( O
2 O
) O
on O
day O
1 O
and O
600 O
mg/m O
( O
2 O
) O
on O
day O
8 O
every O
3 O
weeks O
. O

Patients O
were O
stratified O
for O
platinum-refractory O
and O
platinum-sensitive O
disease O
according O
to O
a O
recurrence-free O
interval O
of O
less O
or O
more O
than O
12 O
months O
, O
respectively O
. O

The O
primary O
end O
point O
was O
overall O
survival O
. O

Secondary O
end O
points O
included O
progression-free O
survival O
, O
objective O
response O
rates O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
as O
measured O
by O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
[ O
EORTC O
] O
30-item O
Quality-of-Life O
Questionnaire O
) O
. O

The O
trial O
enrolled O
502 O
patients O
with O
a O
mean O
age O
of O
60.5 O
years O
( O
+/- O
10.2 O
years O
) O
, O
208 O
of O
whom O
were O
platinum O
resistant O
. O

Median B-Premise
overall I-Premise
survival I-Premise
was I-Premise
17.2 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
13.5 I-Premise
to I-Premise
21.9 I-Premise
months I-Premise
) I-Premise
with I-Premise
topotecan I-Premise
, I-Premise
17.8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
13.7 I-Premise
to I-Premise
20.0 I-Premise
months I-Premise
) I-Premise
with I-Premise
topotecan I-Premise
plus I-Premise
etoposide I-Premise
( I-Premise
log-rank I-Premise
P I-Premise
= I-Premise
.7647 I-Premise
) I-Premise
, I-Premise
and I-Premise
15.2 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
11.3 I-Premise
to I-Premise
20.9 I-Premise
months I-Premise
) I-Premise
with I-Premise
topotecan I-Premise
plus I-Premise
gemcitabine I-Premise
( I-Premise
log-rank I-Premise
P I-Premise
= I-Premise
.2344 I-Premise
) I-Premise
. I-Premise

Platinum-sensitive B-Premise
patients I-Premise
lived I-Premise
significantly I-Premise
longer I-Premise
than I-Premise
platinum-refractory I-Premise
patients I-Premise
( I-Premise
21.9 I-Premise
v I-Premise
10.6 I-Premise
months I-Premise
) I-Premise
. I-Premise

The O
median O
progression-free O
survival O
was O
7.0 O
, O
7.8 O
, O
and O
6.3 O
months O
, O
respectively O
. O

Objective O
response O
rates O
were O
27.8 O
% O
, O
36.1 O
% O
, O
and O
31.6 O
% O
, O
respectively O
. O

Patients B-Premise
under I-Premise
combined I-Premise
treatment I-Premise
were I-Premise
at I-Premise
higher I-Premise
risk I-Premise
of I-Premise
severe I-Premise
thrombocytopenia I-Premise
. I-Premise

Nonplatinum B-Claim
topotecan I-Claim
combinations I-Claim
do I-Claim
not I-Claim
provide I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
topotecan I-Claim
alone I-Claim
in I-Claim
women I-Claim
with I-Claim
relapsed I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

Cutaneous B-Claim
T-cell I-Claim
lymphoma I-Claim
( I-Claim
CTCL I-Claim
) I-Claim
can I-Claim
be I-Claim
associated I-Claim
with I-Claim
painful I-Claim
, I-Claim
pruritic I-Claim
, I-Claim
disfiguring I-Claim
lesions I-Claim
. I-Claim

As O
part O
of O
a O
multicenter O
, O
randomized O
phase O
III O
trial O
in O
patients O
with O
heavily O
pretreated O
advanced O
and/or O
recurrent O
CTCL O
, O
the O
effects O
of O
an O
interleukin-2 O
receptor-targeted O
fusion O
protein O
, O
denileukin O
diftitox O
( O
DAB389IL-2 O
, O
ONTAK O
) O
, O
on O
patient-rated O
overall O
quality O
of O
life O
( O
QOL O
) O
, O
skin O
appearance O
, O
and O
pruritus O
severity O
were O
evaluated O
. O

A O
total O
of O
71 O
patients O
with O
stage O
IB-IVA O
CTCL O
received O
intravenous O
denileukin O
diftitox O
9 O
microg/kg/day O
or O
18 O
microg/kg/day O
over O
15-60 O
minutes O
for O
5 O
consecutive O
days O
on O
an O
outpatient O
basis O
";" O
cycles O
were O
planned O
for O
every O
21 O
days O
for O
a O
total O
of O
8 O
cycles O
over O
6 O
months O
. O

Prior O
to O
each O
treatment O
cycle O
, O
patients O
were O
evaluated O
for O
disease O
response O
and O
were O
asked O
to O
self-rate O
their O
overall O
QOL O
via O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-General O
( O
FACT-G O
) O
questionnaire O
, O
skin O
appearance O
( O
7-point O
scale O
) O
, O
and O
pruritus O
severity O
( O
10-cm O
visual O
analogue O
scale O
) O
. O

Composite B-Premise
FACT-G I-Premise
and I-Premise
most I-Premise
individual I-Premise
subscale I-Premise
scores I-Premise
( I-Premise
physical I-Premise
, I-Premise
social/family I-Premise
, I-Premise
emotional I-Premise
, I-Premise
and I-Premise
functional I-Premise
well I-Premise
being I-Premise
) I-Premise
in I-Premise
documented I-Premise
responders I-Premise
( I-Premise
n I-Premise
= I-Premise
21 I-Premise
) I-Premise
gradually I-Premise
increased I-Premise
during I-Premise
the I-Premise
study I-Premise
period I-Premise
, I-Premise
generally I-Premise
reaching I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
by I-Premise
cycle I-Premise
3 I-Premise
, I-Premise
and I-Premise
were I-Premise
significantly I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
0.041 I-Premise
) I-Premise
higher I-Premise
than I-Premise
the I-Premise
scores I-Premise
of I-Premise
nonresponders I-Premise
at I-Premise
endpoint I-Premise
. I-Premise

Additionally B-Premise
for I-Premise
responders I-Premise
, I-Premise
assessments I-Premise
of I-Premise
skin I-Premise
severity I-Premise
and I-Premise
pruritus I-Premise
severity I-Premise
showed I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
improvements I-Premise
at I-Premise
study I-Premise
endpoint I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
. I-Premise

Adverse B-Premise
transfusion-related I-Premise
events I-Premise
( I-Premise
eg I-Premise
, I-Premise
hypersensitivity I-Premise
reactions I-Premise
, I-Premise
flu-like I-Premise
syndrome I-Premise
) I-Premise
were I-Premise
common I-Premise
during I-Premise
cycles I-Premise
1 I-Premise
and I-Premise
2 I-Premise
, I-Premise
and I-Premise
vascular-leak I-Premise
syndrome I-Premise
occurred I-Premise
in I-Premise
25 I-Premise
% I-Premise
of I-Premise
patients I-Premise
. I-Premise

Denileukin B-Claim
diftitox I-Claim
was I-Claim
not I-Claim
associated I-Claim
with I-Claim
any I-Claim
clinically I-Claim
significant I-Claim
myelosuppression I-Claim
. I-Claim

Heavily B-Claim
pretreated I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
and/or I-Claim
recurrent I-Claim
CTCL I-Claim
who I-Claim
responded I-Claim
to I-Claim
denileukin I-Claim
diftitox I-Claim
therapy I-Claim
showed I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
self-rated I-Claim
overall I-Claim
QOL I-Claim
, I-Claim
skin I-Claim
appearance I-Claim
, I-Claim
and I-Claim
pruritus I-Claim
severity I-Claim
. I-Claim

Recombinant B-Claim
human I-Claim
erythropoietin I-Claim
( I-Claim
r-HuEPO I-Claim
) I-Claim
corrects I-Claim
cancer-related I-Claim
anemia I-Claim
and I-Claim
, I-Claim
thereby I-Claim
, I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

The O
purpose O
of O
the O
present O
study O
was O
to O
measure O
the O
impact O
of O
erythropoietin O
on O
hemoglobin O
and O
mood O
state O
in O
patients O
with O
metastatic O
breast O
cancer O
and O
mild O
anemia O
( O
Hgb O
< O
12.0 O
g/dL O
) O
. O

Women O
were O
randomized O
to O
receive O
usual O
care O
( O
G1 O
) O
or O
usual O
care O
plus O
r-HuEPO O
( O
G2 O
) O
. O

Usual O
care O
included O
transfusions O
as O
necessary O
and O
fatigue O
education O
. O

R-HuEPO O
was O
begun O
at O
40,000U O
subcutaneously O
per O
week O
. O

At O
4 O
weeks O
, O
the O
dose O
was O
increased O
to O
60,000U O
if O
Hgb O
had O
not O
increased O
> O
or O
= O
1.0 O
g/dL O
. O

The O
drug O
was O
discontinued O
at O
8 O
weeks O
if O
hemoglobin O
improvement O
was O
< O
1.0 O
g/dL O
. O

The O
study O
was O
terminated O
early O
( O
n O
= O
27 O
, O
G1 O
= O
13 O
, O
G2 O
= O
14 O
) O
when O
4/14 O
( O
28.5 O
% O
) O
subjects O
in O
G2 O
developed O
thrombotic O
events O
( O
deep O
vein O
thrombosis O
[ O
DVT O
] O
in O
1 O
";" O
DVT O
plus O
pulmonary O
embolism O
[ O
PE O
] O
in O
1 O
";" O
DVT O
plus O
PE O
1 O
month O
after O
drug O
discontinuation O
in O
1 O
";" O
and O
brachial O
vein O
thrombosis O
with O
infected O
Mediport O
in O
1 O
) O
. O

In B-Premise
all I-Premise
four I-Premise
patients I-Premise
, I-Premise
Hgb I-Premise
levels I-Premise
were I-Premise
normal I-Premise
at I-Premise
the I-Premise
time I-Premise
of I-Premise
the I-Premise
event I-Premise
. I-Premise

No B-Premise
patient I-Premise
in I-Premise
G1 I-Premise
developed I-Premise
a I-Premise
thrombotic I-Premise
event I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
demographic I-Premise
characteristics I-Premise
or I-Premise
current I-Premise
chemotherapy I-Premise
regimen I-Premise
in I-Premise
G1 I-Premise
vs. I-Premise
G2 I-Premise
. I-Premise

The O
decision O
to O
terminate O
the O
trial O
was O
made O
after O
considerable O
deliberation O
. O

The B-Premise
increased I-Premise
incidence I-Premise
of I-Premise
thrombotic I-Premise
events I-Premise
in I-Premise
the I-Premise
r-HuEPO I-Premise
( I-Premise
G2 I-Premise
) I-Premise
arm I-Premise
of I-Premise
this I-Premise
study I-Premise
exceeds I-Premise
that I-Premise
in I-Premise
prior I-Premise
studies I-Premise
in I-Premise
this I-Premise
population I-Premise
and I-Premise
prior I-Premise
r-HuEPO I-Premise
trials I-Premise
. I-Premise

This B-Claim
may I-Claim
relate I-Claim
to I-Claim
the I-Claim
administration I-Claim
of I-Claim
r-HuEPO I-Claim
in I-Claim
this I-Claim
high-risk I-Claim
population I-Claim
, I-Claim
but B-Claim
the I-Claim
small I-Claim
sample I-Claim
size I-Claim
and I-Claim
possible I-Claim
predisposing I-Claim
risk I-Claim
factors I-Claim
preclude I-Claim
definitive I-Claim
conclusions I-Claim
. I-Claim

Shoulder O
pain O
and O
disability O
are O
well O
recognized O
complications O
associated O
with O
surgery O
for O
head O
and O
neck O
cancer O
. O

This O
study O
was O
designed O
to O
examine O
the O
effects O
of O
progressive O
resistance O
exercise O
training O
( O
PRET O
) O
on O
upper O
extremity O
pain O
and O
dysfunction O
in O
postsurgical O
head O
and O
neck O
cancer O
survivors O
. O

Fifty-two O
head O
and O
neck O
cancer O
survivors O
were O
assigned O
randomly O
to O
PRET O
( O
n O
= O
27 O
) O
or O
a O
standardized O
therapeutic O
exercise O
protocol O
( O
TP O
) O
( O
n O
= O
25 O
) O
for O
12 O
weeks O
. O

The O
primary O
endpoint O
was O
change O
in O
patient-rated O
shoulder O
pain O
and O
disability O
from O
baseline O
to O
postintervention O
. O

Secondary O
endpoints O
were O
upper O
extremity O
strength O
and O
endurance O
, O
range O
of O
motion O
, O
fatigue O
, O
and O
quality O
of O
life O
. O

Follow-up O
assessment O
for O
the O
primary O
outcome O
was O
92 O
% O
, O
and O
adherence O
to O
the O
supervised O
PRET O
and O
TP O
programs O
were O
95 O
% O
and O
87 O
% O
, O
respectively O
. O

On B-Premise
the I-Premise
basis I-Premise
of I-Premise
intention-to-treat I-Premise
analyses I-Premise
, I-Premise
PRET I-Premise
was I-Premise
superior I-Premise
to I-Premise
TP I-Premise
for I-Premise
improving I-Premise
shoulder I-Premise
pain I-Premise
and I-Premise
disability I-Premise
( I-Premise
-9.6 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
, I-Premise
-16.4 I-Premise
to I-Premise
-4.5 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
, I-Premise
upper I-Premise
extremity I-Premise
strength I-Premise
( I-Premise
+10.8 I-Premise
kg I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
5.4-16.2 I-Premise
kg I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
upper I-Premise
extremity I-Premise
endurance I-Premise
( I-Premise
194 I-Premise
repetitions I-Premise
x I-Premise
kg I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
10-378 I-Premise
repetitions I-Premise
x I-Premise
kg I-Premise
";" I-Premise
P I-Premise
= I-Premise
.039 I-Premise
) I-Premise
. I-Premise

Changes B-Premise
in I-Premise
neck I-Premise
dissection I-Premise
impairment I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
favored I-Premise
the I-Premise
PRET I-Premise
group I-Premise
but B-Premise
did I-Premise
not I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
. I-Premise

The B-Premise
PRET I-Premise
program I-Premise
significantly I-Premise
reduced I-Premise
shoulder I-Premise
pain I-Premise
and I-Premise
disability I-Premise
and I-Premise
improved I-Premise
upper I-Premise
extremity I-Premise
muscular I-Premise
strength I-Premise
and I-Premise
endurance I-Premise
in I-Premise
head I-Premise
and I-Premise
neck I-Premise
cancer I-Premise
survivors I-Premise
who I-Premise
had I-Premise
shoulder I-Premise
dysfunction I-Premise
because I-Premise
of I-Premise
spinal I-Premise
accessory I-Premise
nerve I-Premise
damage I-Premise
. I-Premise

Clinicians B-Claim
should I-Claim
consider I-Claim
the I-Claim
addition I-Claim
of I-Claim
PRET I-Claim
in I-Claim
the I-Claim
rehabilitation I-Claim
of I-Claim
postsurgical I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

To O
examine O
the O
impact O
of O
advanced O
practice O
nurse O
( O
APN O
) O
-administered O
low-level O
laser O
therapy O
( O
LLLT O
) O
as O
both O
a O
stand-alone O
and O
complementary O
treatment O
for O
arm O
volume O
, O
symptoms O
, O
and O
quality O
of O
life O
( O
QOL O
) O
in O
women O
with O
breast O
cancer-related O
lymphedema O
. O

A O
three-group O
, O
pilot O
, O
randomized O
clinical O
trial O
. O

A O
private O
rehabilitation O
practice O
in O
the O
southeastern O
United O
States O
. O

46 O
breast O
cancer O
survivors O
with O
treatment-related O
lymphedema O
. O

Patients O
were O
screened O
for O
eligibility O
and O
then O
randomized O
to O
either O
manual O
lymphatic O
drainage O
( O
MLD O
) O
for O
40 O
minutes O
, O
LLLT O
for O
20 O
minutes O
, O
or O
20 O
minutes O
of O
MLD O
followed O
by O
20 O
minutes O
of O
LLLT O
. O

Compression O
bandaging O
was O
applied O
after O
each O
treatment O
. O

Data O
were O
collected O
pretreatment O
, O
daily O
, O
weekly O
, O
and O
at O
the O
end O
of O
treatment O
. O

Independent O
variables O
consisted O
of O
three O
types O
of O
APN-administered O
lymphedema O
treatment O
. O

Outcome O
variables O
included O
limb O
volume O
, O
extracellular O
fluid O
, O
psychological O
and O
physical O
symptoms O
, O
and O
QOL O
. O

No B-Premise
statistically I-Premise
significant I-Premise
between-group I-Premise
differences I-Premise
were I-Premise
found I-Premise
in I-Premise
volume I-Premise
reduction I-Premise
";" I-Premise
however B-Premise
, I-Premise
all I-Premise
groups I-Premise
had I-Premise
clinically I-Premise
and I-Premise
statistically I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
volume I-Premise
. I-Premise

No B-Premise
group I-Premise
differences I-Premise
were I-Premise
noted I-Premise
in I-Premise
psychological I-Premise
and I-Premise
physical I-Premise
symptoms I-Premise
or I-Premise
QOL I-Premise
";" I-Premise
however B-Premise
, I-Premise
treatment-related I-Premise
improvements I-Premise
were I-Premise
noted I-Premise
in I-Premise
symptom I-Premise
burden I-Premise
within I-Premise
all I-Premise
groups I-Premise
. I-Premise

Skin B-Premise
improvement I-Premise
was I-Premise
noted I-Premise
in I-Premise
each I-Premise
group I-Premise
that I-Premise
received I-Premise
LLLT I-Premise
. I-Premise

LLLT B-Claim
with I-Claim
bandaging I-Claim
may I-Claim
offer I-Claim
a I-Claim
time-saving I-Claim
therapeutic I-Claim
option I-Claim
to I-Claim
conventional I-Claim
MLD I-Claim
. I-Claim

Alternatively O
, O
compression B-Claim
bandaging I-Claim
alone I-Claim
could I-Claim
account I-Claim
for I-Claim
the I-Claim
demonstrated I-Claim
volume I-Claim
reduction I-Claim
. I-Claim

APNs B-Claim
can I-Claim
effectively I-Claim
treat I-Claim
lymphedema I-Claim
. I-Claim

APNs O
in O
private O
healthcare O
practices O
can O
serve O
as O
valuable O
research O
collaborators O
. O

Lasers B-Claim
may I-Claim
provide I-Claim
effective I-Claim
, I-Claim
less I-Claim
burdensome I-Claim
treatment I-Claim
for I-Claim
lymphedema I-Claim
. I-Claim

APNs B-Claim
with I-Claim
lymphedema I-Claim
certification I-Claim
can I-Claim
effectively I-Claim
treat I-Claim
this I-Claim
patient I-Claim
population I-Claim
with I-Claim
the I-Claim
use I-Claim
of I-Claim
LLLT I-Claim
. I-Claim

In O
addition O
, O
bioelectrical B-Claim
impedance I-Claim
and I-Claim
tape I-Claim
measurements I-Claim
can I-Claim
be I-Claim
used I-Claim
to I-Claim
assess I-Claim
lymphedema I-Claim
. I-Claim

There O
are O
patients O
with O
stage O
I-III O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
who O
are O
not O
suitable O
for O
curative O
radical O
chemoradiation O
therapy O
. O

There O
are O
patients O
with O
an O
isolated O
solitary O
extracranial O
metastasis O
who O
have O
improved O
outcomes O
compared O
with O
those O
with O
cranial O
or O
multiple O
metastases O
. O

Patients O
of O
good O
performance O
status O
receiving O
moderate O
dose O
radiation O
therapy O
have O
improved O
survival O
. O

Two O
regimens O
of O
moderate O
dose O
chemoradiation O
therapy O
for O
such O
patients O
were O
compared O
in O
a O
randomized O
phase O
II O
trial O
. O

Patients O
were O
eligible O
if O
they O
had O
stage O
I-IIIB O
NSCLC O
, O
unsuitable O
for O
curative O
therapy O
, O
or O
stage O
IV O
with O
a O
PET-detected O
extracranial O
solitary O
metastasis O
. O

Patients O
were O
randomized O
to O
the O
following O
groups-arm O
A O
: O
40 O
Gy/20 O
fractions/4 O
weeks O
with O
concurrent O
weekly O
vinorelbine O
25 O
mg/m O
+ O
cisplatin O
20 O
mg/m O
or O
arm O
B O
: O
30 O
Gy/15 O
fractions/3 O
weeks O
with O
concurrent O
weekly O
gemcitabine O
200 O
mg. O
Primary O
end O
points O
were O
feasibility O
, O
response O
rates O
, O
and O
toxicity O
. O

Secondary O
end O
points O
were O
progression-free O
survival O
, O
overall O
survival O
, O
and O
quality O
of O
life O
. O

Eighty-four O
patients O
were O
randomized O
. O

Compliance O
was O
above O
90 O
% O
for O
both O
arms O
. O

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
51 I-Premise
% I-Premise
in I-Premise
arm I-Premise
A I-Premise
and I-Premise
38 I-Premise
% I-Premise
in I-Premise
arm I-Premise
B I-Premise
( I-Premise
p I-Premise
= I-Premise
0.147 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
toxicity I-Premise
in I-Premise
both I-Premise
arms I-Premise
was I-Premise
acceptable I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
( I-Premise
5.5 I-Premise
versus I-Premise
5.0 I-Premise
months I-Premise
, I-Premise
p I-Premise
= I-Premise
0.19 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
arm I-Premise
A I-Premise
had I-Premise
longer I-Premise
median I-Premise
survival I-Premise
but B-Premise
this I-Premise
did I-Premise
not I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
13.1 I-Premise
versus I-Premise
8.3 I-Premise
months I-Premise
, I-Premise
p I-Premise
= I-Premise
0.25 I-Premise
) I-Premise
. I-Premise

No B-Claim
difference I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
was I-Claim
observed I-Claim
. I-Claim

Arm O
A O
was O
chosen O
for O
a O
future O
phase O
II O
comparison O
with O
radiation B-Claim
therapy I-Claim
alone I-Claim
as I-Claim
it I-Claim
demonstrated I-Claim
a I-Claim
response I-Claim
rate I-Claim
greater I-Claim
than I-Claim
50 I-Claim
% I-Claim
, I-Claim
and I-Claim
data I-Claim
suggested I-Claim
that I-Claim
arm I-Claim
A I-Claim
had I-Claim
superior I-Claim
survival I-Claim
to I-Claim
arm I-Claim
B I-Claim
. I-Claim

To O
evaluate O
whether O
3-month O
administration O
of O
CDB-2914 O
, O
a O
selective O
progesterone O
receptor O
modulator O
, O
reduces O
leiomyoma O
size O
and O
symptoms O
. O

Premenopausal O
women O
with O
symptomatic O
uterine O
leiomyomata O
were O
randomly O
assigned O
to O
CDB-2914 O
at O
10 O
mg O
( O
T1 O
) O
or O
20 O
mg O
( O
T2 O
) O
daily O
or O
to O
placebo O
( O
PLC O
) O
for O
3 O
cycles O
or O
90-102 O
days O
if O
no O
menses O
occurred O
. O

The O
primary O
outcome O
was O
leiomyoma O
volume O
change O
determined O
by O
magnetic O
resonance O
imaging O
at O
study O
entry O
and O
within O
2 O
weeks O
of O
hysterectomy O
. O

Secondary O
outcomes O
included O
the O
proportion O
of O
amenorrhea O
, O
change O
in O
hemoglobin O
and O
hematocrit O
, O
ovulation O
inhibition O
, O
and O
quality-of-life O
assessment O
. O

Twenty-two O
patients O
were O
allocated O
, O
and O
18 O
completed O
the O
trial O
. O

Age O
and O
body O
mass O
index O
were O
similar O
among O
groups O
. O

Leiomyoma O
volume O
was O
significantly O
reduced O
with O
CDB-2914 O
administration O
( O
PLC O
6 O
% O
";" O
CDB-2914 O
-29 O
% O
";" O
P=.01 O
) O
, O
decreasing O
36 O
% O
and O
21 O
% O
in O
the O
T1 O
and O
T2 O
groups O
, O
respectively O
. O

During O
treatment O
, O
hemoglobin O
was O
unchanged O
, O
and O
the O
median O
estradiol O
was O
greater O
than O
50 O
pg/mL O
in O
all O
groups O
. O

CDB-2914 O
eliminated O
menstrual O
bleeding O
and O
inhibited O
ovulation O
( O
% O
ovulatory O
cycles O
: O
CDB-2914 O
, O
20 O
% O
";" O
PLC O
, O
83 O
% O
";" O
P=.001 O
) O
. O

CDB-2914 O
improved O
the O
concern O
scores O
of O
the O
uterine O
leiomyoma O
symptom O
quality-of-life O
subscale O
( O
P=.04 O
) O
. O

One O
CDB-2914 O
woman O
developed O
endometrial O
cystic O
hyperplasia O
without O
evidence O
of O
atypia O
. O

No B-Premise
serious I-Premise
adverse I-Premise
events I-Premise
were I-Premise
reported I-Premise
. I-Premise

Compared B-Premise
with I-Premise
PLC I-Premise
, I-Premise
CDB-2914 I-Premise
significantly I-Premise
reduced I-Premise
leiomyoma I-Premise
volume I-Premise
after I-Premise
three I-Premise
cycles I-Premise
, I-Premise
or I-Premise
90-102 I-Premise
days I-Premise
. I-Premise

CDB-2914 B-Premise
treatment I-Premise
resulted I-Premise
in I-Premise
improvements I-Premise
in I-Premise
the I-Premise
concern I-Premise
subscale I-Premise
of I-Premise
the I-Premise
Uterine I-Premise
Fibroid I-Premise
Symptom I-Premise
Quality I-Premise
of I-Premise
Life I-Premise
assessment I-Premise
. I-Premise

In B-Claim
this I-Claim
small I-Claim
study I-Claim
, I-Claim
CDB-2914 I-Claim
was I-Claim
well-tolerated I-Claim
without I-Claim
serious I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Thus B-Claim
, I-Claim
there I-Claim
may I-Claim
be I-Claim
a I-Claim
role I-Claim
for I-Claim
CDB-2914 I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
leiomyomata I-Claim
. I-Claim

To O
observe O
the O
clinical O
effectiveness O
of O
a O
topical O
application O
of O
Xiaozheng O
Zhitong O
: O
Paste O
( O
, O
XZP O
) O
in O
alleviating O
the O
cancerous O
pain O
of O
patients O
with O
middle/late O
stage O
cancer O
By O
: O
adopting O
a O
random O
number O
table O
, O
124 O
patients O
enrolled O
were O
randomized O
into O
the O
treatment O
group O
( O
64 O
patients O
) O
and O
the O
control O
group O
( O
60 O
patients O
) O
. O

In O
addition O
to O
the O
basic O
therapy O
[ O
including O
the O
three-ladder O
( O
3L O
) O
analgesia O
] O
used O
in O
both O
groups O
, O
topical O
application O
of O
XZP O
was O
given O
to O
patients O
in O
the O
treatment O
group O
for O
pain O
alleviation O
. O

The O
analgesic O
efficacy O
was O
recorded O
in O
terms O
of O
pain O
intensity O
, O
analgesia O
initiating O
time O
and O
sustaining O
time O
, O
and O
the O
optimal O
analgesic O
effect O
revealing O
time O
. O

Meanwhile O
, O
the O
quality O
of O
life O
( O
QOL O
) O
and O
adverse O
reactions O
that O
occurred O
in O
patients O
were O
recorded O
as O
well O
. O

The B-Premise
total I-Premise
effective I-Premise
rate I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
was I-Premise
: I-Premise
84.38 I-Premise
% I-Premise
( I-Premise
54/64 I-Premise
) I-Premise
, I-Premise
and I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
it I-Premise
was I-Premise
88.33 I-Premise
% I-Premise
( I-Premise
53/60 I-Premise
) I-Premise
, I-Premise
showing I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
them I-Premise
( I-Premise
P I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
but B-Premise
the I-Premise
analgesia I-Premise
initiating I-Premise
time I-Premise
and I-Premise
the I-Premise
optimal I-Premise
analgesia I-Premise
effect I-Premise
revealing I-Premise
time I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
were I-Premise
significantly I-Premise
shorter I-Premise
( I-Premise
both I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Moreover O
, O
XZP B-Premise
was I-Premise
better I-Premise
in I-Premise
improving I-Premise
patients I-Premise
' I-Premise
QOL I-Premise
, I-Premise
showing I-Premise
more I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
than I-Premise
those I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
in I-Premise
aspects I-Premise
of I-Premise
mental I-Premise
condition I-Premise
, I-Premise
walking I-Premise
capacity I-Premise
, I-Premise
working I-Premise
capacity I-Premise
, I-Premise
social I-Premise
acceptability I-Premise
, I-Premise
sleep I-Premise
and I-Premise
joy I-Premise
of I-Premise
living I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
or I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Lower B-Premise
incidence I-Premise
of I-Premise
adverse I-Premise
reactions I-Premise
, I-Premise
such I-Premise
as I-Premise
nausea I-Premise
, I-Premise
vomiting I-Premise
, I-Premise
mouth I-Premise
dryness I-Premise
, I-Premise
dizziness I-Premise
, I-Premise
etc. I-Premise
, I-Premise
especially I-Premise
constipation I-Premise
, I-Premise
was I-Premise
noted I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
or I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Applying B-Claim
an I-Claim
external I-Claim
compress I-Claim
: I-Claim
of I-Claim
XZP I-Claim
showed I-Claim
a I-Claim
synergistic I-Claim
action I-Claim
with I-Claim
3L I-Claim
analgesia I-Claim
for I-Claim
shortening I-Claim
the I-Claim
initiating I-Claim
time I-Claim
and I-Claim
the I-Claim
optimal I-Claim
effect I-Claim
revealing I-Claim
time I-Claim
, I-Claim
and I-Claim
could I-Claim
evidently I-Claim
enhance I-Claim
patients I-Claim
' I-Claim
QOL I-Claim
with I-Claim
fewer I-Claim
adverse I-Claim
reactions I-Claim
. I-Claim

Metal O
stent O
placement O
and O
single O
dose O
brachytherapy O
are O
commonly O
used O
treatment O
modalities O
for O
the O
palliation O
of O
inoperable O
oesophageal O
carcinoma O
. O

We O
investigated O
generic O
and O
disease-specific O
health-related O
quality O
of O
life O
( O
HRQoL O
) O
after O
these O
palliative O
treatments O
. O

Patients O
with O
dysphagia O
from O
inoperable O
oesophageal O
carcinoma O
were O
randomised O
to O
placement O
of O
a O
covered O
Ultraflex O
stent O
( O
n O
= O
108 O
) O
or O
single O
dose O
( O
12 O
Gy O
) O
brachytherapy O
( O
n O
= O
101 O
) O
. O

We O
obtained O
longitudinal O
data O
on O
disease-specific O
( O
dysphagia O
score O
, O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
OES-23 O
, O
visual O
analogue O
pain O
scale O
) O
and O
generic O
( O
EORTC O
Quality O
of O
Life-Core O
30 O
Questionnaire O
( O
QLQ-C30 O
) O
, O
Euroqol O
( O
EQ O
) O
-5D O
) O
HRQoL O
at O
monthly O
home O
visits O
by O
a O
specially-trained O
research O
nurse O
. O

We O
compared O
HRQoL O
between O
the O
two O
treatments O
and O
analysed O
changes O
in O
HRQoL O
during O
follow-up O
. O

Dysphagia B-Premise
improved I-Premise
more I-Premise
rapidly I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
brachytherapy I-Premise
, I-Premise
but B-Premise
long-term I-Premise
relief I-Premise
of I-Premise
dysphagia I-Premise
was I-Premise
better I-Premise
after I-Premise
brachytherapy I-Premise
. I-Premise

For B-Premise
generic I-Premise
HRQoL I-Premise
, I-Premise
there I-Premise
was I-Premise
an I-Premise
overall I-Premise
significant I-Premise
difference I-Premise
in I-Premise
favour I-Premise
of I-Premise
brachytherapy I-Premise
on I-Premise
four I-Premise
out I-Premise
of I-Premise
five I-Premise
functional I-Premise
scales I-Premise
of I-Premise
the I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
( I-Premise
role I-Premise
, I-Premise
emotional I-Premise
, I-Premise
cognitive I-Premise
and I-Premise
social I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Generic B-Premise
HRQoL I-Premise
deteriorated I-Premise
over I-Premise
time I-Premise
on I-Premise
all I-Premise
functional I-Premise
scales I-Premise
of I-Premise
the I-Premise
EORTC I-Premise
QLQ I-Premise
C-30 I-Premise
and I-Premise
EQ-5D I-Premise
, I-Premise
in I-Premise
particular I-Premise
physical I-Premise
and I-Premise
role I-Premise
functioning I-Premise
( I-Premise
on I-Premise
average I-Premise
-23 I-Premise
and I-Premise
-24 I-Premise
on I-Premise
a I-Premise
100 I-Premise
points I-Premise
scale I-Premise
during I-Premise
0.5 I-Premise
years I-Premise
of I-Premise
follow-up I-Premise
) I-Premise
. I-Premise

This B-Premise
decline I-Premise
was I-Premise
more I-Premise
pronounced I-Premise
in I-Premise
the I-Premise
stent I-Premise
group I-Premise
. I-Premise

Major B-Premise
improvements I-Premise
were I-Premise
seen I-Premise
on I-Premise
the I-Premise
dysphagia I-Premise
and I-Premise
eating I-Premise
scales I-Premise
of I-Premise
the I-Premise
EORTC I-Premise
OES-23 I-Premise
, I-Premise
in I-Premise
contrast I-Premise
to I-Premise
other I-Premise
scales I-Premise
of I-Premise
this I-Premise
disease-specific I-Premise
measure I-Premise
, I-Premise
which I-Premise
remained I-Premise
almost I-Premise
stable I-Premise
during I-Premise
follow-up I-Premise
. I-Premise

Reported B-Premise
levels I-Premise
of I-Premise
chest I-Premise
or I-Premise
abdominal I-Premise
pain I-Premise
remained I-Premise
stable I-Premise
during I-Premise
follow-up I-Premise
in I-Premise
both I-Premise
treatment I-Premise
groups I-Premise
, I-Premise
general B-Premise
pain I-Premise
levels I-Premise
increased I-Premise
to I-Premise
a I-Premise
minor I-Premise
extent I-Premise
. I-Premise

The B-Claim
effects I-Claim
of I-Claim
single I-Claim
dose I-Claim
brachytherapy I-Claim
on I-Claim
HRQoL I-Claim
compared I-Claim
favourably I-Claim
to I-Claim
those I-Claim
of I-Claim
stent I-Claim
placement I-Claim
for I-Claim
the I-Claim
palliation I-Claim
of I-Claim
oesophageal I-Claim
cancer I-Claim
. I-Claim

Future B-Claim
studies I-Claim
on I-Claim
palliative I-Claim
care I-Claim
for I-Claim
oesophageal I-Claim
cancer I-Claim
should I-Claim
at I-Claim
least I-Claim
include I-Claim
generic I-Claim
HRQoL I-Claim
scales I-Claim
, I-Claim
since B-Premise
these I-Premise
were I-Premise
more I-Premise
responsive I-Premise
in I-Premise
measuring I-Premise
patients I-Premise
' I-Premise
functioning I-Premise
and I-Premise
well-being I-Premise
during I-Premise
follow-up I-Premise
than I-Premise
disease-specific I-Premise
HRQoL I-Premise
scales I-Premise
. I-Premise

To O
evaluate O
the O
efficacy O
and O
tolerability O
of O
'Casodex O
' O
monotherapy O
( O
150 O
mg O
daily O
) O
for O
metastatic O
and O
locally O
advanced O
prostate O
cancer O
. O

A O
total O
of O
1,453 O
patients O
with O
either O
confirmed O
metastatic O
disease O
( O
M1 O
) O
, O
or O
T3/T4 O
non-metastatic O
disease O
with O
elevated O
prostate-specific O
antigen O
( O
M0 O
) O
were O
recruited O
into O
one O
of O
two O
identical O
, O
multicentre O
, O
randomised O
studies O
to O
compare O
'Casodex O
' O
150 O
mg/day O
with O
castration O
. O

The O
protocols O
allowed O
for O
combined O
analysis O
. O

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
period I-Premise
of I-Premise
approximately I-Premise
100 I-Premise
weeks I-Premise
for I-Premise
both I-Premise
studies I-Premise
, I-Premise
'Casodex I-Premise
' I-Premise
150 I-Premise
mg I-Premise
was I-Premise
found I-Premise
to I-Premise
be I-Premise
less I-Premise
effective I-Premise
than I-Premise
castration I-Premise
in I-Premise
patients I-Premise
with I-Premise
metastatic I-Premise
disease I-Premise
( I-Premise
M1 I-Premise
) I-Premise
at I-Premise
entry I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
of I-Premise
1.30 I-Premise
for I-Premise
time I-Premise
to I-Premise
death I-Premise
) I-Premise
with I-Premise
a I-Premise
difference I-Premise
in I-Premise
median I-Premise
survival I-Premise
of I-Premise
6 I-Premise
weeks I-Premise
. I-Premise

In B-Premise
symptomatic I-Premise
M1 I-Premise
patients I-Premise
, I-Premise
'Casodex I-Premise
' I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
subjective I-Premise
response I-Premise
( I-Premise
70 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
castration I-Premise
( I-Premise
58 I-Premise
% I-Premise
) I-Premise
. I-Premise

Analysis B-Premise
of I-Premise
a I-Premise
validated I-Premise
quality-of-life I-Premise
questionnaire I-Premise
proved I-Premise
an I-Premise
advantage I-Premise
for I-Premise
'Casodex I-Premise
' I-Premise
in I-Premise
sexual I-Premise
interest I-Premise
and I-Premise
physical I-Premise
capacity I-Premise
. I-Premise

'Casodex B-Premise
' I-Premise
had I-Premise
a I-Premise
substantially I-Premise
lower I-Premise
incidence I-Premise
of I-Premise
hot I-Premise
flushes I-Premise
compared I-Premise
to I-Premise
castration I-Premise
( I-Premise
6-13 I-Premise
% I-Premise
compared I-Premise
with I-Premise
39-44 I-Premise
% I-Premise
) I-Premise
and I-Premise
the I-Premise
most I-Premise
commonly I-Premise
reported I-Premise
adverse I-Premise
events I-Premise
were I-Premise
those I-Premise
expected I-Premise
for I-Premise
a I-Premise
potent I-Premise
antiandrogen I-Premise
. I-Premise

However O
, O
in B-Claim
patients I-Claim
with I-Claim
M0 I-Claim
disease I-Claim
at I-Claim
entry I-Claim
, I-Claim
the I-Claim
data I-Claim
are I-Claim
still I-Claim
immature I-Claim
with I-Claim
only I-Claim
13 I-Claim
% I-Claim
of I-Claim
M0 I-Claim
patients I-Claim
having I-Claim
died I-Claim
. I-Claim

An B-Claim
initial I-Claim
analysis I-Claim
of I-Claim
this I-Claim
immature I-Claim
data I-Claim
has I-Claim
suggested I-Claim
that I-Claim
the I-Claim
results I-Claim
in I-Claim
these I-Claim
patients I-Claim
may I-Claim
be I-Claim
different I-Claim
to I-Claim
those I-Claim
obtained I-Claim
in I-Claim
patients I-Claim
with I-Claim
M1 I-Claim
disease I-Claim
. I-Claim

A O
further O
survival O
analysis O
in O
patients O
with O
M0 O
disease O
is O
therefore O
planned O
when O
the O
data O
are O
more O
mature O
. O

'Casodex B-Claim
' I-Claim
150 I-Claim
mg I-Claim
is I-Claim
less I-Claim
effective I-Claim
than I-Claim
castration I-Claim
in I-Claim
patients I-Claim
with I-Claim
M1 I-Claim
disease I-Claim
. I-Claim

However O
, O
'Casodex B-Claim
' I-Claim
has I-Claim
shown I-Claim
a I-Claim
benefit I-Claim
in I-Claim
terms I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
subjective I-Claim
response I-Claim
when I-Claim
compared I-Claim
to I-Claim
castration I-Claim
and I-Claim
has I-Claim
an I-Claim
acceptable I-Claim
tolerability I-Claim
profile I-Claim
. I-Claim

Thus B-Claim
'Casodex I-Claim
' I-Claim
150 I-Claim
mg I-Claim
monotherapy I-Claim
is I-Claim
an I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
M1 I-Claim
prostate I-Claim
cancer I-Claim
for I-Claim
whom I-Claim
surgical I-Claim
or I-Claim
medical I-Claim
castration I-Claim
is I-Claim
not I-Claim
indicated I-Claim
or I-Claim
is I-Claim
not I-Claim
acceptable I-Claim
. I-Claim

We O
compared O
the O
clinical O
effects O
and O
impact O
on O
quality O
of O
life O
( O
QOL O
) O
of O
patients O
who O
received O
a O
3-month O
course O
of O
flutamide O
monotherapy O
before O
radical O
prostatectomy O
with O
those O
who O
received O
a O
3-month O
course O
of O
luteinizing O
hormone-releasing O
hormone O
( O
LHRH O
) O
agonist O
monotherapy O
. O

Thirty-seven O
patients O
with O
non-metastatic O
prostate O
cancer O
were O
enrolled O
in O
this O
study O
( O
19 O
, O
flutamide O
";" O
18 O
, O
LHRH O
agonist O
) O
. O

The O
rates O
of O
change O
of O
serum O
prostate-specific O
antigen O
( O
PSA O
) O
and O
testosterone O
levels O
, O
downsizing O
of O
prostate O
volume O
, O
the O
rate O
of O
organ O
confined O
disease O
, O
adverse O
effects O
and O
perioperative O
scores O
measured O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Prostate O
Cancer O
Quality O
of O
Life O
Questionnaire O
( O
EORTC-P O
) O
and O
the O
Sapporo O
Medical O
University O
Sexual O
Function O
Questionnaire O
( O
SMUF O
) O
were O
analyzed O
. O

At B-Premise
radical I-Premise
prostatectomy I-Premise
, I-Premise
pathological I-Premise
variables I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

Serum B-Premise
testosterone I-Premise
level I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
( I-Premise
mean I-Premise
359.2 I-Premise
compared I-Premise
to I-Premise
10.5 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
complete B-Premise
response I-Premise
rate I-Premise
of I-Premise
PSA I-Premise
( I-Premise
13 I-Premise
% I-Premise
compared I-Premise
to I-Premise
57 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0.028 I-Premise
) I-Premise
and I-Premise
rate I-Premise
of I-Premise
downsizing I-Premise
of I-Premise
prostate I-Premise
volume I-Premise
( I-Premise
mean I-Premise
, I-Premise
-17.7 I-Premise
% I-Premise
compared I-Premise
to I-Premise
-35.4 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0.038 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
flutamide I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
LHRH I-Premise
group I-Premise
. I-Premise

After B-Premise
neoadjuvant I-Premise
hormone I-Premise
therapy I-Premise
, I-Premise
the I-Premise
scores I-Premise
on I-Premise
the I-Premise
sexual I-Premise
problem I-Premise
domain I-Premise
of I-Premise
EORTC-P I-Premise
( I-Premise
P I-Premise
= I-Premise
0.033 I-Premise
) I-Premise
and I-Premise
sexual I-Premise
desire I-Premise
score I-Premise
of I-Premise
SMUF I-Premise
( I-Premise
P I-Premise
= I-Premise
0.021 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
flutamide I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
LHRH I-Premise
group I-Premise
. I-Premise

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
34 I-Premise
months I-Premise
after I-Premise
prostatectomy I-Premise
, I-Premise
biochemical I-Premise
failure-free I-Premise
survival I-Premise
rate I-Premise
in I-Premise
the I-Premise
flutamide I-Premise
group I-Premise
did I-Premise
not I-Premise
differ I-Premise
from I-Premise
that I-Premise
in I-Premise
the I-Premise
LHRH I-Premise
group I-Premise
. I-Premise

This B-Claim
study I-Claim
suggests I-Claim
that I-Claim
flutamide I-Claim
monotherapy I-Claim
can I-Claim
be I-Claim
an I-Claim
acceptable I-Claim
modality I-Claim
as I-Claim
an I-Claim
option I-Claim
for I-Claim
neoadjuvant I-Claim
hormone I-Claim
therapy I-Claim
. I-Claim

To O
compare O
two O
cisplatin O
based O
chemotherapy O
schedules O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

A O
total O
of O
332 O
patients O
with O
advanced O
NSCLC O
were O
randomized O
to O
receive O
cisplatin O
80 O
mg/m2 O
on O
day O
1 O
either O
in O
combination O
with O
teniposide O
100 O
mg/m2 O
on O
days O
1 O
, O
3 O
, O
and O
5 O
( O
arm O
A O
) O
or O
paclitaxel O
175 O
mg/m2 O
by O
3-hour O
infusion O
on O
day O
1 O
( O
arm O
B O
) O
";" O
cycles O
were O
repeated O
every O
3 O
weeks O
. O

Fifteen O
patients O
were O
ineligible O
";" O
patient O
characteristics O
were O
well O
balanced O
between O
the O
two O
arms O
: O
71 O
% O
were O
male O
, O
71 O
% O
had O
less O
than O
5 O
% O
weight O
loss O
, O
89 O
% O
had O
a O
World O
Health O
Organization O
( O
WHO O
) O
performance O
status O
of O
0 O
to O
1 O
, O
51 O
% O
had O
adenocarcinoma O
, O
and O
61 O
% O
had O
stage O
IV O
disease O
. O

Hematologic B-Premise
toxicity I-Premise
was I-Premise
significantly I-Premise
more I-Premise
severe I-Premise
in I-Premise
arm I-Premise
A I-Premise
( I-Premise
leukopenia I-Premise
, I-Premise
neutropenia I-Premise
, I-Premise
and I-Premise
thrombocytopenia I-Premise
grade I-Premise
3 I-Premise
or I-Premise
4 I-Premise
: I-Premise
66 I-Premise
% I-Premise
v I-Premise
19 I-Premise
% I-Premise
, I-Premise
83 I-Premise
% I-Premise
v I-Premise
55 I-Premise
% I-Premise
, I-Premise
36 I-Premise
% I-Premise
v I-Premise
2 I-Premise
% I-Premise
in I-Premise
arms I-Premise
A I-Premise
and I-Premise
B I-Premise
, I-Premise
respectively I-Premise
) I-Premise
, I-Premise
which I-Premise
resulted I-Premise
in I-Premise
more I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
27 I-Premise
% I-Premise
v I-Premise
3 I-Premise
% I-Premise
in I-Premise
arms I-Premise
A I-Premise
and I-Premise
B I-Premise
, I-Premise
respectively I-Premise
) I-Premise
, I-Premise
dose I-Premise
reductions I-Premise
, I-Premise
and I-Premise
treatment I-Premise
delays I-Premise
. I-Premise

There B-Premise
were I-Premise
a I-Premise
total I-Premise
of I-Premise
nine I-Premise
toxic I-Premise
deaths I-Premise
, I-Premise
six I-Premise
due I-Premise
to I-Premise
neutropenic I-Premise
sepsis I-Premise
: I-Premise
five I-Premise
in I-Premise
arm I-Premise
A I-Premise
and I-Premise
one I-Premise
in I-Premise
arm I-Premise
B I-Premise
. I-Premise

In B-Premise
contrast I-Premise
, I-Premise
arthralgia/myalgia I-Premise
( I-Premise
grade I-Premise
2 I-Premise
or I-Premise
3 I-Premise
, I-Premise
4 I-Premise
% I-Premise
v I-Premise
17 I-Premise
% I-Premise
) I-Premise
, I-Premise
peripheral I-Premise
neurotoxicity I-Premise
( I-Premise
grade I-Premise
2 I-Premise
or I-Premise
3 I-Premise
, I-Premise
6 I-Premise
% I-Premise
v I-Premise
29 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
hypersensitivity I-Premise
reactions I-Premise
( I-Premise
1 I-Premise
% I-Premise
v I-Premise
7 I-Premise
% I-Premise
, I-Premise
all I-Premise
grades I-Premise
) I-Premise
were I-Premise
significantly I-Premise
more I-Premise
frequent I-Premise
in I-Premise
arm I-Premise
B I-Premise
. I-Premise

The B-Claim
frequency I-Claim
and I-Claim
severity I-Claim
of I-Claim
other I-Claim
toxicities I-Claim
were I-Claim
comparable I-Claim
between I-Claim
the I-Claim
two I-Claim
arms I-Claim
. I-Claim

Responses B-Premise
were I-Premise
one I-Premise
complete I-Premise
and I-Premise
44 I-Premise
partial I-Premise
on I-Premise
arm I-Premise
A I-Premise
( I-Premise
28 I-Premise
% I-Premise
) I-Premise
and I-Premise
two I-Premise
complete I-Premise
and I-Premise
61 I-Premise
partial I-Premise
( I-Premise
41 I-Premise
% I-Premise
) I-Premise
on I-Premise
arm I-Premise
B I-Premise
( I-Premise
P I-Premise
= I-Premise
.018 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
survival I-Premise
, I-Premise
with I-Premise
median I-Premise
and I-Premise
1-year I-Premise
survivals I-Premise
9.9 I-Premise
versus I-Premise
9.7 I-Premise
months I-Premise
and I-Premise
41 I-Premise
% I-Premise
versus I-Premise
43 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
in I-Premise
arm I-Premise
A I-Premise
and I-Premise
B. I-Premise
Progression-free B-Premise
survival I-Premise
was I-Premise
4.9 I-Premise
and I-Premise
5.4 I-Premise
months I-Premise
in I-Premise
arm I-Premise
A I-Premise
and I-Premise
B I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Selected O
centers O
participated O
in O
a O
quality-of-life O
( O
QoL O
) O
assessment O
, O
which O
was O
performed O
by O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
QLQ-C30 O
and O
LC-13 O
administered O
at O
baseline O
and O
every O
6 O
weeks O
thereafter O
. O

Arm B-Premise
B I-Premise
achieved I-Premise
a I-Premise
better I-Premise
score I-Premise
at I-Premise
week I-Premise
6 I-Premise
for I-Premise
emotional I-Premise
, I-Premise
cognitive I-Premise
and I-Premise
social I-Premise
functioning I-Premise
, I-Premise
global I-Premise
health I-Premise
status I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
appetite I-Premise
loss I-Premise
, I-Premise
which I-Premise
was I-Premise
lost I-Premise
at I-Premise
12 I-Premise
weeks I-Premise
. I-Premise

In B-Claim
conclusion I-Claim
, I-Claim
arm I-Claim
B I-Claim
appears I-Claim
superior I-Claim
to I-Claim
arm I-Claim
A I-Claim
with I-Claim
regard I-Claim
to I-Claim
response I-Claim
rate I-Claim
, I-Claim
side I-Claim
effects I-Claim
, I-Claim
and I-Claim
QoL I-Claim
. I-Claim

Although B-Claim
survival I-Claim
was I-Claim
not I-Claim
improved I-Claim
, I-Claim
arm B-Claim
B I-Claim
offers I-Claim
a I-Claim
better I-Claim
palliation I-Claim
for I-Claim
advanced I-Claim
NSCLC I-Claim
patients I-Claim
than I-Claim
arm I-Claim
A I-Claim
. I-Claim

To O
evaluate O
if O
raising O
baseline O
and O
maintaining O
hemoglobin O
( O
Hb O
) O
levels O
with O
red O
blood O
cell O
( O
RBC O
) O
transfusion O
could O
improve O
the O
outcomes O
of O
chemotherapy O
for O
advanced O
gastric O
cancer O
( O
AGC O
) O
. O

Patients O
were O
randomized O
to O
receive O
RBC O
transfusion O
to O
maintain O
their O
Hb O
levels O
> O
or=10 O
g/dl O
( O
arm O
1 O
) O
or O
> O
or=12 O
( O
arm O
2 O
) O
before O
the O
start O
of O
their O
5-fluorouracil-based O
first-line O
chemotherapy O
. O

Objective O
response O
, O
KPS O
and O
quality O
of O
life O
( O
QOL O
) O
data O
were O
measured O
. O

For O
87 O
patients O
enrolled O
, O
mean O
baseline O
Hb O
was O
10.1 O
g/dl O
, O
and O
54 O
patients O
received O
RBC O
prior O
to O
chemotherapy O
initiation O
. O

Despite O
transfusion O
, O
we O
failed O
to O
maintain O
the O
Hb O
level O
above O
the O
predefined O
target O
range O
. O

Eighteen B-Premise
patients I-Premise
experienced I-Premise
brief I-Premise
and I-Premise
reversible I-Premise
adverse I-Premise
events I-Premise
during I-Premise
transfusion I-Premise
, I-Premise
including I-Premise
two I-Premise
patients I-Premise
with I-Premise
acute I-Premise
pulmonary I-Premise
edema I-Premise
. I-Premise

KPS B-Premise
was I-Premise
improved I-Premise
from I-Premise
baseline I-Premise
to I-Premise
post-chemotherapy I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

QOL B-Premise
data I-Premise
showed I-Premise
improvement I-Premise
in I-Premise
some I-Premise
symptom I-Premise
scores I-Premise
, I-Premise
but B-Premise
there I-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
the I-Premise
QOL I-Premise
scores I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
at I-Premise
baseline I-Premise
and I-Premise
all I-Premise
four I-Premise
cycles I-Premise
of I-Premise
treatment I-Premise
. I-Premise

Similar B-Premise
response I-Premise
rates I-Premise
were I-Premise
observed I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
arm I-Premise
1 I-Premise
, I-Premise
30 I-Premise
% I-Premise
";" I-Premise
arm I-Premise
2 I-Premise
, I-Premise
35 I-Premise
% I-Premise
) I-Premise
. I-Premise

Both B-Premise
arms I-Premise
showed I-Premise
similar I-Premise
chemotherapy I-Premise
duration I-Premise
( I-Premise
3.8 I-Premise
and I-Premise
4.1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
) I-Premise
, I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
4.0 I-Premise
and I-Premise
4.1 I-Premise
months I-Premise
) I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
9.9 I-Premise
and I-Premise
9.3 I-Premise
months I-Premise
) I-Premise
. I-Premise

Red B-Claim
blood I-Claim
cell I-Claim
transfusion I-Claim
achieving I-Claim
Hb I-Claim
level I-Claim
above I-Claim
10 I-Claim
g/dl I-Claim
might I-Claim
contribute I-Claim
to I-Claim
the I-Claim
improvement I-Claim
of I-Claim
the I-Claim
KPS I-Claim
and I-Claim
QOL I-Claim
seen I-Claim
in I-Claim
patients I-Claim
with I-Claim
AGC I-Claim
. I-Claim

The B-Claim
observation I-Claim
of I-Claim
equivalent I-Claim
outcomes I-Claim
at I-Claim
the I-Claim
two I-Claim
target I-Claim
Hb I-Claim
levels I-Claim
supports I-Claim
the I-Claim
feasibility I-Claim
of I-Claim
anemia I-Claim
correction I-Claim
to I-Claim
Hb I-Claim
10 I-Claim
g/dl I-Claim
, I-Claim
which I-Claim
merits I-Claim
further I-Claim
evaluation I-Claim
. O

To O
determine O
whether O
cisplatin O
plus O
paclitaxel O
( O
C+P O
) O
improved O
response O
rate O
, O
progression-free O
survival O
( O
PFS O
) O
, O
or O
survival O
compared O
with O
cisplatin O
alone O
in O
patients O
with O
stage O
IVB O
, O
recurrent O
, O
or O
persistent O
squamous O
cell O
carcinoma O
of O
the O
cervix O
. O

PATIENTS O
AND O
METHODS O
Eligible O
: O
patients O
with O
measurable O
disease O
, O
performance O
status O
( O
PS O
) O
0 O
to O
2 O
, O
and O
adequate O
hematologic O
, O
hepatic O
, O
and O
renal O
function O
received O
either O
cisplatin O
50 O
mg/m2 O
or O
C+P O
( O
cisplatin O
50 O
mg/m2 O
plus O
paclitaxel O
135 O
mg/m2 O
) O
every O
3 O
weeks O
for O
six O
cycles O
. O

Tumor O
measurements O
and O
quality-of-life O
( O
QOL O
) O
assessments O
were O
obtained O
before O
each O
treatment O
cycle O
. O

Of O
280 O
patients O
entered O
, O
6 O
% O
were O
ineligible O
. O

Among O
264 O
eligible O
patients O
, O
134 O
received O
cisplatin O
and O
130 O
received O
C+P O
. O

Groups O
were O
well O
matched O
with O
respect O
to O
age O
, O
ethnicity O
, O
PS O
, O
tumor O
grade O
, O
disease O
site O
, O
and O
number O
of O
cycles O
received O
. O

The O
majority O
of O
all O
patients O
had O
prior O
radiation O
therapy O
( O
cisplatin O
, O
92 O
% O
";" O
C+P O
, O
91 O
% O
) O
. O

Objective B-Premise
responses I-Premise
occurred I-Premise
in I-Premise
19 I-Premise
% I-Premise
( I-Premise
6 I-Premise
% I-Premise
complete I-Premise
plus I-Premise
13 I-Premise
% I-Premise
partial I-Premise
) I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
cisplatin I-Premise
versus I-Premise
36 I-Premise
% I-Premise
( I-Premise
15 I-Premise
% I-Premise
complete I-Premise
plus I-Premise
21 I-Premise
% I-Premise
partial I-Premise
) I-Premise
receiving I-Premise
C+P I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
2.8 I-Premise
and I-Premise
4.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
cisplatin I-Premise
versus I-Premise
C+P I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
median I-Premise
survival I-Premise
( I-Premise
8.8 I-Premise
months I-Premise
v I-Premise
9.7 I-Premise
months I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
to I-Premise
4 I-Premise
anemia I-Premise
and I-Premise
neutropenia I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
combination I-Premise
arm I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
QOL I-Premise
scores I-Premise
, I-Premise
although B-Premise
a I-Premise
disproportionate I-Premise
number I-Premise
of I-Premise
patients I-Premise
( I-Premise
cisplatin I-Premise
, I-Premise
n I-Premise
= I-Premise
50 I-Premise
";" I-Premise
C+P I-Premise
, I-Premise
n I-Premise
= I-Premise
33 I-Premise
) I-Premise
dropped I-Premise
out I-Premise
of I-Premise
the I-Premise
QOL I-Premise
component I-Premise
, I-Premise
presumably I-Premise
because I-Premise
of I-Premise
increasing I-Premise
disease I-Premise
, I-Premise
deteriorating I-Premise
health I-Premise
status I-Premise
, I-Premise
or I-Premise
early I-Premise
death I-Premise
. I-Premise

C+P B-Claim
is I-Claim
superior I-Claim
to I-Claim
cisplatin I-Claim
alone I-Claim
with I-Claim
respect I-Claim
to I-Claim
response I-Claim
rate I-Claim
and I-Claim
PFS I-Claim
with I-Claim
sustained I-Claim
QOL I-Claim
. I-Claim

To O
investigate O
whether O
docetaxel O
plus O
platinum O
regimens O
improve O
survival O
and O
affect O
quality O
of O
life O
( O
QoL O
) O
in O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
compared O
with O
vinorelbine O
plus O
cisplatin O
as O
first-line O
chemotherapy O
. O

Patients O
( O
n O
= O
1,218 O
) O
with O
stage O
IIIB O
to O
IV O
NSCLC O
were O
randomly O
assigned O
to O
receive O
docetaxel O
75 O
mg/m2 O
and O
cisplatin O
75 O
mg/m2 O
every O
3 O
weeks O
( O
DC O
) O
";" O
docetaxel O
75 O
mg/m2 O
and O
carboplatin O
area O
under O
the O
curve O
of O
6 O
mg/mL O
* O
min O
every O
3 O
weeks O
( O
DCb O
) O
";" O
or O
vinorelbine O
25 O
mg/m2/wk O
and O
cisplatin O
100 O
mg/m2 O
every O
4 O
weeks O
( O
VC O
) O
. O

Patients B-Premise
treated I-Premise
with I-Premise
DC I-Premise
had I-Premise
a I-Premise
median I-Premise
survival I-Premise
of I-Premise
11.3 I-Premise
v I-Premise
10.1 I-Premise
months I-Premise
for I-Premise
VC-treated I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.044 I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.183 I-Premise
[ I-Premise
97.2 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
0.989 I-Premise
to I-Premise
1.416 I-Premise
] I-Premise
) I-Premise
. I-Premise

The B-Premise
2-year I-Premise
survival I-Premise
rate I-Premise
was I-Premise
21 I-Premise
% I-Premise
for I-Premise
DC-treated I-Premise
patients I-Premise
and I-Premise
14 I-Premise
% I-Premise
for I-Premise
VC-treated I-Premise
patients I-Premise
. I-Premise

Overall B-Premise
response I-Premise
rate I-Premise
was I-Premise
31.6 I-Premise
% I-Premise
for I-Premise
DC-treated I-Premise
patients I-Premise
v I-Premise
24.5 I-Premise
% I-Premise
for I-Premise
VC-treated I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.029 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
( I-Premise
9.4 I-Premise
v I-Premise
9.9 I-Premise
months I-Premise
[ I-Premise
for I-Premise
VC I-Premise
] I-Premise
";" I-Premise
P I-Premise
=.657 I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.048 I-Premise
[ I-Premise
97.2 I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
0.877 I-Premise
to I-Premise
1.253 I-Premise
] I-Premise
) I-Premise
and I-Premise
response I-Premise
( I-Premise
23.9 I-Premise
% I-Premise
) I-Premise
with I-Premise
DCb I-Premise
were I-Premise
similar I-Premise
to I-Premise
those I-Premise
results I-Premise
for I-Premise
VC I-Premise
. I-Premise

Neutropenia B-Premise
, I-Premise
thrombocytopenia I-Premise
, I-Premise
infection I-Premise
, I-Premise
and I-Premise
febrile I-Premise
neutropenia I-Premise
were I-Premise
similar I-Premise
with I-Premise
all I-Premise
three I-Premise
regimens I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
to I-Premise
4 I-Premise
anemia I-Premise
, I-Premise
nausea I-Premise
, I-Premise
and I-Premise
vomiting I-Premise
were I-Premise
more I-Premise
common I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
with I-Premise
VC I-Premise
than I-Premise
with I-Premise
DC I-Premise
or I-Premise
DCb I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
either I-Premise
docetaxel I-Premise
regimen I-Premise
had I-Premise
consistently I-Premise
improved I-Premise
QoL I-Premise
compared I-Premise
with I-Premise
VC-treated I-Premise
patients I-Premise
, I-Premise
who I-Premise
experienced I-Premise
deterioration I-Premise
in I-Premise
QoL I-Premise
. I-Premise

DC B-Claim
resulted I-Claim
in I-Claim
a I-Claim
more I-Claim
favorable I-Claim
overall I-Claim
response I-Claim
and I-Claim
survival I-Claim
rate I-Claim
than I-Claim
VC I-Claim
. I-Claim

Both B-Claim
DC I-Claim
and I-Claim
DCb I-Claim
were I-Claim
better I-Claim
tolerated I-Claim
and I-Claim
provided I-Claim
patients I-Claim
with I-Claim
consistently I-Claim
improved I-Claim
QoL I-Claim
compared I-Claim
with I-Claim
VC I-Claim
. I-Claim

These B-Claim
findings I-Claim
demonstrate I-Claim
that I-Claim
a I-Claim
docetaxel I-Claim
plus I-Claim
platinum I-Claim
combination I-Claim
is I-Claim
an I-Claim
effective I-Claim
treatment I-Claim
option I-Claim
with I-Claim
a I-Claim
favorable I-Claim
therapeutic I-Claim
index I-Claim
for I-Claim
first-line I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
or I-Claim
metastatic I-Claim
NSCLC I-Claim
. I-Claim

Tivozanib B-Claim
is I-Claim
a I-Claim
potent I-Claim
and I-Claim
selective I-Claim
tyrosine I-Claim
kinase I-Claim
inhibitor I-Claim
of I-Claim
vascular I-Claim
endothelial I-Claim
growth I-Claim
factor I-Claim
receptor I-Claim
1 I-Claim
( I-Claim
VEGFR1 I-Claim
) I-Claim
, I-Claim
-2 I-Claim
, I-Claim
and I-Claim
-3 I-Claim
. I-Claim

This O
phase O
III O
trial O
compared O
tivozanib O
with O
sorafenib O
as O
initial O
targeted O
therapy O
in O
patients O
with O
metastatic O
renal O
cell O
carcinoma O
( O
RCC O
) O
. O

Patients O
with O
metastatic O
RCC O
, O
with O
a O
clear O
cell O
component O
, O
prior O
nephrectomy O
, O
measurable O
disease O
, O
and O
0 O
or O
1 O
prior O
therapies O
for O
metastatic O
RCC O
were O
randomly O
assigned O
to O
tivozanib O
or O
sorafenib O
. O

Prior O
VEGF-targeted O
therapy O
and O
mammalian O
target O
of O
rapamycin O
inhibitor O
were O
not O
permitted O
. O

The O
primary O
end O
point O
was O
progression-free O
survival O
( O
PFS O
) O
by O
independent O
review O
. O

A O
total O
of O
517 O
patients O
were O
randomly O
assigned O
to O
tivozanib O
( O
n O
= O
260 O
) O
or O
sorafenib O
( O
n O
= O
257 O
) O
. O

PFS B-Premise
was I-Premise
longer I-Premise
with I-Premise
tivozanib I-Premise
than I-Premise
with I-Premise
sorafenib I-Premise
in I-Premise
the I-Premise
overall I-Premise
population I-Premise
( I-Premise
median I-Premise
, I-Premise
11.9 I-Premise
v I-Premise
9.1 I-Premise
months I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.797 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.639 I-Premise
to I-Premise
0.993 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.042 I-Premise
) I-Premise
. I-Premise

One O
hundred O
fifty-six O
patients O
( O
61 O
% O
) O
who O
progressed O
on O
sorafenib O
crossed O
over O
to O
receive O
tivozanib O
. O

The B-Premise
final I-Premise
overall I-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
analysis I-Premise
showed I-Premise
a I-Premise
trend I-Premise
toward I-Premise
longer I-Premise
survival I-Premise
on I-Premise
the I-Premise
sorafenib I-Premise
arm I-Premise
than I-Premise
on I-Premise
the I-Premise
tivozanib I-Premise
arm I-Premise
( I-Premise
median I-Premise
, I-Premise
29.3 I-Premise
v I-Premise
28.8 I-Premise
months I-Premise
";" I-Premise
HR I-Premise
, I-Premise
1.245 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.954 I-Premise
to I-Premise
1.624 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.105 I-Premise
) I-Premise
. I-Premise

Adverse B-Premise
events I-Premise
( I-Premise
AEs I-Premise
) I-Premise
more I-Premise
common I-Premise
with I-Premise
tivozanib I-Premise
than I-Premise
with I-Premise
sorafenib I-Premise
were I-Premise
hypertension I-Premise
( I-Premise
44 I-Premise
% I-Premise
v I-Premise
34 I-Premise
% I-Premise
) I-Premise
and I-Premise
dysphonia I-Premise
( I-Premise
21 I-Premise
% I-Premise
v I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise

AEs B-Premise
more I-Premise
common I-Premise
with I-Premise
sorafenib I-Premise
than I-Premise
with I-Premise
tivozanib I-Premise
were I-Premise
hand-foot I-Premise
skin I-Premise
reaction I-Premise
( I-Premise
54 I-Premise
% I-Premise
v I-Premise
14 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhea I-Premise
( I-Premise
33 I-Premise
% I-Premise
v I-Premise
23 I-Premise
% I-Premise
) I-Premise
. I-Premise

Tivozanib B-Claim
demonstrated I-Claim
improved I-Claim
PFS I-Claim
, I-Claim
but I-Claim
not I-Claim
OS I-Claim
, I-Claim
and I-Claim
a I-Claim
differentiated I-Claim
safety I-Claim
profile I-Claim
, I-Claim
compared I-Claim
with I-Claim
sorafenib I-Claim
, I-Claim
as I-Claim
initial I-Claim
targeted I-Claim
therapy I-Claim
for I-Claim
metastatic I-Claim
RCC I-Claim
. I-Claim

To O
compare O
the O
health-related O
quality O
of O
life O
in O
patients O
with O
narrow O
gastric O
tube O
and O
whole O
stomach O
reconstructions O
after O
oncologic O
esophagectomy O
. O

In O
a O
prospective O
randomized O
single-center O
study O
from O
2007 O
to O
2008 O
, O
104 O
patients O
underwent O
esophagectomy O
for O
cancer O
. O

To O
assess O
health-related O
quality O
of O
life O
, O
the O
questionnaire O
( O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
Core O
30 O
and O
the O
Oesophagus-Specific O
Quality O
of O
Life O
Questionnaire O
18 O
) O
was O
administered O
at O
3 O
weeks O
, O
6 O
months O
, O
1 O
year O
, O
and O
2 O
years O
after O
surgery O
. O

The B-Premise
perioperative I-Premise
complication I-Premise
rate I-Premise
was I-Premise
26.9 I-Premise
% I-Premise
in I-Premise
narrow I-Premise
gastric I-Premise
tube I-Premise
group I-Premise
and I-Premise
48.1 I-Premise
% I-Premise
in I-Premise
whole I-Premise
stomach I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.31 I-Premise
) I-Premise
. I-Premise

At B-Premise
the I-Premise
time I-Premise
of I-Premise
3 I-Premise
weeks I-Premise
after I-Premise
surgery I-Premise
, I-Premise
the I-Premise
reflux I-Premise
and I-Premise
dyspnea I-Premise
scores I-Premise
were I-Premise
higher I-Premise
in I-Premise
whole I-Premise
stomach I-Premise
group I-Premise
than I-Premise
in I-Premise
narrow I-Premise
gastric I-Premise
tube I-Premise
group I-Premise
, I-Premise
which I-Premise
meant I-Premise
that I-Premise
the I-Premise
patients I-Premise
in I-Premise
whole I-Premise
stomach I-Premise
group I-Premise
suffered I-Premise
more I-Premise
severe I-Premise
problem I-Premise
. I-Premise

At B-Premise
the I-Premise
time I-Premise
of I-Premise
6 I-Premise
months I-Premise
and I-Premise
1 I-Premise
year I-Premise
after I-Premise
surgery I-Premise
, I-Premise
the I-Premise
reflux I-Premise
scores I-Premise
were I-Premise
lower I-Premise
in I-Premise
narrow I-Premise
gastric I-Premise
tube I-Premise
group I-Premise
than I-Premise
in I-Premise
whole I-Premise
stomach I-Premise
group I-Premise
, I-Premise
which I-Premise
revealed I-Premise
that I-Premise
there I-Premise
were I-Premise
less I-Premise
problems I-Premise
of I-Premise
reflux I-Premise
in I-Premise
the I-Premise
patients I-Premise
of I-Premise
narrow I-Premise
gastric I-Premise
tube I-Premise
group I-Premise
";" I-Premise
meanwhile O
, O
the B-Premise
score I-Premise
of I-Premise
physical I-Premise
function I-Premise
scale I-Premise
in I-Premise
narrow I-Premise
gastric I-Premise
tube I-Premise
group I-Premise
was I-Premise
higher I-Premise
conversely I-Premise
, I-Premise
which I-Premise
suggested I-Premise
that I-Premise
the I-Premise
patients I-Premise
gain I-Premise
a I-Premise
better I-Premise
status I-Premise
in I-Premise
physical I-Premise
function I-Premise
. I-Premise

Nausea B-Premise
and I-Premise
vomiting I-Premise
is I-Premise
the I-Premise
only I-Premise
notable I-Premise
symptom I-Premise
that I-Premise
was I-Premise
worse I-Premise
in I-Premise
whole I-Premise
stomach I-Premise
group I-Premise
at I-Premise
the I-Premise
time I-Premise
of I-Premise
2 I-Premise
years I-Premise
after I-Premise
surgery I-Premise
, I-Premise
which O
suggested O
that O
patients B-Claim
in I-Claim
whole I-Claim
stomach I-Claim
group I-Claim
suffered I-Claim
more I-Claim
severe I-Claim
nausea I-Claim
and I-Claim
vomiting I-Claim
. I-Claim

Narrow B-Claim
gastric I-Claim
tube I-Claim
reconstruction I-Claim
may I-Claim
be I-Claim
a I-Claim
good I-Claim
alternative I-Claim
choice I-Claim
for I-Claim
patients I-Claim
undergoing I-Claim
oncologic I-Claim
esophagectomy I-Claim
in I-Claim
view I-Claim
of I-Claim
better I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
after I-Claim
the I-Claim
surgery I-Claim
. I-Claim

This O
randomised O
trial O
compared O
three O
chemotherapy O
regimens O
in O
the O
first-line O
treatment O
of O
advanced O
colorectal O
cancer O
, O
in O
terms O
of O
their O
effect O
on O
overall O
and O
progression-free O
survival O
";" O
other O
endpoints O
included O
toxicity O
, O
symptom O
palliation O
, O
and O
quality O
of O
life O
. O

905 O
patients O
were O
randomly O
assigned O
the O
de O
Gramont O
regimen O
( O
n=303 O
";" O
folinic O
acid O
200 O
mg/m O
( O
2 O
) O
, O
fluorouracil O
bolus O
400 O
mg/m O
( O
2 O
) O
, O
and O
infusion O
600 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
2 O
, O
repeated O
every O
14 O
days O
) O
, O
the O
Lokich O
regimen O
( O
n=301 O
";" O
protracted O
venous O
infusion O
of O
fluorouracil O
300 O
mg/m O
( O
2 O
) O
daily O
) O
, O
or O
raltitrexed O
( O
n=301 O
";" O
3 O
mg/m O
( O
2 O
) O
intravenously O
every O
21 O
days O
) O
. O

Analyses O
were O
by O
intention O
to O
treat O
. O

Median O
follow-up O
of O
survivors O
was O
67 O
weeks O
. O

For B-Premise
the I-Premise
de I-Premise
Gramont I-Premise
, I-Premise
Lokich I-Premise
, I-Premise
and I-Premise
raltitrexed I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
, I-Premise
median I-Premise
survival I-Premise
was I-Premise
294 I-Premise
, I-Premise
302 I-Premise
, I-Premise
and I-Premise
266 I-Premise
days I-Premise
. I-Premise

The B-Premise
hazard I-Premise
ratios I-Premise
for I-Premise
overall I-Premise
survival I-Premise
were I-Premise
0.88 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.70-1.12 I-Premise
, I-Premise
p=0.17 I-Premise
) I-Premise
for I-Premise
de I-Premise
Gramont I-Premise
versus I-Premise
Lokich I-Premise
, I-Premise
and I-Premise
0.99 I-Premise
( I-Premise
0.79-1.25 I-Premise
, I-Premise
p=0.94 I-Premise
) I-Premise
for I-Premise
de I-Premise
Gramont I-Premise
versus I-Premise
raltitrexed I-Premise
. I-Premise

An B-Premise
increase I-Premise
in I-Premise
treatment-related I-Premise
deaths I-Premise
was I-Premise
seen I-Premise
on I-Premise
raltitrexed I-Premise
( I-Premise
de I-Premise
Gramont I-Premise
one I-Premise
, I-Premise
Lokich I-Premise
two I-Premise
, I-Premise
raltitrexed I-Premise
18 I-Premise
) I-Premise
due I-Premise
to I-Premise
combined I-Premise
gastrointestinal I-Premise
and I-Premise
haematological I-Premise
toxicity I-Premise
. I-Premise

Patients B-Premise
' I-Premise
assessment I-Premise
of I-Premise
quality I-Premise
of I-Premise
life I-Premise
showed I-Premise
that I-Premise
raltitrexed I-Premise
was I-Premise
inferior I-Premise
to I-Premise
the I-Premise
fluorouracil-based I-Premise
regimens I-Premise
, I-Premise
especially I-Premise
in I-Premise
terms I-Premise
of I-Premise
palliation I-Premise
and I-Premise
functioning I-Premise
. I-Premise

The B-Claim
deGramont I-Claim
and I-Claim
Lokich I-Claim
regimens I-Claim
were I-Claim
similar I-Claim
in I-Claim
terms I-Claim
of I-Claim
survival I-Claim
, I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
response I-Claim
rates I-Claim
. I-Claim

The B-Claim
Lokich I-Claim
regimen I-Claim
was I-Claim
associated I-Claim
with I-Claim
more I-Claim
central I-Claim
line I-Claim
complications I-Claim
and I-Claim
hand-foot I-Claim
syndrome I-Claim
. I-Claim

Raltitrexed B-Claim
showed I-Claim
similar I-Claim
response I-Claim
rates I-Claim
and I-Claim
overall I-Claim
survival I-Claim
to I-Claim
the I-Claim
de I-Claim
Gramont I-Claim
regimen I-Claim
and I-Claim
was I-Claim
easier I-Claim
to I-Claim
administer I-Claim
, I-Claim
but B-Claim
resulted I-Claim
in I-Claim
greater I-Claim
toxicity I-Claim
and I-Claim
inferior I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

This O
study O
aims O
to O
describe O
and O
compare O
health-related O
quality O
of O
life O
( O
HRQL O
) O
in O
patients O
with O
node-positive O
and O
high-risk O
node-negative O
HER2-positive O
early O
breast O
cancer O
receiving O
adjuvant O
docetaxel O
and O
trastuzumab-based O
or O
docetaxel-based O
regimens O
alone O
. O

Eligible O
patients O
( O
n O
= O
3,222 O
) O
were O
randomly O
assigned O
to O
either O
four O
cycles O
of O
adjuvant O
doxorubicin O
and O
cyclophosphamide O
followed O
by O
four O
cycles O
of O
docetaxel O
( O
AC→T O
) O
or O
one O
of O
two O
trastuzumab-containing O
regimens O
: O
adjuvant O
doxorubicin O
and O
cyclophosphamide O
followed O
by O
docetaxel O
plus O
trastuzumab O
administered O
for O
1 O
year O
( O
AC→TH O
) O
or O
six O
cycles O
of O
docetaxel O
plus O
carboplatin O
combined O
with O
trastuzumab O
administered O
for O
1 O
year O
( O
TCH O
) O
. O

The O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
C30 O
and O
BR-23 O
were O
administered O
at O
baseline O
, O
the O
start O
of O
cycle O
4 O
( O
mid O
) O
, O
and O
the O
end O
of O
chemotherapy O
( O
EOC O
) O
, O
as O
well O
as O
at O
6 O
, O
12 O
, O
and O
24 O
months O
after O
chemotherapy O
. O

Compliance B-Premise
rates I-Premise
for I-Premise
the I-Premise
EORTC I-Premise
questionnaires I-Premise
were I-Premise
acceptable I-Premise
at I-Premise
72 I-Premise
% I-Premise
-93 I-Premise
% I-Premise
of I-Premise
eligible I-Premise
patients I-Premise
out I-Premise
to I-Premise
the I-Premise
12-month I-Premise
assessment I-Premise
. I-Premise

Systemic B-Premise
side I-Premise
effect I-Premise
( I-Premise
SE I-Premise
) I-Premise
change I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
improved I-Premise
for I-Premise
TCH-treated I-Premise
patients I-Premise
compared I-Premise
with I-Premise
AC→TH I-Premise
and I-Premise
AC→T I-Premise
at I-Premise
EOC I-Premise
, I-Premise
suggesting I-Premise
improved I-Premise
tolerability I-Premise
. I-Premise

Physical B-Premise
functioning I-Premise
( I-Premise
PF I-Premise
) I-Premise
was I-Premise
only I-Premise
slightly I-Premise
worse I-Premise
at I-Premise
midpoint I-Premise
for I-Premise
those I-Premise
receiving I-Premise
TCH I-Premise
, I-Premise
compared I-Premise
with I-Premise
patients I-Premise
who I-Premise
were I-Premise
just I-Premise
starting I-Premise
on I-Premise
taxane I-Premise
in I-Premise
an I-Premise
AC→TH I-Premise
regimen I-Premise
, I-Premise
but I-Premise
was I-Premise
otherwise I-Premise
similar I-Premise
between I-Premise
arms I-Premise
. I-Premise

All B-Claim
treatment I-Claim
arms I-Claim
recovered I-Claim
from I-Claim
the I-Claim
deterioration I-Claim
in I-Claim
SE I-Claim
, I-Claim
PF I-Claim
, I-Claim
and I-Claim
Global I-Claim
Health I-Claim
Scale I-Claim
scores I-Claim
by I-Claim
1 I-Claim
year I-Claim
and I-Claim
median I-Claim
future I-Claim
perspective I-Claim
change I-Claim
scores I-Claim
continued I-Claim
to I-Claim
improve I-Claim
throughout I-Claim
treatment I-Claim
and I-Claim
follow-up I-Claim
. I-Claim

HRQL B-Claim
outcomes I-Claim
for I-Claim
adjuvant I-Claim
docetaxel I-Claim
and I-Claim
trastuzumab-based I-Claim
regimens I-Claim
are I-Claim
favorable I-Claim
and I-Claim
support I-Claim
TCH I-Claim
as I-Claim
a I-Claim
more I-Claim
tolerable I-Claim
treatment I-Claim
option I-Claim
. I-Claim

Patients O
undergoing O
gastrectomy O
because O
of O
stomach O
cancer O
often O
face O
weight O
loss O
in O
the O
perioperational O
period O
, O
which O
can O
lead O
to O
malnutrition O
and O
negative O
treatment O
outcomes O
. O

The O
purpose O
of O
this O
study O
was O
to O
develop O
a O
patient O
participation-based O
dietary O
intervention O
( O
PPDI O
) O
and O
evaluate O
its O
effects O
on O
patient O
outcomes O
. O

This O
was O
a O
prospective O
, O
randomized O
controlled O
trial O
in O
which O
the O
patients O
were O
recruited O
in O
a O
cancer O
center O
in O
South O
Korea O
. O

The O
participants O
( O
N O
= O
56 O
) O
, O
who O
underwent O
gastrectomy O
with O
stomach O
cancer O
stage O
I O
to O
III O
, O
were O
randomly O
assigned O
into O
either O
the O
experimental O
or O
the O
control O
group O
. O

The O
PPDI O
, O
which O
was O
given O
on O
the O
day O
before O
the O
hospital O
discharge O
, O
comprised O
2 O
face-to-face O
and O
2 O
telephone O
interventions O
. O

The O
outcome O
variables O
included O
body O
weight O
, O
body O
mass O
index O
, O
muscle O
mass O
, O
the O
Patient-Generated O
Subjective O
Global O
Assessment O
, O
Dietary O
Symptom O
Scale O
, O
Functional O
Assessment O
Cancer O
Therapy-General O
, O
Karnofsky O
Performance O
Status O
, O
Adherence O
to O
Dietary O
Guidelines O
Scale O
, O
Scale O
of O
Dietary O
Knowledge O
, O
Patient O
Satisfaction O
Scale O
, O
and O
a O
3-day O
food O
diary O
. O

Participants B-Premise
in I-Premise
the I-Premise
PPDI I-Premise
intervention I-Premise
demonstrated I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
reductions I-Premise
in I-Premise
adverse I-Premise
dietary I-Premise
symptoms I-Premise
and I-Premise
significant I-Premise
improvements I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
in I-Premise
functional I-Premise
status I-Premise
, I-Premise
performance I-Premise
status I-Premise
, I-Premise
dietary I-Premise
intake I-Premise
, I-Premise
adherence I-Premise
to I-Premise
dietary I-Premise
guidelines I-Premise
, I-Premise
dietary I-Premise
knowledge I-Premise
, I-Premise
and I-Premise
satisfaction I-Premise
with I-Premise
the I-Premise
intervention I-Premise
as I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
over I-Premise
time I-Premise
. I-Premise

The B-Claim
PPDI I-Claim
was I-Claim
an I-Claim
effective I-Claim
dietary I-Claim
intervention I-Claim
for I-Claim
patients I-Claim
undergoing I-Claim
a I-Claim
gastrectomy I-Claim
for I-Claim
gastric I-Claim
cancer I-Claim
and I-Claim
deserves I-Claim
additional I-Claim
study I-Claim
in I-Claim
other I-Claim
populations I-Claim
of I-Claim
patients I-Claim
. I-Claim

Incorporating B-Claim
patients I-Claim
' I-Claim
perspectives I-Claim
into I-Claim
a I-Claim
dietary I-Claim
intervention I-Claim
after I-Claim
gastrectomy I-Claim
for I-Claim
gastric I-Claim
cancer I-Claim
may I-Claim
contribute I-Claim
to I-Claim
improved I-Claim
patient I-Claim
outcomes I-Claim
and I-Claim
quality I-Claim
care I-Claim
. I-Claim

Colonic O
pouches O
have O
been O
used O
for O
20 O
years O
to O
provide O
reservoir O
function O
after O
reconstructive O
proctectomy O
for O
rectal O
cancer O
. O

More B-Claim
recently I-Claim
coloplasty I-Claim
has I-Claim
been I-Claim
advocated I-Claim
as I-Claim
an I-Claim
alternative I-Claim
to I-Claim
a I-Claim
colonic I-Claim
pouch I-Claim
. I-Claim

However O
there O
have O
been O
no O
long-term O
randomized O
, O
controlled O
trials O
to O
compare O
functional O
outcomes O
of O
coloplasty O
, O
colonic O
J-Pouch O
( O
JP O
) O
, O
or O
a O
straight O
anastomosis O
( O
SA O
) O
after O
the O
treatment O
of O
low O
rectal O
cancer O
. O

: O
To O
compare O
the O
complications O
, O
long-term O
functional O
outcome O
, O
and O
quality O
of O
life O
( O
QOL O
) O
of O
patients O
undergoing O
a O
coloplasty O
, O
JP O
, O
or O
an O
SA O
in O
reconstruction O
of O
the O
lower O
gastrointestinal O
tract O
after O
proctectomy O
for O
low O
rectal O
cancer O
. O

A O
multicenter O
study O
enrolled O
patients O
with O
low O
rectal O
cancer O
, O
who O
were O
randomized O
intraoperatively O
to O
coloplasty O
( O
CP-1 O
) O
or O
SA O
if O
JP O
was O
not O
feasible O
, O
or O
JP O
or O
coloplasty O
( O
CP-2 O
) O
if O
a O
JP O
was O
feasible O
. O

Patients O
were O
followed O
for O
24 O
months O
with O
SF-36 O
surveys O
to O
evaluate O
the O
QOL O
. O

Bowel O
function O
was O
measured O
quantitatively O
and O
using O
Fecal O
Incontinence O
Severity O
Index O
( O
FISI O
) O
. O

Urinary O
function O
and O
sexual O
function O
were O
also O
assessed O
. O

Three O
hundred O
sixty-four O
patients O
were O
randomized O
. O

All O
patients O
were O
evaluated O
for O
complications O
and O
recurrence O
. O

Mean O
age O
was O
60 O
+/-12 O
years O
, O
71 O
% O
were O
male O
. O

Twenty-three B-Premise
( I-Premise
7.4 I-Premise
% I-Premise
) I-Premise
died I-Premise
within I-Premise
24 I-Premise
months I-Premise
of I-Premise
surgery I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
complications I-Premise
among I-Premise
the I-Premise
4 I-Premise
groups I-Premise
. I-Premise

Two O
hundred O
ninety-seven O
of O
364 O
were O
evaluated O
for O
functional O
outcome O
at O
24 O
months O
. O

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
bowel I-Premise
function I-Premise
between I-Premise
the I-Premise
CP-1 I-Premise
and I-Premise
SA I-Premise
groups I-Premise
. I-Premise

JP B-Premise
patients I-Premise
had I-Premise
fewer I-Premise
bowel I-Premise
movements I-Premise
, I-Premise
less I-Premise
clustering I-Premise
, I-Premise
used I-Premise
fewer I-Premise
pads I-Premise
and I-Premise
had I-Premise
a I-Premise
lower I-Premise
FISI I-Premise
than I-Premise
the I-Premise
CP-2 I-Premise
group I-Premise
. I-Premise

Other B-Premise
parameters I-Premise
were I-Premise
not I-Premise
statistically I-Premise
different I-Premise
. I-Premise

QOL B-Premise
scores I-Premise
at I-Premise
24 I-Premise
months I-Premise
were I-Premise
similar I-Premise
for I-Premise
each I-Premise
of I-Premise
the I-Premise
4 I-Premise
groups I-Premise
. I-Premise

In B-Claim
patients I-Claim
undergoing I-Claim
a I-Claim
restorative I-Claim
resection I-Claim
for I-Claim
low I-Claim
rectal I-Claim
cancer I-Claim
, I-Claim
a I-Claim
colonic I-Claim
JP I-Claim
offers I-Claim
significant I-Claim
advantages I-Claim
in I-Claim
function I-Claim
over I-Claim
an I-Claim
SA I-Claim
or I-Claim
a I-Claim
coloplasty I-Claim
. I-Claim

In B-Claim
patients I-Claim
who I-Claim
can I-Claim
not I-Claim
have I-Claim
a I-Claim
pouch I-Claim
, I-Claim
coloplasty I-Claim
seems I-Claim
not I-Claim
to I-Claim
improve I-Claim
the I-Claim
bowel I-Claim
function I-Claim
of I-Claim
patients I-Claim
over I-Claim
that I-Claim
with I-Claim
an I-Claim
SA I-Claim
. I-Claim

Combined B-Claim
radiation I-Claim
therapy I-Claim
and I-Claim
chemotherapy I-Claim
after I-Claim
surgery I-Claim
, I-Claim
compared I-Claim
with I-Claim
postsurgical I-Claim
radiation I-Claim
therapy I-Claim
alone I-Claim
, I-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
improve I-Claim
disease-free I-Claim
survival I-Claim
and I-Claim
overall I-Claim
survival I-Claim
significantly I-Claim
among I-Claim
patients I-Claim
with I-Claim
poor-prognosis I-Claim
( I-Claim
i.e. I-Claim
, I-Claim
advanced I-Claim
stage I-Claim
disease I-Claim
or I-Claim
metastasis I-Claim
to I-Claim
regional I-Claim
lymph I-Claim
nodes I-Claim
) I-Claim
resectable I-Claim
rectal I-Claim
cancer I-Claim
. I-Claim

However B-Claim
, I-Claim
the I-Claim
combined I-Claim
therapy I-Claim
is I-Claim
associated I-Claim
with I-Claim
more I-Claim
toxic I-Claim
effects I-Claim
, I-Claim
raising I-Claim
the I-Claim
question I-Claim
of I-Claim
whether I-Claim
the I-Claim
benefits I-Claim
of I-Claim
the I-Claim
treatment I-Claim
justify I-Claim
its I-Claim
quality-of-life I-Claim
costs I-Claim
for I-Claim
the I-Claim
individual I-Claim
patient I-Claim
. I-Claim

To O
assess O
the O
trade-offs O
between O
improved O
survival O
and O
increased O
treatment O
toxicity O
, O
we O
reanalyzed O
data O
from O
a O
randomized O
clinical O
trial O
that O
compared O
the O
efficacy O
of O
combined O
adjuvant O
chemotherapy O
and O
radiation O
therapy O
with O
adjuvant O
radiation O
therapy O
alone O
in O
the O
treatment O
of O
patients O
with O
poor-prognosis O
resectable O
rectal O
cancer O
. O

The O
data O
were O
from O
a O
North O
Central O
Cancer O
Treatment O
Group O
trial O
in O
which O
204 O
patients O
with O
poor-prognosis O
rectal O
cancer O
were O
randomly O
assigned O
to O
receive O
either O
postoperative O
radiation O
therapy O
alone O
or O
radiation O
therapy O
plus O
fluorouracil-based O
chemotherapy O
. O

A O
quality-adjusted O
time O
without O
symptoms O
or O
toxicity O
( O
Q-TWiST O
) O
analysis O
was O
used O
to O
account O
for O
freedom O
from O
symptomatic O
disease O
and O
from O
early O
and O
late O
side O
effects O
of O
treatment O
. O

All O
reported O
P O
values O
are O
two-sided O
. O

As B-Premise
reported I-Premise
previously I-Premise
, I-Premise
the I-Premise
combined I-Premise
therapy I-Premise
reduced I-Premise
the I-Premise
risk I-Premise
of I-Premise
relapse I-Premise
by I-Premise
34 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
12 I-Premise
% I-Premise
-50 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0016 I-Premise
) I-Premise
and I-Premise
reduced I-Premise
the I-Premise
overall I-Premise
death I-Premise
rate I-Premise
by I-Premise
29 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
7 I-Premise
% I-Premise
-45 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.025 I-Premise
) I-Premise
in I-Premise
comparison I-Premise
with I-Premise
adjuvant I-Premise
radiation I-Premise
therapy I-Premise
alone I-Premise
. I-Premise

In B-Premise
the I-Premise
5 I-Premise
years I-Premise
following I-Premise
assignment I-Premise
to I-Premise
treatment I-Premise
, I-Premise
patients I-Premise
who I-Premise
received I-Premise
the I-Premise
combined I-Premise
therapy I-Premise
had I-Premise
more I-Premise
time I-Premise
with I-Premise
toxicity I-Premise
( I-Premise
3.1 I-Premise
months I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
2.0-4.1 I-Premise
months I-Premise
) I-Premise
, I-Premise
shorter I-Premise
survival I-Premise
after I-Premise
relapse I-Premise
( I-Premise
3.6 I-Premise
months I-Premise
less I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.9-6.3 I-Premise
months I-Premise
less I-Premise
) I-Premise
, I-Premise
and I-Premise
more I-Premise
TWiST I-Premise
( I-Premise
6.1 I-Premise
months I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.2-12.0 I-Premise
months I-Premise
) I-Premise
than I-Premise
patients I-Premise
who I-Premise
received I-Premise
adjuvant I-Premise
radiation I-Premise
therapy I-Premise
alone I-Premise
. I-Premise

Despite B-Claim
an I-Claim
increase I-Claim
in I-Claim
the I-Claim
amount I-Claim
of I-Claim
time I-Claim
that I-Claim
individuals I-Claim
spent I-Claim
with I-Claim
early I-Claim
and I-Claim
late I-Claim
toxic I-Claim
effects I-Claim
, I-Claim
the I-Claim
Q-TWiST I-Claim
analysis I-Claim
indicated I-Claim
that I-Claim
the I-Claim
combined I-Claim
therapy I-Claim
conferred I-Claim
significantly I-Claim
greater I-Claim
benefit I-Claim
for I-Claim
a I-Claim
wide I-Claim
range I-Claim
of I-Claim
patient I-Claim
preferences I-Claim
about I-Claim
living I-Claim
with I-Claim
the I-Claim
toxicity I-Claim
of I-Claim
treatment I-Claim
or I-Claim
the I-Claim
symptoms I-Claim
of I-Claim
overt I-Claim
disease I-Claim
. I-Claim

Use B-Claim
of I-Claim
combined I-Claim
chemotherapy I-Claim
and I-Claim
radiation I-Claim
therapy I-Claim
as I-Claim
an I-Claim
adjuvant I-Claim
to I-Claim
surgery I-Claim
for I-Claim
patients I-Claim
with I-Claim
poor-prognosis I-Claim
resectable I-Claim
rectal I-Claim
cancer I-Claim
is I-Claim
justified I-Claim
, I-Claim
since B-Premise
the I-Premise
improved I-Premise
outcome I-Premise
in I-Premise
terms I-Premise
of I-Premise
delayed I-Premise
recurrence I-Premise
and I-Premise
increased I-Premise
survival I-Premise
balances I-Premise
the I-Premise
time I-Premise
spent I-Premise
with I-Premise
early I-Premise
and I-Premise
late I-Premise
toxic I-Premise
effects I-Premise
. I-Premise

The B-Claim
Q-TWiST I-Claim
method I-Claim
is I-Claim
an I-Claim
excellent I-Claim
way I-Claim
to I-Claim
compare I-Claim
treatment I-Claim
outcomes I-Claim
that I-Claim
include I-Claim
quality-of-life I-Claim
considerations I-Claim
. I-Claim

Malnutrition B-Claim
occurs I-Claim
frequently I-Claim
in I-Claim
patients I-Claim
with I-Claim
cancer I-Claim
of I-Claim
the I-Claim
gastrointestinal I-Claim
( I-Claim
GI I-Claim
) I-Claim
or I-Claim
head I-Claim
and I-Claim
neck I-Claim
area I-Claim
and I-Claim
can I-Claim
lead I-Claim
to I-Claim
negative I-Claim
outcomes I-Claim
. I-Claim

The O
aim O
of O
this O
study O
is O
to O
determine O
the O
impact O
of O
early O
and O
intensive O
nutrition O
intervention O
( O
NI O
) O
on O
body O
weight O
, O
body O
composition O
, O
nutritional O
status O
, O
global O
quality O
of O
life O
( O
QoL O
) O
and O
physical O
function O
compared O
to O
usual O
practice O
in O
oncology O
outpatients O
receiving O
radiotherapy O
to O
the O
GI O
or O
head O
and O
neck O
area O
. O

Outpatients O
commencing O
at O
least O
20 O
fractions O
of O
radiotherapy O
to O
the O
GI O
or O
head O
and O
neck O
area O
were O
randomised O
to O
receive O
intensive O
, O
individualised O
nutrition O
counselling O
by O
a O
dietitian O
using O
a O
standard O
protocol O
and O
oral O
supplements O
if O
required O
, O
or O
the O
usual O
practice O
of O
the O
centre O
( O
general O
advice O
and O
nutrition O
booklet O
) O
. O

Outcome O
parameters O
were O
measured O
at O
baseline O
and O
4 O
, O
8 O
and O
12 O
weeks O
after O
commencing O
radiotherapy O
using O
valid O
and O
reliable O
tools O
. O

A O
total O
of O
60 O
patients O
( O
51 O
M O
: O
9 O
F O
";" O
mean O
age O
61.9+/-14.0 O
years O
) O
were O
randomised O
to O
receive O
either O
NI O
( O
n=29 O
) O
or O
usual O
care O
( O
UC O
) O
( O
n=31 O
) O
. O

The B-Premise
NI I-Premise
group I-Premise
had I-Premise
statistically I-Premise
smaller I-Premise
deteriorations I-Premise
in I-Premise
weight I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
nutritional I-Premise
status I-Premise
( I-Premise
P=0.020 I-Premise
) I-Premise
and I-Premise
global I-Premise
QoL I-Premise
( I-Premise
P=0.009 I-Premise
) I-Premise
compared I-Premise
with I-Premise
those I-Premise
receiving I-Premise
UC I-Premise
. I-Premise

Clinically B-Premise
, I-Premise
but I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
fat-free I-Premise
mass I-Premise
were I-Premise
observed I-Premise
between I-Premise
the I-Premise
groups I-Premise
( I-Premise
P=0.195 I-Premise
) I-Premise
. I-Premise

Early B-Claim
and I-Claim
intensive I-Claim
NI I-Claim
appears I-Claim
beneficial I-Claim
in I-Claim
terms I-Claim
of I-Claim
minimising I-Claim
weight I-Claim
loss I-Claim
, I-Claim
deterioration I-Claim
in I-Claim
nutritional I-Claim
status I-Claim
, I-Claim
global I-Claim
QoL I-Claim
and I-Claim
physical I-Claim
function I-Claim
in I-Claim
oncology I-Claim
outpatients I-Claim
receiving I-Claim
radiotherapy I-Claim
to I-Claim
the I-Claim
GI I-Claim
or I-Claim
head I-Claim
and I-Claim
neck I-Claim
area I-Claim
. I-Claim

Weight B-Claim
maintenance I-Claim
in I-Claim
this I-Claim
population I-Claim
leads I-Claim
to I-Claim
beneficial I-Claim
outcomes I-Claim
and I-Claim
suggests I-Claim
that I-Claim
this I-Claim
, I-Claim
rather I-Claim
than I-Claim
weight I-Claim
gain I-Claim
, I-Claim
may I-Claim
be I-Claim
a I-Claim
more I-Claim
appropriate I-Claim
aim I-Claim
of I-Claim
NI I-Claim
. I-Claim

There O
is O
a O
paucity O
of O
methodologically O
robust O
vocational O
rehabilitation O
( O
VR O
) O
intervention O
trials O
. O

This O
study O
assessed O
the O
feasibility O
and O
acceptability O
of O
a O
VR O
trial O
of O
women O
with O
breast O
cancer O
to O
inform O
the O
development O
of O
a O
larger O
interventional O
study O
. O

Women O
were O
recruited O
in O
Scotland O
and O
randomised O
to O
either O
a O
case O
management O
VR O
service O
or O
to O
usual O
care O
. O

Data O
were O
collected O
on O
eligibility O
, O
recruitment O
and O
attrition O
rates O
to O
assess O
trial O
feasibility O
, O
and O
interviews O
conducted O
to O
determine O
trial O
acceptability O
. O

Sick O
leave O
days O
( O
primary O
outcome O
) O
were O
self-reported O
via O
postal O
questionnaire O
every O
4 O
weeks O
during O
the O
first O
6 O
months O
post-surgery O
and O
at O
12 O
months O
. O

Secondary O
outcome O
measures O
were O
change O
in O
employment O
pattern O
, O
quality O
of O
life O
and O
fatigue O
. O

Of O
the O
1,114 O
women O
assessed O
for O
eligibility O
, O
163 O
( O
15 O
% O
) O
were O
eligible O
. O

The O
main O
reason O
for O
ineligibility O
was O
age O
( O
> O
65 O
years O
, O
n O
= O
637 O
, O
67 O
% O
) O
. O

Of O
those O
eligible O
, O
111 O
( O
68 O
% O
) O
received O
study O
information O
, O
of O
which O
23 O
( O
21 O
% O
) O
consented O
to O
participate O
in O
the O
study O
. O

Data O
for O
18 O
( O
78 O
% O
) O
women O
were O
analysed O
( O
intervention O
: O
n O
= O
7 O
";" O
control O
: O
n O
= O
11 O
) O
. O

Participants B-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
reported I-Premise
, I-Premise
on I-Premise
average I-Premise
, I-Premise
53 I-Premise
fewer I-Premise
days I-Premise
of I-Premise
sick I-Premise
leave I-Premise
over I-Premise
the I-Premise
first I-Premise
6 I-Premise
months I-Premise
post-surgery I-Premise
than I-Premise
those I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
";" I-Premise
however B-Premise
, I-Premise
this I-Premise
difference I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
p I-Premise
= I-Premise
0.122 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-15.8 I-Premise
, I-Premise
122.0 I-Premise
) I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
were I-Premise
found I-Premise
for I-Premise
secondary I-Premise
outcomes I-Premise
. I-Premise

Interviews B-Premise
with I-Premise
trial I-Premise
participants I-Premise
indicated I-Premise
that I-Premise
trial I-Premise
procedures I-Premise
, I-Premise
including I-Premise
recruitment I-Premise
, I-Premise
randomisation I-Premise
and I-Premise
research I-Premise
instruments I-Premise
, I-Premise
were I-Premise
acceptable I-Premise
. I-Premise

Conducting B-Claim
a I-Claim
pragmatic I-Claim
trial I-Claim
of I-Claim
effectiveness I-Claim
of I-Claim
a I-Claim
VR I-Claim
intervention I-Claim
among I-Claim
cancer I-Claim
survivors I-Claim
is I-Claim
both I-Claim
feasible I-Claim
and I-Claim
acceptable I-Claim
, I-Claim
but B-Claim
more I-Claim
research I-Claim
about I-Claim
the I-Claim
exact I-Claim
components I-Claim
of I-Claim
a I-Claim
VR I-Claim
intervention I-Claim
and I-Claim
choice I-Claim
of I-Claim
outcomes I-Claim
to I-Claim
measure I-Claim
effectiveness I-Claim
is I-Claim
required I-Claim
. I-Claim

VR B-Claim
to I-Claim
assist I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
in I-Claim
the I-Claim
return I-Claim
to I-Claim
work I-Claim
process I-Claim
is I-Claim
an I-Claim
important I-Claim
component I-Claim
of I-Claim
cancer I-Claim
survivorship I-Claim
plans I-Claim
. I-Claim

Intravenous O
( O
IV O
) O
granulocyte O
colony O
stimulating O
factor O
( O
G-CSF O
) O
might O
be O
safer O
and O
more O
convenient O
than O
subcutaneous O
( O
SC O
) O
administration O
to O
hospitalized O
hemato-oncological O
patients O
receiving O
chemotherapy O
. O

To O
compare O
IV O
vs. O
SC O
G-CSF O
administration O
, O
we O
conducted O
a O
randomized O
, O
open-label O
trial O
. O

We O
included O
inpatients O
receiving O
chemotherapy O
for O
acute O
myeloid O
leukemia O
, O
acute O
lymphoblastic O
leukemia O
, O
lymphoma O
or O
multiple O
myeloma O
, O
and O
allogeneic O
or O
autologous O
hematopoietic O
cell O
transplantation O
( O
HCT O
) O
. O

Patients O
were O
randomized O
to O
5 O
mcg/kg O
single O
daily O
dose O
of O
IV O
bolus O
versus O
SC O
filgrastim O
given O
for O
its O
clinical O
indications O
. O

Patients O
were O
crossed-over O
to O
the O
alternate O
study O
arm O
on O
the O
subsequent O
chemotherapy O
course O
. O

The O
primary O
outcomes O
were O
time O
from O
initiation O
of O
filgrastim O
to O
recovery O
of O
stable O
neutrophil O
count O
of O
> O
500 O
cells/µL O
and O
a O
composite O
clinical O
outcome O
of O
infection O
or O
death O
assessed O
for O
the O
first O
course O
post-randomization O
. O

The O
study O
was O
stopped O
on O
the O
second O
interim O
analysis O
. O

Of O
120 O
patients O
randomized O
, O
118 O
were O
evaluated O
in O
the O
first O
treatment O
course O
. O

The B-Premise
mean I-Premise
time I-Premise
to I-Premise
neutropenia I-Premise
resolution I-Premise
was I-Premise
longer I-Premise
with I-Premise
IV I-Premise
G-CSF I-Premise
[ I-Premise
7.9 I-Premise
days I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
6.6-9.1 I-Premise
] I-Premise
compared I-Premise
with I-Premise
SC I-Premise
G-CSF I-Premise
( I-Premise
5.4 I-Premise
days I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
4.6-6.2 I-Premise
) I-Premise
, I-Premise
log-rank I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
. I-Premise

Longer B-Premise
neutropenia I-Premise
duration I-Premise
was I-Premise
observed I-Premise
in I-Premise
all I-Premise
patient I-Premise
subgroups I-Premise
, I-Premise
except B-Premise
for I-Premise
patients I-Premise
undergoing I-Premise
autologous I-Premise
HCT I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
groups I-Premise
in I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
infection I-Premise
or I-Premise
death I-Premise
, I-Premise
but B-Premise
more I-Premise
deaths I-Premise
were I-Premise
observed I-Premise
with I-Premise
IV I-Premise
( I-Premise
4/57 I-Premise
, I-Premise
7 I-Premise
% I-Premise
) I-Premise
versus I-Premise
SC I-Premise
( I-Premise
1/61 I-Premise
, I-Premise
1.6 I-Premise
% I-Premise
) I-Premise
G-CSF I-Premise
administration I-Premise
, I-Premise
P I-Premise
= I-Premise
0.196 I-Premise
. I-Premise

Similar O
results O
were O
observed O
when O
all O
158 O
courses O
following O
cross-over O
were O
analyzed O
. O

Patients B-Claim
reported I-Claim
similar I-Claim
pain I-Claim
and I-Claim
satisfaction I-Claim
scores I-Claim
in I-Claim
both I-Claim
groups I-Claim
. I-Claim

Bolus B-Claim
IV I-Claim
administration I-Claim
of I-Claim
G-CSF I-Claim
results I-Claim
in I-Claim
longer I-Claim
neutropenia I-Claim
duration I-Claim
than I-Claim
SC I-Claim
administration I-Claim
, I-Claim
with I-Claim
no I-Claim
difference I-Claim
in I-Claim
clinical I-Claim
or I-Claim
quality-of-life I-Claim
measures I-Claim
. I-Claim

Fatigue B-Claim
has I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
of I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Recent B-Claim
research I-Claim
has I-Claim
suggested I-Claim
that I-Claim
physical I-Claim
activity I-Claim
can I-Claim
reduce I-Claim
fatigue I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
active I-Claim
cancer I-Claim
treatment I-Claim
. I-Claim

In O
this O
project O
, O
we O
examined O
the O
impact O
that O
participation O
in O
a O
randomized O
controlled O
trial O
of O
a O
multidisciplinary O
intervention O
designed O
to O
impact O
overall O
QOL O
had O
on O
fatigue O
for O
advanced O
cancer O
patients O
actively O
receiving O
treatment O
. O

Patients O
with O
newly O
diagnosed O
cancer O
were O
randomly O
assigned O
to O
an O
8-session O
structured O
multidisciplinary O
intervention O
or O
a O
standard-care O
arm O
at O
the O
beginning O
of O
their O
course O
of O
radiotherapy O
( O
RT O
) O
designed O
to O
impact O
QOL O
. O

Ninety-minute O
sessions O
were O
led O
by O
either O
a O
psychiatrist O
or O
psychologist O
, O
collaborating O
with O
a O
nurse O
, O
physical O
therapist O
, O
chaplain O
, O
or O
social O
worker O
, O
depending O
on O
the O
session O
's O
theme O
. O

The O
fatigue O
assessments O
used O
in O
this O
trial O
included O
the O
Linear O
Analogue O
Self O
Assessment O
( O
LASA O
) O
, O
the O
Profile O
of O
Mood O
States O
( O
POMS O
) O
, O
Spielberger O
's O
State-Trait O
Anxiety O
Inventory O
( O
STAI O
) O
, O
and O
the O
Symptom O
Distress O
Scale O
( O
SDS O
) O
. O

There O
were O
115 O
participants O
enrolled O
and O
the O
2 O
randomization O
arms O
were O
well O
balanced O
in O
terms O
of O
baseline O
characteristics O
and O
treatment O
received O
except O
for O
increased O
commuting O
distance O
for O
the O
patients O
in O
the O
intervention O
arm O
( O
P O
= O
0.042 O
) O
. O

Most B-Premise
of I-Premise
scores I-Premise
indicated I-Premise
less I-Premise
fatigue I-Premise
( I-Premise
higher I-Premise
score I-Premise
) I-Premise
in I-Premise
the I-Premise
standard I-Premise
treatment I-Premise
group I-Premise
, I-Premise
but B-Premise
there I-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
found I-Premise
at I-Premise
baseline I-Premise
and I-Premise
weeks I-Premise
4 I-Premise
, I-Premise
8 I-Premise
, I-Premise
and I-Premise
27 I-Premise
except I-Premise
for I-Premise
SDS I-Premise
at I-Premise
week I-Premise
8 I-Premise
( I-Premise
P I-Premise
= I-Premise
0.018 I-Premise
) I-Premise
with I-Premise
less I-Premise
patients I-Premise
reporting I-Premise
significant I-Premise
fatigue I-Premise
in I-Premise
the I-Premise
standard I-Premise
treatment I-Premise
arm I-Premise
. I-Premise

For B-Premise
the I-Premise
entire I-Premise
participant I-Premise
population I-Premise
, I-Premise
fatigue I-Premise
levels I-Premise
initially I-Premise
worsened I-Premise
with I-Premise
radiotherapy I-Premise
, I-Premise
stabilized I-Premise
at I-Premise
week I-Premise
8 I-Premise
, I-Premise
and I-Premise
returned I-Premise
to I-Premise
baseline I-Premise
by I-Premise
week I-Premise
27 I-Premise
. I-Premise

Disease B-Premise
site I-Premise
, I-Premise
chemotherapy I-Premise
use I-Premise
, I-Premise
and I-Premise
radiotherapy I-Premise
dose I-Premise
did I-Premise
not I-Premise
have I-Premise
a I-Premise
significant I-Premise
impact I-Premise
on I-Premise
fatigue I-Premise
levels I-Premise
. I-Premise

Radiotherapy B-Premise
initially I-Premise
caused I-Premise
a I-Premise
worsening I-Premise
of I-Premise
fatigue I-Premise
but I-Premise
with I-Premise
time I-Premise
fatigue I-Premise
levels I-Premise
returned I-Premise
to I-Premise
baseline I-Premise
. O

Clinically B-Claim
, I-Claim
this I-Claim
structured I-Claim
multidisciplinary I-Claim
intervention I-Claim
had I-Claim
no I-Claim
impact I-Claim
on I-Claim
fatigue I-Claim
, I-Claim
and O
there B-Claim
was I-Claim
the I-Claim
suggestion I-Claim
the I-Claim
multiple I-Claim
sessions I-Claim
may I-Claim
have I-Claim
contributed I-Claim
to I-Claim
worse I-Claim
fatigue I-Claim
during I-Claim
active I-Claim
cancer I-Claim
treatment I-Claim
. I-Claim

This O
study O
aims O
to O
evaluate O
the O
feasibility O
and O
efficacy O
of O
an O
8-week O
supervised O
exercise O
program O
in O
de-conditioned O
cancer O
survivors O
within O
2-6 O
months O
of O
chemotherapy O
completion O
. O

Participants O
were O
randomly O
assigned O
to O
an O
8-week O
, O
twice-weekly O
, O
supervised O
aerobic O
exercise O
training O
regime O
( O
n O
= O
23 O
) O
or O
a O
usual O
care O
group O
( O
n O
= O
20 O
) O
. O

Feasibility O
was O
assessed O
by O
recruitment O
rate O
, O
program O
adherence O
and O
participant O
feedback O
. O

The O
primary O
outcome O
was O
aerobic O
fitness O
assessed O
by O
the O
Modified O
Bruce O
fitness O
test O
at O
baseline O
( O
0 O
weeks O
) O
, O
post-intervention O
( O
8 O
weeks O
) O
and O
at O
3-month O
follow-up O
. O

Secondary O
outcomes O
included O
physical O
activity O
, O
waist O
circumference O
, O
fatigue O
and O
quality O
of O
life O
. O

The O
recruitment O
rate O
was O
81 O
% O
and O
adherence O
to O
the O
supervised O
exercise O
was O
78.3 O
% O
. O

Meaningful B-Premise
differences I-Premise
in I-Premise
aerobic I-Premise
fitness I-Premise
between I-Premise
the I-Premise
exercise I-Premise
and I-Premise
usual I-Premise
care I-Premise
groups I-Premise
at I-Premise
both I-Premise
the I-Premise
8-week I-Premise
[ I-Premise
mean I-Premise
3.0 I-Premise
mL I-Premise
kg I-Premise
( I-Premise
-1 I-Premise
) I-Premise
min I-Premise
( I-Premise
-1 I-Premise
) I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-1.1-7.0 I-Premise
) I-Premise
] I-Premise
and I-Premise
3-month I-Premise
follow-up I-Premise
[ I-Premise
2.1 I-Premise
mL I-Premise
kg I-Premise
( I-Premise
-1 I-Premise
) I-Premise
min I-Premise
( I-Premise
-1 I-Premise
) I-Premise
( I-Premise
-2.3-6.6 I-Premise
) I-Premise
] I-Premise
were I-Premise
found I-Premise
, I-Premise
although B-Premise
these I-Premise
differences I-Premise
did I-Premise
not I-Premise
achieve I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
p I-Premise
values I-Premise
> I-Premise
0.14 I-Premise
) I-Premise
. I-Premise

Self-reported B-Premise
physical I-Premise
activity I-Premise
increased I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
( I-Premise
EG I-Premise
) I-Premise
compared I-Premise
to I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
at I-Premise
both I-Premise
8-week I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
3-month I-Premise
follow-up I-Premise
( I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
and I-Premise
significant I-Premise
differences I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
EG I-Premise
were I-Premise
found I-Premise
for I-Premise
physical I-Premise
well-being I-Premise
at I-Premise
both I-Premise
the I-Premise
8-week I-Premise
( I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
and I-Premise
3-month I-Premise
follow-up I-Premise
( I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

Improvements B-Premise
in I-Premise
fatigue I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
total I-Premise
quality I-Premise
of I-Premise
life I-Premise
plus I-Premise
fatigue I-Premise
( I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
a I-Premise
composite I-Premise
physical I-Premise
functioning I-Premise
score I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
at I-Premise
the I-Premise
3-month I-Premise
follow-up I-Premise
were I-Premise
also I-Premise
found I-Premise
. I-Premise

The B-Claim
PEACH I-Claim
trial I-Claim
suggests I-Claim
that I-Claim
8 I-Claim
weeks I-Claim
of I-Claim
supervised I-Claim
aerobic I-Claim
exercise I-Claim
training I-Claim
was I-Claim
feasible I-Claim
and I-Claim
may I-Claim
improve I-Claim
aerobic I-Claim
fitness I-Claim
, I-Claim
fatigue I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
de-conditioned I-Claim
cancer I-Claim
survivors I-Claim
during I-Claim
the I-Claim
early I-Claim
survivorship I-Claim
phase I-Claim
. I-Claim

Exercise B-Claim
interventions I-Claim
commenced I-Claim
in I-Claim
the I-Claim
early I-Claim
survivorship I-Claim
phase I-Claim
appear I-Claim
safe I-Claim
, I-Claim
feasible I-Claim
and I-Claim
may I-Claim
lead I-Claim
to I-Claim
improvements I-Claim
in I-Claim
QOL I-Claim
and I-Claim
fatigue I-Claim
. I-Claim

Tumor B-Claim
necrosis I-Claim
factor-alpha I-Claim
( I-Claim
TNF-alpha I-Claim
) I-Claim
is I-Claim
a I-Claim
putative I-Claim
mediator I-Claim
of I-Claim
the I-Claim
cancer I-Claim
anorexia/weight I-Claim
loss I-Claim
syndrome I-Claim
. I-Claim

The O
current O
study O
was O
designed O
to O
determine O
whether O
etanercept O
( O
a O
dimeric O
fusion O
protein O
consisting O
of O
the O
extracellular O
ligand-binding O
portion O
of O
the O
human O
75-kilodalton O
TNF O
receptor O
linked O
to O
the O
Fc O
portion O
of O
human O
immunoglobulin O
[ O
Ig O
] O
G1 O
) O
could O
palliate O
this O
syndrome O
. O

A O
total O
of O
63 O
evaluable O
patients O
were O
randomly O
assigned O
to O
receive O
either O
etanercept O
at O
a O
dose O
of O
25 O
mg O
subcutaneously O
twice O
weekly O
versus O
a O
comparably O
administered O
placebo O
. O

All O
patients O
had O
an O
incurable O
malignancy O
, O
acknowledged O
loss O
of O
weight O
and/or O
appetite O
as O
a O
concern O
, O
and O
reported O
a O
weight O
loss O
of O
> O
2.27 O
kg O
over O
2 O
months O
and/or O
a O
daily O
intake O
of O
< O
20 O
calories/kg O
body O
weight O
. O

Over B-Premise
time I-Premise
, I-Premise
weight I-Premise
gain I-Premise
was I-Premise
found I-Premise
to I-Premise
be I-Premise
minimal I-Premise
in I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
";" I-Premise
no I-Premise
patient I-Premise
gained I-Premise
> I-Premise
or=10 I-Premise
% I-Premise
of I-Premise
their I-Premise
baseline I-Premise
weight I-Premise
. I-Premise

Previously B-Premise
validated I-Premise
appetite I-Premise
questionnaires I-Premise
revealed I-Premise
negligible I-Premise
improvements I-Premise
in I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
was I-Premise
also I-Premise
comparable I-Premise
( I-Premise
175 I-Premise
days I-Premise
vs I-Premise
148 I-Premise
days I-Premise
in I-Premise
etanercept-treated I-Premise
and I-Premise
placebo-exposed I-Premise
patients I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.82 I-Premise
) I-Premise
. I-Premise

Finally O
, O
preliminary B-Premise
data I-Premise
regarding I-Premise
adverse I-Premise
events I-Premise
demonstrated I-Premise
that I-Premise
patients I-Premise
treated I-Premise
with I-Premise
etanercept I-Premise
had I-Premise
higher I-Premise
rates I-Premise
of I-Premise
neurotoxicity I-Premise
( I-Premise
29 I-Premise
% I-Premise
vs I-Premise
0 I-Premise
% I-Premise
) I-Premise
but I-Premise
lower I-Premise
rates I-Premise
of I-Premise
anemia I-Premise
( I-Premise
0 I-Premise
% I-Premise
vs I-Premise
19 I-Premise
% I-Premise
) I-Premise
and I-Premise
thrombocytopenia I-Premise
( I-Premise
0 I-Premise
% I-Premise
vs I-Premise
14 I-Premise
% I-Premise
) I-Premise
. I-Premise

Infection B-Premise
rates I-Premise
were I-Premise
negligible I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

Genotyping B-Premise
for I-Premise
TNF-alpha-238 I-Premise
and I-Premise
TNF-alpha-308 I-Premise
polymorphisms I-Premise
revealed I-Premise
no I-Premise
clinical I-Premise
significance I-Premise
for I-Premise
these I-Premise
genotypes I-Premise
, I-Premise
except I-Premise
for I-Premise
a I-Premise
preliminary I-Premise
association I-Premise
between I-Premise
presence I-Premise
of I-Premise
the I-Premise
-238 I-Premise
G/A I-Premise
genotype I-Premise
and I-Premise
relatively I-Premise
less I-Premise
favorable I-Premise
survival I-Premise
. I-Premise

Etanercept B-Claim
, I-Claim
as I-Claim
prescribed I-Claim
in I-Claim
the I-Claim
current I-Claim
trial I-Claim
, I-Claim
does I-Claim
not I-Claim
appear I-Claim
to I-Claim
palliate I-Claim
the I-Claim
cancer I-Claim
anorexia/weight I-Claim
loss I-Claim
syndrome I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
disease I-Claim
. I-Claim

Hepatic O
metastases O
derive O
most O
of O
their O
blood O
supply O
from O
the O
hepatic O
artery O
";" O
therefore O
, O
for B-Claim
patients I-Claim
with I-Claim
hepatic I-Claim
metastases I-Claim
from I-Claim
colorectal I-Claim
cancer I-Claim
, I-Claim
hepatic I-Claim
arterial I-Claim
infusion I-Claim
( I-Claim
HAI I-Claim
) I-Claim
of I-Claim
chemotherapy I-Claim
may I-Claim
improve I-Claim
outcome I-Claim
. I-Claim

In O
a O
multi-institutional O
trial O
, O
135 O
patients O
were O
randomly O
assigned O
to O
receive O
HAI O
versus O
systemic O
bolus O
fluorouracil O
and O
leucovorin O
. O

The O
primary O
end O
point O
was O
survival O
";" O
secondary O
end O
points O
were O
response O
, O
recurrence O
, O
toxicity O
, O
quality O
of O
life O
, O
cost O
, O
and O
the O
influence O
of O
molecular O
markers O
. O

Overall B-Premise
survival I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
for I-Premise
HAI I-Premise
versus I-Premise
systemic I-Premise
treatment I-Premise
( I-Premise
median I-Premise
, I-Premise
24.4 I-Premise
v I-Premise
20 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0034 I-Premise
) I-Premise
, I-Premise
as I-Premise
were I-Premise
response I-Premise
rates I-Premise
( I-Premise
47 I-Premise
% I-Premise
and I-Premise
24 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.012 I-Premise
) I-Premise
and I-Premise
time I-Premise
to I-Premise
hepatic I-Premise
progression I-Premise
( I-Premise
THP I-Premise
";" I-Premise
9.8 I-Premise
v I-Premise
7.3 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.034 I-Premise
) I-Premise
. I-Premise

Time B-Premise
to I-Premise
extrahepatic I-Premise
progression I-Premise
( I-Premise
7.7 I-Premise
v I-Premise
14.8 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.029 I-Premise
) I-Premise
was I-Premise
significantly I-Premise
shorter I-Premise
in I-Premise
the I-Premise
HAI I-Premise
group I-Premise
. I-Premise

Quality-of-life B-Premise
measurements I-Premise
showed I-Premise
improved I-Premise
physical I-Premise
functioning I-Premise
in I-Premise
the I-Premise
HAI I-Premise
group I-Premise
at I-Premise
the I-Premise
-3 I-Premise
and I-Premise
6-month I-Premise
follow-up I-Premise
assessments I-Premise
. I-Premise

Toxicity B-Premise
included I-Premise
grade I-Premise
> I-Premise
or I-Premise
= I-Premise
3 I-Premise
neutropenia I-Premise
( I-Premise
2 I-Premise
% I-Premise
and I-Premise
45 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
, I-Premise
stomatitis I-Premise
( I-Premise
0 I-Premise
% I-Premise
and I-Premise
24 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
bilirubin I-Premise
elevation I-Premise
( I-Premise
18.6 I-Premise
% I-Premise
and I-Premise
0 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
in I-Premise
the I-Premise
HAI I-Premise
and I-Premise
systemic I-Premise
treatment I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
. I-Premise

A B-Premise
greater I-Premise
proportion I-Premise
of I-Premise
men I-Premise
versus I-Premise
women I-Premise
receiving I-Premise
HAI I-Premise
experienced I-Premise
biliary I-Premise
toxicity I-Premise
( I-Premise
37 I-Premise
% I-Premise
and I-Premise
15 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.05 I-Premise
) I-Premise
. I-Premise

For B-Premise
HAI I-Premise
patients I-Premise
with I-Premise
thymidylate I-Premise
synthase I-Premise
levels I-Premise
in I-Premise
tumor I-Premise
less I-Premise
than I-Premise
or I-Premise
> I-Premise
or I-Premise
= I-Premise
4 I-Premise
, I-Premise
the I-Premise
median I-Premise
survival I-Premise
was I-Premise
24 I-Premise
and I-Premise
14 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
.17 I-Premise
) I-Premise
. I-Premise

HAI B-Claim
therapy I-Claim
increased I-Claim
overall I-Claim
survival I-Claim
, I-Claim
response I-Claim
rate I-Claim
, I-Claim
THP I-Claim
, I-Claim
and I-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
physical I-Claim
functioning I-Claim
compared I-Claim
with I-Claim
systemic I-Claim
therapy I-Claim
. I-Claim

Additional B-Claim
studies I-Claim
need I-Claim
to I-Claim
address I-Claim
the I-Claim
overall I-Claim
benefit I-Claim
and I-Claim
cost I-Claim
of I-Claim
new I-Claim
chemotherapy I-Claim
agents I-Claim
versus I-Claim
HAI I-Claim
alone I-Claim
or I-Claim
the I-Claim
combination I-Claim
of I-Claim
HAI I-Claim
with I-Claim
new I-Claim
agents I-Claim
. I-Claim

Previous O
studies O
have O
demonstrated O
that O
both O
anastrozole O
and O
letrozole O
are O
well O
tolerated O
. O

Letrozole O
suppresses O
estrogen O
to O
a O
greater O
degree O
than O
anastrozole O
in O
the O
serum O
and O
breast O
tumor O
. O

Concerns O
have O
been O
raised O
that O
greater O
potency O
may O
adversely O
affect O
patients O
' O
quality O
of O
life O
( O
QOL O
) O
. O

One O
hundred O
eighty-one O
postmenopausal O
women O
with O
invasive O
estrogen O
receptor-positive O
breast O
cancers O
were O
randomized O
to O
receive O
either O
12 O
weeks O
of O
letrozole O
followed O
by O
12 O
weeks O
of O
anastrozole O
or O
the O
reverse O
sequence O
. O

One O
hundred O
and O
six O
received O
immediate O
adjuvant O
aromatase O
inhibitors O
( O
AIs O
) O
following O
surgery O
, O
and O
75 O
received O
extended O
adjuvant O
therapy O
. O

The O
Functional O
Assessment O
of O
Cancer O
Therapy O
Endocrine O
Subscale O
( O
FACT-B-ES O
) O
QOL O
questionnaires O
were O
completed O
to O
assess O
QOL O
on O
each O
drug O
. O

Additional O
side-effect O
profiles O
were O
collected O
. O

Each O
patient O
completed O
a O
patient O
preference O
form O
. O

Twenty-one O
patients O
withdrew O
before O
study O
end O
, O
10/179 O
( O
5.6 O
% O
) O
while O
taking O
letrozole O
and O
4/173 O
( O
2.3 O
% O
) O
while O
taking O
anastrozole O
( O
P O
= O
0.12 O
) O
. O

Tamoxifen-naïve B-Premise
patients I-Premise
had I-Premise
a I-Premise
higher I-Premise
mean I-Premise
ES I-Premise
( I-Premise
endocrine I-Premise
symptoms I-Premise
subscale I-Premise
) I-Premise
score I-Premise
at I-Premise
entry I-Premise
versus I-Premise
those I-Premise
having I-Premise
extended I-Premise
therapy I-Premise
( I-Premise
66.0 I-Premise
vs. I-Premise
61.9 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
change I-Premise
in I-Premise
FACT-B-ES I-Premise
( I-Premise
overall I-Premise
) I-Premise
scores I-Premise
or I-Premise
ES I-Premise
scores I-Premise
while I-Premise
patients I-Premise
were I-Premise
taking I-Premise
anastrozole I-Premise
or I-Premise
letrozole I-Premise
and I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
drugs I-Premise
. I-Premise

Nearly B-Premise
80 I-Premise
% I-Premise
of I-Premise
patients I-Premise
reported I-Premise
one I-Premise
or I-Premise
more I-Premise
side I-Premise
effects I-Premise
with I-Premise
either I-Premise
agent I-Premise
. I-Premise

No B-Premise
differences I-Premise
in I-Premise
frequency I-Premise
, I-Premise
grade I-Premise
, I-Premise
or I-Premise
range I-Premise
of I-Premise
side I-Premise
effects I-Premise
were I-Premise
seen I-Premise
between I-Premise
drugs I-Premise
. I-Premise

Of O
160 O
patients O
, O
49 O
( O
30.6 O
% O
) O
preferred O
letrozole O
, O
57 O
( O
35.6 O
% O
) O
preferred O
anastrozole O
, O
and O
54 O
( O
33.8 O
% O
) O
had O
no O
preference O
( O
P O
= O
0.26 O
, O
Pearson O
's O
Chi-squared O
test O
) O
. O

In O
conclusion O
, O
both B-Claim
AIs I-Claim
are I-Claim
equally I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

There B-Claim
were I-Claim
no I-Claim
significant I-Claim
differences I-Claim
in I-Claim
QOL I-Claim
scores I-Claim
between I-Claim
the I-Claim
two I-Claim
drugs I-Claim
. I-Claim

Patient-reported O
symptoms O
and O
health-related O
quality O
of O
life O
( O
QoL O
) O
benefits O
were O
investigated O
in O
a O
randomized O
, O
phase O
III O
trial O
of O
afatinib O
or O
cisplatin/pemetrexed O
. O

Three O
hundred O
forty-five O
patients O
with O
advanced O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
mutation-positive O
lung O
adenocarcinoma O
were O
randomly O
assigned O
2:1 O
to O
afatinib O
40 O
mg O
per O
day O
or O
up O
to O
six O
cycles O
of O
cisplatin/pemetrexed O
. O

Lung O
cancer O
symptoms O
and O
health-related O
QoL O
were O
assessed O
every O
21 O
days O
until O
progression O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
and O
Lung O
Cancer-13 O
questionnaires O
. O

Analyses O
of O
cough O
, O
dyspnea O
, O
and O
pain O
were O
preplanned O
, O
including O
percentage O
of O
patients O
who O
improved O
on O
therapy O
, O
time O
to O
deterioration O
of O
symptoms O
, O
and O
change O
in O
symptoms O
over O
time O
. O

Questionnaire O
compliance O
was O
high O
. O

Compared B-Premise
with I-Premise
chemotherapy I-Premise
, I-Premise
afatinib I-Premise
significantly I-Premise
delayed I-Premise
the I-Premise
time I-Premise
to I-Premise
deterioration I-Premise
for I-Premise
cough I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.60 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.41 I-Premise
to I-Premise
0.87 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.007 I-Premise
) I-Premise
and I-Premise
dyspnea I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.68 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.50 I-Premise
to I-Premise
0.93 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.015 I-Premise
) I-Premise
, I-Premise
but I-Premise
not I-Premise
pain I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.83 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.62 I-Premise
to I-Premise
1.10 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.19 I-Premise
) I-Premise
. I-Premise

More B-Premise
patients I-Premise
on I-Premise
afatinib I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
versus I-Premise
chemotherapy I-Premise
( I-Premise
50 I-Premise
% I-Premise
) I-Premise
experienced I-Premise
improvements I-Premise
in I-Premise
dyspnea I-Premise
scores I-Premise
( I-Premise
P I-Premise
= I-Premise
.010 I-Premise
) I-Premise
. I-Premise

Differences B-Premise
in I-Premise
mean I-Premise
scores I-Premise
over I-Premise
time I-Premise
significantly I-Premise
favored I-Premise
afatinib I-Premise
over I-Premise
chemotherapy I-Premise
for I-Premise
cough I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
dyspnea I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Afatinib B-Premise
showed I-Premise
significantly I-Premise
better I-Premise
mean I-Premise
scores I-Premise
over I-Premise
time I-Premise
in I-Premise
global I-Premise
health I-Premise
status/QoL I-Premise
( I-Premise
P I-Premise
= I-Premise
.015 I-Premise
) I-Premise
and I-Premise
physical I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
role I-Premise
( I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
, I-Premise
and I-Premise
cognitive I-Premise
( I-Premise
P I-Premise
= I-Premise
.007 I-Premise
) I-Premise
functioning I-Premise
compared I-Premise
with I-Premise
chemotherapy I-Premise
. I-Premise

Fatigue B-Premise
and I-Premise
nausea I-Premise
were I-Premise
worse I-Premise
with I-Premise
chemotherapy I-Premise
, I-Premise
whereas I-Premise
diarrhea I-Premise
, I-Premise
dysphagia I-Premise
, I-Premise
and I-Premise
sore I-Premise
mouth I-Premise
were I-Premise
worse I-Premise
with I-Premise
afatinib I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

In B-Claim
patients I-Claim
with I-Claim
lung I-Claim
adenocarcinoma I-Claim
with I-Claim
EGFR I-Claim
mutations I-Claim
, I-Claim
first-line I-Claim
afatinib I-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
control I-Claim
of I-Claim
cough I-Claim
and I-Claim
dyspnea I-Claim
compared I-Claim
with I-Claim
chemotherapy I-Claim
, I-Claim
although I-Claim
diarrhea I-Claim
, I-Claim
dysphagia I-Claim
, I-Claim
and I-Claim
sore I-Claim
mouth I-Claim
were I-Claim
worse I-Claim
. I-Claim

Global B-Claim
health I-Claim
status/QoL I-Claim
was I-Claim
also I-Claim
improved I-Claim
over I-Claim
time I-Claim
with I-Claim
afatinib I-Claim
compared I-Claim
with I-Claim
chemotherapy I-Claim
. I-Claim

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
effects O
on O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
of O
two O
treatment O
regimens O
in O
the O
TEX O
trial O
during O
9 O
month O
from O
random O
assignment O
, O
with O
emphasis O
on O
the O
-2 O
and O
9-months O
assessments O
. O

A O
total O
of O
287 O
patients O
were O
randomized O
to O
treatment O
in O
3-week O
cycles O
with O
either O
epirubicin O
plus O
paclitaxel O
( O
ET O
, O
143 O
patients O
) O
, O
or O
epirubicin O
, O
paclitaxel O
and O
capecitabine O
( O
TEX O
, O
144 O
patients O
) O
. O

HRQOL O
was O
assessed O
by O
the O
EORTC-QLQ O
C30 O
and O
EORTC O
QLQ-BR23 O
questionnaires O
at O
five O
points O
during O
9 O
months O
. O

A O
total O
of O
252 O
( O
88 O
% O
) O
completed O
questionnaires O
before O
randomization O
. O

Response O
rate O
for O
the O
following O
assessments O
was O
> O
75 O
% O
. O

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
TEX I-Premise
group I-Premise
and I-Premise
the I-Premise
ET I-Premise
group I-Premise
on I-Premise
any I-Premise
of I-Premise
the I-Premise
subscales I-Premise
2 I-Premise
months I-Premise
after I-Premise
randomization I-Premise
. I-Premise

Small B-Premise
clinical I-Premise
differences I-Premise
( I-Premise
5-10 I-Premise
points I-Premise
) I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
ET I-Premise
group I-Premise
were I-Premise
found I-Premise
for I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
role I-Premise
functioning I-Premise
, I-Premise
social I-Premise
functioning I-Premise
, I-Premise
and I-Premise
insomnia I-Premise
. I-Premise

At B-Premise
the I-Premise
9-months I-Premise
assessment I-Premise
, I-Premise
the I-Premise
TEX I-Premise
group I-Premise
scored I-Premise
statistically I-Premise
significantly I-Premise
higher I-Premise
on I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
and I-Premise
physical I-Premise
functioning I-Premise
. I-Premise

Small B-Premise
clinically I-Premise
significant I-Premise
differences I-Premise
were I-Premise
found I-Premise
for I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
physical I-Premise
functioning I-Premise
, I-Premise
role I-Premise
functioning I-Premise
, I-Premise
emotional I-Premise
functioning I-Premise
, I-Premise
dyspnoea I-Premise
, I-Premise
and I-Premise
insomnia I-Premise
, I-Premise
all I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
TEX I-Premise
group I-Premise
. I-Premise

At B-Claim
the I-Claim
2-months I-Claim
assessment I-Claim
, I-Claim
when I-Claim
side-effects I-Claim
of I-Claim
chemotherapy I-Claim
were I-Claim
present I-Claim
, I-Claim
patients I-Claim
in I-Claim
the I-Claim
TEX I-Claim
group I-Claim
appeared I-Claim
to I-Claim
fare I-Claim
a I-Claim
bit I-Claim
worse I-Claim
than I-Claim
those I-Claim
receiving I-Claim
ET I-Claim
. I-Claim

However O
, O
after B-Claim
9 I-Claim
months I-Claim
, I-Claim
when I-Claim
the I-Claim
patients I-Claim
had I-Claim
adapted I-Claim
to I-Claim
treatment I-Claim
, I-Claim
the I-Claim
TEX I-Claim
group I-Claim
seemed I-Claim
to I-Claim
have I-Claim
a I-Claim
slightly I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
laparoscopy-assisted O
distal O
gastrectomy O
( O
LADG O
) O
compared O
to O
open O
distal O
gastrectomy O
( O
ODG O
) O
in O
the O
treatment O
of O
early O
gastric O
cancer O
with O
respect O
to O
survival O
, O
surgical O
outcomes O
, O
complications O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

One O
hundred O
sixty-four O
patients O
with O
cT1N0M0 O
and O
cT1N1M0 O
distal O
gastric O
cancer O
were O
randomly O
assigned O
to O
either O
the O
LADG O
group O
or O
the O
ODG O
group O
. O

The O
primary O
end O
point O
was O
the O
5-year O
disease-free O
survival O
( O
DFS O
) O
rate O
. O

Complications O
were O
classified O
using O
the O
accordion O
severity O
classification O
of O
postoperative O
complications O
scheme O
. O

QOL O
was O
measured O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
and O
QLQ-STO22 O
preoperatively O
and O
postoperatively O
during O
regular O
follow-up O
visits O
. O

This O
trial O
is O
registered O
at O
ClinicalTrials.gov O
. O

The O
median O
( O
range O
) O
follow-up O
period O
was O
74.3 O
( O
24.8-90.8 O
) O
months O
. O

The B-Premise
LADG I-Premise
and I-Premise
ODG I-Premise
groups I-Premise
showed I-Premise
similar I-Premise
survival I-Premise
[ I-Premise
5-year I-Premise
DFS I-Premise
rate I-Premise
: I-Premise
98.8 I-Premise
% I-Premise
vs. I-Premise
97.6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
0.514 I-Premise
) I-Premise
, I-Premise
5-year I-Premise
overall I-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
rate I-Premise
: I-Premise
97.6 I-Premise
vs. I-Premise
96.3 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
0.721 I-Premise
) I-Premise
] I-Premise
or I-Premise
overall I-Premise
complication I-Premise
rate I-Premise
( I-Premise
29.3 I-Premise
vs. I-Premise
42.7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.073 I-Premise
) I-Premise
. I-Premise

Mild B-Premise
complications I-Premise
were I-Premise
significantly I-Premise
less I-Premise
frequent I-Premise
in I-Premise
the I-Premise
LADG I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
ODG I-Premise
group I-Premise
( I-Premise
23.2 I-Premise
vs. I-Premise
41.5 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.012 I-Premise
) I-Premise
. I-Premise

The B-Premise
rates I-Premise
of I-Premise
moderate I-Premise
, I-Premise
severe I-Premise
, I-Premise
and I-Premise
long-term I-Premise
complications I-Premise
( I-Premise
i.e. I-Premise
, I-Premise
31 I-Premise
days I-Premise
to I-Premise
5 I-Premise
years I-Premise
after I-Premise
surgery I-Premise
) I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
between I-Premise
groups I-Premise
. I-Premise

No B-Premise
clinically I-Premise
meaningful I-Premise
differences I-Premise
were I-Premise
detected I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
in I-Premise
long-term I-Premise
QOL I-Premise
. I-Premise

LADG B-Claim
showed I-Claim
similar I-Claim
DFS I-Claim
and I-Claim
OS I-Claim
compared I-Claim
to I-Claim
ODG I-Claim
in I-Claim
treating I-Claim
early I-Claim
gastric I-Claim
cancer I-Claim
. I-Claim

Marginal B-Claim
benefits I-Claim
in I-Claim
mild I-Claim
complications I-Claim
were I-Claim
observed I-Claim
with I-Claim
LADG I-Claim
. I-Claim

LADG B-Claim
did I-Claim
not I-Claim
show I-Claim
advantages I-Claim
over I-Claim
ODG I-Claim
regarding I-Claim
other I-Claim
complications I-Claim
and I-Claim
long-term I-Claim
QOL I-Claim
. I-Claim

To O
evaluate O
the O
efficacy O
and O
economic O
efficiency O
of O
a O
multimedia O
, O
multimodal O
physical O
activity O
program O
for O
women O
undergoing O
adjuvant O
therapy O
following O
surgery O
for O
breast O
cancer O
. O

We O
conducted O
a O
randomized O
trial O
with O
concurrent O
incremental O
cost-effectiveness O
analysis O
and O
blinded O
baseline O
, O
3 O
, O
6 O
and O
12-month O
follow-up O
assessments O
amongst O
women O
undergoing O
adjuvant O
therapy O
following O
surgery O
for O
breast O
cancer O
( O
n O
= O
89 O
) O
. O

The O
intervention O
was O
a O
multimedia O
, O
multimodal O
exercise O
program O
comprising O
strength O
, O
balance O
and O
endurance O
training O
elements O
. O

The O
control O
was O
sham O
flexibility O
and O
relaxation O
program O
delivered O
using O
similar O
materials O
. O

The O
primary O
outcome O
was O
health-related O
quality O
of O
life O
( O
EQ-5D O
& O
amp O
";" O
VAS O
, O
EORTC O
C30 O
, O
BR23 O
) O
. O

Economic O
outcomes O
included O
direct O
health O
care O
costs O
and O
productivity O
gains O
and O
losses O
. O

Participants B-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
demonstrated I-Premise
greater I-Premise
improvement I-Premise
in I-Premise
health-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
baseline I-Premise
and I-Premise
the I-Premise
3-month I-Premise
assessment I-Premise
[ I-Premise
mean I-Premise
( I-Premise
sd I-Premise
) I-Premise
EQ-5D I-Premise
VAS I-Premise
( I-Premise
0-100 I-Premise
) I-Premise
baseline I-Premise
: I-Premise
72.6 I-Premise
( I-Premise
15.6 I-Premise
) I-Premise
, I-Premise
3 I-Premise
month I-Premise
: I-Premise
80.6 I-Premise
( I-Premise
11.6 I-Premise
) I-Premise
] I-Premise
when I-Premise
compared I-Premise
to I-Premise
control I-Premise
group I-Premise
participants I-Premise
[ I-Premise
baseline I-Premise
: I-Premise
77.5 I-Premise
( I-Premise
13.5 I-Premise
) I-Premise
, I-Premise
3 I-Premise
month I-Premise
: I-Premise
74.1 I-Premise
( I-Premise
20.6 I-Premise
) I-Premise
, I-Premise
P I-Premise
= I-Premise
0.006 I-Premise
] I-Premise
and I-Premise
also I-Premise
improved I-Premise
more I-Premise
in I-Premise
terms I-Premise
of I-Premise
physical I-Premise
function I-Premise
[ I-Premise
mean I-Premise
( I-Premise
sd I-Premise
) I-Premise
EORTC I-Premise
C30 I-Premise
physical I-Premise
function I-Premise
scale I-Premise
intervention I-Premise
( I-Premise
0-100 I-Premise
) I-Premise
baseline I-Premise
: I-Premise
84.9 I-Premise
( I-Premise
14.8 I-Premise
) I-Premise
, I-Premise
3 I-Premise
month I-Premise
: I-Premise
86.9 I-Premise
( I-Premise
10.7 I-Premise
) I-Premise
, I-Premise
control I-Premise
baseline I-Premise
: I-Premise
91.3 I-Premise
( I-Premise
9.6 I-Premise
) I-Premise
, I-Premise
3 I-Premise
month I-Premise
: I-Premise
86.7 I-Premise
( I-Premise
14.9 I-Premise
) I-Premise
, I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
] I-Premise
. I-Premise

These O
improvements O
were O
not O
sustained O
beyond O
this O
point O
. O

Upper B-Premise
limb I-Premise
volumes I-Premise
were I-Premise
also I-Premise
lower I-Premise
amongst I-Premise
intervention I-Premise
group I-Premise
participants I-Premise
. I-Premise

However O
, O
there B-Premise
was I-Premise
low I-Premise
probability I-Premise
that I-Premise
the I-Premise
intervention I-Premise
would I-Premise
be I-Premise
both I-Premise
less I-Premise
costly I-Premise
and I-Premise
more I-Premise
effective I-Premise
than I-Premise
the I-Premise
control I-Premise
condition I-Premise
( I-Premise
range I-Premise
probability I-Premise
= I-Premise
0.05-50.02 I-Premise
% I-Premise
depending I-Premise
on I-Premise
approach I-Premise
) I-Premise
. I-Premise

Provision B-Claim
of I-Claim
multimodal I-Claim
exercise I-Claim
programs I-Claim
will I-Claim
improve I-Claim
the I-Claim
short-term I-Claim
health I-Claim
of I-Claim
women I-Claim
undergoing I-Claim
adjuvant I-Claim
therapy I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
but I-Claim
are I-Claim
of I-Claim
questionable I-Claim
economic I-Claim
efficiency I-Claim
. I-Claim

Somatostatin O
analogs O
act O
directly O
on O
breast O
cancer O
cells O
and O
indirectly O
on O
insulin O
and O
insulin-like O
growth O
factor O
1 O
( O
IGF-1 O
) O
levels O
. O

This O
trial O
was O
undertaken O
to O
assess O
whether O
octreotide B-Claim
would I-Claim
lower I-Claim
insulin I-Claim
and I-Claim
IGF-1 I-Claim
levels I-Claim
and I-Claim
reduce I-Claim
risk I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
recurrence I-Claim
. I-Claim

The O
NCIC O
CTG O
MA.14 O
( O
NCIC O
Clinical O
Trials O
Group O
MA.14 O
) O
trial O
randomly O
assigned O
postmenopausal O
women O
to O
5 O
years O
of O
tamoxifen O
20 O
mg O
daily O
( O
TAM O
) O
or O
TAM O
plus O
2 O
years O
of O
octreotide O
90 O
mg O
depot O
intramuscular O
injections O
monthly O
( O
TAM-OCT O
) O
as O
adjuvant O
therapy O
. O

The O
primary O
end O
point O
was O
event-free O
survival O
( O
EFS O
) O
. O

Secondary O
end O
points O
were O
relapse-free O
survival O
( O
RFS O
) O
, O
overall O
survival O
( O
OS O
) O
, O
toxicity O
, O
and O
effects O
of O
treatment O
on O
IGF O
physiology O
. O

Among O
667 O
women O
with O
a O
median O
follow-up O
of O
7.9 O
years O
, O
220 O
events O
occurred-108 O
with O
TAM-OCT O
and O
112 O
with O
TAM O
. O

Adjusted B-Premise
hazard I-Premise
ratios I-Premise
( I-Premise
HRs I-Premise
";" I-Premise
TAM-OCT I-Premise
to I-Premise
TAM I-Premise
) I-Premise
were I-Premise
0.93 I-Premise
for I-Premise
EFS I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.71 I-Premise
to I-Premise
1.22 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.62 I-Premise
) I-Premise
, I-Premise
0.84 I-Premise
for I-Premise
RFS I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.59 I-Premise
to I-Premise
1.18 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.31 I-Premise
) I-Premise
, I-Premise
and I-Premise
0.97 I-Premise
for I-Premise
OS I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.69 I-Premise
to I-Premise
1.37 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.86 I-Premise
) I-Premise
. I-Premise

Among B-Premise
patients I-Premise
with I-Premise
normal I-Premise
baseline I-Premise
gallbladder I-Premise
imaging I-Premise
, I-Premise
cholecystectomy I-Premise
was I-Premise
required I-Premise
in I-Premise
23.0 I-Premise
% I-Premise
of I-Premise
those I-Premise
receiving I-Premise
TAM-OCT I-Premise
but I-Premise
in I-Premise
only I-Premise
1.4 I-Premise
% I-Premise
of I-Premise
those I-Premise
receiving I-Premise
TAM I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

At B-Premise
4 I-Premise
months I-Premise
, I-Premise
TAM-OCT I-Premise
had I-Premise
significantly I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
lowered I-Premise
IGF-1 I-Premise
, I-Premise
IGF I-Premise
binding I-Premise
protein I-Premise
3 I-Premise
, I-Premise
and I-Premise
C-peptide I-Premise
levels I-Premise
. I-Premise

Older B-Premise
age I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
tumor I-Premise
size I-Premise
( I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
, I-Premise
nodal I-Premise
status I-Premise
( I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
, I-Premise
high I-Premise
C-peptide I-Premise
levels I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
higher I-Premise
body I-Premise
mass I-Premise
index I-Premise
( I-Premise
BMI I-Premise
) I-Premise
in I-Premise
models I-Premise
excluding I-Premise
C-peptide I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
were I-Premise
associated I-Premise
with I-Premise
poorer I-Premise
EFS I-Premise
in I-Premise
multivariate I-Premise
analysis I-Premise
. I-Premise

Octreotide-related O
changes O
in O
circulating O
IGF-1 O
and O
C-peptide O
levels O
were O
statistically O
significant O
. O

Octreotide B-Claim
did I-Claim
not I-Claim
add I-Claim
significant I-Claim
clinical I-Claim
benefit I-Claim
. I-Claim

High B-Claim
C-peptide I-Claim
levels I-Claim
( I-Claim
surrogate I-Claim
for I-Claim
insulin I-Claim
secretion I-Claim
rate I-Claim
) I-Claim
and I-Claim
high I-Claim
BMI I-Claim
were I-Claim
associated I-Claim
with I-Claim
poor I-Claim
outcome I-Claim
. I-Claim

There O
are O
few O
reports O
about O
the O
course O
of O
vestibular O
schwannoma O
( O
VS O
) O
patients O
following O
gamma O
knife O
radiosurgery O
( O
GKRS O
) O
compared O
with O
the O
course O
following O
conservative O
management O
( O
CM O
) O
. O

In O
this O
study O
, O
we O
present O
prospectively O
collected O
data O
of O
237 O
patients O
with O
unilateral O
VS O
extending O
outside O
the O
internal O
acoustic O
canal O
who O
received O
either O
GKRS O
( O
113 O
) O
or O
CM O
( O
124 O
) O
. O

The O
aim O
was O
to O
measure O
the O
effect O
of O
GKRS O
compared O
with O
the O
natural O
course O
on O
tumor O
growth O
rate O
and O
hearing O
loss O
. O

Secondary O
end O
points O
were O
postinclusion O
additional O
treatment O
, O
quality O
of O
life O
( O
QoL O
) O
, O
and O
symptom O
development O
. O

The O
patients O
underwent O
magnetic O
resonance O
imaging O
scans O
, O
clinical O
examination O
, O
and O
QoL O
assessment O
by O
SF-36 O
questionnaire O
. O

Statistics O
were O
performed O
by O
using O
Spearman O
correlation O
coefficient O
, O
Kaplan-Meier O
plot O
, O
Poisson O
regression O
model O
, O
mixed O
linear O
regression O
models O
, O
and O
mixed O
logistic O
regression O
models O
. O

Mean O
follow-up O
time O
was O
55.0 O
months O
( O
26.1 O
standard O
deviation O
, O
range O
10-132 O
) O
. O

Thirteen O
patients O
were O
lost O
to O
follow-up O
. O

Serviceable B-Premise
hearing I-Premise
was I-Premise
lost I-Premise
in I-Premise
54 I-Premise
of I-Premise
71 I-Premise
( I-Premise
76 I-Premise
% I-Premise
) I-Premise
( I-Premise
CM I-Premise
) I-Premise
and I-Premise
34 I-Premise
of I-Premise
53 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
( I-Premise
GKRS I-Premise
) I-Premise
patients I-Premise
during I-Premise
the I-Premise
study I-Premise
period I-Premise
( I-Premise
not I-Premise
significant I-Premise
, I-Premise
log-rank I-Premise
test I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
tumor I-Premise
volume I-Premise
over I-Premise
time I-Premise
in I-Premise
the I-Premise
GKRS I-Premise
group I-Premise
. I-Premise

The B-Premise
need I-Premise
for I-Premise
treatment I-Premise
following I-Premise
initial I-Premise
GKRS I-Premise
or I-Premise
CM I-Premise
differed I-Premise
at I-Premise
highly I-Premise
significant I-Premise
levels I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Symptom B-Premise
and I-Premise
QoL I-Premise
development I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
between I-Premise
the I-Premise
groups I-Premise
. I-Premise

In B-Claim
VS I-Claim
patients I-Claim
, I-Claim
GKRS I-Claim
reduces I-Claim
the I-Claim
tumor I-Claim
growth I-Claim
rate I-Claim
and I-Claim
thereby I-Claim
the I-Claim
incidence I-Claim
rate I-Claim
of I-Claim
new I-Claim
treatment I-Claim
about I-Claim
tenfold I-Claim
. I-Claim

Hearing B-Claim
is I-Claim
lost I-Claim
at I-Claim
similar I-Claim
rates I-Claim
in I-Claim
both I-Claim
groups I-Claim
. I-Claim

Symptoms B-Claim
and I-Claim
QoL I-Claim
seem I-Claim
not I-Claim
to I-Claim
be I-Claim
significantly I-Claim
affected I-Claim
by I-Claim
GKRS I-Claim
. I-Claim

The O
AGO-ETC O
trial O
compared O
5-year O
relapse-free O
survival O
of O
intense O
dose-dense O
( O
IDD O
) O
sequential O
chemotherapy O
with O
epirubicin O
( O
E O
) O
, O
paclitaxel O
( O
T O
) O
, O
and O
cyclophosphamide O
( O
C O
) O
( O
IDD-ETC O
) O
every O
2 O
weeks O
vs O
conventional O
scheduled O
epirubicin/cyclophosphamide O
followed O
by O
paclitaxel O
( O
EC→T O
) O
( O
every O
3 O
weeks O
) O
as O
adjuvant O
treatment O
in O
high-risk O
breast O
cancer O
patients O
. O

The O
objective O
of O
this O
study O
was O
to O
evaluate O
the O
safety O
and O
efficacy O
of O
epoetin O
alfa O
in O
a O
second O
randomization O
of O
the O
intense O
dose-dense O
arm O
. O

One O
thousand O
two O
hundred O
eighty-four O
patients O
were O
enrolled O
";" O
658 O
patients O
were O
randomly O
assigned O
to O
the O
IDD-ETC O
treatment O
group O
. O

Within O
the O
IDD-ETC O
group O
, O
324 O
patients O
were O
further O
randomly O
assigned O
to O
the O
epoetin O
alfa O
group O
, O
and O
319 O
were O
randomly O
assigned O
to O
the O
non-erythropoiesis-stimulating O
agent O
( O
ESA O
) O
control O
group O
. O

Primary O
efficacy O
endpoints O
included O
change O
in O
hemoglobin O
level O
from O
baseline O
to O
Cycle O
9 O
and O
the O
percentage O
of O
subjects O
requiring O
red O
blood O
cell O
transfusion O
. O

Relapse-free O
survival O
, O
overall O
survival O
, O
and O
intramammary O
relapse O
were O
secondary O
endpoints O
estimated O
with O
Kaplan-Meier O
and O
Cox O
regression O
methods O
. O

Except O
for O
the O
primary O
hypothesis O
, O
all O
statistical O
tests O
were O
two-sided O
. O

Epoetin B-Premise
alfa I-Premise
avoided I-Premise
the I-Premise
decrease I-Premise
in I-Premise
hemoglobin I-Premise
level I-Premise
( I-Premise
no I-Premise
decrease I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
vs I-Premise
-2.20g/dL I-Premise
change I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
statistically I-Premise
significantly I-Premise
reduced I-Premise
the I-Premise
percentage I-Premise
of I-Premise
subjects I-Premise
requiring I-Premise
red I-Premise
blood I-Premise
cell I-Premise
transfusion I-Premise
( I-Premise
12.8 I-Premise
% I-Premise
vs I-Premise
28.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
thrombotic I-Premise
events I-Premise
was I-Premise
7 I-Premise
% I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
arm I-Premise
vs I-Premise
3 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
. I-Premise

After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
62 I-Premise
months I-Premise
, I-Premise
epoetin I-Premise
alfa I-Premise
treatment I-Premise
did I-Premise
not I-Premise
affect I-Premise
overall I-Premise
survival I-Premise
, I-Premise
relapse-free I-Premise
survival I-Premise
, I-Premise
or I-Premise
intramammary I-Premise
relapse I-Premise
. I-Premise

Epoetin B-Claim
alfa I-Claim
resulted I-Claim
in I-Claim
improved I-Claim
hemoglobin I-Claim
levels I-Claim
and I-Claim
decreased I-Claim
transfusions I-Claim
without I-Claim
an I-Claim
impact I-Claim
on I-Claim
relapse-free I-Claim
or I-Claim
overall I-Claim
survival I-Claim
. I-Claim

However B-Claim
, I-Claim
epoetin I-Claim
alfa I-Claim
had I-Claim
an I-Claim
adverse I-Claim
effect I-Claim
, I-Claim
resulting I-Claim
in I-Claim
increased I-Claim
thrombosis I-Claim
. I-Claim

Capecitabine/taxane O
combinations O
are O
highly O
active O
in O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O

We O
conducted O
a O
randomized O
, O
phase O
III O
, O
noninferiority O
trial O
comparing O
capecitabine O
plus O
paclitaxel O
( O
XP O
) O
with O
epirubicin O
plus O
paclitaxel O
( O
EP O
) O
as O
first-line O
therapy O
for O
MBC O
, O
regarding O
progression-free O
survival O
( O
PFS O
) O
as O
primary O
efficacy O
endpoint O
. O

Females O
who O
had O
received O
no O
prior O
chemotherapy O
for O
MBC O
were O
randomized O
to O
six O
3-weekly O
cycles O
of O
XP O
( O
capecitabine O
1000 O
mg/m O
( O
2 O
) O
b.i.d. O
, O
days O
1-14 O
";" O
paclitaxel O
175 O
mg/m O
( O
2 O
) O
3-h O
infusion O
, O
day O
1 O
) O
or O
EP O
( O
epirubicin O
60 O
mg/m O
( O
2 O
) O
1-h O
infusion O
, O
day O
1 O
";" O
paclitaxel O
as O
above O
) O
. O

Secondary O
endpoints O
included O
response O
rate O
, O
overall O
survival O
, O
tolerability O
, O
and O
quality O
of O
life O
( O
QoL O
) O
. O

Each O
arm O
included O
170 O
patients O
, O
most O
of O
whom O
received O
all O
six O
cycles O
as O
planned O
. O

The O
difference O
in O
means O
of O
( O
logarithmic O
) O
PFS O
times O
( O
-0.205 O
) O
did O
not O
meet O
the O
pre-defined O
level O
for O
noninferiority O
( O
-0.186 O
) O
. O

However O
, O
PFS B-Premise
was I-Premise
similar I-Premise
in I-Premise
the I-Premise
two I-Premise
arms I-Premise
[ I-Premise
HR I-Premise
: I-Premise
XP I-Premise
vs. I-Premise
EP I-Premise
: I-Premise
1.012 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.785-1.304 I-Premise
) I-Premise
";" I-Premise
median I-Premise
10.4 I-Premise
months I-Premise
XP I-Premise
vs. I-Premise
9.2 I-Premise
months I-Premise
EP I-Premise
] I-Premise
. I-Premise

Overall B-Premise
survival I-Premise
was I-Premise
also I-Premise
similar I-Premise
[ I-Premise
HR I-Premise
1.027 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.740-1.424 I-Premise
) I-Premise
";" I-Premise
median I-Premise
22.0 I-Premise
vs. I-Premise
26.1 I-Premise
months I-Premise
] I-Premise
, I-Premise
and I-Premise
response I-Premise
rate I-Premise
was I-Premise
47 I-Premise
% I-Premise
versus I-Premise
42 I-Premise
% I-Premise
. I-Premise

Both B-Premise
regimens I-Premise
were I-Premise
tolerable I-Premise
: I-Premise
there I-Premise
were I-Premise
more I-Premise
grade I-Premise
3/4 I-Premise
diarrhea I-Premise
and I-Premise
grade I-Premise
3 I-Premise
hand-foot I-Premise
syndromes I-Premise
with I-Premise
XP I-Premise
and I-Premise
more I-Premise
grade I-Premise
3/4 I-Premise
hematologic I-Premise
toxicities I-Premise
with I-Premise
EP I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
major I-Premise
differences I-Premise
in I-Premise
QoL I-Premise
. I-Premise

Although B-Claim
, I-Claim
noninferiority I-Claim
of I-Claim
XP I-Claim
to I-Claim
EP I-Claim
was I-Claim
formally I-Claim
not I-Claim
proven I-Claim
, I-Claim
first-line B-Claim
XP I-Claim
was I-Claim
active I-Claim
and I-Claim
feasible I-Claim
. I-Claim

XP B-Claim
is I-Claim
a I-Claim
valid I-Claim
first-line I-Claim
alternative I-Claim
to I-Claim
anthracycline/taxane I-Claim
regimens I-Claim
, I-Claim
especially I-Claim
in I-Claim
patients I-Claim
previously I-Claim
treated I-Claim
with I-Claim
adjuvant I-Claim
anthracyclines I-Claim
. I-Claim

Androgen B-Claim
deprivation I-Claim
therapy I-Claim
is I-Claim
a I-Claim
common I-Claim
treatment I-Claim
in I-Claim
men I-Claim
with I-Claim
prostate I-Claim
cancer I-Claim
that I-Claim
may I-Claim
cause I-Claim
fatigue I-Claim
, I-Claim
functional I-Claim
decline I-Claim
, I-Claim
increased I-Claim
body I-Claim
fatness I-Claim
, I-Claim
and I-Claim
loss I-Claim
of I-Claim
lean I-Claim
body I-Claim
tissue I-Claim
. I-Claim

These B-Claim
physical I-Claim
changes I-Claim
can I-Claim
negatively I-Claim
affect I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Resistance B-Claim
exercise I-Claim
may I-Claim
help I-Claim
to I-Claim
counter I-Claim
some I-Claim
of I-Claim
these I-Claim
side I-Claim
effects I-Claim
by I-Claim
reducing I-Claim
fatigue I-Claim
, I-Claim
elevating I-Claim
mood I-Claim
, I-Claim
building I-Claim
muscle I-Claim
mass I-Claim
, I-Claim
and I-Claim
reducing I-Claim
body I-Claim
fat I-Claim
. I-Claim

In O
a O
two-site O
study O
, O
155 O
men O
with O
prostate O
cancer O
who O
were O
scheduled O
to O
receive O
androgen O
deprivation O
therapy O
for O
at O
least O
3 O
months O
after O
recruitment O
were O
randomly O
assigned O
to O
an O
intervention O
group O
that O
participated O
in O
a O
resistance O
exercise O
program O
three O
times O
per O
week O
for O
12 O
weeks O
( O
82 O
men O
) O
or O
to O
a O
waiting O
list O
control O
group O
( O
73 O
men O
) O
. O

The O
primary O
outcomes O
were O
fatigue O
and O
disease-specific O
quality O
of O
life O
as O
assessed O
by O
self-reported O
questionnaires O
after O
12 O
weeks O
. O

Secondary O
outcomes O
were O
muscular O
fitness O
and O
body O
composition O
. O

Men B-Premise
assigned I-Premise
to I-Premise
resistance I-Premise
exercise I-Premise
had I-Premise
less I-Premise
interference I-Premise
from I-Premise
fatigue I-Premise
on I-Premise
activities I-Premise
of I-Premise
daily I-Premise
living I-Premise
( I-Premise
P I-Premise
=.002 I-Premise
) I-Premise
and I-Premise
higher I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
=.001 I-Premise
) I-Premise
than I-Premise
men I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Men B-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
demonstrated I-Premise
higher I-Premise
levels I-Premise
of I-Premise
upper I-Premise
body I-Premise
( I-Premise
P I-Premise
=.009 I-Premise
) I-Premise
and I-Premise
lower I-Premise
body I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
muscular I-Premise
fitness I-Premise
than I-Premise
men I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

The B-Premise
12-week I-Premise
resistance I-Premise
exercise I-Premise
intervention I-Premise
did I-Premise
not I-Premise
improve I-Premise
body I-Premise
composition I-Premise
as I-Premise
measured I-Premise
by I-Premise
changes I-Premise
in I-Premise
body I-Premise
weight I-Premise
, I-Premise
body I-Premise
mass I-Premise
index I-Premise
, I-Premise
waist I-Premise
circumference I-Premise
, I-Premise
or I-Premise
subcutaneous I-Premise
skinfolds I-Premise
. I-Premise

Resistance B-Claim
exercise I-Claim
reduces I-Claim
fatigue I-Claim
and I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
muscular I-Claim
fitness I-Claim
in I-Claim
men I-Claim
with I-Claim
prostate I-Claim
cancer I-Claim
receiving I-Claim
androgen I-Claim
deprivation I-Claim
therapy I-Claim
. I-Claim

This B-Claim
form I-Claim
of I-Claim
exercise I-Claim
can I-Claim
be I-Claim
an I-Claim
important I-Claim
component I-Claim
of I-Claim
supportive I-Claim
care I-Claim
for I-Claim
these I-Claim
patients I-Claim
. I-Claim

Morbidity B-Claim
is I-Claim
an I-Claim
important I-Claim
issue I-Claim
in I-Claim
cancer I-Claim
research I-Claim
. I-Claim

The B-Claim
observer-based I-Claim
toxicity I-Claim
scoring I-Claim
system I-Claim
used I-Claim
by I-Claim
DAHANCA I-Claim
( I-Claim
the I-Claim
Danish I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
study I-Claim
group I-Claim
) I-Claim
has I-Claim
proved I-Claim
itself I-Claim
sensitive I-Claim
to I-Claim
differences I-Claim
in I-Claim
toxicity I-Claim
in I-Claim
a I-Claim
large I-Claim
randomised I-Claim
study I-Claim
, I-Claim
but B-Claim
like I-Claim
other I-Claim
toxicity I-Claim
scoring I-Claim
systems I-Claim
it I-Claim
has I-Claim
not I-Claim
been I-Claim
formally I-Claim
validated I-Claim
. I-Claim

Conversely O
, O
the O
EORTC O
quality O
of O
life O
questionnaire O
( O
QLQ O
) O
has O
been O
validated O
as O
a O
tool O
for O
collecting O
information O
about O
the O
consequences O
of O
disease O
and O
treatment O
on O
the O
well O
being O
of O
cancer O
patients O
. O

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
relationship O
between O
the O
two O
methods O
of O
side O
effect O
recording O
. O

One O
hundred O
and O
sixteen O
recurrence O
free O
patients O
with O
laryngeal O
( O
n=44 O
) O
, O
pharyngeal O
( O
n=34 O
) O
and O
oral O
cavity O
( O
n=38 O
) O
cancer O
attending O
follow-up O
after O
radiotherapy O
( O
n=83 O
) O
or O
surgery O
( O
n=33 O
) O
completed O
EORTC O
C30 O
, O
the O
core O
questionnaire O
concerning O
general O
symptoms O
and O
function O
and O
EORTC O
H O
& O
amp O
";" O
N35 O
the O
head O
and O
neck O
specific O
questionnaire O
. O

The O
attending O
physicians O
in O
the O
follow-up O
clinic O
evaluated O
and O
recorded O
DAHANCA O
toxicity O
scores O
on O
the O
same O
patients O
. O

The B-Premise
DAHANCA I-Premise
toxicity I-Premise
scoring I-Premise
system I-Premise
and I-Premise
the I-Premise
EORTC I-Premise
QLQ I-Premise
correlated I-Premise
with I-Premise
several I-Premise
clinical I-Premise
endpoints I-Premise
. I-Premise

The B-Premise
conceptually I-Premise
similar I-Premise
endpoints I-Premise
of I-Premise
the I-Premise
two I-Premise
methods I-Premise
correlated I-Premise
significantly I-Premise
. I-Premise

The B-Premise
objective I-Premise
endpoints I-Premise
of I-Premise
the I-Premise
DAHANCA I-Premise
scoring I-Premise
system I-Premise
were I-Premise
only I-Premise
correlated I-Premise
with I-Premise
quality I-Premise
of I-Premise
life I-Premise
endpoints I-Premise
to I-Premise
a I-Premise
very I-Premise
low I-Premise
degree I-Premise
. I-Premise

The B-Premise
DAHANCA I-Premise
toxicity I-Premise
scores I-Premise
had I-Premise
a I-Premise
low I-Premise
sensitivity I-Premise
( I-Premise
0.48-0.74 I-Premise
) I-Premise
in I-Premise
detecting I-Premise
equivalent I-Premise
subjective I-Premise
complaints I-Premise
from I-Premise
the I-Premise
questionnaires I-Premise
and I-Premise
the I-Premise
observer-based I-Premise
scoring I-Premise
system I-Premise
severely I-Premise
underestimated I-Premise
patient I-Premise
complaints I-Premise
. I-Premise

A B-Premise
specific I-Premise
patient I-Premise
group I-Premise
where I-Premise
the I-Premise
DAHANCA I-Premise
score I-Premise
had I-Premise
a I-Premise
higher I-Premise
tendency I-Premise
to I-Premise
fail I-Premise
could I-Premise
not I-Premise
be I-Premise
detected I-Premise
. I-Premise

The B-Claim
DAHANCA I-Claim
toxicity I-Claim
score I-Claim
is I-Claim
an I-Claim
effective I-Claim
instrument I-Claim
in I-Claim
assessing I-Claim
objective I-Claim
treatment I-Claim
induced I-Claim
toxicity I-Claim
in I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
patients I-Claim
but I-Claim
insensitive I-Claim
and I-Claim
non-specific I-Claim
with I-Claim
regard I-Claim
to I-Claim
patient I-Claim
assessed I-Claim
subjective I-Claim
endpoints I-Claim
. I-Claim

This B-Claim
weakness I-Claim
seems I-Claim
inherent I-Claim
in I-Claim
an I-Claim
observer-based I-Claim
scoring I-Claim
system I-Claim
, I-Claim
and I-Claim
will I-Claim
probably I-Claim
also I-Claim
apply I-Claim
to I-Claim
newer I-Claim
ones I-Claim
like I-Claim
CTCAE I-Claim
3.0 I-Claim
. I-Claim

To O
compare O
protracted O
venous O
infusion O
( O
PVI O
) O
fluorouracil O
( O
5-FU O
) O
with O
PVI O
5-FU O
plus O
mitomycin O
( O
MMC O
) O
in O
patients O
with O
advanced O
pancreatic O
cancer O
in O
a O
multicenter O
, O
prospectively O
randomized O
study O
. O

Two O
hundred O
eight O
patients O
were O
randomized O
to O
PVI O
5-FU O
( O
300 O
mg/m O
( O
2 O
) O
/d O
for O
a O
maximum O
of O
24 O
weeks O
) O
or O
PVI O
5-FU O
plus O
MMC O
( O
7 O
mg/m O
( O
2 O
) O
every O
6 O
weeks O
for O
four O
courses O
) O
. O

The O
major O
end O
points O
were O
tumor O
response O
, O
survival O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

The O
two O
treatment O
groups O
were O
balanced O
for O
baseline O
demographic O
factors O
, O
and O
62 O
% O
had O
metastatic O
disease O
. O

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
8.4 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
) I-Premise
3.2 I-Premise
% I-Premise
to I-Premise
13.7 I-Premise
% I-Premise
for I-Premise
patients I-Premise
treated I-Premise
with I-Premise
PVI I-Premise
5-FU I-Premise
alone I-Premise
compared I-Premise
with I-Premise
17.6 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
10.3 I-Premise
% I-Premise
to I-Premise
25.1 I-Premise
% I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
plus I-Premise
MMC I-Premise
( I-Premise
P I-Premise
=.04 I-Premise
) I-Premise
. I-Premise

Median B-Premise
failure-free I-Premise
survival I-Premise
was I-Premise
2.8 I-Premise
months I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
and I-Premise
3.8 I-Premise
months I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
plus I-Premise
MMC I-Premise
( I-Premise
P I-Premise
=.14 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
5.1 I-Premise
months I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
and I-Premise
6.5 I-Premise
months I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
plus I-Premise
MMC I-Premise
( I-Premise
P I-Premise
=.34 I-Premise
) I-Premise
. I-Premise

Toxicities B-Premise
in I-Premise
both I-Premise
arms I-Premise
were I-Premise
mild I-Premise
. I-Premise

There B-Premise
was I-Premise
an I-Premise
increased I-Premise
incidence I-Premise
of I-Premise
neutropenia I-Premise
in I-Premise
the I-Premise
5-FU I-Premise
plus I-Premise
MMC I-Premise
arm I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
, I-Premise
although I-Premise
no I-Premise
differences I-Premise
in I-Premise
infection I-Premise
were I-Premise
seen I-Premise
. I-Premise

No B-Premise
patients I-Premise
developed I-Premise
hemolytic I-Premise
uremic I-Premise
syndrome I-Premise
. I-Premise

Global B-Claim
QOL I-Claim
improved I-Claim
significantly I-Claim
after I-Claim
24 I-Claim
weeks I-Claim
of I-Claim
treatment I-Claim
compared I-Claim
with I-Claim
baseline I-Claim
for I-Claim
patients I-Claim
receiving I-Claim
5-FU I-Claim
plus I-Claim
MMC I-Claim
, I-Claim
although B-Premise
there I-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
QOL I-Premise
between I-Premise
arms I-Premise
. I-Premise

PVI B-Claim
5-FU I-Claim
plus I-Claim
MMC I-Claim
resulted I-Claim
in I-Claim
a I-Claim
superior I-Claim
response I-Claim
rate I-Claim
in I-Claim
comparison I-Claim
with I-Claim
PVI I-Claim
5-FU I-Claim
alone I-Claim
in I-Claim
advanced I-Claim
pancreatic I-Claim
cancer I-Claim
, I-Claim
but B-Claim
this I-Claim
did I-Claim
not I-Claim
translate I-Claim
into I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
. I-Claim

These B-Claim
results I-Claim
emphasize I-Claim
the I-Claim
importance I-Claim
of I-Claim
chemotherapy I-Claim
in I-Claim
this I-Claim
setting I-Claim
and I-Claim
the I-Claim
continuing I-Claim
value I-Claim
of I-Claim
the I-Claim
fluoropyrimidines I-Claim
in I-Claim
pancreatic I-Claim
cancer I-Claim
. I-Claim

Research B-Claim
suggests I-Claim
that I-Claim
stress-reduction I-Claim
programs I-Claim
tailored I-Claim
to I-Claim
the I-Claim
cancer I-Claim
setting I-Claim
help I-Claim
patients I-Claim
cope I-Claim
with I-Claim
the I-Claim
effects I-Claim
of I-Claim
treatment I-Claim
and I-Claim
improve I-Claim
their I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Yoga O
, O
an O
ancient O
Eastern O
science O
, O
incorporates O
stress-reduction O
techniques O
that O
include O
regulated O
breathing O
, O
visual O
imagery O
, O
and O
meditation O
as O
well O
as O
various O
postures O
. O

The O
authors O
examined O
the O
effects O
of O
the O
Tibetan O
yoga O
( O
TY O
) O
practices O
of O
Tsa O
lung O
and O
Trul O
khor O
, O
which O
incorporate O
controlled O
breathing O
and O
visualization O
, O
mindfulness O
techniques O
, O
and O
low-impact O
postures O
in O
patients O
with O
lymphoma O
. O

Thirty-nine O
patients O
with O
lymphoma O
who O
were O
undergoing O
treatment O
or O
who O
had O
concluded O
treatment O
within O
the O
past O
12 O
months O
were O
assigned O
to O
a O
TY O
group O
or O
to O
a O
wait-list O
control O
group O
. O

Patients O
in O
the O
TY O
group O
participated O
in O
7 O
weekly O
yoga O
sessions O
, O
and O
patients O
in O
the O
wait-list O
control O
group O
were O
free O
to O
participate O
in O
the O
TY O
program O
after O
the O
3-month O
follow-up O
assessment O
. O

Eighty O
nine O
percent O
of O
TY O
participants O
completed O
at O
least O
2-3 O
three O
yoga O
sessions O
, O
and O
58 O
% O
completed O
at O
least O
5 O
sessions O
. O

Patients B-Premise
in I-Premise
the I-Premise
TY I-Premise
group I-Premise
reported I-Premise
significantly I-Premise
lower I-Premise
sleep I-Premise
disturbance I-Premise
scores I-Premise
during I-Premise
follow-up I-Premise
compared I-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
wait-list I-Premise
control I-Premise
group I-Premise
( I-Premise
5.8 I-Premise
vs. I-Premise
8.1 I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.004 I-Premise
) I-Premise
. I-Premise

This B-Premise
included I-Premise
better I-Premise
subjective I-Premise
sleep I-Premise
quality I-Premise
( I-Premise
P I-Premise
< I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
faster I-Premise
sleep I-Premise
latency I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
longer I-Premise
sleep I-Premise
duration I-Premise
( I-Premise
P I-Premise
< I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
and I-Premise
less I-Premise
use I-Premise
of I-Premise
sleep I-Premise
medications I-Premise
( I-Premise
P I-Premise
< I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
intrusion I-Premise
or I-Premise
avoidance I-Premise
, I-Premise
state I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
or I-Premise
fatigue I-Premise
. I-Premise

The B-Claim
participation I-Claim
rates I-Claim
suggested I-Claim
that I-Claim
a I-Claim
TY I-Claim
program I-Claim
is I-Claim
feasible I-Claim
for I-Claim
patients I-Claim
with I-Claim
cancer I-Claim
and I-Claim
that I-Claim
such I-Claim
a I-Claim
program I-Claim
significantly I-Claim
improves I-Claim
sleep-related I-Claim
outcomes I-Claim
. I-Claim

However B-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
groups I-Premise
for I-Premise
the I-Premise
other I-Premise
outcomes I-Premise
. I-Premise

Bone B-Claim
metastases I-Claim
occur I-Claim
in I-Claim
most I-Claim
women I-Claim
with I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
and I-Claim
can I-Claim
lead I-Claim
to I-Claim
considerable I-Claim
morbidity I-Claim
and I-Claim
a I-Claim
rapid I-Claim
deterioration I-Claim
in I-Claim
the I-Claim
patient I-Claim
's I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

It O
was O
the O
aim O
of O
the O
present O
study O
to O
assess O
changes O
in O
quality O
of O
life O
and O
bone O
pain O
due O
to O
intravenous O
( O
i.v O
. O
) O

ibandronate O
, O
a O
potent O
third-generation O
bisphosphonate O
. O

In O
a O
phase O
III O
randomised O
, O
double-blind O
, O
placebo-controlled O
trial O
in O
patients O
with O
bone O
metastases O
due O
to O
breast O
cancer O
, O
466 O
women O
were O
randomised O
to O
receive O
placebo O
, O
2 O
mg O
ibandronate O
or O
6 O
mg O
ibandronate O
for O
up O
to O
96 O
weeks O
. O

Treatment O
was O
administered O
i.v O
. O

at O
-3 O
or O
4-weekly O
intervals O
. O

Clinical O
endpoints O
included O
the O
incidence O
of O
adverse O
events O
, O
quality O
of O
life O
( O
assessed O
using O
the O
European O
Organisation O
for O
the O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Scale O
- O
Core O
30 O
questionnaire O
( O
QLQ-C30 O
) O
) O
, O
and O
bone O
pain O
( O
assessed O
on O
a O
5-point O
scale O
from O
0=none O
to O
4=intolerable O
) O
. O

Ibandronate B-Premise
was I-Premise
generally I-Premise
well I-Premise
tolerated I-Premise
. I-Premise

Compared B-Premise
with I-Premise
baseline I-Premise
measurements I-Premise
, I-Premise
the I-Premise
bone I-Premise
pain I-Premise
score I-Premise
was I-Premise
increased I-Premise
at I-Premise
the I-Premise
last I-Premise
assessment I-Premise
in I-Premise
both I-Premise
the I-Premise
placebo I-Premise
and I-Premise
2 I-Premise
mg I-Premise
ibandronate I-Premise
groups I-Premise
, I-Premise
but B-Premise
was I-Premise
significantly I-Premise
reduced I-Premise
in I-Premise
the I-Premise
patients I-Premise
receiving I-Premise
6 I-Premise
mg I-Premise
ibandronate I-Premise
( I-Premise
-0.28+/-1.11 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

A B-Premise
significant I-Premise
improvement I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
demonstrated I-Premise
for I-Premise
patients I-Premise
treated I-Premise
with I-Premise
ibandronate I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
for I-Premise
all I-Premise
global I-Premise
health I-Premise
status I-Premise
. I-Premise

Overall B-Premise
, I-Premise
at I-Premise
the I-Premise
last I-Premise
assessment I-Premise
, I-Premise
the I-Premise
6 I-Premise
mg I-Premise
ibandronate I-Premise
group I-Premise
showed I-Premise
significantly I-Premise
better I-Premise
functioning I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
P I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
, I-Premise
and I-Premise
had I-Premise
significantly I-Premise
better I-Premise
scores I-Premise
on I-Premise
the I-Premise
domains I-Premise
of I-Premise
physical I-Premise
, I-Premise
emotional I-Premise
, I-Premise
and I-Premise
social I-Premise
functioning I-Premise
, I-Premise
and I-Premise
in I-Premise
global I-Premise
health I-Premise
status I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Significant B-Premise
improvements I-Premise
in I-Premise
the I-Premise
symptoms I-Premise
of I-Premise
fatigue I-Premise
and I-Premise
pain I-Premise
were I-Premise
also I-Premise
observed I-Premise
in I-Premise
the I-Premise
6 I-Premise
mg I-Premise
ibandronate I-Premise
group I-Premise
. I-Premise

I.v B-Claim
. I-Claim
ibandronate I-Claim
treatment I-Claim
leads I-Claim
to I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
is I-Claim
an I-Claim
effective I-Claim
and I-Claim
well-tolerated I-Claim
palliative I-Claim
treatment I-Claim
in I-Claim
patients I-Claim
with I-Claim
bone I-Claim
metastases I-Claim
due I-Claim
to I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Advice B-Claim
to I-Claim
rest I-Claim
and I-Claim
take I-Claim
things I-Claim
easy I-Claim
if I-Claim
patients I-Claim
become I-Claim
fatigued I-Claim
during I-Claim
radiotherapy I-Claim
may I-Claim
be I-Claim
detrimental I-Claim
. I-Claim

Aerobic B-Premise
walking I-Premise
improves I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
has I-Premise
been I-Premise
an I-Premise
intervention I-Premise
for I-Premise
chemotherapy-related I-Premise
fatigue I-Premise
. I-Premise

A O
prospective O
, O
randomized O
, O
controlled O
trial O
was O
performed O
to O
determine O
whether O
aerobic O
exercise O
would O
reduce O
the O
incidence O
of O
fatigue O
and O
prevent O
deterioration O
in O
physical O
functioning O
during O
radiotherapy O
for O
localized O
prostate O
carcinoma O
. O

Sixty-six O
men O
were O
randomized O
before O
they O
received O
radical O
radiotherapy O
for O
localized O
prostate O
carcinoma O
, O
with O
33 O
men O
randomized O
to O
an O
exercise O
group O
and O
33 O
men O
randomized O
to O
a O
control O
group O
. O

Outcome O
measures O
were O
fatigue O
and O
distance O
walked O
in O
a O
modified O
shuttle O
test O
before O
and O
after O
radiotherapy O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
between I-Premise
group I-Premise
differences I-Premise
noted I-Premise
with I-Premise
regard I-Premise
to I-Premise
fatigue I-Premise
scores I-Premise
at I-Premise
baseline I-Premise
( I-Premise
P I-Premise
= I-Premise
0.55 I-Premise
) I-Premise
or I-Premise
after I-Premise
4 I-Premise
weeks I-Premise
of I-Premise
radiotherapy I-Premise
( I-Premise
P I-Premise
= I-Premise
0.18 I-Premise
) I-Premise
. I-Premise

Men B-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
had I-Premise
significant I-Premise
increases I-Premise
in I-Premise
fatigue I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
to I-Premise
the I-Premise
end I-Premise
of I-Premise
radiotherapy I-Premise
( I-Premise
P I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
, I-Premise
with I-Premise
no I-Premise
significant I-Premise
increases I-Premise
observed I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.203 I-Premise
) I-Premise
. I-Premise

A B-Premise
nonsignificant I-Premise
reduction I-Premise
( I-Premise
2.4 I-Premise
% I-Premise
) I-Premise
in I-Premise
shuttle I-Premise
test I-Premise
distance I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
radiotherapy I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
";" I-Premise
however I-Premise
, I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
, I-Premise
there I-Premise
was I-Premise
a I-Premise
significant I-Premise
increase I-Premise
( I-Premise
13.2 I-Premise
% I-Premise
) I-Premise
in I-Premise
distance I-Premise
walked I-Premise
( I-Premise
P I-Premise
= I-Premise
0.0003 I-Premise
) I-Premise
. I-Premise

Men B-Premise
who I-Premise
followed I-Premise
advice I-Premise
to I-Premise
rest I-Premise
and I-Premise
take I-Premise
things I-Premise
easy I-Premise
if I-Premise
they I-Premise
became I-Premise
fatigued I-Premise
demonstrated I-Premise
a I-Premise
slight I-Premise
deterioration I-Premise
in I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
fatigue I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
radiotherapy I-Premise
. I-Premise

Home-based B-Claim
, I-Claim
moderate-intensity I-Claim
walking I-Claim
produced I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
physical I-Claim
functioning I-Claim
with I-Claim
no I-Claim
significant I-Claim
increase I-Claim
in I-Claim
fatigue I-Claim
. I-Claim

Improved B-Claim
physical I-Claim
functioning I-Claim
may I-Claim
be I-Claim
necessary I-Claim
to I-Claim
combat I-Claim
radiation I-Claim
fatigue I-Claim
. I-Claim

To O
determine O
the O
effects O
of O
exercise O
training O
on O
cardiopulmonary O
function O
and O
quality O
of O
life O
( O
QOL O
) O
in O
postmenopausal O
breast O
cancer O
survivors O
who O
had O
completed O
surgery O
, O
radiotherapy O
, O
and/or O
chemotherapy O
with O
or O
without O
current O
hormone O
therapy O
use O
. O

Fifty-three O
postmenopausal O
breast O
cancer O
survivors O
were O
randomly O
assigned O
to O
an O
exercise O
( O
n O
= O
25 O
) O
or O
control O
( O
n O
= O
28 O
) O
group O
. O

The O
exercise O
group O
trained O
on O
cycle O
ergometers O
three O
times O
per O
week O
for O
15 O
weeks O
at O
a O
power O
output O
that O
elicited O
the O
ventilatory O
equivalent O
for O
carbon O
dioxide O
. O

The O
control O
group O
did O
not O
train O
. O

The O
primary O
outcomes O
were O
changes O
in O
peak O
oxygen O
consumption O
and O
overall O
QOL O
from O
baseline O
to O
postintervention O
. O

Peak O
oxygen O
consumption O
was O
assessed O
by O
a O
graded O
exercise O
test O
using O
gas O
exchange O
analysis O
. O

Overall O
QOL O
was O
assessed O
by O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Breast O
scale O
. O

Fifty-two O
participants O
completed O
the O
trial O
. O

The O
exercise O
group O
completed O
98.4 O
% O
of O
the O
exercise O
sessions O
. O

Baseline O
values O
for O
peak O
oxygen O
consumption O
( O
P O
=.254 O
) O
and O
overall O
QOL O
( O
P O
=.286 O
) O
did O
not O
differ O
between O
groups O
. O

Peak B-Premise
oxygen I-Premise
consumption I-Premise
increased I-Premise
by I-Premise
0.24 I-Premise
L/min I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
, I-Premise
whereas B-Premise
it I-Premise
decreased I-Premise
by I-Premise
0.05 I-Premise
L/min I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
0.29 I-Premise
L/min I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
0.18 I-Premise
to I-Premise
0.40 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Overall B-Premise
QOL I-Premise
increased I-Premise
by I-Premise
9.1 I-Premise
points I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
compared I-Premise
with I-Premise
0.3 I-Premise
points I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
8.8 I-Premise
points I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.6 I-Premise
to I-Premise
14.0 I-Premise
";" I-Premise
P I-Premise
=.001 I-Premise
) I-Premise
. I-Premise

Pearson B-Premise
correlations I-Premise
indicated I-Premise
that I-Premise
change I-Premise
in I-Premise
peak I-Premise
oxygen I-Premise
consumption I-Premise
correlated I-Premise
with I-Premise
change I-Premise
in I-Premise
overall I-Premise
QOL I-Premise
( I-Premise
r I-Premise
= I-Premise
0.45 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Exercise B-Claim
training I-Claim
had I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
cardiopulmonary I-Claim
function I-Claim
and I-Claim
QOL I-Claim
in I-Claim
postmenopausal I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

This O
randomized O
, O
double-blind O
, O
placebo-controlled O
clinical O
trial O
assessed O
the O
effects O
of O
epoetin O
alfa O
on O
transfusion O
requirements O
, O
hematopoietic O
parameters O
, O
quality O
of O
life O
( O
QOL O
) O
, O
and O
safety O
in O
anemic O
cancer O
patients O
receiving O
nonplatinum O
chemotherapy O
. O

The O
study O
also O
explored O
a O
possible O
relationship O
between O
increased O
hemoglobin O
and O
survival O
. O

Three O
hundred O
seventy-five O
patients O
with O
solid O
or O
nonmyeloid O
hematologic O
malignancies O
and O
hemoglobin O
levels O
< O
or O
= O
10.5 O
g/dL O
, O
or O
greater O
than O
10.5 O
g/dL O
but O
< O
or O
= O
12.0 O
g/dL O
after O
a O
hemoglobin O
decrease O
of O
> O
or O
= O
1.5 O
g/dL O
per O
cycle O
since O
starting O
chemotherapy O
, O
were O
randomized O
2:1 O
to O
epoetin O
alfa O
150 O
to O
300 O
IU/kg O
( O
n O
= O
251 O
) O
or O
placebo O
( O
n O
= O
124 O
) O
three O
times O
per O
week O
subcutaneously O
for O
12 O
to O
24 O
weeks O
. O

The O
primary O
end O
point O
was O
proportion O
of O
patients O
transfused O
";" O
secondary O
end O
points O
were O
change O
in O
hemoglobin O
and O
QOL O
. O

The O
protocol O
was O
amended O
before O
unblinding O
to O
prospectively O
collect O
and O
assess O
survival O
data O
12 O
months O
after O
the O
last O
patient O
completed O
the O
study O
. O

Epoetin B-Premise
alfa I-Premise
, I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
, I-Premise
significantly I-Premise
decreased I-Premise
transfusion I-Premise
requirements I-Premise
( I-Premise
P I-Premise
=.0057 I-Premise
) I-Premise
and I-Premise
increased I-Premise
hemoglobin I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Improvement B-Premise
of I-Premise
all I-Premise
primary I-Premise
cancer- I-Premise
and I-Premise
anemia-specific I-Premise
QOL I-Premise
domains I-Premise
, I-Premise
including I-Premise
energy I-Premise
level I-Premise
, I-Premise
ability I-Premise
to I-Premise
do I-Premise
daily I-Premise
activities I-Premise
, I-Premise
and I-Premise
fatigue I-Premise
, I-Premise
was I-Premise
significantly I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
greater I-Premise
for I-Premise
epoetin I-Premise
alfa I-Premise
versus I-Premise
placebo I-Premise
patients I-Premise
. I-Premise

Although O
the O
study O
was O
not O
powered O
for O
survival O
as O
an O
end O
point O
, O
Kaplan-Meier B-Premise
estimates I-Premise
showed I-Premise
a I-Premise
trend I-Premise
in I-Premise
overall I-Premise
survival I-Premise
favoring I-Premise
epoetin I-Premise
alfa I-Premise
( I-Premise
P I-Premise
=.13 I-Premise
, I-Premise
log-rank I-Premise
test I-Premise
) I-Premise
, I-Premise
and O
Cox B-Premise
regression I-Premise
analysis I-Premise
showed I-Premise
an I-Premise
estimated I-Premise
hazards I-Premise
ratio I-Premise
of I-Premise
1.309 I-Premise
( I-Premise
P I-Premise
=.052 I-Premise
) I-Premise
favoring I-Premise
epoetin I-Premise
alfa I-Premise
. I-Premise

Adverse B-Premise
events I-Premise
were I-Premise
comparable I-Premise
between I-Premise
groups I-Premise
. I-Premise

Epoetin B-Claim
alfa I-Claim
safely I-Claim
and I-Claim
effectively I-Claim
ameliorates I-Claim
anemia I-Claim
and I-Claim
significantly I-Claim
improves I-Claim
QOL I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
nonplatinum I-Claim
chemotherapy I-Claim
. I-Claim

Encouraging B-Claim
results I-Claim
regarding I-Claim
increased I-Claim
survival I-Claim
warrant I-Claim
another I-Claim
trial I-Claim
designed I-Claim
to I-Claim
confirm I-Claim
these I-Claim
findings I-Claim
. I-Claim

To O
investigate O
whether O
the O
relative O
dose-intensity O
of O
cyclophosphamide O
, O
doxorubicin O
, O
vincristine O
, O
and O
prednisone O
( O
CHOP O
) O
chemotherapy O
could O
be O
improved O
by O
prophylactic O
administration O
of O
granulocyte O
colony-stimulating O
factor O
( O
G-CSF O
) O
in O
elderly O
patients O
with O
aggressive O
non-Hodgkin O
's O
lymphoma O
( O
NHL O
) O
. O

Patients O
aged O
65 O
to O
90 O
years O
( O
median O
, O
72 O
years O
) O
with O
stage O
II O
to O
IV O
aggressive O
NHL O
were O
randomly O
assigned O
to O
receive O
standard O
CHOP O
every O
3 O
weeks O
or O
CHOP O
plus O
G-CSF O
every O
3 O
weeks O
on O
days O
2 O
to O
11 O
of O
each O
cycle O
. O

In B-Premise
389 I-Premise
eligible I-Premise
patients I-Premise
, I-Premise
the I-Premise
relative I-Premise
dose I-Premise
intensities I-Premise
( I-Premise
RDIs I-Premise
) I-Premise
of I-Premise
cyclophosphamide I-Premise
( I-Premise
median I-Premise
, I-Premise
96.3 I-Premise
% I-Premise
v I-Premise
93.9 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
and I-Premise
doxorubicin I-Premise
( I-Premise
median I-Premise
, I-Premise
95.4 I-Premise
% I-Premise
v I-Premise
93.3 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.04 I-Premise
) I-Premise
were I-Premise
higher I-Premise
in I-Premise
patients I-Premise
treated I-Premise
with I-Premise
CHOP I-Premise
plus I-Premise
G-CSF I-Premise
. I-Premise

The B-Premise
complete I-Premise
response I-Premise
rates I-Premise
were I-Premise
55 I-Premise
% I-Premise
and I-Premise
52 I-Premise
% I-Premise
for I-Premise
CHOP I-Premise
and I-Premise
CHOP I-Premise
plus I-Premise
G-CSF I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
=.63 I-Premise
) I-Premise
. I-Premise

The B-Premise
actuarial I-Premise
overall I-Premise
survival I-Premise
at I-Premise
5 I-Premise
years I-Premise
was I-Premise
22 I-Premise
% I-Premise
with I-Premise
CHOP I-Premise
alone I-Premise
, I-Premise
compared I-Premise
with I-Premise
24 I-Premise
% I-Premise
with I-Premise
CHOP I-Premise
plus I-Premise
G-CSF I-Premise
( I-Premise
P I-Premise
=.76 I-Premise
) I-Premise
, I-Premise
with I-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
33 I-Premise
months I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
CHOP I-Premise
plus I-Premise
G-CSF I-Premise
had I-Premise
an I-Premise
identical I-Premise
incidence I-Premise
of I-Premise
infections I-Premise
, I-Premise
with I-Premise
World I-Premise
Health I-Premise
Organization I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
( I-Premise
34 I-Premise
of I-Premise
1,191 I-Premise
cycles I-Premise
v I-Premise
36 I-Premise
of I-Premise
1,195 I-Premise
cycles I-Premise
) I-Premise
. I-Premise

Only B-Premise
the I-Premise
cumulative I-Premise
days I-Premise
with I-Premise
antibiotics I-Premise
were I-Premise
fewer I-Premise
with I-Premise
CHOP I-Premise
plus I-Premise
G-CSF I-Premise
( I-Premise
median I-Premise
, I-Premise
0 I-Premise
v I-Premise
6 I-Premise
days I-Premise
";" I-Premise
P I-Premise
=.006 I-Premise
) I-Premise
than I-Premise
with I-Premise
CHOP I-Premise
alone I-Premise
. I-Premise

The B-Premise
number I-Premise
of I-Premise
hospital I-Premise
admissions I-Premise
and I-Premise
the I-Premise
number I-Premise
of I-Premise
days I-Premise
in I-Premise
hospital I-Premise
were I-Premise
not I-Premise
different I-Premise
. I-Premise

In B-Claim
elderly I-Claim
patients I-Claim
, I-Claim
G-CSF I-Claim
improved I-Claim
the I-Claim
RDI I-Claim
of I-Claim
CHOP I-Claim
, I-Claim
but B-Premise
this I-Premise
did I-Premise
not I-Premise
lead I-Premise
to I-Premise
a I-Premise
higher I-Premise
complete I-Premise
response I-Premise
rate I-Premise
or I-Premise
better I-Premise
overall I-Premise
survival I-Premise
. I-Premise

G-CSF B-Claim
did I-Claim
not I-Claim
prevent I-Claim
serious I-Claim
infections I-Claim
. I-Claim

The O
study O
was O
designed O
to O
compare O
the O
effects O
of O
treatment O
with O
a O
combination O
of O
trastuzumab O
( O
Herceptin O
";" O
Genentech O
, O
Inc O
, O
South O
San O
Francisco O
, O
CA O
) O
and O
chemotherapy O
versus O
chemotherapy O
alone O
on O
health-related O
quality O
of O
life O
( O
HRQL O
) O
in O
patients O
with O
HER-2/neu O
overexpressing O
, O
metastatic O
breast O
cancer O
. O

A O
sample O
of O
400 O
patients O
, O
not O
previously O
treated O
for O
metastatic O
disease O
and O
randomized O
to O
receive O
either O
trastuzumab O
plus O
chemotherapy O
( O
208 O
patients O
) O
or O
chemotherapy O
alone O
( O
192 O
patients O
) O
, O
completed O
the O
European O
Organization O
for O
Research O
and O
Treatment O
Care O
Quality O
of O
Life O
Questionnaire O
at O
baseline O
and O
on O
at O
least O
one O
subsequent O
occasion O
at O
8 O
, O
20 O
, O
32 O
, O
44 O
, O
and O
56 O
weeks O
. O

HRQL O
improvement O
or O
worsening O
was O
defined O
as O
a O
> O
or= O
10-point O
change O
( O
range O
, O
0 O
to O
100 O
points O
) O
in O
the O
scores O
of O
six O
preselected O
domains O
( O
global O
quality O
of O
life O
[ O
QOL O
] O
, O
physical O
, O
role O
, O
social O
, O
and O
emotional O
functioning O
, O
and O
fatigue O
) O
. O

Stable O
HRQL O
was O
defined O
as O
a O
change O
of O
less O
than O
10 O
. O

A O
Bonferroni O
correction O
was O
applied O
for O
multiple O
testing O
. O

After B-Premise
completion I-Premise
of I-Premise
chemotherapy I-Premise
, I-Premise
patients I-Premise
treated I-Premise
with I-Premise
trastuzumab I-Premise
and I-Premise
chemotherapy I-Premise
reported I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
fatigue I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
as I-Premise
compared I-Premise
with I-Premise
their I-Premise
baseline I-Premise
scores I-Premise
. I-Premise

Higher B-Premise
proportions I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
the I-Premise
combined I-Premise
therapy I-Premise
achieved I-Premise
improvement I-Premise
in I-Premise
global I-Premise
QOL I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
than I-Premise
did I-Premise
patients I-Premise
treated I-Premise
with I-Premise
chemotherapy I-Premise
alone I-Premise
. I-Premise

Higher B-Premise
proportions I-Premise
of I-Premise
the I-Premise
combined I-Premise
therapy I-Premise
group I-Premise
also I-Premise
achieved I-Premise
improvement I-Premise
in I-Premise
physical I-Premise
and I-Premise
role I-Premise
functioning I-Premise
and I-Premise
in I-Premise
fatigue I-Premise
as I-Premise
compared I-Premise
with I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
, I-Premise
but B-Premise
the I-Premise
differences I-Premise
were I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
proportions I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
that I-Premise
reported I-Premise
worsening I-Premise
. I-Premise

Statistically B-Claim
significantly I-Claim
higher I-Claim
proportions I-Claim
of I-Claim
patients I-Claim
treated I-Claim
with I-Claim
a I-Claim
combination I-Claim
of I-Claim
trastuzumab I-Claim
and I-Claim
chemotherapy I-Claim
reported I-Claim
improved I-Claim
global I-Claim
QOL I-Claim
than I-Claim
did I-Claim
patients I-Claim
treated I-Claim
by I-Claim
chemotherapy I-Claim
alone I-Claim
. I-Claim

